



HU000025900T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 025 900**(13) **T2****EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA

- (21) Magyar ügyszám: **E 10 011773**
(22) A bejelentés napja: **2006. 11. 24.**
(96) Az európai bejelentés bejelentési száma:
EP 20060011773
(97) Az európai bejelentés közzétételi adatai:
EP 2311877 A2 **2011. 04. 20.**
(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2311877 B1 **2015. 08. 26.**
- (51) Int. Cl.: **C07K 16/30** (2006.01)
A61K 393/95 (2006.01)
A61K 47/48 (2006.01)
C12N 5/12 (2006.01)
A61K 51/10 (2006.01)
A61P 35/00 (2006.01)

(30) Elsőbbségi adatok: 05025657 2005. 11. 24. EP	(73) Jogosult(ak): Ganymed Pharmaceuticals AG, 55131 Mainz (DE) Johannes Gutenberg-Universität Mainz, vertreten durch den Präsidenten, 55122 Mainz (DE)
(72) Feltaláló(k): SAHIN, Ugur, 55116 Mainz (DE) TÜRECI, Özlem, 55116 Mainz (DE) USENER, Dirk, 65193 Wiesbaden (DE) FRITZ, Stefan, 55237 Flonheim (DE) Uherek, Christoph, 63500 Seligenstadt (DE) BRANDENBURG, Gunda, 22880 Wedel (DE) Geppert, Harald-Gerhard, 42697 Solingen (DE) SCHRÖDER, Anja Kristina, 55122 Mainz (DE) THIEL, Philippe, 82152 Planegg (DE)	(74) Képviselő: Lengyel Zsolt, DANUBIA Szabadalmi és Jogi Iroda Kft., Budapest

(54) **Klaudin-18 elleni monoklonális ellenanyagok rák kezelésére**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 311 877 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
26.08.2015 Bulletin 2015/35

(51) Int Cl.:
C07K 16/30 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 35/00 ^(2006.01) **C12N 5/12** ^(2006.01)
A61K 47/48 ^(2006.01) **A61K 51/10** ^(2006.01)

(21) Application number: **10011773.8**

(22) Date of filing: **24.11.2006**

(54) **Monoclonal antibodies against claudin-18 for treatment of cancer**

Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs

Anticorps monoclonaux contre claudin-18 pour le traitement du cancer

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**
Designated Extension States:
AL BA HR MK RS

(30) Priority: **24.11.2005 EP 05025657**

(43) Date of publication of application:
20.04.2011 Bulletin 2011/16

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
06818817.6 / 1 948 693

(73) Proprietors:
• **Ganymed Pharmaceuticals AG**
55131 Mainz (DE)
• **Johannes Gutenberg-Universität Mainz,**
vertreten
durch den Präsidenten
55122 Mainz (DE)

(72) Inventors:
• **Sahin, Ugur**
55116 Mainz (DE)
• **Türeci, Özlem**
55116 Mainz (DE)
• **Usener, Dirk**
65193 Wiesbaden (DE)

- **Fritz, Stefan**
55237 Flonheim (DE)
- **Uherek, Christoph**
63500 Seligenstadt (DE)
- **Brandenburg, Gunda**
22880 Wedel (DE)
- **Geppert, Harald-Gerhard**
42697 Solingen (DE)
- **Schröder, Anja Kristina**
55122 Mainz (DE)
- **Thiel, Philippe**
82152 Planegg (DE)

(74) Representative: **Schnappauf, Georg et al**
ZSP Patentanwälte
Partnerschaftsgesellschaft
Radtkoferstrasse 2
81373 München (DE)

(56) References cited:
WO-A-2004/047863

- **T. NIIMI ET AL: "cLAUDIN-18, A NOVEL
DOWSTREAM TARGET GENE FOR THE
T/EBP/NKX2.1 HOMEODOMAIN
TRANSCRIPTION FACTOR, ENCODES LUNG-
AND STOMACH-SPECIFIC ISOFORMS
THROUGH ALTERNATIVE SPLICING.",
MOLECULAR AND CELLULAR BIOLOGY, vol. 21,
no. 21, 2001, pages 7380-7390, XP002375751,**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] Antibody-based therapies for cancer have the potential of higher specificity and lower side effect profile as compared to conventional drugs. The reason is a precise distinction between normal and neoplastic cells by antibodies and the fact, that their mode of action relies on less toxic immunological anti-tumor mechanisms, such as complement activation and recruitment of cytotoxic immune cells.

[0002] Targets for antibody-based therapies need to have particular qualities, which form the basis for proper discrimination between normal and neoplastic cells. Obviously, a target with either exclusive restriction to tumor cells and entirely undetectable on normal tissues is ideal for the development of efficient and safe antibody therapeutics. In another aspect, a high-level overexpression may be the basis for the therapeutic window and low side effects exemplified by the human epidermal growth factor receptor type 2 (HER-2), which as a result of gene amplification is a good target for the antibody trastuzumab (Herceptin).

[0003] Other targets for antibodies which are either already approved or in clinical development for tumor therapy have distinct qualities, which are not based on a numeric overexpression of target molecules on tumor cells. In the case of antibodies to the proteoglycan MUC-1, a peptide repeat epitope in the backbone of the target is underglycosylated in tumor cells and thus altered to its normal counterpart. In the case of antibodies to CD20 (rituximab), CD52 (Campath-1H) and CD22 (epratuzumab), antibody targets have comparable expression levels on tumor cells and normal lymphocytes. Here, the ablation of normal cells by the antibody is tolerable since target-negative stem cells restore the normal lymphocyte repertoire. Other examples of differential accessibility of antibody targets are carcinoembryonal antigen (CEA) and carboanhydrase IX (CA9). Both antigens are expressed on normal epithelia of colon and kidney, respectively. However, radioactively labeled imaging antibodies do distinguish well between tumor and normal tissue, and cytotoxic antibodies are well tolerated. This is most likely due to a restricted expression of CA9 and CEA on the luminal side of normal epithelial tissue where IgG antibodies do not have access. Also antigen epithelial cell adhesion molecule (Ep-CAM) belongs to this category. As a homotypic cell adhesion molecule for epithelial cells it is localized in the intercellular space. Intriguingly, whereas high-affinity anti-Ep-CAM antibodies are very toxic, intermediate-affinity antibodies are well tolerated. This suggests accessibility of the Ep-CAM target on normal cells but also indicates that kinetics of antibody binding may open a therapeutic window.

[0004] One possibility is that other epithelial cell-specific proteins involved in cell/cell adhesion may be also attractive for antibody approaches, since they may be barely accessible in well-structured epithelia to antibodies but become exposed on tumor cells. We therefore analyzed proteins involved in organizing epithelial tissue architecture for their suitability as targets for therapeutic antibodies. A protein, which particularly attracted our attention is claudin 18. The claudin 18 (CLD18) molecule (Genbank accession number: splice variant 1 (CLD18A1): NP_057453, NM_016369, and splice variant 2 (CLD18A2): NM_001002026, NP_001002026) is an integral transmembrane protein with a molecular weight of approximately 27,9/27,72 kD. Claudins are integral membrane proteins located within the tight junctions of epithelia and endothelia. Tight junctions organize a network of interconnected strands of intramembranous particles between adjacent cells. In tight junctions, occludin and claudins are the most prominent transmembrane protein components. Due to their strong intercellular adhesion properties they create a primary barrier to prevent and control the paracellular transport of solutes and restrict the lateral diffusion of membrane lipids and proteins to maintain cellular polarity. Tight junction forming proteins are critically involved in organizing epithelial tissue architecture. We assumed that such proteins may be barely accessible to antibodies in well-structured epithelia but become exposed on tumor cells. WO2004/047863 describes various tumors which express the splice variants of CLD18 in a tumor-specific manner. In addition WO2004/047863 describes antibodies which can be used for diagnosing these tumors.

[0005] CLD18 is a tetraspanin and has as such 4 hydrophobic regions. We have generated data indicating that CLD18 displays several different conformations, which may be selectively addressed by antibodies. One conformation (CLD18-Conformation-1) implies, that all four hydrophobic regions serve as regular transmembrane domains (TM) and two extracellular loops (loop1 embraced by hydrophobic region 1 and hydrophobic region 2; loop2 embraced by hydrophobic regions 3 and 4) are formed, as described for the vast majority of claudin family members. A second conformation (CLD18-Conformation-2) implies that, as described for PMP22, another member of the tetraspanin family (Taylor et al., J. Neurosc. Res. 62:15-27, 2000), that the second and third hydrophobic domains do not fully cross the plasma membrane so that portion (loopD3) in between the first and fourth transmembrane domain is extracellular. A third conformation (CLD18-Conformation-3) implies, a large extracellular domain with two internal hydrophobic regions embraced by the first and fourth hydrophobic region, which serve as regular transmembrane domains. Due to the presence of classical N-glycosylation site in loopD3 the Claudin-18 topology variants CLD18 topology-2-and CLD18 topology-3 harbour an additional extracellular N-glycosylation site.

[0006] Another level of complexity is added to CLD18 molecule by the presence of two different splice variants, which are described in mouse and in human (Niimi, Mol. Cell. Biol. 21:7380-90,2001). The splice variants CLD18A1 and CLD18A2 differ in the first 21 N-terminal amino acids, which comprise the first TM and loop1, whereas the primary protein sequence of the C-terminus is identical.

[0007] CLD18A1 is selectively expressed on normal lung and stomach epithelia, whereas CLD18A2 is expressed only on gastric cells (Niimi, Mol. Cell. Biol. 21:7380-90, 2001). Most importantly, CLD18A2 is restricted to the differentiated short-lived cells of stomach epithelium but is devoid from the gastric stem cell region. Using sensitive RT-PCR, we have shown that both variants are not detectable at all in any other normal human organ, but are robustly expressed in several cancer types including stomach, esophageal, pancreatic and lung tumors as well as human cancer cell lines. Expression is most prominent in the adenocarcinoma subtypes of these indications.

[0008] The molecular weight of the protein differs in some cancers and adjacent normal tissue. The higher molecular weight protein observed in healthy tissue can be transferred into the same molecular weight as observed in cancer by treating tissue lysates with the deglycosylating compound PNGase F. This suggests, that CLD18 is less N-glycosylated in cancer as compared to its normal tissue counterpart. This structural difference is likely to give rise to an altered epitope. A classical N-glycosylation motif is in position aa 116 within the loopD3 domain of the molecule.

[0009] The terms "CLD18" and "CLD18-variant" according to the invention shall encompass (i) CLD18-splice variants, (ii) CLD18-N-glycosylation variants, (iii) CLD18-conformation variants, (iv) CLD18-free and homotypically/heterotypically associated variants localized at intercellular tight junctions and (v) CLD18-cancer related and CLD18-non-cancer cell related variants.

[0010] The molecular and functional characteristics of CLD18 make this molecule a highly interesting target for antibody based cancer therapy. These are in particular (i) the absence of CLD18 from the vast majority of toxicity relevant normal tissues, (ii) the restriction of CLD18A2 variant expression to a dispensible cell population as differentiated gastric cells, which can be replenished by target-negative stem cells of the stomach, (iii) hints to potential differential glycosylation between normal and neoplastic cells, and (iv) the presence of different conformational topologies. Moreover, the role of CLD18 as tight junction protein may further contribute to a good therapeutic window. Because tumor cells express claudins but often do not form classical tight junctions by homotypic and heterotypic association of claudins as found in normal epithelial tissue, tumor cells may have a considerable pool of free claudin that is amenable to extracellular antibody binding and immunotherapy. It is possible that binding epitopes of claudins in healthy epithelium are shielded within tight junctions from the access by such antibodies. The object of the invention is to provide antibodies useful for therapy of diseases wherein CLD18 is expressed, such as tumor diseases. The antibodies described herein have also utility in diagnosing such diseases.

SUMMARY OF THE INVENTION

[0011] The present invention generally provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

[0012] In one aspect the invention relates to a monoclonal antibody having the ability of binding to CLD18A2 and mediating killing of cells expressing CLD18A2, wherein the antibody binds to an epitope localized on the CLD 8A2-loop1 or the CLD18A2-loopD3 and wherein killing is induced by binding of the antibody to CLD18A2 expressed by said cells, wherein the antibody mediates killing of cells by inducing complement dependent cytotoxicity (CDC) mediated lysis and/or antibody dependent cellular cytotoxicity (ADCC) mediated lysis.

In one aspect the invention relates to an antibody having the ability of binding to CLD18 and mediating killing of cells expressing CLD18. Preferably, the antibody binds to CLD18A1 and CLD18A2 and more preferably binds to CLD18A2 but not to CLD18A1. Preferably, antibodies of the invention bind to and are specific for loop1. In further preferred embodiments, the antibody of the invention binds to and is specific for loopD3 of CLD-conformation-2. The antibody may bind, for example, at or around a potential N-glycosylation site at position 116 within loopD3. The antibody may be specific for the unglycosylated form of the potential N-glycosylation site at position 116 within loopD3.

[0013] Killing of cells by the antibody of the invention is preferably induced by binding of the antibody to CLD18 expressed by said cells, more preferably by binding of the antibody to CLD18A2 expressed by said cells. In one embodiment, binding of the antibody of the invention to CLD18A1 expressed by said cells does not induce killing of said cells.

[0014] The cells expressing CLD18 are preferably cancer cells and are, in particular, selected from the group consisting of tumorigenic gastric, esophageal, pancreatic, lung, ovarian, colon, hepatic, head-neck, and gallbladder cancer cells.

[0015] Preferably the antibody of the invention mediates killing of cells by inducing complement dependent cytotoxicity (CDC) mediated lysis and/or antibody dependent cellular cytotoxicity (ADCC) mediated lysis.

[0016] In one embodiment the antibody of the invention does not induce CDC mediated lysis of cells.

[0017] Preferably, ADCC mediated lysis of cells takes place in the presence of effector cells, which in particular embodiments are selected from the group consisting of monocytes, mononuclear cells, NK cells and PMNs, and phagocytosis is by macrophages.

[0018] The antibody of the invention may be a monoclonal, chimeric, human, or humanized antibody, or a fragment of an antibody and may be selected from the group consisting of an IgG1, an IgG2, preferably IgG2a and IgG2b, an

IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody.

[0019] According to all aspects of the invention, CLD18 is preferably human CLD18, preferably human CLD18A2, and CLD 18A2 preferably has the amino acid sequence according to SEQ ID NO:2 and CLD18A1 preferably has the amino acid sequence according to SEQ ID NO:8.

[0020] In particular preferred embodiments, the antibody of the invention binds to native epitopes of CLD18 present on the surface of living cells. In further preferred embodiments, the antibody of the invention is specific for cancer cells, preferably stomach cancer cells.

[0021] In certain embodiments of the invention CLD18 is expressed on the surface of cells.

[0022] Antibodies of the invention may be obtained by a method comprising the step of immunizing an animal with a protein or peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 16, 18, 20, 21-23, and 26-31, or an immunogenic fragment thereof, or a nucleic acid or host cell expressing said protein or peptide, or immunogenic fragment thereof. Preferably, an antibody of the invention is specific for the aforementioned proteins, peptides or immunogenic fragments thereof.

[0023] The antibody of the invention is for example produced by a clone having the accession no. DSM ACC2737 (182-D1106-055), DSM ACC2738 (182-D1106-056), DSM ACC2739 (182-D1106-057), DSM ACC2740 (182-D1106-058), DSM ACC2741 (182-D1106-059), DSM ACC2742 (182-D1106-062), DSM ACC2743 (182-D1106-067), DSM ACC2745 (182-D758-035), DSM ACC2746 (182-D758-036), DSM ACC2747 (182-D758-040), DSM ACC2748 (182-D1106-061), DSM ACC2808 (182-D1106-279), DSM ACC2809 (182-D1106-294), or DSM ACC2810 (182-D1106-362).

[0024] In one aspect, the antibody of the invention comprises one or more of the complementarity-determining regions (CDRs), preferably at least the CDR3, of the heavy chain variable region (VH) and/or of the light chain variable region (VL) of an antibody which comprises a combination of VH and VL each comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (ix):

(i) VH: CDR1: positions 45-52 of SEQ ID NO: 115, CDR2: positions 70-77 of SEQ ID NO: 115, CDR3: positions 116-125 of SEQ ID NO: 115, VL: CDR1: positions 49-53 of SEQ ID NO: 122, CDR2: positions 71-73 of SEQ ID NO: 122, CDR3: positions 110-118 of SEQ ID NO: 122,

(ii) VH: CDR1: positions 45-52 of SEQ ID NO: 116, CDR2: positions 70-77 of SEQ ID NO: 116, CDR3: positions 116-126 of SEQ ID NO: 116, VL: CDR1: positions 47-58 of SEQ ID NO: 121, CDR2: positions 76-78 of SEQ ID NO: 121, CDR3: positions 115-123 of SEQ ID NO: 121,

(iii) VH: CDR1: positions 45-52 of SEQ ID NO: 117, CDR2: positions 70-77 of SEQ ID NO: 117, CDR3: positions 116-124 of SEQ ID NO: 117, VL: CDR1: positions 47-52 of SEQ ID NO: 123, CDR2: positions 70-72 of SEQ ID NO: 123, CDR3: positions 109-117 of SEQ ID NO: 123,

(iv) VH: CDR1: positions 44-51 of SEQ ID NO: 119, CDR2: positions 69-76 of SEQ ID NO: 119, CDR3: positions 115-125 of SEQ ID NO: 119, VL: CDR1: positions 47-58 of SEQ ID NO: 126, CDR2: positions 76-78 of SEQ ID NO: 126, CDR3: positions 115-122 of SEQ ID NO: 126,

(v) VH: CDR1: positions 45-52 of SEQ ID NO: 118, CDR2: positions 70-77 of SEQ ID NO: 118, CDR3: positions 116-126 of SEQ ID NO: 118, VL: CDR1: positions 47-58 of SEQ ID NO: 125, CDR2: positions 76-78 of SEQ ID NO: 125, CDR3: positions 115-123 of SEQ ID NO: 125,

(vi) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 124, CDR2: positions 76-78 of SEQ ID NO: 124, CDR3: positions 115-123 of SEQ ID NO: 124,

(vii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 127, CDR2: positions 76-78 of SEQ ID NO: 127, CDR3: positions 115-123 of SEQ ID NO: 127,

(viii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 128, CDR2: positions 76-78 of SEQ ID NO: 128, CDR3: positions 115-123 of SEQ ID NO: 128, and

(ix) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-52 of SEQ ID NO: 129, CDR2: positions 70-72 of SEQ ID NO: 129, CDR3: positions 109-117 of SEQ ID NO: 129.

[0025] In another aspect, the antibody of the invention comprises a VH comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (vi):

(i) CDR1: positions 45-52 of SEQ ID NO: 115, CDR2: positions 70-77 of SEQ ID NO: 115, CDR3: positions 116-125 of SEQ ID NO: 115,

(ii) CDR1: positions 45-52 of SEQ ID NO: 116, CDR2: positions 70-77 of SEQ ID NO: 116, CDR3: positions 116-126 of SEQ ID NO: 116,

- (iii) CDR1: positions 45-52 of SEQ ID NO: 117, CDR2: positions 70-77 of SEQ ID NO: 117, CDR3: positions 116-124 of SEQ ID NO: 117,
- (iv) CDR1: positions 45-52 of SEQ ID NO: 118, CDR2: positions 70-77 of SEQ ID NO: 118, CDR3: positions 116-126 of SEQ ID NO: 118,
- (v) CDR1: positions 44-51 of SEQ ID NO: 119, CDR2: positions 69-76 of SEQ ID NO: 119, CDR3: positions 115-125 of SEQ ID NO: 119, and
- (vi) CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120.

[0026] In another aspect, the antibody of the invention comprises a VL comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (ix):

- (i) CDR1: positions 47-58 of SEQ ID NO: 121, CDR2: positions 76-78 of SEQ ID NO: 121, CDR3: positions 115-123 of SEQ ID NO: 121,
- (ii) CDR1: positions 49-53 of SEQ ID NO: 122, CDR2: positions 71-73 of SEQ ID NO: 122, CDR3: positions 110-118 of SEQ ID NO: 122,
- (iii) CDR1: positions 47-52 of SEQ ID NO: 123, CDR2: positions 70-72 of SEQ ID NO: 123, CDR3: positions 109-117 of SEQ ID NO: 123,
- (iv) CDR1: positions 47-58 of SEQ ID NO: 124, CDR2: positions 76-78 of SEQ ID NO: 124, CDR3: positions 115-123 of SEQ ID NO: 124,
- (v) CDR1: positions 47-58 of SEQ ID NO: 125, CDR2: positions 76-78 of SEQ ID NO: 125, CDR3: positions 115-123 of SEQ ID NO: 125,
- (vi) CDR1: positions 47-58 of SEQ ID NO: 126, CDR2: positions 76-78 of SEQ ID NO: 126, CDR3: positions 115-122 of SEQ ID NO: 126,
- (vii) CDR1: positions 47-58 of SEQ ID NO: 127, CDR2: positions 76-78 of SEQ ID NO: 127, CDR3: positions 115-123 of SEQ ID NO: 127,
- (viii) CDR1: positions 47-58 of SEQ ID NO: 128, CDR2: positions 76-78 of SEQ ID NO: 128, CDR3: positions 115-123 of SEQ ID NO: 128, and
- (ix) CDR1: positions 47-52 of SEQ ID NO: 129, CDR2: positions 70-72 of SEQ ID NO: 129, CDR3: positions 109-117 of SEQ ID NO: 129.

[0027] In another aspect, the antibody of the invention comprises a combination of VH and VL each comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (ix):

- (i) VH: CDR1: positions 45-52 of SEQ ID NO: 115, CDR2: positions 70-77 of SEQ ID NO: 115, CDR3: positions 116-125 of SEQ ID NO: 115, VL: CDR1: positions 49-53 of SEQ ID NO: 122, CDR2: positions 71-73 of SEQ ID NO: 122, CDR3: positions 110-118 of SEQ ID NO: 122,
- (ii) VH: CDR1: positions 45-52 of SEQ ID NO: 116, CDR2: positions 70-77 of SEQ ID NO: 116, CDR3: positions 116-126 of SEQ ID NO: 116, VL: CDR1: positions 47-58 of SEQ ID NO: 121, CDR2: positions 76-78 of SEQ ID NO: 121, CDR3: positions 115-123 of SEQ ID NO: 121,
- (iii) VH: CDR1: positions 45-52 of SEQ ID NO: 117, CDR2: positions 70-77 of SEQ ID NO: 117, CDR3: positions 116-124 of SEQ ID NO: 117, VL: CDR1: positions 47-52 of SEQ ID NO: 123, CDR2: positions 70-72 of SEQ ID NO: 123, CDR3: positions 109-117 of SEQ ID NO: 123,
- (iv) VH: CDR1: positions 44-51 of SEQ ID NO: 119, CDR2: positions 69-76 of SEQ ID NO: 119, CDR3: positions 115-125 of SEQ ID NO: 119, VL: CDR1: positions 47-58 of SEQ ID NO: 126, CDR2: positions 76-78 of SEQ ID NO: 126, CDR3: positions 115-122 of SEQ ID NO: 126,
- (v) VH: CDR1: positions 45-52 of SEQ ID NO: 118, CDR2: positions 70-77 of SEQ ID NO: 118, CDR3: positions 116-126 of SEQ ID NO: 118, VL: CDR1: positions 47-58 of SEQ ID NO: 125, CDR2: positions 76-78 of SEQ ID NO: 125, CDR3: positions 115-123 of SEQ ID NO: 125,
- (vi) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 124, CDR2: positions 76-78 of SEQ ID NO: 124, CDR3: positions 115-123 of SEQ ID NO: 124,
- (vii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 127, CDR2: positions 76-78 of SEQ ID NO: 127, CDR3: positions 115-123 of SEQ ID NO: 127,
- (viii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 128, CDR2: positions 76-78 of SEQ ID NO: 128, CDR3: positions 115-123 of SEQ ID NO: 128, and

(ix) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-52 of SEQ ID NO: 129, CDR2: positions 70-72 of SEQ ID NO: 129, CDR3: positions 109-117 of SEQ ID NO: 129.

[0028] In another aspect, the antibody of the invention comprises a heavy chain variable region (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 132, 133, 134, 135, 136, 137, and a fragment thereof.

[0029] In another aspect, the antibody of the invention comprises a light chain variable region (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 138, 139, 140, 141, 142, 143, 144, 145, 146, and a fragment thereof.

[0030] In another aspect, the antibody of the invention comprises a combination of heavy chain variable region (VH) and light chain variable region (VL) selected from the following possibilities (i) to (ix):

- (i) the VH comprises an amino acid sequence represented by SEQ ID NO: 132 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 139 or a fragment thereof,
- (ii) the VH comprises an amino acid sequence represented by SEQ ID NO: 133 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 138 or a fragment thereof,
- (iii) the VH comprises an amino acid sequence represented by SEQ ID NO: 134 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 140 or a fragment thereof,
- (iv) the VH comprises an amino acid sequence represented by SEQ ID NO: 136 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 143 or a fragment thereof,
- (v) the VH comprises an amino acid sequence represented by SEQ ID NO: 135 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 142 or a fragment thereof,
- (vi) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 141 or a fragment thereof,
- (vii) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 144 or a fragment thereof,
- (viii) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 145 or a fragment thereof,
- (ix) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 146 or a fragment thereof.

[0031] In another aspect, the antibody of the invention comprises

- (i) a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 115, 116, 117, 118, 119, 120, and a fragment thereof and/or
- (ii) a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 121, 122, 123, 124, 125, 126, 127, 128, 129, and a fragment thereof.

[0032] In another aspect, the antibody of the invention comprises a combination of heavy chains and light chains selected from the following possibilities (i) to (ix):

- (i) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 115 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 122 or a fragment thereof,
- (ii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 116 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 121 or a fragment thereof,
- (iii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 117 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 123 or a fragment thereof,
- (iv) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 119 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 126 or a fragment thereof,
- (v) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 118 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 125 or a fragment thereof,
- (vi) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 124 or a fragment thereof,
- (vii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 127 or a fragment thereof,
- (viii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 128 or a fragment thereof, and

(ix) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 129 or a fragment thereof.

[0033] In one embodiment the antibody of the invention is coupled to a therapeutic agent such as a toxin, a radioisotope, a drug or a cytotoxic agent.

[0034] In a further aspect the invention relates to a hybridoma capable of producing the antibody of the invention. Antibodies of the invention are designated herein by referring to the designation of the antibody, e.g. 182-D758-035, and/or by referring to the clone producing the antibody, e.g. 26D12.

[0035] The invention also relates to a pharmaceutical composition comprising an antibody of the invention and/or a conjugate thereof with a therapeutic agent, and a pharmaceutically acceptable carrier.

[0036] In a further aspect the invention relates to a method of inhibiting growth and/or killing of a cell expressing CLD18, preferably CLD18A2, comprising contacting the cell with an effective amount of an antibody of the invention and/or a conjugate thereof with a therapeutic agent. CLD18 is preferably expressed on the surface of said cell.

[0037] In a further aspect the invention relates to a method of treating or preventing a disease or disorder involving cells expressing CLD18A2, comprising administering to a subject an antibody of the invention, a conjugate thereof with a therapeutic agent, or a pharmaceutical composition comprising the antibody of the invention or the conjugate thereof with a therapeutic agent. Preferably the disease or disorder is a tumor-related disease and in particular embodiments is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. CLD18A2 is preferably expressed on the surface of said cells. Antibodies may have the ability to discriminate CLD18-variants expressed by different cell types including cancer cells and non-malignant cells. In a particularly preferred embodiment, the antibodies of the invention have the ability to bind to CLD18A2 while they do not bind to CLD18A1. Antibodies may bind to CLD18A1 with a lower specificity compared to the binding specificity to CLD18A2.

[0038] The term "binding" according to the invention preferably relates to a specific binding. "Specific binding" means that an agent such as an antibody binds stronger to a target such as an epitope for which it is specific compared to the binding to another target. An agent binds stronger to a first target compared to a second target if it binds to the first target with a dissociation constant (K_D) which is lower than the dissociation constant for the second target. Preferably the dissociation constant (K_D) for the target to which the agent binds specifically is more than 10-fold, preferably more than 20-fold, more preferably more than 50-fold, even more preferably more than 100-fold, 200-fold, 500-fold or 1000-fold lower than the dissociation constant (K_D) for the target to which the agent does not bind specifically.

[0039] The antibodies of the invention mediate killing of cells expressing CLD18, preferably CLD18A2, by binding to CLD18, preferably expressed on the surface of said cells. In one embodiment, antibodies of the invention induce complement dependent cytotoxicity (CDC), e.g. at least about 20-40% CDC mediated lysis, preferably about 40-50% CDC mediated lysis, and more preferably more than 50 % CDC mediated lysis of cells expressing CLD18. Such antibodies are exemplified herein by the following antibodies: 37H8, 38G5, 38H3, 39F11, 61C2, 26B5, 26D12, 28D10, 163E12, 175D10, 45C1, 125E1, ch-163E12, and ch-175D10. Alternatively or in addition to inducing CDC, antibodies of the invention may induce antibody dependent cellular cytotoxicity (ADCC) of cells expressing CLD18 in the presence of effector cells (e.g., monocytes, mononuclear cells, NK cells and PMNs). Such antibodies are exemplified herein by the following antibodies: 37G11, 37H8, 38G5, 38H3, 39F11, 43A11, 61C2, 26B5, 26D12, 28D10, 42E12, 163E12, 175D10, 45C1, and 125E1. Antibodies of the invention may have the ability to induce apoptosis of cells expressing CLD18, induce homotypic adhesion of cells expressing CLD18 and/or induce phagocytosis of cells expressing CLD18 in the presence of macrophages. The antibodies of the invention may have one or more of the above described functional properties. Preferably, antibodies of the invention induce CDC mediated lysis and ADCC mediated lysis of cells expressing CLD18 and more preferably induce ADCC mediated lysis of cells expressing CLD18 while they do not induce CDC mediated lysis of said cells. Exemplary target cells for antibodies of the present invention include, but are not limited to, cancer cells expressing CLD18, preferably CLD18A2, such as tumorigenic gastric, pancreatic, esophageal and lung cancer cells. In a particular preferred embodiment, killing of cells mediated by antibodies of the invention is CLD18A2 specific, i.e. antibodies of the invention mediate killing of cells, preferably CDC and/or ADCC mediated lysis of cells, expressing CLD18A2 but do not mediate killing of cells expressing CLD18A1 but not expressing CLD18A2. The antibodies described above may be used to mediate killing of tumor cells in the treatment or prevention of cancer such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

[0040] Antibodies of the invention may be categorized into distinct classes according to their binding properties and their ability to mediate effector function on cells expressing CLD18. The antibodies of the invention may be categorized according to their

- binding properties to and/or effector functions mediated on cells expressing either CLD18A1 or CLD18A2 (discrimination of CLD18 splice variants),

EP 2 311 877 B1

- binding properties to and/or effector functions mediated on cells expressing either glycosylated or non-glycosylated CLD18 variants (discrimination between CLD18-variants with and without N-glycosylation),
- binding properties to and/or effector functions mediated on either cancer cells or normal cell types (discrimination between CLD18-variants expressed by tumor cells or normal nonmalignant cells).
- binding properties to CLD18-epitopes masked by the formation of tight junctions,
- abilities to induce aggregate formation of CLD18 on living cells, and
- abilities to bind a non-human CLD18 variant, particularly CLD18 variants from mice, rats, rabbits and primates.

[0041] Antibodies of the invention may have one or more of the following properties whereby reference is given to specific examples of antibodies of the invention described herein (24H5, 26B5, 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, 61C2, 75B8, 85A3, 9E8, 19B9, 45C1, 125E1, 163E12, 166E2, 175D10, ch-43A11 ch-45C1, ch-125E1, ch-163E12, ch-166E2, ch-175D10):

- a) binding to CLD18A2 as well as to CLD18A1 (e.g. 26D12, 28D10, 37H8, 38H3, 39F11, 61C2, and 41C6)
- b) binding to CLD18A2 but not to CLD18A1 (e.g. 26B5, 37G11, 38G5, 42E12, and 43A11, 45C1, 125E1, 163E12, 166E2, 175D10, ch-43A11, ch-45C1, ch-125E1, ch-163E12, ch-166E2, ch-175D10)
- c) binding to CLD18 naturally expressed by tumor cells but not to CLD18 naturally expressed by non-cancer cells or tissues such as cells of stomach and lung (e.g. 26B5, 75B8, 24H5, 39F11, 45C1, 125E1, 163E12, 166E2, 175D10).
- d) mediating CDC induced killing of cells, which express CLD18A2 but not of cells which express CLD18A1 (e.g. 26D12, 28D10, 37H8, and 39F11, 163E12, ch-125E1, ch-163E12, ch-175D10)
- e) mediating ADCC induced killing of cells expressing CLD18 (e.g. 26B5, 37G11, 37H8, 38G5, 38H3, 39F11, 43A11, 47D12, and 61C2, ch-163E12, ch-175D10)
- f) mediating ADCC induced killing but not CDC mediated killing of cells expressing CLD18 (e.g. 37G11, 42E12, and 43A11)
- g) mediating ADCC induced killing and CDC induced killing of cells expressing CLD18A2 (e.g. 37H8, 38H3, 39F11, ch-163E12, ch-175D10).

[0042] As exemplified herein, antibodies of the invention further encompasses molecules, which

- a) bind to differentiated cells of normal stomach, but not to stem cells of stomach (e.g. 39F11)
- b) do not bind to normal gastric tissue as well as other normal organs but exclusively to cancer cells (e.g. 26B5)
- c) bind to an epitope encompassing a non-glycosylated Asn at position 116 of CLD18
- d) which bind to human as well as to mouse CLD18 allowing to thoroughly perform preclinical toxicity studies in mice.

[0043] Antibodies of the invention may be derived from different species, including but not limited to mouse, rat, rabbit, guinea pig and human. Antibodies of the invention also include chimeric molecules in which an antibody constant region derived from one species, preferably human, is combined with the antigen binding site derived from another species. Moreover antibodies of the invention include humanized molecules in which the antigen binding sites of an antibody derived from a non-human species are combined with constant and framework regions of human origin.

[0044] Antibodies of the invention include polyclonal and monoclonal antibodies and include IgG2a (e.g. IgG2a, λ), IgG2b (e.g. IgG2b, λ), IgG3 (e.g. IgG3, λ) and IgM antibodies. However, other antibody isotypes are also encompassed by the invention, including IgG1, IgA1, IgA2, secretory IgA, IgD, and IgE antibodies. The antibodies can be whole antibodies or antigen-binding fragments thereof including, for example, Fab, F(ab')₂, Fv, single chain Fv fragments or bispecific antibodies. Furthermore, the antigen-binding fragments include binding-domain immunoglobulin fusion proteins comprising (i) a binding domain polypeptide (such as a heavy chain variable region or a light chain variable region) that is fused to an immunoglobulin hinge region polypeptide, (ii) an immunoglobulin heavy chain CH2 constant region fused to the hinge region, and (iii) an immunoglobulin heavy chain CH3 constant region fused to the CH2 constant region. Such binding-domain immunoglobulin fusion proteins are further disclosed in US2003/0118592 and US 2003/0133939.

[0045] Antibodies of the present invention preferably dissociate from CLD18 with a dissociation equilibrium constant (KD) of approximately 1-100nM or less. Preferably, Antibodies of the invention do not cross-react with related cell-surface antigens and thus do not inhibit their function.

[0046] In preferred embodiments, antibodies of the present invention can be characterized by one or more of the following properties:

- a) specificity for CLD18, in particular specificity for CLD18A2;
- b) a binding affinity to CLD18, in particular CLD18A2, of about 100 nM or less, preferably, about 5-10 nM or less and, more preferably, about 1-3 nM or less,
- c) the ability to mediate a high level of CDC on either CD55/59 negative or CD55/59 positive cells;
- 5 d) the ability to inhibit the growth of cells which express CLD18;
- e) the ability to induce apoptosis of cells which express CLD18;
- f) the ability to induce homotypic adhesion of cells which express CLD18;
- g) the ability to induce ADCC of cells which express CLD18 in the presence of effector cells;
- h) the ability to prolong survival of a subject having tumor cells which express CLD18;
- 10 i) the ability to deplete cells which express CLD18;
- j) the ability to deplete cells which express low levels of CLD18 and/or
- k) the ability to aggregate CLD18 on the surface of living cells

[0047] The anti-CLD18 antibodies of the present invention can be derivatized, linked to or co-expressed to other binding specificities. In a particular embodiment, the invention discloses a bispecific or multispecific molecule comprising at least one first binding specificity for CLD18 (e.g., an anti-CLD18 antibody or mimetic thereof), and a second binding specificity for a effector cell, such as a binding specificity for an Fc receptor (e.g., a Fc-gamma receptor, such as Fc-gamma RI, or any other Fc receptor) or a T cell receptor, e.g., CD3.

[0048] Accordingly, the present invention discloses bispecific and multispecific molecules that bind to both CLD18 and to an Fc receptor or a T cell receptor, e.g. CD3. Examples of Fc receptors are IgG receptor, Fc-gamma receptor (FcγR), such as FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16). Other Fc receptors, such as IgA receptors (e.g., FcαRI), also can be targeted. The Fc receptor is preferably located on the surface of an effector cell, e.g., a monocyte, macrophage or an activated mononuclear cell. In a preferred embodiment, the bispecific and multispecific molecules bind to an Fc receptor at a site which is distinct from the immunoglobulin Fc (e.g., IgG or IgA) binding site of the receptor. Therefore, the binding of the bispecific and multispecific molecules is not blocked by physiological levels of immunoglobulins.

[0049] The anti-CLD18 antibodies of the invention may be derivatized, linked to or co-expressed with another functional molecule, e.g., another peptide or protein (e.g., a Fab' fragment). For example, an antibody of the invention can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g. to produce a bispecific or a multispecific antibody), a cytotoxin, cellular ligand or antigen (e.g. to produce an immunoconjugate, such as an immunotoxin). An antibody of the present invention can be linked to other therapeutic moieties, e.g., a radioisotope, a small molecule anti-cancer drug, a recombinant cytokine or chemokine. Accordingly, the present invention discloses a large variety of antibody conjugates, bispecific and multispecific molecules, and fusion proteins, all of which bind to CLD18 expressing cells and which can be used to target other molecules to such cells.

[0050] In still another aspect, the invention provides compositions, e.g., pharmaceutical and discloses diagnostic compositions/kits, comprising a pharmaceutically acceptable carrier formulated along with one or a combination of antibodies of the invention. In a particular embodiment, the composition includes a combination of antibodies which bind to distinct epitopes or which possess distinct functional characteristics, such as inducing CDC and/or ADCC and inducing apoptosis. In this embodiment of the invention, antibodies may be used in combination, e. g., as a pharmaceutical composition comprising two or more anti-CLD18 monoclonal antibodies. For example, anti-CLD18 antibodies having different but complementary activities can be combined in a single therapy to achieve a desired therapeutic effect. The composition may include an anti-CLD18 antibody that mediates CDC combined with another anti-CLD18 antibody that induces apoptosis. Alternatively, the composition may include an anti-CLD18 antibody that mediates highly effective killing of target cells in the presence of effector cells, combined with another anti-CLD18 antibody that inhibits the growth of cells expressing CLD18.

[0051] The present disclosure also includes the simultaneous or sequential administration of two or more anti-CLD18 antibodies of the invention, wherein at least one of said antibodies is a chimeric anti-CLD18 antibody and at least one further antibody is a human anti-CLD18 antibody, the antibodies binding to the same or different epitopes of CLD18. Preferably, a chimeric CLD18 antibody of the invention is administered first followed by the administration of a human anti-CLD18 antibody of the invention, wherein the human anti-CLD18 antibody is preferably administered for an extended period of time, i.e. as maintenance therapy.

[0052] Antibodies, immunoconjugates, bispecific and multispecific molecules and compositions of the present invention can be used in a variety of methods for inhibiting growth of cells expressing CLD18, in particular CLD18A2 and/or selectively killing cells expressing CLD18, in particular CLD18A2 by contacting the cells with an effective amount of the antibody, immunoconjugate, bispecific/multispecific molecule or composition, such that the growth of the cell is inhibited and/or the cell is killed. In one embodiment, the method includes killing of the cell expressing CLD18, optionally in the presence of effector cells, for example, by CDC, apoptosis, ADCC, phagocytosis, or by a combination of two or more

of these mechanisms. Cells expressing CLD18 which can be inhibited or killed using the antibodies of the invention include cancer cells such as tumorigenic stomach, pancreatic, esophageal, lung, ovarian, colon, hepatic, head-neck, and gallbladder cells.

[0053] Accordingly, antibodies of the present invention can be used to treat and/or prevent a variety of diseases involving cells expressing CLD18 by administering the antibodies to patients suffering from such diseases. Exemplary diseases that can be treated (e.g., ameliorated) or prevented include, but are not limited to, tumorigenic diseases. Examples of tumorigenic diseases, which can be treated and/or prevented include gastric cancer, pancreatic cancer, esophageal cancer, lung cancer, ovarian cancer, colorectal cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

[0054] The subject being administered the antibody of the invention, may additionally be treated with a chemotherapeutic agent, radiation, or an agent that modulates, e.g., enhances or inhibits, the expression or activity of an Fc receptor, e.g. an Fc-gamma receptor, such as a cytokine. Typical cytokines for administration during treatment include granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon- γ (IFN- γ), and tumor necrosis factor (TNF). Typical therapeutic agents include, among others, antineoplastic agents such as doxorubicin, cisplatin, taxotere, 5-fluoruracil, methotrexat, gemcitabin and cyclophosphamide.

[0055] Also disclosed herein is an immunization strategy to immunize non-human animals such as mice with human CLD18 or a peptide fragment thereof, preferably CLD18A2 or a peptid fragment thereof to obtain antibodies. Preferred peptides for immunization are those selected from the group consisting of SEQ ID NO:2, 4, 6, 16, 18, 20-23, and 26-31. Accordingly, in preferred embodiments, the antibodies of the invention are those obtained by immunization using peptides selected from the group consisting of SEQ ID NO: 2, 4, 6, 16, 18, 20-23, and 26-31. Analogously, antibodies to CLD18 can be generated in a transgenic non-human animal, such as a transgenic mouse. The transgenic non-human animal may be a transgenic mouse having a genome comprising a heavy chain transgene and a light chain transgene encoding all or a portion of an antibody.

[0056] Wildtype as well as transgenic non-human animals can be immunized with a purified or enriched preparation of CLD18 antigen and/or nucleic acids and/or cells expressing CLD18 or a peptide fragment thereof. Preferably, the non-human animal, is capable of producing multiple isotypes of human monoclonal antibodies to CLD18 (e.g., IgG, IgA and/or IgM) by undergoing V-D-J recombination and isotype switching. Isotype switching may occur by e.g., classical or non-classical isotype switching.

[0057] Isolated B cells from a non-human animal as described above can be immortalized by fusion to an immortalized cell to provide a source (e.g., a hybridoma) of antibodies of the invention. Such hybridomas (i.e., which produce antibodies of the invention) are also included within the scope of the invention.

[0058] As exemplified herein, antibodies of the invention can be obtained directly from hybridomas which express the antibody, or can be cloned and recombinantly expressed in a host cell (e.g., a CHO cell, or a lymphocytic cell). Further examples of host cells are microorganisms, such as E. coli, and fungi, such as yeast. Alternatively, they can be produced recombinantly in a transgenic non-human animal or plant.

[0059] Hybridoma cells for producing antibodies of the invention are for example those sequenced or deposited at the DSMZ (Mascheroder Weg 1b, 31824 Braunschweig, Germany; new address: Inhoffenstr. 7B, 31824 Braunschweig, Germany) having the following designations and accession numbers:

- a. 182-D1106-055, accesssion no. DSM ACC2737, deposited on October 19, 2005
- b. 182-D1106-056, accesssion no. DSM ACC2738, deposited on October 19, 2005
- c. 182-D1106-057, accesssion no. DSM ACC2739, deposited on October 19, 2005
- d. 182-D1106-058, accesssion no. DSM ACC2740, deposited on October 19, 2005
- e. 182-D1106-059, accesssion no. DSM ACC2741, deposited on October 19, 2005
- f. 182-D1106-062, accesssion no. DSM ACC2742, deposited on October 19, 2005,
- g. 182-D1106-067, accesssion no. DSM ACC2743, deposited on October 19, 2005
- h. 182-D758-035, accesssion no. DSM ACC2745, deposited on Nov. 17, 2005
- i. 182-D758-036, accesssion no. DSM ACC2746, deposited on Nov. 17, 2005
- j. 182-D758-040, accesssion no. DSM ACC2747, deposited on Nov. 17, 2005
- k. 182-D1106-061, accesssion no. DSM ACC2748, deposited on Nov. 17, 2005
- l. 182-D1106-279, accesssion no. DSM ACC2808, deposited on Oct. 26, 2006
- m. 182-D1106-294, accesssion no. DSM ACC2809, deposited on Oct. 26, 2006,
- n. 182-D1106-362, accesssion no. DSM ACC2810, deposited on Oct. 26, 2006.

[0060] Preferred antibodies of the invention are those produced by and obtainable from the above-described hybridomas; i.e. 37G11 in the case of 182-D1106-055, 37H8 in the case of 182-D1106-056, 38G5 in the case of 182-D1106-057, 38H3 in the case of 182-D1106-058, 39F11 in the case of 182-D1106-059, 43A11 in the case of 182-D1106-062, 61C2 in the case of 182-D1106-067, 26B5 in the case of 182-D758-035, 26D12 in the case of 182-D758-036, 28D10 in the

case of 182-D758-040, 42E12 in the case of 182-D1106-061, 125E1 in the case of 182-D1106-279, 163E12 in the case of 182-D1106-294, and 175D10 in the case of 182-D1106-362; and the chimerized and humanized forms thereof.

[0061] In preferred embodiments, antibodies, in particular chimerised forms of antibodies according to the invention include antibodies comprising a heavy chain constant region (CH) comprising an amino acid sequence derived from a human heavy chain constant region such as the amino acid sequence represented by SEQ ID NO: 46 or 150 or a fragment thereof. In further preferred embodiments, antibodies, in particular chimerised forms of antibodies according to the invention include antibodies comprising a light chain constant region (CL) comprising an amino acid sequence derived from a human light chain constant region such as the amino acid sequence represented by SEQ ID NO: 41 or 148 or a fragment thereof. In a particular preferred embodiment, antibodies, in particular chimerised forms of antibodies according to the invention include antibodies which comprise a CH comprising an amino acid sequence derived from a human CH such as the amino acid sequence represented by SEQ ID NO: 46 or 150 or a fragment thereof and which comprise a CL comprising an amino acid sequence derived from a human CL such as the amino acid sequence represented by SEQ ID NO: 41 or 148 or a fragment thereof.

[0062] A CH comprising the amino acid sequence represented by SEQ ID NO: 46 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 45. A CH comprising the amino acid sequence represented by SEQ ID NO: 150 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 149. A CL comprising the amino acid sequence represented by SEQ ID NO: 41 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 40. A CL comprising the amino acid sequence represented by SEQ ID NO: 148 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 147.

[0063] In certain preferred embodiments, chimerised forms of antibodies include antibodies comprising a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 115, 116, 117, 118, 119, 120, and a fragment thereof and/or comprising a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 121, 122, 123, 124, 125, 126, 127, 128, 129, and a fragment thereof.

[0064] In certain preferred embodiments, chimerised forms of antibodies include antibodies comprising a combination of heavy chains and light chains selected from the following possibilities (i) to (ix):

- (i) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 115 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 122 or a fragment thereof,
- (ii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 116 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 121 or a fragment thereof,
- (iii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 117 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 123 or a fragment thereof,
- (iv) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 119 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 126 or a fragment thereof,
- (v) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 118 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 125 or a fragment thereof,
- (vi) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 124 or a fragment thereof,
- (vii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 127 or a fragment thereof,
- (viii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 128 or a fragment thereof, and
- (ix) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 129 or a fragment thereof.

[0065] "Fragment" or "fragment of an amino acid sequence" as used above relates to a part of an antibody sequence, i.e. a sequence which represents the antibody sequence shortened at the N- and/or C-terminus, which when it replaces said antibody sequence in an antibody retains binding of said antibody to CLD18 and preferably functions of said antibody as described herein, e.g. CDC mediated lysis or ADCC mediated lysis. Preferably, a fragment of an amino acid sequence comprises at least 80%, preferably at least 90%, 95%, 96%, 97%, 98%, or 99% of the amino acid residues from said amino acid sequence. A fragment of an amino acid sequence selected from the group consisting of SEQ ID NO: 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, and 129 preferably relates to said sequence wherein 17, 18, 19, 20, 21, 22 or 23 amino acids at the N-terminus are removed. Fragments of amino acid sequences described herein may be encoded by respective fragments of nucleic acid sequences encoding said amino acid sequences.

[0066] A heavy chain comprising an amino acid sequence represented by SEQ ID NO: 115 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 100. A heavy chain comprising an amino acid sequence represented by SEQ ID NO: 116 may be encoded by a nucleic acid comprising the nucleic acid sequence

represented by SEQ ID NO: 101. A heavy chain comprising an amino acid sequence represented by SEQ ID NO: 117 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 102. A heavy chain comprising an amino acid sequence represented by SEQ ID NO: 119 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 104. A heavy chain comprising an amino acid sequence represented by SEQ ID NO: 118 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 103. A heavy chain comprising an amino acid sequence represented by SEQ ID NO: 120 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 105.

[0067] A light chain comprising an amino acid sequence represented by SEQ ID NO: 122 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 107. A light chain comprising an amino acid sequence represented by SEQ ID NO: 121 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 106. A light chain comprising an amino acid sequence represented by SEQ ID NO: 123 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 108. A light chain comprising an amino acid sequence represented by SEQ ID NO: 126 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 111. A light chain comprising an amino acid sequence represented by SEQ ID NO: 125 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 110. A light chain comprising an amino acid sequence represented by SEQ ID NO: 124 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 109. A light chain comprising an amino acid sequence represented by SEQ ID NO: 127 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 112. A light chain comprising an amino acid sequence represented by SEQ ID NO: 128 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 113. A light chain comprising an amino acid sequence represented by SEQ ID NO: 129 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 114.

[0068] In a preferred embodiment, an antibody of the invention comprises a heavy chain variable region (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 132, 133, 134, 135, 136, 137, and a fragment thereof.

[0069] In a preferred embodiment, an antibody of the invention comprises a light chain variable region (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 138, 139, 140, 141, 142, 143, 144, 145, 146, and a fragment thereof.

[0070] In certain preferred embodiments, an antibody of the invention comprises a combination of heavy chain variable region (VH) and light chain variable region (VL) selected from the following possibilities (i) to (ix):

- (i) the VH comprises an amino acid sequence represented by SEQ ID NO: 132 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 139 or a fragment thereof,
- (ii) the VH comprises an amino acid sequence represented by SEQ ID NO: 133 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 138 or a fragment thereof,
- (iii) the VH comprises an amino acid sequence represented by SEQ ID NO: 134 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 140 or a fragment thereof,
- (iv) the VH comprises an amino acid sequence represented by SEQ ID NO: 136 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 143 or a fragment thereof,
- (v) the VH comprises an amino acid sequence represented by SEQ ID NO: 135 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 142 or a fragment thereof,
- (vi) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 141 or a fragment thereof,
- (vii) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 144 or a fragment thereof,
- (viii) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 145 or a fragment thereof,
- (ix) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 146 or a fragment thereof.

[0071] A VH comprising an amino acid sequence represented by SEQ ID NO: 132 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 55. A VH comprising an amino acid sequence represented by SEQ ID NO: 133 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 56. A VH comprising an amino acid sequence represented by SEQ ID NO: 134 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 57. A VH comprising an amino acid sequence represented by SEQ ID NO: 136 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 59. A VH comprising an amino acid sequence represented by SEQ ID NO: 135 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 58. A VH comprising an

amino acid sequence represented by SEQ ID NO: 137 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 60.

[0072] A VL comprising an amino acid sequence represented by SEQ ID NO: 139 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 62. A VL comprising an amino acid sequence represented by SEQ ID NO: 138 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 61. A VL comprising an amino acid sequence represented by SEQ ID NO: 140 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 63. A VL comprising an amino acid sequence represented by SEQ ID NO: 143 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 66. A VL comprising an amino acid sequence represented by SEQ ID NO: 142 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 65. A VL comprising an amino acid sequence represented by SEQ ID NO: 141 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 64. A VL comprising an amino acid sequence represented by SEQ ID NO: 144 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 67. A VL comprising an amino acid sequence represented by SEQ ID NO: 145 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 68. A VL comprising an amino acid sequence represented by SEQ ID NO: 146 may be encoded by a nucleic acid comprising the nucleic acid sequence represented by SEQ ID NO: 69.

[0073] In a preferred embodiment, an antibody of the invention comprises a VH comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following embodiments (i) to (vi):

- (i) CDR1: positions 45-52 of SEQ ID NO: 115, CDR2: positions 70-77 of SEQ ID NO: 115, CDR3: positions 116-125 of SEQ ID NO: 115,
- (ii) CDR1: positions 45-52 of SEQ ID NO: 116, CDR2: positions 70-77 of SEQ ID NO: 116, CDR3: positions 116-126 of SEQ ID NO: 116,
- (iii) CDR1: positions 45-52 of SEQ ID NO: 117, CDR2: positions 70-77 of SEQ ID NO: 117, CDR3: positions 116-124 of SEQ ID NO: 117,
- (iv) CDR1: positions 45-52 of SEQ ID NO: 118, CDR2: positions 70-77 of SEQ ID NO: 118, CDR3: positions 116-126 of SEQ ID NO: 118,
- (v) CDR1: positions 44-51 of SEQ ID NO: 119, CDR2: positions 69-76 of SEQ ID NO: 119, CDR3: positions 115-125 of SEQ ID NO: 119, and
- (vi) CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120.

[0074] In a preferred embodiment, an antibody of the invention comprises a VL comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following embodiments (i) to (ix):

- (i) CDR1: positions 47-58 of SEQ ID NO: 121, CDR2: positions 76-78 of SEQ ID NO: 121, CDR3: positions 115-123 of SEQ ID NO: 121,
- (ii) CDR1: positions 49-53 of SEQ ID NO: 122, CDR2: positions 71-73 of SEQ ID NO: 122, CDR3: positions 110-118 of SEQ ID NO: 122,
- (iii) CDR1: positions 47-52 of SEQ ID NO: 123, CDR2: positions 70-72 of SEQ ID NO: 123, CDR3: positions 109-117 of SEQ ID NO: 123,
- (iv) CDR1: positions 47-58 of SEQ ID NO: 124, CDR2: positions 76-78 of SEQ ID NO: 124, CDR3: positions 115-123 of SEQ ID NO: 124,
- (v) CDR1: positions 47-58 of SEQ ID NO: 125, CDR2: positions 76-78 of SEQ ID NO: 125, CDR3: positions 115-123 of SEQ ID NO: 125,
- (vi) CDR1: positions 47-58 of SEQ ID NO: 126, CDR2: positions 76-78 of SEQ ID NO: 126, CDR3: positions 115-122 of SEQ ID NO: 126,
- (vii) CDR1: positions 47-58 of SEQ ID NO: 127, CDR2: positions 76-78 of SEQ ID NO: 127, CDR3: positions 115-123 of SEQ ID NO: 127,
- (viii) CDR1: positions 47-58 of SEQ ID NO: 128, CDR2: positions 76-78 of SEQ ID NO: 128, CDR3: positions 115-123 of SEQ ID NO: 128, and
- (ix) CDR1: positions 47-52 of SEQ ID NO: 129, CDR2: positions 70-72 of SEQ ID NO: 129, CDR3: positions 109-117 of SEQ ID NO: 129.

[0075] In a preferred embodiment, an antibody of the invention comprises a combination of VH and VL each comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following embodiments (i) to (ix):

- (i) VH: CDR1: positions 45-52 of SEQ ID NO: 115, CDR2: positions 70-77 of SEQ ID NO: 115, CDR3: positions

116-125 of SEQ ID NO: 115, VL: CDR1: positions 49-53 of SEQ ID NO: 122, CDR2: positions 71-73 of SEQ ID NO: 122, CDR3: positions 110-118 of SEQ ID NO: 122,

(ii) VH: CDR1: positions 45-52 of SEQ ID NO: 116, CDR2: positions 70-77 of SEQ ID NO: 116, CDR3: positions 116-126 of SEQ ID NO: 116, VL: CDR1: positions 47-58 of SEQ ID NO: 121, CDR2: positions 76-78 of SEQ ID NO: 121, CDR3: positions 115-123 of SEQ ID NO: 121,

(iii) VH: CDR1: positions 45-52 of SEQ ID NO: 117, CDR2: positions 70-77 of SEQ ID NO: 117, CDR3: positions 116-124 of SEQ ID NO: 117, VL: CDR1: positions 47-52 of SEQ ID NO: 123, CDR2: positions 70-72 of SEQ ID NO: 123, CDR3: positions 109-117 of SEQ ID NO: 123,

(iv) VH: CDR1: positions 44-51 of SEQ ID NO: 119, CDR2: positions 69-76 of SEQ ID NO: 119, CDR3: positions 115-125 of SEQ ID NO: 119, VL: CDR1: positions 47-58 of SEQ ID NO: 126, CDR2: positions 76-78 of SEQ ID NO: 126, CDR3: positions 115-122 of SEQ ID NO: 126,

(v) VH: CDR1: positions 45-52 of SEQ ID NO: 118, CDR2: positions 70-77 of SEQ ID NO: 118, CDR3: positions 116-126 of SEQ ID NO: 118, VL: CDR1: positions 47-58 of SEQ ID NO: 125, CDR2: positions 76-78 of SEQ ID NO: 125, CDR3: positions 115-123 of SEQ ID NO: 125,

(vi) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 124, CDR2: positions 76-78 of SEQ ID NO: 124, CDR3: positions 115-123 of SEQ ID NO: 124,

(vii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 127, CDR2: positions 76-78 of SEQ ID NO: 127, CDR3: positions 115-123 of SEQ ID NO: 127,

(viii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 128, CDR2: positions 76-78 of SEQ ID NO: 128, CDR3: positions 115-123 of SEQ ID NO: 128, and

(ix) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-52 of SEQ ID NO: 129, CDR2: positions 70-72 of SEQ ID NO: 129, CDR3: positions 109-117 of SEQ ID NO: 129.

[0076] An antibody of the invention preferably comprises one or more of the complementarity-determining regions (CDRs), preferably at least the CDR3 variable region, of the heavy chain variable region (VH) and/or of the light chain variable region (VL) of a monoclonal antibody against CLD18, preferably of a monoclonal antibody against CLD18 described herein, and preferably comprises one or more of the complementarity-determining regions (CDRs), preferably at least the CDR3 variable region, of the heavy chain variable regions (VH) and/or light chain variable regions (VL) described herein. In one embodiment said one or more of the complementarity-determining regions (CDRs) are selected from a set of complementarity-determining regions CDR1, CDR2 and CDR3 described herein. In a particularly preferred embodiment, an antibody of the invention preferably comprises the complementarity-determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) and/or of the light chain variable region (VL) of a monoclonal antibody against CLD18, preferably of a monoclonal antibody against CLD18 described herein, and preferably comprises the complementarity-determining regions CDR1, CDR2 and CDR3 of the heavy chain variable regions (VH) and/or light chain variable regions (VL) described herein.

[0077] An antibody of the invention comprising one or more CDRs, a set of CDRs or a combination of sets of CDRs as described herein comprises said CDRs together with their intervening framework regions. Preferably, the portion will also include at least about 50% of either or both of the first and fourth framework regions, the 50% being the C-terminal 50% of the first framework region and the N-terminal 50% of the fourth framework region. Construction of antibodies of the present invention made by recombinant DNA techniques may result in the introduction of residues N- or C-terminal to the variable regions encoded by linkers introduced to facilitate cloning or other manipulation steps, including the introduction of linkers to join variable regions of the invention to further protein sequences including immunoglobulin heavy chains, other variable domains (for example in the production of diabodies) or protein labels.

[0078] An antibody of the invention comprising one or more CDRs, a set of CDRs or a combination of sets of CDRs as described herein comprises said CDRs in a human antibody framework.

[0079] Reference herein to an antibody comprising with respect to the heavy chain thereof a particular chain, or a particular region or sequence preferably relates to the situation wherein all heavy chains of said antibody comprise said particular chain, region or sequence. This applies correspondingly to the light chain of an antibody.

[0080] The present disclosure also relates to nucleic acids comprising genes or nucleic acid sequences encoding antibodies or parts thereof, e.g. an antibody chain, as described herein. The nucleic acids may be comprised in a vector, e.g., a plasmid, cosmid, virus, bacteriophage or another vector used e.g. conventionally in genetic engineering. The vector may comprise further genes such as marker genes which allow for the selection of the vector in a suitable host cell and under suitable conditions. Furthermore, the vector may comprise expression control elements allowing proper expression of the coding regions in suitable hosts. Such control elements are known to the artisan and may include a

promoter, a splice cassette, and a translation initiation codon.

[0081] The nucleic acid can be operatively attached to the above expression control sequences allowing expression in eukaryotic or prokaryotic cells. Control elements ensuring expression in eukaryotic or prokaryotic cells are well known to those skilled in the art.

[0082] Methods for construction of nucleic acid molecules described herein, for construction of vectors comprising the above nucleic acid molecules, for introduction of the vectors into appropriately chosen host cells, for causing or achieving the expression are well-known in the art.

[0083] The present disclosure also relates to a host cell comprising a nucleic acid or vector as disclosed herein.

[0084] Other features and advantages of the instant invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0085]

Fig. 1 shows an immunofluorescence analysis of HEK293 cells transfected with CLD18A2 coupled to a green fluorochrome and reacted with mouse serum after DNA immunisation with SEQ ID NO: 15 fused to a helper epitope.

Fig. 2 shows a Western blot analysis of HEK293 cells transfected with CLD18A2-myc (SEQ ID NO: 3) and untransfected HEK293 cells with the monoclonal mouse-anti-c-myc antibody 9E11 (Serotec, CRL MCA2200).

Fig. 3 shows an immunofluorescence analysis using CHO cells transfected with CLD18A2 and a polyclonal rabbit-anti-CLD18 antibody (Zymed, CRL 38-8000).

Fig. 4A and B show the binding of hybridoma supernatants 24H5 and 85A3 to HEK293 cells transiently transfected with human CLD18A2 and a fluorescent marker as determined by flow cytometry. Figure 4C shows the binding of hybridoma supernatants 45C1, 125E1, 163E12, 166E2 and 175D10 to HEK293 cells stably transfected with human CLD18A2 and counterstained with propidium iodide.

Fig. 5 shows binding of hybridoma supernatants 24H5 (A), 9E8 (B), 26B5 (C) and 19B9 (D) to HEK293 cells transiently transfected with a fluorescent marker and either human CLD18A2 or CLD18A2-Myc or CLD18A2-HA as analyzed by flow cytometry.

Fig. 6A and B show binding of hybridoma supernatants 37H8, 43A11, 45C1 and 163E12 to HEK293 cells stably transfected with either human CLD18A2 or CLD18A1 as determined by flow cytometry.

Fig. 7 shows an immunofluorescence analysis of the CLD18A2 isoform specific monoclonal antibody 37G11 by staining HEK293 cells transfected with CLD18A2 (A, C) and CLD18A1 (B, D), respectively, under native (A, B) and paraformaldehyde fixation (C, D) conditions.

Fig. 8 shows an immunofluorescence analysis of the CLD18 monoclonal antibody 26B5 by staining HEK293 cells transfected with CLD18A2 (A, C) and CLD18A1 (B, D), respectively, under native (A, B) and paraformaldehyde fixation (C, D) conditions.

Fig. 9. Cell line RT-PCR
RT-PCR analysis with CLD18A2-specific primers showed clear expression in 4/5 tested cell lines.

Fig. 10 shows an immunofluorescence analysis of DAN-G cells (subclone F2) and a polyclonal rabbit-anti-CLD18 antibody (Zymed, CRL 38-8000).

Fig. 11 shows an immunofluorescence analysis of KATO-III cells (subclone 3B9 4D5) and a polyclonal rabbit-anti-CLD18 antibody (Zymed, CRL 38-8000).

Fig. 12A shows an immunofluorescence analysis of SNU-16 cells (subclone G5) with a polyclonal rabbit-anti-CLD18 antibody (Zymed, CRL 38-8000). Fig. 12 B shows an immunofluorescence analysis of KATO-III cells with monoclonal antibodies of the invention.

Fig. 13 shows surface expression of CLD18 on KATO-III and NUGC-4 cells as analyzed by staining of cells with

monoclonal antibodies 61C2 and 163E12 followed by flow cytometrical analysis.

Fig. 14. Protein-alignment of human CLD18A1 (NP_057453), human CLD18A2 (NP_001002026), mouse CLD18A1 (NP_062789) and mouse CLD18A2 (AAL15636).

Fig. 15A and B show binding of hybridoma supernatants 38G5, 38H3, 37G11, 45C1, and 163E12, respectively, to HEK293 cells transiently transfected with a fluorescent marker and either murine CLD18A1 or murine CLD18A2 as analyzed by flow cytometry.

Fig. 16. Immunohistochemical analyses with polyclonal AB p105. Immunohistochemical stainings on a subset of normal tissues (stomach, lung, bone marrow and prostate) confirm gastric tissue specificity (A). Expression was also detected in stomach carcinomas (upper row) and lung carcinomas (B). Only differentiated cells but not stem cells do express CLD18A2 (C).

Fig. 17. Immunohistochemical analyses with monoclonal AB 39F11D7

(A) Specific protein expression was detected in normal stomach mucosa, whereas all other tested normal tissue were negative.

(B) Strong CLD18A2 expression was found in stomach and lung carcinomas.

Fig. 18. Immunohistochemical analyses with monoclonal AB 26B5 (A), 175D10 (B), 43A11 (C), 163E12 (D), and 45C1 (E). All antibodies show strong staining of HEK293-CLD18A2 xenograft tumors and gastric cancer specimens, but not HEK293-Mock control-transfected tumors.

Fig. 19 is a graph comparing the percentage of dead cells after induction of CDC by 85A3, 28D10, 24H5, or 26D12 against HEK293 cells stably transfected with human CLD18A2 using flow cytometry.

Fig. 20 is a graph comparing the percentage of specific cell lysis after induction of CDC by 24H5, 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, or 61C2 against adherent CHO cells stably transfected with either human CLD18A2 or human CLD18A1 as determined by fluorescence measurement.

Fig. 21 shows concentration-dependent induction of CDC against CHO cells stably transfected with human CLD18A2 by 75B8 (A), 28D10 (B), or 37H8 (C) as determined by fluorescence measurement.

Fig. 22 shows lysis of HEK293-CLD18A2 cells by 26B5, 37H8, 38G5, 47D12, and 61C2, respectively, in the presence of MNCs.

Fig. 23 shows lysis of HEK293-CLD18A1 cells by 26B5, 37H8, 38G5, 47D12, and 61C2, respectively, in the presence of MNCs.

Fig. 24 shows tumor growth inhibition by antibodies of the invention in an early treatment xenograft model with HEK293-CLD18A2 cells.

Fig. 25A and B show prolonged survival by treatment with antibodies of the invention in two early treatment xenograft models with HEK293-CLD18A2 cells.

Fig. 26 shows prolongation of survival by antibodies of the invention in an advanced treatment xenograft model with HEK293-CLD18A2 cells.

Fig. 27A shows tumor growth inhibition by antibodies of the invention in an early treatment xenograft model. Fig. 27B shows prolongation of survival by antibodies of the invention in an early treatment xenograft model. Endogenously CLD18A2 expressing DAN-G cells were used.

Fig. 28 shows CLD18A2 mRNA expression in mouse tissues. RT-PCR investigations with CLD18A2-specific primers showed no significant expression within all tested normal tissues except stomach. The following normal tissues were analysed: 1: small intestine, 2: spleen, 3: skin, 4: stomach, 5: lung, 6: pancreas, 7: lymph node, 8: thymus, 9: negative control

Fig. 29 shows CLD18 expression in normal stomach. Immunohistochemical analysis with CL18 specific antibody of mouse stomach reveals conserved expression pattern. While the surface epithelia and deeper crypts express CLD18 in their cell surface, the central neck region is CLD18 negative.

Fig. 30 shows haematoxylin and eosin staining of mice stomach tissues. Shown is in overview (A) and in detail (B) the stomach of a 37G11-treated mouse in comparison to a control mouse (C and D), which was treated with PBS only.

Fig 31A and B show flowcytometric staining of HEK293 cells stably transfected with human CLD18A1 and A2, respectively, as well as endogenously expressing KATO-III cells with antibodies of the invention (43A11, 125E1, 163E12, 166E2, and 175D10).

Fig. 32 shows CDC on CLD18A2 expressing cells mediated by chimeric antibodies of the invention.

Fig. 33 shows ADCC on KATO-III cells mediated by chimeric antibodies of the invention.

DETAILED DESCRIPTION OF THE INVENTION

[0086] The antibodies described herein may be isolated monoclonal antibodies which specifically bind to an epitope present on CLD18. Isolated monoclonal antibodies encompassed by the present invention include IgA, IgG1-4, IgE, IgM, and IgD antibodies. In one embodiment the antibody is an IgG1 antibody, more particularly an IgG1, kappa or IgG1, lambda isotype. In another embodiment the antibody is an IgG3 antibody, more particularly an IgG3, kappa or IgG3, lambda isotype. In yet another embodiment the antibody is an IgG4 antibody, more particularly an IgG4, kappa or IgG4, lambda isotype. In still another embodiment the antibody is an IgA1 or IgA2 antibody. In still another embodiment the antibody is an IgM antibody.

[0087] In one embodiment the invention relates to antibodies which specifically bind to cells expressing CLD18, and preferably (i) bind to cells expressing CLD18A2, and (ii) do not bind to cells not expressing CLD18A2 but expressing CLD18A1. The antibodies of the invention preferably (i) mediate killing of cells expressing CLD18A2, and (ii) do not mediate killing of cells not expressing CLD18A2 but expressing CLD18A1.

[0088] In another embodiment, the invention relates to antibodies which (i) bind to tumor cells expressing CLD18, (ii) do not bind to CLD18 expressing cells of normal stomach mucosa, and/or (iii) do not bind to CLD18 expressing cells of non-cancer lung tissue.

[0089] The invention also includes antibodies which (i) mediate killing of tumor cells expressing CLD18, (ii) do not mediate killing of CLD18 expressing cells of normal stomach mucosa, and/or (iii) do not mediate killing of CLD18 expressing cells of non-cancer lung tissue.

[0090] In particular embodiments, the antibodies of the invention (i) bind to an epitope on CLD18A2 which is not present on CLD18A1, preferably SEQ ID NO: 21, 22, and 23, (ii) bind to an epitope localized on the CLD18A2-loop1, preferably SEQ ID NO: 28, (iii) bind to an epitope localized on the CLD18A2-loop2, preferably SEQ ID NO: 30, (iv) bind to an epitope localized on the CLD18A2-loopD3, preferably SEQ ID NO: 31, (v) bind to an epitope, which encompass CLD18A2-loop1 and CLD18A2-loopD3, (vi) bind to a non-glycosylated epitope localized on the CLD18A2-loopD3, preferably SEQ ID NO: 29, or (vii) bind to an epitope present in human and mouse CLD18 (SEQ ID NO: 2, SEQ ID NO: 8 and SEQ ID NO: 35, SEQ ID NO: 37, respectively).

[0091] In particularly preferred embodiments, the antibodies of the invention bind to an epitope on CLD18A2 which is not present on CLD18A1.

[0092] Antibodies of the invention include fully human antibodies. Such antibodies may be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies to CLD18 by undergoing V-D-J recombination and isotype switching. Such transgenic animal can also be a transgenic rabbit for producing polyclonal antibodies such as disclosed in US 2003/0017534.

[0093] Binding of an antibody of the invention to the CLD18 antigen may mediate the killing of cells expressing CLD18 (e.g. a tumor cell), e.g. by activation of the complement system. The killing of cells expressing CLD18 may occur by one or more of the following mechanisms: complement dependent cytotoxicity (CDC) of cells expressing CLD18; apoptosis of cells expressing CLD18; effector cell phagocytosis of cells expressing CLD18; or effector cell antibody dependent cellular cytotoxicity (ADCC) of cells expressing CLD18.

[0094] In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

DEFINITION OF TERMS

[0095] The term "CLD18" relates to claudin-18 and includes any variants, including CLD18A1 and CLD18A2, confor-

mations, isoforms and species homologs of CLD18 which are naturally expressed by cells or are expressed by cells transfected with the CLD18 gene. Preferably, "CLD18" relates to human CLD18, in particular CLD18A2 (SEQ ID NOs: 1, 2) and/or CLD18A1 (SEQ ID NOs: 7, 8), more preferably CLD18A2.

[0096] The term "CLD18A1" includes posttranslationally modified variants, isoforms and species homologs of human CLD18A1 which are naturally expressed by cells or are expressed on cells transfected with the CLD18A1 gene.

[0097] The term "CLD18A2" includes posttranslationally modified variants, isoforms and species homologs of human CLD18A2 which are naturally expressed by cells or are expressed on cells transfected with the CLD18A2 gene.

[0098] The term "CLD18 variant" shall encompass (i) CLD18 splice variants, (ii) CLD18-posttranslationally modified variants, particularly including variants with different N-glycosylation status, (iii) CLD18 conformation variants, particularly including CLD18-conformation-1, CLD18-conformation-2 and CLD18-conformation-3, (iv) CLD18 free and homotypically/heterotypically associated variants localized at intercellular tight junctions, (v) CLD18 cancer related and CLD18 non-cancer related variants.

[0099] The term "raft" refers to the sphingolipid- and cholesterol-rich membrane microdomains located in the outer leaflet area of the plasma membrane of a cell. The ability of certain proteins to associate within such domains and their ability of forming "aggregates" or "focal aggregates" can effect the protein's function. For example, the translocation of CLD18 molecules into such structures, after being bound by antibodies of the present invention, creates a high density of CLD18 antigen-antibody complexes in the plasma membranes. Such a high density of CLD18 antigen-antibody complexes can enable efficient activation of the complement system during CDC.

[0100] The terms "conformation" and "topology" describe how an integrale membrane molecule is positioned in the cell surface membrane, and, in particular, which of its regions are extracellular and thus eligible for antibodies. CLD18 for example can exist in three different conformations, which most likely depend on whether it is prevalent as homomers or heteromers and whether it is integrated in supramolecular tight junction structures or "free". These different states result in different epitopes eligible to antibodies.

[0101] According to the invention, the term "disease" refers to any pathological state, including cancer, in particular those forms of cancer described herein.

[0102] By "tumor" is meant an abnormal group of cells or tissue that grows by a rapid, uncontrolled cellular proliferation and continues to grow after the stimuli that initiated the new growth cease. Tumors show partial or complete lack of structural organization and functional coordination with the normal tissue, and usually form a distinct mass of tissue, which may be either benign or malignant.

[0103] By "metastasis" is meant the spread of cancer cells from its original site to another part of the body. The formation of metastasis is a very complex process and depends on detachment of malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the endothelial basement membranes to enter the body cavity and vessels, and then, after being transported by the blood, infiltration of target organs. Finally, the growth of a new tumor at the target site depends on angiogenesis. Tumor metastasis often occurs even after the removal of the primary tumor because tumor cells or components may remain and develop metastatic potential. In one embodiment, the term "metastasis" according to the invention relates to "distant metastasis" which relates to a metastasis which is remote from the primary tumor and the regional lymph node system.

[0104] The term "treatment of a disease" includes curing, shortening the duration, ameliorating, preventing, slowing down or inhibiting progression or worsening, or preventing or delaying the onset of a disease or the symptoms thereof.

[0105] According to the invention, a sample may be any sample useful according to the present invention, in particular a biological sample such a tissue sample, including bodily fluids, and/or a cellular sample and may be obtained in the conventional manner such as by tissue biopsy, including punch biopsy, and by taking blood, bronchial aspirate, sputum, urine, feces or other body fluids. According to the invention, the term "biological sample" also includes fractions of biological samples.

[0106] The term "antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, or an antigen binding portion thereof. The term "antibody" also includes all recombinant forms of antibodies, in particular of the antibodies described herein, e.g., antibodies expressed in prokaryotes, unglycosylated antibodies, and any antigen-binding antibody fragments and derivatives as described below. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0107] The term "humanized antibody" refers to a molecule having an antigen binding site that is substantially derived

from an immunoglobulin from a non-human species, wherein the remaining immunoglobulin structure of the molecule is based upon the structure and/or sequence of a human immunoglobulin. The antigen binding site may either comprise complete variable domains fused onto constant domains or only the complementarity determining regions (CDR) grafted onto appropriate framework regions in the variable domains. Antigen binding sites may be wild-type or modified by one or more amino acid substitutions, e.g. modified to resemble human immunoglobulins more closely. Some forms of humanized antibodies preserve all CDR sequences (for example a humanized mouse antibody which contains all six CDRs from the mouse antibody). Other forms have one or more CDRs which are altered with respect to the original antibody.

[0108] The term "chimeric antibody" refers to those antibodies wherein one portion of each of the amino acid sequences of heavy and light chains is homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular class, while the remaining segment of the chain is homologous to corresponding sequences in another. Typically the variable region of both light and heavy chains mimics the variable regions of antibodies derived from one species of mammals, while the constant portions are homologous to sequences of antibodies derived from another. One clear advantage to such chimeric forms is that the variable region can conveniently be derived from presently known sources using readily available B-cells or hybridomas from non-human host organisms in combination with constant regions derived from, for example, human cell preparations. While the variable region has the advantage of ease of preparation and the specificity is not affected by the source, the constant region being human, is less likely to elicit an immune response from a human subject when the antibodies are injected than would the constant region from a non human source. However the definition is not limited to this particular example.

[0109] The term "antigen-binding portion" of an antibody (or simply "binding portion"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) Fab fragments, monovalent fragments consisting of the VL, VH, CL and CH domains; (ii) F(ab')₂ fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) Fd fragments consisting of the VH and CH domains; (iv) Fv fragments consisting of the VL and VH domains of a single arm of an antibody, (v) dAb fragments (Ward et al., (1989) Nature 341: 544-546), which consist of a VH domain; (vi) isolated complementarity determining regions (CDRs), and (vii) combinations of two or more isolated CDRs which may optionally be joined by a synthetic linker. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. A further example is binding-domain immunoglobulin fusion proteins comprising (i) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, (ii) an immunoglobulin heavy chain CH₂ constant region fused to the hinge region, and (iii) an immunoglobulin heavy chain CH₃ constant region fused to the CH₂ constant region. The binding domain polypeptide can be a heavy chain variable region or a light chain variable region. The binding-domain immunoglobulin fusion proteins are further disclosed in US 2003/0118592 and US 2003/0133939. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0110] The term "epitope" means a protein determinant capable of binding to an antibody, wherein the term "binding" herein preferably relates to a specific binding. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

[0111] The term "discontinuous epitope" as used herein, means a conformational epitope on a protein antigen which is formed from at least two separate regions in the primary sequence of the protein.

[0112] The term "bispecific molecule" is intended to include any agent, e.g., a protein, peptide, or protein or peptide complex, which has two different binding specificities. For example, the molecule may bind to, or interact with (a) a cell surface antigen, and (b) an Fc receptor on the surface of an effector cell. The term "multispecific molecule" or "heterospecific molecule" is intended to include any agent, e.g., a protein, peptide, or protein or peptide complex, which has more than two different binding specificities. For example, the molecule may bind to, or interact with (a) a cell surface antigen, (b) an Fc receptor on the surface of an effector cell, and (c) at least one other component. Accordingly, the invention includes, but is not limited to, bispecific, trispecific, tetraspecific, and other multispecific molecules which are directed to CLD18, and to other targets, such as Fc receptors on effector cells. The term "bispecific antibodies" also includes diabodies. Diabodies are bivalent, bispecific antibodies in which the VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding

sites (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448; Poljak, R. J., et al. (1994) Structure 2: 1121-1123).

[0113] The invention also includes derivatives of the antibodies described herein. The term "antibody derivatives" refers to any modified form of an antibody, e.g., a conjugate of the antibody and another agent or antibody. As used herein, an antibody is "derived from" a particular germline sequence if the antibody is obtained from a system by immunizing an animal or by screening an immunoglobulin gene library, and wherein the selected antibody is at least 90%, more preferably at least 95%, even more preferably at least 96 %, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. Typically, an antibody derived from a particular germline sequence will display no more than 10 amino acid differences, more preferably, no more than 5, or even more preferably, no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene.

[0114] As used herein, the term "heteroantibodies" refers to two or more antibodies, derivatives thereof, or antigen binding regions linked together, at least two of which have different specificities. These different specificities include a binding specificity for an Fc receptor on an effector cell, and a binding specificity for an antigen or epitope on a target cell, e.g., a tumor cell.

[0115] The antibodies described herein may be human antibodies. The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).

[0116] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope. In one embodiment, the monoclonal antibodies are produced by a hybridoma which includes a B cell obtained from a non-human animal, e.g., mouse, fused to an immortalized cell.

[0117] The term "recombinant antibody", as used herein, includes all antibodies that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal with respect to the immunoglobulin genes or a hybridoma prepared therefrom, (b) antibodies isolated from a host cell transformed to express the antibody, e.g., from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of immunoglobulin gene sequences to other DNA sequences.

[0118] The term "transfectoma", as used herein, includes recombinant eukaryotic host cells expressing an antibody, such as CHO cells, NS/0 cells, HEK293 cells, HEK293T cells, plant cells, or fungi, including yeast cells.

[0119] As used herein, a "heterologous antibody" is defined in relation to a transgenic organism producing such an antibody. This term refers to an antibody having an amino acid sequence or an encoding nucleic acid sequence corresponding to that found in an organism not consisting of the transgenic organism, and being generally derived from a species other than the transgenic organism.

[0120] As used herein, a "heterohybrid antibody" refers to an antibody having light and heavy chains of different organismal origins. For example, an antibody having a human heavy chain associated with a murine light chain is a heterohybrid antibody.

[0121] The antibodies described herein are preferably isolated. An "isolated antibody" as used herein, is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to CLD18 is substantially free of antibodies that specifically bind antigens other than CLD18). An isolated antibody that specifically binds to an epitope, isoform or variant of human CLD18 may, however, have cross-reactivity to other related antigens, e.g., from other species (e.g., CLD18 species homologs). Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals. In one embodiment of the invention, a combination of "isolated" monoclonal antibodies relates to antibodies having different specificities and being combined in a well defined composition.

[0122] According to the invention, the term "binding" preferably relates to "specific binding". As used herein, "specific binding" refers to antibody binding to a predetermined antigen. Typically, the antibody binds with an affinity corresponding to a KD of about 1×10^{-7} M or less, and binds to the predetermined antigen with an affinity corresponding to a KD that is at least two orders of magnitude lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.

[0123] The term "KD" (M), as used herein, is intended to refer to the dissociation equilibrium constant of a particular antibody-antigen interaction.

[0124] As used herein, "isotype" refers to the antibody class (e.g., IgM or IgG1) that is encoded by heavy chain constant region genes.

[0125] As used herein, "isotype switching" refers to the phenomenon by which the class, or isotype, of an antibody changes from one Ig class to one of the other Ig classes.

[0126] The term "naturally occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally occurring.

[0127] The term "rearranged" as used herein refers to a configuration of a heavy chain or light chain immunoglobulin locus wherein a V segment is positioned immediately adjacent to a D-J or J segment in a conformation encoding essentially a complete VH or VL domain, respectively. A rearranged immunoglobulin (antibody) gene locus can be identified by comparison to germline DNA; a rearranged locus will have at least one recombined heptamer/nonamer homology element.

[0128] The term "unrearranged" or "germline configuration" as used herein in reference to a V segment refers to the configuration wherein the V segment is not recombined so as to be immediately adjacent to a D or J segment.

[0129] The term "nucleic acid molecule", as used herein, is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.

[0130] The nucleic acids described according to the invention have preferably been isolated. The term "isolated nucleic acid" means according to the invention that the nucleic acid was (i) amplified *in vitro*, for example by polymerase chain reaction (PCR), (ii) recombinantly produced by cloning, (iii) purified, for example by cleavage and gel-electrophoretic fractionation, or (iv) synthesized, for example by chemical synthesis. An isolated nucleic acid is a nucleic acid which is available for manipulation by recombinant DNA techniques.

[0131] Nucleic acids may, according to the invention, be present alone or in combination with other nucleic acids, which may be homologous or heterologous. In preferred embodiments, a nucleic acid is functionally linked to expression control sequences which may be homologous or heterologous with respect to said nucleic acid. The term "homologous" means that a nucleic acid is also functionally linked to the expression control sequence naturally and the term "heterologous" means that a nucleic acid is not functionally linked to the expression control sequence naturally.

[0132] A nucleic acid, such as a nucleic acid expressing RNA and/or protein or peptide, and an expression control sequence are "functionally" linked to one another, if they are covalently linked to one another in such a way that expression or transcription of said nucleic acid is under the control or under the influence of said expression control sequence. If the nucleic acid is to be translated into a functional protein, then, with an expression control sequence functionally linked to a coding sequence, induction of said expression control sequence results in transcription of said nucleic acid, without causing a frame shift in the coding sequence or said coding sequence not being capable of being translated into the desired protein or peptide.

[0133] The term "expression control sequence" comprises according to the invention promoters, ribosome binding sites, enhancers and other control elements which regulate transcription of a gene or translation of a mRNA. In particular embodiments of the invention, the expression control sequences can be regulated. The exact structure of expression control sequences may vary as a function of the species or cell type, but generally comprises 5'-untranscribed and 5'- and 3'-untranslated sequences which are involved in initiation of transcription and translation, respectively, such as TATA box, capping sequence and CAAT sequence. More specifically, 5'-untranscribed expression control sequences comprise a promoter region which includes a promoter sequence for transcriptional control of the functionally linked nucleic acid. Expression control sequences may also comprise enhancer sequences or upstream activator sequences.

[0134] According to the invention the term "promoter" or "promoter region" relates to a nucleic acid sequence which is located upstream (5') to the nucleic acid sequence being expressed and controls expression of the sequence by providing a recognition and binding site for RNA-polymerase. The "promoter region" may include further recognition and binding sites for further factors which are involved in the regulation of transcription of a gene. A promoter may control the transcription of a prokaryotic or eukaryotic gene. Furthermore, a promoter may be "inducible" and may initiate transcription in response to an inducing agent or may be "constitutive" if transcription is not controlled by an inducing agent. A gene which is under the control of an inducible promoter is not expressed or only expressed to a small extent if an inducing agent is absent. In the presence of the inducing agent the gene is switched on or the level of transcription is increased. This is mediated, in general, by binding of a specific transcription factor.

[0135] Promoters which are preferred according to the invention include promoters for SP6, T3 and T7 polymerase, human U6 RNA promoter, CMV promoter, and artificial hybrid promoters thereof (e.g. CMV) where a part or parts are fused to a part or parts of promoters of genes of other cellular proteins such as e.g. human GAPDH (glyceraldehyde-3-phosphate dehydrogenase), and including or not including (an) additional intron(s).

[0136] According to the invention, the term "expression" is used in its most general meaning and comprises the production of RNA or of RNA and protein/peptide. It also comprises partial expression of nucleic acids. Furthermore, expression may be carried out transiently or stably.

[0137] In a preferred embodiment, a nucleic acid molecule is according to the invention present in a vector, where appropriate with a promoter, which controls expression of the nucleic acid. The term "vector" is used here in its most general meaning and comprises any intermediary vehicle for a nucleic acid which enables said nucleic acid, for example, to be introduced into prokaryotic and/or eukaryotic cells and, where appropriate, to be integrated into a genome. Vectors

of this kind are preferably replicated and/or expressed in the cells. Vectors comprise plasmids, phagemids, bacteriophages or viral genomes. The term "plasmid" as used herein generally relates to a construct of extrachromosomal genetic material, usually a circular DNA duplex, which can replicate independently of chromosomal DNA.

[0138] As the vector for expression of an antibody, either of a vector type in which the antibody heavy chain and light chain are present in different vectors or a vector type in which the heavy chain and light chain are present in the same vector can be used.

[0139] The teaching given herein with respect to specific nucleic acid and amino acid sequences, e.g. those shown in the sequence listing, is to be construed so as to also relate to modifications of said specific sequences resulting in sequences which are functionally equivalent to said specific sequences, e.g. amino acid sequences exhibiting properties identical or similar to those of the specific amino acid sequences and nucleic acid sequences encoding amino acid sequences exhibiting properties identical or similar to those of the amino acid sequences encoded by the specific nucleic acid sequences. One important property is to retain binding of an antibody to its target or to sustain effector functions of an antibody. Preferably, a sequence modified with respect to a specific sequence, when it replaces the specific sequence in an antibody retains binding of said antibody to CLD18 and preferably functions of said antibody as described herein, e.g. CDC mediated lysis or ADCC mediated lysis.

[0140] It will be appreciated by those skilled in the art that in particular the sequences of the CDR, hypervariable and variable regions can be modified without losing the ability to bind CLD18. For example, CDR regions will be either identical or highly homologous to the regions specified herein. By "highly homologous" it is contemplated that from 1 to 5, preferably from 1 to 4, such as 1 to 3 or 1 or 2 substitutions may be made in the CDRs. In addition, the hypervariable and variable regions may be modified so that they show substantial homology with the regions specifically disclosed herein.

[0141] It is to be understood that the specific nucleic acids described herein also include nucleic acids modified for the sake of optimizing the codon usage in a particular host cell or organism. Differences in codon usage among organisms can lead to a variety of problems concerning heterologous gene expression. Codon optimization by changing one or more nucleotides of the original sequence can result in an optimization of the expression of a nucleic acid, in particular in optimization of translation efficacy, in a homologous or heterologous host in which said nucleic acid is to be expressed. For example if nucleic acids derived from human and encoding constant regions and/or framework regions of antibodies are to be used according to the present invention, e.g. for preparing chimeric or humanised antibodies, it may be preferred to modify said nucleic acids for the sake of optimization of codon usage, in particular if said nucleic acids, optionally fused to heterologous nucleic acids such as nucleic acids derived from other organisms as described herein, are to be expressed in cells from an organism different from human such as mouse or hamster. For example, the nucleic acid sequences encoding human light and heavy chain constant regions such as those according to SEQ ID NOs: 40 and 45, respectively, can be modified to include one or more, preferably, at least 1, 2, 3, 4, 5, 10, 15, 20 and preferably up to 10, 15, 20, 25, 30, 50, 70 or 100 or more nucleotide replacements resulting in an optimized codon usage but not resulting in a change of the amino acid sequence. Such nucleotide replacements preferably relate to replacements of nucleotides in SEQ ID Nos: 40 and 45, respectively, selected from the replacements shown in the following alignment of SEQ ID Nos: 40 and 45, respectively, with their modified counterparts and not resulting in a change in the encoded amino acid sequence or relate to corresponding replacements at corresponding positions in other nucleic acid sequences encoding human light and heavy chain constant regions, respectively. Preferably, all of the replacements shown in the following alignments of SEQ ID Nos: 40 and 45, respectively, with their modified counterparts not resulting in a change in the encoded amino acid sequence are effected in nucleic acid sequences encoding human light and heavy chain constant regions, respectively.

Alignment of SEQ ID NO: 40 and SEQ ID NO: 147:

EP 2 311 877 B1

CGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCCGCCATCTGATGAGCAGTTGAAATCT	60
CGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCCCCCAGCGACGAGCAGCTGAAGTCC	60
GGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG	120
GGCACCGCCAGCGTGGTGTGCCTGCTGAACAAC'TTCTACCCCCGGGAGGCCAAGGTGCAG	120
TGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGAC	180
TGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTCAACGAGCAGGAC	180
AGCAAGGACAGCACCTACAGCCTCAGCAGCACCC'TGACGCTGAGCAAAGCAGACTACGAG	240
AGCAAGGACTCCACCTACAGCCTGAGCAGCACCC'TGACCC'TGAGCAAGGCCGACTACGAG	240
AAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCCGTACAAAG	300
AAGCACAAGGTGTACGCCTGCGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAG	300
AGCTTCAACAGGGGAGAGTGTTAG	324
AGCTTCAACAGGGGCGAGTGCTAG	324

Alignment of SEQ ID NO: 45 and SEQ ID NO: 149:

	GGCCCATCGGTCTTCCCCCTGGCCACCCCTCCTCCAAGAGCACCTCTGCGGGGCACAGCGGGC	60
	GGCCCAAGCGTGTTCCTCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCC	60
5	CTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGC	120
	CTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACAGCGGA	120
10	GCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCTACAGTCTTCAGGACTCTACTCC	180
	GCCCTGACCTCCGGCGTGCACACCTTCCCGCCCGTGCTGCAGAGCAGCGGCCTGTACAGC	180
15	CTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAGCCAGACCTACATCTGCAAC	240
	CTGAGCAGCGTGGTGACCGTGCCAGCAGCAGCCTGGGCAGCCAGACCTACATCTGCAAC	240
20	GTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGAC	300
	GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGAC	300
25	AAAACCTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTC	360
	AAGACCCACACCTGCCCCCCTGCCAGCCCCAGAGCTGCTGGGCGGACCCAGCGTGTTCC	360
30	CTCTTCCCCCCTAAACCCCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACATGC	420
	CTGTTCCCCCCTAAGCCCAAGGACACCCCTGATGATCAGCAGGACCCCGAGGTGACCTGC	420
35	GTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGC	480
	GTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCAACTGGTACGTGGACGGC	480

```

GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAA CAGCACGTACCGT 540
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GTGGAGGTGCACAACGCCAAGACCAAGCCAGAGAGGAGCAGTACAA CAGCACCTACAGG 540

5
GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGC 600
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTGC 600

10
AAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC CAAAGCCAAAGGG 660
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AAGGTCTCCAACAAAGCCCTGCCAGCCCCCATCGAAAAGACCATCAG CAAGGCCAAGGGC 660

15
CAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAAC 720
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCAGCCGGGAGGAGATGACCAAGAAC 720

20
CAGGTTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGG 780
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCAGCGACATCGCCGTGGAGTGG 780

25
GAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC 840
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GAGAGCAACGGCCAGCCCGAGAACAACACTACAAGACCACCCCCCAGTGCTGGACAGCGAC 840

30
GGCTCCTTCTTCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAAC 900
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GGCAGCTTCTTCTGTACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAAC 900

35
GTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTC 960
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GTGTTTCAGCTGCAGCGTATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTG 960

TCCCTGTCTCCGGGTAAATGA 981
||||| ||||| |||||
AGCCTGAGCCCCGGCAAGTAG 981

```

[0142] Furthermore, it may be desired according to the present invention to modify the amino acid sequences described herein, in particular those of human heavy chain constant regions to adapt the sequence to a desired allotype, e.g. an allotype found in the Caucasian population. Such modifications are preferably selected from the group consisting of the following amino acid replacements within SEQ ID NO: 46 or at corresponding positions within other human heavy chain constant regions: K93R, D235E, and L237M. Preferably, all of these modifications are included in amino acid sequences of human heavy chain constant regions.

[0143] According the invention, the term "corresponding positions" relates to nucleotides or amino acid residues which in a sequence alignment of two nucleic acid or protein sequences are aligned to each other.

[0144] Preferably the degree of identity between a specific nucleic acid sequence described herein and a nucleic acid sequence which is modified with respect to said specific nucleic acid sequence will be at least 70%, preferably at least 75%, more preferably at least 80%, even more preferably at least 90% or most preferably at least 95%, 96%, 97%, 98% or 99%. Preferably, the two sequences are capable of hybridizing and forming a stable duplex with one another, with hybridization preferably being carried out under conditions which allow specific hybridization between polynucleotides (stringent conditions). Stringent conditions are described, for example, in Molecular Cloning: A Laboratory Manual, J. Sambrook et al., Editors, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989 or Current Protocols in Molecular Biology, F.M. Ausubel et al., Editors, John Wiley & Sons, Inc., New York and refer, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin, 2.5 mM NaH₂PO₄ (pH 7), 0.5% SDS, 2 mM EDTA). SSC is 0.15 M sodium chloride/0.15 M sodium citrate, pH 7. After hybridization, the membrane to which the DNA has been transferred is washed, for example, in 2 x SSC at room temperature and then in 0.1-0.5 x SSC/0.1 x SDS at temperatures of up to 68°C.

[0145] Preferably the degree of similarity, preferably identity between a specific amino acid sequence described herein

and an amino acid sequence which is modified with respect to said specific amino acid sequence such as between amino acid sequences showing substantial homology will be at least 70%, preferably at least 80%, even more preferably at least 90% or most preferably at least 95%, 96%, 97%, 98% or 99%.

[0146] All of the above described modified sequences are within the scope of the present invention.

[0147] "Sequence similarity" indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions. "Sequence identity" between two polypeptide or nucleic acid sequences indicates the percentage of amino acids or nucleotides that are identical between the sequences.

[0148] The "percentage identity" is obtained after the best alignment, this percentage being purely statistical and the differences between the two sequences being distributed randomly and over their entire length. Sequence comparisons between two nucleotide or amino acid sequences are conventionally carried out by comparing these sequences after having aligned them optimally, said comparison being carried out by segment or by "window of comparison" in order to identify and compare local regions of sequence similarity. The optimal alignment of the sequences for comparison may be produced, besides manually, by means of the local homology algorithm of Smith and Waterman, 1981, *Ads App. Math.* 2, 482, by means of the local homology algorithm of Neddleman and Wunsch, 1970, *J. Mol. Biol.* 48,443, by means of the similarity search method of Pearson and Lipman, 1988, *Proc. Natl Acad. Sci. USA* 85, 2444, or by means of computer programs which use these algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.).

[0149] The percentage identity is calculated by determining the number of identical positions between the two sequences being compared, dividing this number by the number of positions compared and multiplying the result obtained by 100 so as to obtain the percentage identity between these two sequences.

[0150] "Conservative substitutions," may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example: (a) nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids include arginine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d). In addition, glycine and proline may be substituted for one another based on their ability to disrupt [alpha]-helices. Some preferred substitutions may be made among the following groups: (i) S and T; (ii) P and G; and (iii) A, V, L and I. Given the known genetic code, and recombinant and synthetic DNA techniques, the skilled scientist readily can construct DNAs encoding the conservative amino acid variants.

[0151] The present invention comprises antibodies in which alterations have been made in the Fc region in order to change the functional or pharmacokinetic properties of the antibodies. Such alterations may result in a decrease or increase of C1q binding and CDC or of FcγR binding and ADCC. Substitutions can, for example, be made in one or more of the amino acid residues of the heavy chain constant region, thereby causing an alteration in an effector function while retaining the ability to bind to the antigen as compared with the modified antibody, cf. US 5,624,821 and US 5,648,260.

[0152] The in vivo half-life of antibodies can be improved by modifying the salvage receptor epitope of the Ig constant domain or an Ig-like constant domain such that the molecule does not comprise an intact CH2 domain or an intact Ig Fc region, cf. US 6,121,022 and US 6,194,551. The in vivo half-life can furthermore be increased by making mutations in the Fc region, e.g., by substituting threonine for leucine at position 252, by substituting threonine for serine at position 254, or by substituting threonine for phenylalanine at position 256, cf. US 6,277,375.

[0153] Furthermore, the glycosylation pattern of antibodies can be modified in order to change the effector function of the antibodies. For example, the antibodies can be expressed in a transfectoma which does not add the fucose unit normally attached to Asn at position 297 of the Fc region in order to enhance the affinity of the Fc region for Fc-Receptors which, in turn, will result in an increased ADCC of the antibodies in the presence of NK cells, cf. Shield et al. (2002) *JBC*, 277: 26733. Furthermore, modification of galactosylation can be made in order to modify CDC.

[0154] Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a anti-CLD18 antibody coding sequence, such as by saturation mutagenesis, and the resulting modified anti-CLD18 antibodies can be screened for binding activity.

[0155] The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. Recombinant host cells include, for example, transfectomas, such as CHO cells, NS/O cells, and lymphocytic cells.

[0156] As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.

[0157] The terms "transgenic animal" refers to an animal having a genome comprising one or more transgenes, preferably heavy and/or light chain transgenes, or transchromosomes (either integrated or non-integrated into the animal's natural genomic DNA) and which is preferably capable of expressing the transgenes. For example, a transgenic mouse can have a human light chain transgene and either a human heavy chain transgene or human heavy chain transchromosome, such that the mouse produces human anti-CLD18 antibodies when immunized with CLD18 antigen and/or cells expressing CLD18. The human heavy chain transgene can be integrated into the chromosomal DNA of the mouse, as is the case for transgenic mice, e.g., HuMAb mice, such as HCo7 or HCo12 mice, or the human heavy chain transgene can be maintained extrachromosomally, as is the case for transchromosomal (e.g., KM) mice as described in WO 02/43478. Such transgenic and transchromosomal mice may be capable of producing multiple isotypes of human monoclonal antibodies to CLD18 (e.g., IgG, IgA and/or IgE) by undergoing V-D-J recombination and isotype switching.

Mechanisms of mAb action

[0158] Although the following provides considerations regarding the mechanism underlying the therapeutic efficacy of antibodies of the invention it is not to be considered as limiting to the invention in any way.

[0159] The antibodies described herein preferably interact with components of the immune system, preferably through ADCC or CDC. Antibodies of the invention can also be used to target payloads (e.g., radioisotopes, drugs or toxins) to directly kill tumor cells or can be used synergistically with traditional chemotherapeutic agents, attacking tumors through complementary mechanisms of action that may include anti-tumor immune responses that may have been compromised owing to a chemotherapeutic's cytotoxic side effects on T lymphocytes.

[0160] **Antibody-dependent cell-mediated** cytotoxicity. ADCC describes the cell-killing ability of effector cells as described herein, in particular lymphocytes, which preferably requires the target cell being marked by an antibody.

[0161] ADCC preferably occurs when antibodies bind to antigens on tumor cells and the antibody Fc domains engage Fc receptors (FcR) on the surface of immune effector cells. Several families of Fc receptors have been identified, and specific cell populations characteristically express defined Fc receptors. ADCC can be viewed as a mechanism to directly induce a variable degree of immediate tumor destruction that leads to antigen presentation and the induction of tumor-directed T-cell responses. Preferably, *in vivo* induction of ADCC will lead to tumor-directed T-cell responses and host-derived antibody responses.

[0162] **Complement-dependent cytotoxicity.** CDC is another cell-killing method that can be directed by antibodies. IgM is the most effective isotype for complement activation. IgG1 and IgG3 are also both very effective at directing CDC via the classical complement-activation pathway. Preferably, in this cascade, the formation of antigen-antibody complexes results in the uncloaking of multiple C1q binding sites in close proximity on the C₁2 domains of participating antibody molecules such as IgG molecules (C1q is one of three subcomponents of complement C1). Preferably these uncloaked C1q binding sites convert the previously low-affinity C1q-IgG interaction to one of high avidity, which triggers a cascade of events involving a series of other complement proteins and leads to the proteolytic release of the effector-cell chemotactic/activating agents C3a and C5a. Preferably, the complement cascade ends in the formation of a membrane attack complex, which creates pores in the cell membrane that facilitate free passage of water and solutes into and out of the cell.

Production of antibodies

[0163] Antibodies of the invention can be produced by a variety of techniques, including conventional monoclonal antibody methodology, e.g., the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256: 495 (1975). Although somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibodies can be employed, e.g., viral or oncogenic transformation of B-lymphocytes or phage display techniques using libraries of antibody genes.

[0164] The preferred animal system for preparing hybridomas that secrete monoclonal antibodies is the murine system. Hybridoma production in the mouse is a very well established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also known.

[0165] Other preferred animal systems for preparing hybridomas that secrete monoclonal antibodies are the rat and the rabbit system (e.g. described in Spieker-Polet et al., Proc. Natl. Acad. Sci. U.S.A. 92:9348 (1995), see also Rossi et al., Am. J. Clin. Pathol. 124: 295 (2005)).

[0166] In yet another preferred embodiment, human monoclonal antibodies directed against CLD18 can be generated using transgenic or transchromosomal mice carrying parts of the human immune system rather than the mouse system. These transgenic and transchromosomal mice include mice known as HuMAb mice and KM mice, respectively, and are collectively referred to herein as "transgenic mice." The production of human antibodies in such transgenic mice can be performed as described in detail for CD20 in WO2004 035607

[0167] Yet another strategy for generating monoclonal antibodies is to directly isolate genes encoding antibodies from

lymphocytes producing antibodies of defined strategy e.g. see Babcock et al., 1996; A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined strategy. For details of recombinant antibody engineering see also Welschof and Kraus, Recombinant antibodies for cancer therapy ISBN-0-89603-918-8 and Benny K.C. Lo Antibody Engineering ISBN 1-58829-092-1.

Immunizations

[0168] To generate antibodies to CLD18, mice can be immunized with carrier-conjugated peptides derived from the CLD18 sequence, an enriched preparation of recombinantly expressed CLD18 antigen or fragments thereof and/or cells expressing CLD18, as described. Alternatively, mice can be immunized with DNA encoding full length human CLD18 (e.g. SEQ ID NO: 1) or fragments thereof, in particular those of SEQ ID Nos:15, 17, and 19. In the event that immunizations using a purified or enriched preparation of the CLD18 antigen do not result in antibodies, mice can also be immunized with cells expressing CLD18, e.g., a cell line, to promote immune responses.

[0169] The immune response can be monitored over the course of the immunization protocol with plasma and serum samples being obtained by tail vein or retroorbital bleeds. Mice with sufficient titers of anti-CLD18 immunoglobulin can be used for fusions. Mice can be boosted intraperitoneally or intravenously with CLD18 expressing cells 3 days before sacrifice and removal of the spleen to increase the rate of specific antibody secreting hybridomas.

Generation of Hybridomas Producing Monoclonal Antibodies

[0170] To generate hybridomas producing monoclonal antibodies to CLD18, splenocytes and lymph node cells from immunized mice can be isolated and fused to an appropriate immortalized cell line, such as a mouse myeloma cell line. The resulting hybridomas can then be screened for the production of antigen-specific antibodies. Individual wells can then be screened by ELISA for antibody secreting hybridomas. By Immunofluorescence and FACS analysis using CLD18 expressing cells, antibodies with specificity for CLD18 can be identified. The antibody secreting hybridomas can be replated, screened again, and if still positive for anti-CLD18 monoclonal antibodies can be subcloned by limiting dilution. The stable subclones can then be cultured in vitro to generate antibody in tissue culture medium for characterization.

Generation of Transfectomas Producing Monoclonal Antibodies

[0171] Antibodies of the invention also can be produced in a host cell transfectoma using, for example, a combination of recombinant DNA techniques and gene transfection methods as are well known in the art (Morrison, S. (1985) Science 229: 1202).

[0172] For example, in one embodiment, the gene(s) of interest, e.g., antibody genes, can be ligated into an expression vector such as a eukaryotic expression plasmid such as used by the GS gene expression system disclosed in WO 87/04462, WO 89/01036 and EP 338 841 or other expression systems well known in the art. The purified plasmid with the cloned antibody genes can be introduced in eukaryotic host cells such as CHO cells, NS/0 cells, HEK293T cells or HEK293 cells or alternatively other eukaryotic cells like plant derived cells, fungal or yeast cells. The method used to introduce these genes can be methods described in the art such as electroporation, lipofectine, lipofectamine or others. After introduction of these antibody genes in the host cells, cells expressing the antibody can be identified and selected. These cells represent the transfectomas which can then be amplified for their expression level and upscaled to produce antibodies. Recombinant antibodies can be isolated and purified from these culture supernatants and/or cells. Alternatively, the cloned antibody genes can be expressed in other expression systems, including prokaryotic cells, such as microorganisms, e.g. E. coli. Furthermore, the antibodies can be produced in transgenic non-human animals, such as in milk from sheep and rabbits or in eggs from hens, or in transgenic plants; see e.g. Verma, R., et al. (1998) J. Immunol. Meth. 216: 165-181; Pollock, et al. (1999) J. Immunol. Meth. 231: 147-157; and Fischer, R., et al. (1999) Biol. Chem. 380: 825-839.

Use of Partial Antibody Sequences to Express Intact Antibodies (i.e. humanization and chimerisation).

a) Chimerization

[0173] Murine monoclonal antibodies can be used as therapeutic antibodies in humans when labeled with toxins or radioactive isotopes. Nonlabeled murine antibodies are highly immunogenic in man when repetitively applied leading to reduction of the therapeutic effect. The main immunogenicity is mediated by the heavy chain constant regions. The immunogenicity of murine antibodies in man can be reduced or completely avoided if respective antibodies are chimerized or humanized. Chimeric antibodies are antibodies, the different portions of which are derived from different animal species, such as those having a variable region derived from a murine antibody and a human immunoglobulin constant

region. Chimerisation of antibodies is achieved by joining of the variable regions of the murine antibody heavy and light chain with the constant region of human heavy and light chain (e.g. as described by Kraus et al., in *Methods in Molecular Biology* series, Recombinant antibodies for cancer therapy ISBN-0-89603-918-8). In a preferred embodiment chimeric antibodies are generated by joining human kappa-light chain constant region to murine light chain variable region. In an also preferred embodiment chimeric antibodies can be generated by joining human lambda-light chain constant region to murine light chain variable region. The preferred heavy chain constant regions for generation of chimeric antibodies are IgG1, IgG3 and IgG4. Other preferred heavy chain constant regions for generation of chimeric antibodies are IgG2, IgA, IgD and IgM.

b) Humanization

[0174] Antibodies interact with target antigens predominantly through amino acid residues that are located in the six heavy and light chain complementarity determining regions (CDRs). For this reason, the amino acid sequences within CDRs are more diverse between individual antibodies than sequences outside of CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of specific naturally occurring antibodies by constructing expression vectors that include CDR sequences from the specific naturally occurring antibody grafted onto framework sequences from a different antibody with different properties (see, e.g., Riechmann, L. et al. (1998) *Nature* 332: 323-327; Jones, P. et al. (1986) *Nature* 321: 522-525; and Queen, C. et al. (1989) *Proc. Natl. Acad. Sci. U. S. A.* 86: 10029-10033). Such framework sequences can be obtained from public DNA databases that include germline antibody gene sequences. These germline sequences will differ from mature antibody gene sequences because they will not include completely assembled variable genes, which are formed by V(D) J joining during B cell maturation. Germline gene sequences will also differ from the sequences of a high affinity secondary repertoire antibody at individual evenly across the variable region. For example, somatic mutations are relatively infrequent in the amino terminal portion of framework region 1 and in the carboxy-terminal portion of framework region 4. Furthermore, many somatic mutations do not significantly alter the binding properties of the antibody. For this reason, it is not necessary to obtain the entire DNA sequence of a particular antibody in order to recreate an intact recombinant antibody having binding properties similar to those of the original antibody (see WO 99/45962). Partial heavy and light chain sequences spanning the CDR regions are typically sufficient for this purpose. The partial sequence is used to determine which germline variable and joining gene segments contributed to the recombined antibody variable genes. The germline sequence is then used to fill in missing portions of the variable regions. Heavy and light chain leader sequences are cleaved during protein maturation and do not contribute to the properties of the final antibody. To add missing sequences, cloned cDNA sequences can be combined with synthetic oligonucleotides by ligation or PCR amplification. Alternatively, the entire variable region can be synthesized as a set of short, overlapping, oligonucleotides and combined by PCR amplification to create an entirely synthetic variable region clone. This process has certain advantages such as elimination or inclusion of particular restriction sites, or optimization of particular codons.

[0175] The nucleotide sequences of heavy and light chain transcripts from hybridomas are used to design an overlapping set of synthetic oligonucleotides to create synthetic V sequences with identical amino acid coding capacities as the natural sequences. The synthetic heavy and kappa chain sequences can differ from the natural sequences in three ways: strings of repeated nucleotide bases are interrupted to facilitate oligonucleotide synthesis and PCR amplification; optimal translation initiation sites are incorporated according to Kozak's rules (Kozak, 1991, *J. Biol. Chem.* 266: 19867-19870); and HindIII sites are engineered upstream of the translation initiation sites.

[0176] For both the heavy and light chain variable regions, the optimized coding and corresponding non-coding, strand sequences are broken down into 30-50 nucleotides approximately at the midpoint of the corresponding non-coding oligonucleotide. Thus, for each chain, the oligonucleotides can be assembled into overlapping double stranded sets that span segments of 150-400 nucleotides. The pools are then used as templates to produce PCR amplification products of 150-400 nucleotides. Typically, a single variable region oligonucleotide set will be broken down into two pools which are separately amplified to generate two overlapping PCR products. These overlapping products are then combined by PCR amplification to form the complete variable region. It may also be desirable to include an overlapping fragment of the heavy or light chain constant region in the PCR amplification to generate fragments that can easily be cloned into the expression vector constructs.

[0177] The reconstructed chimerized or humanized heavy and light chain variable regions are then combined with cloned promoter, leader, translation initiation, constant region, 3' untranslated, polyadenylation, and transcription termination sequences to form expression vector constructs. The heavy and light chain expression constructs can be combined into a single vector, co-transfected, serially transfected, or separately transfected into host cells which are then fused to form a host cell expressing both chains. Plasmids for use in construction of expression vectors for human IgG are described below. The plasmids were constructed so that PCR amplified V heavy and V kappa light chain cDNA sequences could be used to reconstruct complete heavy and light chain minigenes. These plasmids can be used to express completely human, or chimeric IgG1, Kappa or IgG4, Kappa antibodies. Similar plasmids can be constructed for expression

of other heavy chain isotypes, or for expression of antibodies comprising lambda light chains.

[0178] Thus, in another aspect of the invention, the structural features of the anti-CLD18 antibodies of the invention, are used to create structurally related humanized anti-CLD18 antibodies that retain at least one functional property of the antibodies of the invention, such as binding to CLD18. More specifically, one or more CDR regions of mouse monoclonal antibodies can be combined recombinantly with known human framework regions and CDRs to create additional, recombinantly-engineered, humanized anti-CLD18 antibodies of the invention.

Binding to antigen expressing cells

[0179] The ability of the antibody to bind CLD18 can be determined using standard binding assays, such as those set forth in the examples (e.g., ELISA, Western Blot, Immunofluorescence and flow cytometric analysis)

Characterization of binding of antibodies

[0180] To purify anti-CLD18 antibodies, selected hybridomas can be grown in two-liter spinner-flasks for monoclonal antibody purification. Alternatively, anti-CLD18 antibodies can be produced in dialysis based bioreactors. Supernatants can be filtered and, if necessary, concentrated before affinity chromatography with protein G-sepharose or protein A-sepharose. Eluted IgG can be checked by gel electrophoresis and high performance liquid chromatography to ensure purity. The buffer solution can be exchanged into PBS, and the concentration can be determined by OD280 using 1.43 extinction coefficient. The monoclonal antibodies can be aliquoted and stored at -80°C.

[0181] To determine if the selected anti-CLD18 monoclonal antibodies bind to unique epitopes, site-directed or multi-site directed mutagenesis can be used.

Isotype determination

[0182] To determine the isotype of purified antibodies, isotype ELISAs with various commercial kits (e.g. Zymed, Roche Diagnostics) can be performed. Wells of microtiter plates can be coated with anti-mouse Ig. After blocking, the plates are reacted with monoclonal antibodies or purified isotype controls, at ambient temperature for two hours. The wells can then be reacted with either mouse IgG1, IgG2a, IgG2b or IgG3, IgA or mouse IgM-specific peroxidase-conjugated probes. After washing, the plates can be developed with ABTS substrate (1 mg/ml) and analyzed at OD of 405-650. Alternatively, the IsoStrip Mouse Monoclonal Antibody Isotyping Kit (Roche, Cat. No. 1493027) may be used as described by the manufacturer.

Flow cytometric analysis

[0183] In order to demonstrate presence of anti-CLD18 antibodies in sera of immunized mice or binding of monoclonal antibodies to living cells expressing CLD18, flow cytometry can be used. Cell lines expressing naturally or after transfection CLD18 and negative controls lacking CLD18 expression (grown under standard growth conditions) can be mixed with various concentrations of monoclonal antibodies in hybridoma supernatants or in PBS containing 1% FBS, and can be incubated at 4°C for 30 min. After washing, the APC- or Alexa647-labeled anti IgG antibody can bind to CLD18-bound monoclonal antibody under the same conditions as the primary antibody staining. The samples can be analyzed by flow cytometry with a FACS instrument using light and side scatter properties to gate on single, living cells. In order to distinguish CLD18-specific monoclonal antibodies from non-specific binders in a single measurement, the method of co-transfection can be employed. Cells transiently transfected with plasmids encoding CLD18 and a fluorescent marker can be stained as described above. Transfected cells can be detected in a different fluorescence channel than antibody-stained cells. As the majority of transfected cells express both transgenes, CLD18-specific monoclonal antibodies bind preferentially to fluorescence marker expressing cells, whereas non-specific antibodies bind in a comparable ratio to non-transfected cells. An alternative assay using fluorescence microscopy may be used in addition to or instead of the flow cytometry assay. Cells can be stained exactly as described above and examined by fluorescence microscopy.

[0184] Tight junction proteins tend to be internalized, if cell cell contact to neighbouring cells of particularly adherent cells is lost by e.g. detachment of cells. Cell surface expression of CLD18 can be optimized by a) adjusting culture conditions, e.g. culturing in higher cell density in a standardized manner, using mild detachment (e.g. 2mM EDTA/PBS or accutase), processing at room temperature, and adding inhibitors of endocytosis (e.g. sodium azide) or activators of CLD18 transcription or translation, and by b) selecting and cloning of cells maintaining CLD18 in high levels at the cell surface, e.g. by selection with antibiotics in terms of transfected cells, by immunomagnetic or FACS cell sorting, and by limited dilution cloning.

Immunofluorescence microscopy

[0185] In order to demonstrate presence of anti-CLD18 antibodies in sera of immunized mice or binding of monoclonal antibodies to living cells expressing CLD18, immunofluorescence microscopy analysis can be used. For example, cell lines expressing either spontaneously or after transfection CLD18 and negative controls lacking CLD18 expression are grown in chamber slides under standard growth conditions in DMEM/F12 medium, supplemented with 10 % fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin. Cells can then be fixed with methanol or paraformaldehyde or left untreated. Cells can then be reacted with monoclonal antibodies against CLD18 for 30 min. at 25°C. After washing, cells can be reacted with an Alexa555-labelled anti-mouse IgG secondary antibody (Molecular Probes) under the same conditions. Cells can then be examined by fluorescence microscopy.

[0186] Total CL18 levels in cells can be observed when cells are methanol fixed or paraformaldehyde fixed and permeabilized with Triton X-100. In living cells and non-permeabilized, paraformaldehyde fixed cells surface localization of CLD18 can be examined. Additionally targeting of CLD18 to tight junctions can be analyzed by co-staining with tight junction markers such as ZO-1. Furthermore, effects of antibody binding and CLD18 localization within the cell membrane can be examined.

Western Blot

[0187] Anti-CLD18 IgG can be further tested for reactivity with CLD18 antigen by Western Blotting. Briefly, cell extracts from cells expressing CLD18 and appropriate negative controls can be prepared and subjected to sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis. After electrophoresis, the separated antigens will be transferred to nitrocellulose membranes, blocked, and probed with the monoclonal antibodies to be tested. IgG binding can be detected using anti-mouse IgG peroxidase and developed with ECL substrate.

Immunohistochemistry

[0188] Anti-CLD18 mouse IgGs can be further tested for reactivity with CLD18 antigen by Immunohistochemistry in a manner well known to the skilled person, e.g. using paraformaldehyde or acetone fixed cryosections or paraffin embedded tissue sections fixed with paraformaldehyde from non-cancer tissue or cancer tissue samples obtained from patients during routine surgical procedures or from mice carrying xenografted tumors inoculated with cell lines expressing spontaneously (e.g. DAN-G, SNU-16, or KATO-III) or after transfection (e.g. HEK293) CLD18. For immunostaining antibodies reactive to CLD18 can be incubated followed by horseradish-peroxidase conjugated goat anti-mouse or goat anti-rabbit antibodies (DAKO) according to the vendors instructions.

Phagocytic and Cell Killing Activities of Antibodies in vitro

[0189] In addition to binding specifically to CLD18, anti-CLD18 antibodies can be tested for their ability to mediate phagocytosis and killing of cells expressing CLD18. The testing of monoclonal antibody activity in vitro will provide an initial screening prior to testing in vivo models.

Antibody dependent cell-mediated cytotoxicity (ADCC):

[0190] Briefly, polymorphonuclear cells (PMNs), NK cells, monocytes, mononuclear cells or other effector cells, from healthy donors can be purified by Ficoll Hypaque density centrifugation, followed by lysis of contaminating erythrocytes. Washed effector cells can be suspended in RPMI supplemented with 10% heat-inactivated fetal calf serum or, alternatively with 5% heat-inactivated human serum and mixed with ⁵¹Cr labeled target cells expressing CLD18, at various ratios of effector cells to target cells. Alternatively, the target cells may be labeled with a fluorescence enhancing ligand (BATDA). A highly fluorescent chelate of Europium with the enhancing ligand which is released from dead cells can be measured by a fluorometer. Another alternative technique may utilize the transfection of target cells with luciferase. Added lucifer yellow may then be oxidated by viable cells only. Purified anti-CLD18 IgGs can then be added at various concentrations. Irrelevant human IgG can be used as negative control. Assays can be carried out for 4 to 20 hours at 37°C depending on the effector cell type used. Samples can be assayed for cytolysis by measuring ⁵¹Cr release or the presence of the EuTDA chelate in the culture supernatant. Alternatively, luminescence resulting from the oxidation of lucifer yellow can be a measure of viable cells.

[0191] Anti-CLD18 monoclonal antibodies can also be tested in various combinations to determine whether cytolysis is enhanced with multiple monoclonal antibodies.

Complement dependent cytotoxicity (CDC):

[0192] Monoclonal anti-CLD18 antibodies can be tested for their ability to mediate CDC using a variety of known techniques. For example, serum for complement can be obtained from blood in a manner known to the skilled person. To determine the CDC activity of mAbs, different methods can be used. ⁵¹Cr release can for example be measured or elevated membrane permeability can be assessed using a propidium iodide (PI) exclusion assay. Briefly, target cells can be washed and 5 x 10⁵/ml can be incubated with various concentrations of mAb for 10-30 min. at room temperature or at 37°C. Serum or plasma can then be added to a final concentration of 20% (v/v) and the cells incubated at 37°C for 20-30 min. All cells from each sample can be added to the PI solution in a FACS tube. The mixture can then be analyzed immediately by flow cytometry analysis using FACSArray.

[0193] In an alternative assay, induction of CDC can be determined on adherent cells. In one embodiment of this assay, cells are seeded 24 h before the assay with a density of 3 x 10⁴/well in tissue-culture flat-bottom microtiter plates. The next day growth medium is removed and the cells are incubated in triplicates with antibodies. Control cells are incubated with growth medium or growth medium containing 0.2% saponin for the determination of background lysis and maximal lysis, respectively. After incubation for 20 min. at room temperature supernatant is removed and 20% (v/v) human plasma or serum in DMEM (prewarmed to 37°C) is added to the cells and incubated for another 20 min. at 37°C. All cells from each sample are added to propidium iodide solution (10 µg/ml). Then, supernatants are replaced by PBS containing 2.5 µg/ml ethidium bromide and fluorescence emission upon excitation at 520 nm is measured at 600 nm using a Tecan Safire. The percentage specific lysis is calculated as follows: % specific lysis = (fluorescence sample-fluorescence background)/ (fluorescence maximal lysis-fluorescence background) x 100.

Inhibition of cell proliferation by monoclonal antibodies:

[0194] To test for the ability to initiate apoptosis, monoclonal anti-CLD18 antibodies can, for example, be incubated with CLD18 positive tumor cells, e.g., SNU-16, DAN-G, KATO-H or CLD18 transfected tumor cells at 37°C for about 20 hours. The cells can be harvested, washed in Annexin-V binding buffer (BD biosciences), and incubated with Annexin V conjugated with FITC or APC (BD biosciences) for 15 min. in the dark. All cells from each sample can be added to PI solution (10 µg/ml in PBS) in a FACS tube and assessed immediately by flow cytometry (as above). Alternatively, a general inhibition of cell-proliferation by monoclonal antibodies can be detected with commercially available kits. The DELFIA Cell Proliferation Kit (Perkin-Elmer, Cat. No. AD0200) is a non-isotopic immunoassay based on the measurement of 5-bromo-2'-deoxyuridine (BrdU) incorporation during DNA synthesis of proliferating cells in microplates. Incorporated BrdU is detected using europium labelled monoclonal antibody. To allow antibody detection, cells are fixed and DNA denatured using Fix solution. Unbound antibody is washed away and DELFIA inducer is added to dissociate europium ions from the labelled antibody into solution, where they form highly fluorescent chelates with components of the DELFIA Inducer. The fluorescence measured - utilizing time-resolved fluorometry in the detection - is proportional to the DNA synthesis in the cell of each well.

Preclinical studies

[0195] Monoclonal antibodies which bind to CLD18 also can be tested in an in vivo model (e.g. in immune deficient mice carrying xenografted tumors inoculated with cell lines expressing CLD18, e.g. DAN-G, SNU-16, or KATO-III, or after transfection, e.g. HEK293) to determine their efficacy in controlling growth of CLD18-expressing tumor cells.

[0196] In vivo studies after xenografting CLD18 expressing tumor cells into immunocompromised mice or other animals can be performed using antibodies of the invention. Antibodies can be administered to tumor free mice followed by injection of tumor cells to measure the effects of the antibodies to prevent formation of tumors or tumor-related symptoms. Antibodies can be administered to tumor-bearing mice to determine the therapeutic efficacy of respective antibodies to reduce tumor growth, metastasis or tumor related symptoms. Antibody application can be combined with application of other substances as cystostatic drugs, growth factor inhibitors, cell cycle blockers, angiogenesis inhibitors or other antibodies to determine synergistic efficacy and potential toxicity of combinations. To analyze toxic side effects mediated by antibodies of the invention animals can be inoculated with antibodies or control reagents and thoroughly investigated for symptoms possibly related to CLD18-antibody therapy. Possible side effects of in vivo application of CLD18 antibodies particularly include toxicity at CLD18 expressing tissues including stomach and lung. Antibodies recognizing CLD18 in human and in other species, e.g. mice, are particularly useful to predict potential side effects mediated by application of monoclonal CLD18-antibodies in humans.

Epitope mapping

[0197] Mapping of epitopes recognized by antibodies of invention can be performed as described in detail in "Epitope

Mapping Protocols (Methods in Molecular Biology) by Glenn E. Morris ISBN-089603-375-9 and in "Epitope Mapping: A Practical Approach" Practical Approach Series, 248 by Olwyn M. R. Westwood, Frank C. Hay.

I. Bispecific/Multispecific Molecules Which Bind to CLD18

[0198] In yet another embodiment of the invention, antibodies to CLD18 can be derivatized or linked to another functional molecule, e.g., another peptide or protein (e.g., an Fab' fragment) to generate a bispecific or multispecific molecule which binds to multiple binding sites or target epitopes. For example, an antibody of the invention can be functionally linked (e.g. by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other binding molecules, such as another antibody, peptide or binding mimetic.

[0199] Accordingly, the present invention includes bispecific and multispecific molecules comprising at least one first binding specificity for CLD18 and a second binding specificity for a second target epitope. In a particular embodiment of the invention, the second target epitope is an Fc receptor, e.g. human Fc-gammaRI (CD64) or a human Fc-alpha receptor (CD89), or a T cell receptor, e.g. CD3. Therefore, the invention includes bispecific and multispecific molecules capable of binding both to Fc-gammaR, Fc-alphaR or Fc-epsilonR expressing effector cells (e.g. monocytes, macrophages or polymorphonuclear cells (PMNs)), and to target cells expressing CLD18. These bispecific and multispecific molecules may target CLD18 expressing cells to effector cell and may trigger Fc receptor-mediated effector cell activities, such as phagocytosis of CLD18 expressing cells, antibody dependent cellular cytotoxicity (ADCC), cytokine release, or generation of superoxide anion.

[0200] Bispecific and multispecific molecules of the invention can further include a third binding specificity, in addition to an anti-Fc binding specificity and an anti-CLD18 binding specificity. In one embodiment, the third binding specificity is an anti-enhancement factor (EF) portion, e.g. a molecule which binds to a surface protein involved in cytotoxic activity and thereby increases the immune response against the target cell. The "anti-enhancement factor portion" can be an antibody, functional antibody fragment or a ligand that binds to a given molecule, e.g., an antigen or a receptor, and thereby results in an enhancement of the effect of the binding determinants for the Fc receptor or target cell antigen. The "anti-enhancement factor portion" can bind an Fc receptor or a target cell antigen. Alternatively, the anti-enhancement factor portion can bind to an entity that is different from the entity to which the first and second binding specificities bind. For example, the anti-enhancement factor portion can bind a cytotoxic T cell (e.g., via CD2, CD3, CD8, CD28, CD4, CD40, ICAM-1 or other immune cell that results in an increased immune response against the target cell).

[0201] In one embodiment, the bispecific and multispecific molecules of the invention comprise as a binding specificity at least one antibody, including, e.g., an Fab, Fab', F(ab')₂, Fv, or a single chain Fv. The antibody may also be a light chain or heavy chain dimer, or any minimal fragment thereof such as a Fv or a single chain construct as described in Ladner et al., US 4,946,778. The antibody may also be a binding-domain immunoglobulin fusion protein as disclosed in US2003/0118592 and US 2003/0133939.

[0202] In one embodiment bispecific and multispecific molecules of the invention comprise a binding specificity for an Fc-gammaR or an Fc-alphaR present on the surface of an effector cell, and a second binding specificity for a target cell antigen, e.g., CLD18.

[0203] In one embodiment, the binding specificity for an Fc receptor is provided by a monoclonal antibody, the binding of which is not blocked by human immunoglobulin G (IgG). As used herein, the term "IgG receptor" refers to any of the eight gamma-chain genes located on chromosome 1. These genes encode a total of twelve transmembrane or soluble receptor isoforms which are grouped into three Fc-gamma receptor classes: Fc-gammaRI (CD64), Fc-gammaRII (CD32), and Fc-gammaRIII (CD16). In one preferred embodiment, the Fc-gamma receptor is a human high affinity Fc-gammaRI.

[0204] The production and characterization of these preferred monoclonal antibodies are described by Fanger et al. in WO 88/00052 and in US 4,954,617. These antibodies bind to an epitope of Fc-gammaRI, Fc-gammaRII or Fc-gammaRIII at a site which is distinct from the Fcγ binding site of the receptor and, thus, their binding is not blocked substantially by physiological levels of IgG. Specific anti-Fc-gammaRI antibodies useful in this invention are mAb 22, mAb 32, mAb 44, mAb 62 and mAb 197. In other embodiments, the anti-Fcγ receptor antibody is a humanized form of monoclonal antibody 22 (H22). The production and characterization of the H22 antibody is described in Graziano, R. F. et al. (1995) J. Immunol. 155 (10): 4996-5002 and WO 94/10332. The H22 antibody producing cell line was deposited at the American Type Culture Collection on November 4, 1992 under the designation HA022CL1 and has the accession No. CRL 11177.

[0205] In still other preferred embodiments, the binding specificity for an Fc receptor is provided by an antibody that binds to a human IgA receptor, e.g., an Fc-alpha receptor (Fc-alphaRI (CD89)), the binding of which is preferably not blocked by human immunoglobulin A (IgA). The term "IgA receptor" is intended to include the gene product of one alpha-gene (Fc-alphaRI) located on chromosome 19. This gene is known to encode several alternatively spliced transmembrane isoforms of 55 to 110 kDa. Fc-alphaRI (CD89) is constitutively expressed on monocytes/macrophages, eosinophilic and neutrophilic granulocytes, but not on non-effector cell populations. Fc-alphaRI has medium affinity for both IgA1 and IgA2, which is increased upon exposure to cytokines such as G-CSF or GM-CSF (Morton, H. C. et al. (1996) Critical

Reviews in Immunology 16: 423-440). Four Fc-alphaRI-specific monoclonal antibodies, identified as A3, A59, A62 and A77, which bind Fc-alphaRI outside the IgA ligand binding domain, have been described (Monteiro, R. C. et al. (1992) J. Immunol. 148: 1764).

[0206] Fc-alphaRI and Fc-gammaRI are preferred trigger receptors for use in the invention because they (1) are expressed primarily on immune effector cells, e.g., monocytes, PMNs, macrophages and dendritic cells; (2) are expressed at high levels (e.g., 5,000-100,000 per cell); (3) are mediators of cytotoxic activities (e.g., ADCC, phagocytosis); (4) mediate enhanced antigen presentation of antigens, including self-antigens, targeted to them.

[0207] In another embodiment the bispecific molecule is comprised of two monoclonal antibodies according to the invention which have complementary functional activities, such as one antibody predominately working by inducing CDC and the other antibody predominately working by inducing apoptosis.

[0208] An "effector cell specific antibody" as used herein refers to an antibody or functional antibody fragment that binds the Fc receptor of effector cells. Preferred antibodies for use in the subject invention bind the Fc receptor of effector cells at a site which is not bound by endogenous immunoglobulin.

[0209] As used herein, the term "effector cell" refers to an immune cell which is involved in the effector phase of an immune response, as opposed to the cognitive and activation phases of an immune response. Exemplary immune cells include cells of myeloid or lymphoid origin, e.g., lymphocytes (e.g., B cells and T cells including cytolytic T cells (CTLs), killer cells, natural killer cells, macrophages, monocytes, eosinophils, neutrophils, polymorphonuclear cells, granulocytes, mast cells, and basophils. Some effector cells express specific Fc receptors and carry out specific immune functions. In preferred embodiments, an effector cell is capable of inducing antibody-dependent cellular cytotoxicity (ADCC), e.g., a neutrophil capable of inducing ADCC. For example, monocytes, macrophages, which express FcR are involved in specific killing of target cells and presenting antigens to other components of the immune system, or binding to cells that present antigens. In other embodiments, an effector cell can phagocytose a target antigen, target cell, or microorganism. The expression of a particular FcR on an effector cell can be regulated by humoral factors such as cytokines. For example, expression of Fc-gammaRI has been found to be up-regulated by interferon gamma (IFN-γ). This enhanced expression increases the cytotoxic activity of Fc-gammaRI-bearing cells against targets. An effector cell can phagocytose or lyse a target antigen or a target cell.

[0210] "Target cell" shall mean any undesirable cell in a subject (e.g., a human or animal) that can be targeted by an antibody of the invention. In preferred embodiments, the target cell is a cell expressing or overexpressing CLD18. Cells expressing CLD18 typically include tumor cells.

[0211] Bispecific and multispecific molecules of the present invention can be made using chemical techniques (see e.g., D. M. Kranz et al. (1981) Proc. Natl. Acad. Sci. USA 78:5807), "polydome" techniques (See US 4,474,893, to Reading), or recombinant DNA techniques.

[0212] In particular, bispecific and multispecific molecules of the present invention can be prepared by conjugating the constituent binding specificities, e.g., the anti-FcR and anti-CLD18 binding specificities, using methods known in the art. For example, each binding specificity of the bispecific and multispecific molecule can be generated separately and then conjugated to one another. When the binding specificities are proteins or peptides, a variety of coupling or cross-linking agents can be used for covalent conjugation. Examples of cross-linking agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) (see e.g., Karpovsky et al. (1984) J. Exp. Med. 160: 1686; Liu, MA et al. (1985) Proc. Natl. Acad. Sci. USA 82: 8648). Other methods include those described by Paulus (Behring Ins. Mitt. (1985) No. 78, 118-132); Brennan et al. (Science (1985) 229: 81-83), and Glennie et al. (J. Immunol. (1987) 139: 2367-2375). Preferred conjugating agents are SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, IL).

[0213] When the binding specificities are antibodies, they can be conjugated via sulfhydryl bonding of the C-terminus hinge regions of the two heavy chains. In a particularly preferred embodiment, the hinge region is modified to contain an odd number of sulfhydryl residues, preferably one, prior to conjugation.

[0214] Alternatively, both binding specificities can be encoded in the same vector and expressed and assembled in the same host cell. This method is particularly useful where the bispecific and multispecific molecule is a mAb x mAb, mAb x Fab, Fab x F(ab')₂ or ligand x Fab fusion protein. A bispecific and multispecific molecule of the invention, e.g., a bispecific molecule, can be a single chain molecule, such as a single chain bispecific antibody, a single chain bispecific molecule comprising one single chain antibody and a binding determinant, or a single chain bispecific molecule comprising two binding determinants. Bispecific and multispecific molecules can also be single chain molecules or may comprise at least two single chain molecules. Methods for preparing bi- and multispecific molecules are described for example in US 5,260,203; US 5,455,030; US 4,881,175; US 5,132,405; US 5,091,513; US 5,476,786; US 5,013,653; US 5,258,498; and US 5,482,858.

[0215] Binding of the bispecific and multispecific molecules to their specific targets can be confirmed by enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay (RIA), FACS analysis, a bioassay (e.g., growth inhibition), or a Western Blot Assay. Each of these assays generally detects the presence of protein-antibody complexes of particular

interest by employing a labeled reagent (e.g., an antibody) specific for the complex of interest. For example, the FcR-antibody complexes can be detected using e.g., an enzyme-linked antibody or antibody fragment which recognizes and specifically binds to the antibody-FcR complexes. Alternatively, the complexes can be detected using any of a variety of other immunoassays. For example, the antibody can be radioactively labeled and used in a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986). The radioactive isotope can be detected by such means as the use of a γ -counter or a scintillation counter or by autoradiography.

II. Immunoconjugates

[0216] In another aspect, the present invention features an anti-CLD18 antibody conjugated to a therapeutic moiety or agent, such as a cytotoxin, a drug (e.g., an immunosuppressant) or a radioisotope. Such conjugates are referred to herein as "immunoconjugates". Immunoconjugates which include one or more cytotoxins are referred to as "immuno-toxins". A cytotoxin or cytotoxic agent includes any agent that is detrimental to and, in particular, kills cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.

[0217] Suitable therapeutic agents for forming immunoconjugates of the invention include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC), and anti-mitotic agents (e.g., vincristine and vinblastine). In a preferred embodiment, the therapeutic agent is a cytotoxic agent or a radiotoxic agent. In another embodiment, the therapeutic agent is an immunosuppressant. In yet another embodiment, the therapeutic agent is GM-CSF. In a preferred embodiment, the therapeutic agent is doxorubicin, cisplatin, bleomycin, sulfate, carmustine, chlorambucil, cyclophosphamide or ricin A.

[0218] Antibodies of the present invention also can be conjugated to a radioisotope, e.g., iodine-131, yttrium-90 or indium-111, to generate cytotoxic radiopharmaceuticals for treating a CLD18-related disorder, such as a cancer. The antibody conjugates of the invention can be used to modify a given biological response, and the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, an enzymatically active toxin, or active fragment thereof, such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor or interferon- γ ; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

[0219] Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxic Conjugates", Immunol. Rev., 62: 119-58 (1982).

[0220] In a further embodiment, the antibodies according to the invention are attached to a linker-chelator, e.g., tiuxetan, which allows for the antibody to be conjugated to a radioisotope.

III. Pharmaceutical Compositions

[0221] In another aspect, the present invention provides a composition, e.g., a pharmaceutical composition, containing one or a combination of antibodies of the present invention. The pharmaceutical compositions may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. In one embodiment, the compositions include a combination of multiple (e.g., two or more) isolated antibodies of the invention which act by different mechanisms, e.g., one antibody which predominately acts by inducing CDC in combination with another antibody which predominately acts by inducing

apoptosis.

[0222] Pharmaceutical compositions of the invention also can be administered in combination therapy, i.e., combined with other agents. For example, the combination therapy can include a composition of the present invention with at least one anti-inflammatory agent or at least one immunosuppressive agent. In one embodiment such therapeutic agents include one or more anti-inflammatory agents, such as a steroidal drug or a NSAID (nonsteroidal anti-inflammatory drug). Preferred agents include, for example, aspirin and other salicylates, Cox-2 inhibitors, such as rofecoxib (Vioxx) and celecoxib (Celebrex), NSAIDs such as ibuprofen (Motrin, Advil), fenoprofen (Nalfon), naproxen (Naprosyn), sulindac (Clinoril), diclofenac (Voltaren), piroxicam (Feldene), ketoprofen (Orudis), diflunisal (Dolobid), nabumetone (Relafen), etodolac (Lodine), oxaprozin (Daypro), and indomethacin (Indocin).

[0223] In another embodiment, such therapeutic agents include agents leading to the depletion or functional inactivation of regulatory T cells like low dose cyclophosphamid, anti-CTLA4 antibodies, anti-IL2 or anti-IL2-receptor antibodies.

[0224] In yet another embodiment, such therapeutic agents include one or more chemotherapeutics, such as Taxol derivatives, taxotere, gemcitabin, 5-Fluoruracil, doxorubicin (Adriamycin), cisplatin (Platinol), cyclophosphamide (Cytosan, Procytox, Neosar). In another embodiment, antibodies of the present invention may be administered in combination with chemotherapeutic agents, which preferably show therapeutic efficacy in patients suffering from stomach, esophageal, pancreatic and lung cancer.

[0225] In yet another embodiment, the antibodies of the invention may be administered in conjunction with radiotherapy and/or autologous peripheral stem cell or bone marrow transplantation.

[0226] In still another embodiment, the antibodies of the invention may be administered in combination with one or more antibodies selected from anti-CD25 antibodies, anti-EPCAM antibodies, anti-EGFR, anti-Her2/neu, and anti-CD40 antibodies. In yet a further embodiment, the antibodies of the invention may be administered in combination with an anti-C3b(i) antibody in order to enhance complement activation.

[0227] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spiral or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, i.e., antibody, bispecific and multispecific molecule, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

[0228] A "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see e.g., Berge, S. M., et al. (1977) J. Pharm. Sci. 66: 1-19).

[0229] Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic and phosphorous, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanic acids, hydroxy alkanic acids, aromatic acids, aliphatic and aromatic sulfonic acids. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium and calcium, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chlorprocaine, choline, diethanolamine, ethylenediamine and procaine.

[0230] A composition of the present invention can be administered by a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for the preparation of such formulations are generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[0231] To administer a compound of the invention by certain routes of administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. For example, the compound may be administered to a subject in an appropriate carrier, for example, liposomes, or a diluent. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al. (1984) J. Neuroimmunol. 7: 27).

[0232] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0233] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high

drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

[0234] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization microfiltration.

[0235] Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0236] Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

[0237] Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite and sodium sulfite; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate and alpha-tocopherol; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid and phosphoric acid.

[0238] For the therapeutic compositions, formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated, and the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the composition which produces a therapeutic effect.

[0239] Generally, out of one hundred per cent, this amount will range from about 0.01 per cent to about ninety-nine percent of active ingredient, preferably from about 0.1 percent to about 70 percent, most preferably from about 1 percent to about 30 percent.

[0240] Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate. Dosage forms for the topical or transdermal administration of compositions of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

[0241] The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.

[0242] Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol and polyethylene glycol), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0243] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the presence of microorganisms may be ensured both by sterilization procedures, and

by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, and phenol sorbic acid. It may also be desirable to include isotonic agents, such as sugars and sodium chloride into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

[0244] In one embodiment the monoclonal antibodies of the invention are administered in crystalline form by subcutaneous injection, cf. Yang et al. (2003) PNAS, 100 (12): 6934-6939. When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given alone or as a pharmaceutical composition containing, for example, 0.01 to 99.5% (more preferably, 0.1 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.

[0245] Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.

[0246] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0247] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, a suitable daily dose of a composition of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. It is preferred that administration be intravenous, intramuscular, intraperitoneal, or subcutaneous, preferably administered proximal to the site of the target. If desired, the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation (composition).

[0248] In one embodiment, the antibodies of the invention may be administered by infusion, preferably slow continuous infusion over a long period, such as more than 24 hours, in order to reduce toxic side effects. The administration may also be performed by continuous infusion over a period of from 2 to 24 hours, such as of from 2 to 12 hours. Such regimen may be repeated one or more times as necessary, for example, after 6 months or 12 months. The dosage can be determined or adjusted by measuring the amount of circulating monoclonal anti-CLD18 antibodies upon administration in a biological sample by using anti-idiotypic antibodies which target the anti-CLD18 antibodies.

[0249] In yet another embodiment, the antibodies are administered by maintenance therapy, such as, e.g., once a week for a period of 6 months or more.

[0250] In still another embodiment, the antibodies according to the invention may be administered by a regimen including one infusion of an antibody against CLD18 followed by an infusion of an antibody against CLD18 conjugated to a radioisotope. The regimen may be repeated, e.g., 7 to 9 days later.

[0251] Therapeutic compositions can be administered with medical devices known in the art. For example, in a preferred embodiment, a therapeutic composition of the invention can be administered with a needleless hypodermic injection device, such as the devices disclosed in US 5,399,163; US 5,383,851; US 5,312,335; US 5,064,413; US 4,941,880; US 4,790,824; or US 4,596,556. Examples of well-known implants and modules useful in the present invention include those described in: US 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; US 4,486,194, which discloses a therapeutic device for administering medicants through the skin; US 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; US 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; US 4,439,196, which discloses an osmotic drug delivery system having multi-chamber compartments; and US 4,475,196, which discloses an osmotic drug delivery system.

[0252] Many other such implants, delivery systems, and modules are known to those skilled in the art. In certain embodiments, the antibodies of the invention can be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds of the invention cross the BBB (if desired), they can be formulated, for example, in liposomes. For methods of manufacturing liposomes, see, e.g., US 4,522,811; US 5,374,548; and US 5,399,331. The liposomes may comprise one or more moieties which are selectively transported into specific cells or organs, and thus enhance targeted drug delivery (see,

e.g., V.V. Ranade (1989) J. Clin. Pharmacol. 29: 685). Exemplary targeting moieties include folate or biotin (see, e.g., US 5,416,016 to Low et al.); mannosides (Umezawa et al., (1988) Biochem. Biophys. Res. Commun. 153: 1038); antibodies (P.G. Bloeman et al. (1995) FEBS Lett. 357: 140; M. Owais et al. (1995) Antimicrob. Agents Chemother. 39: 180); and surfactant protein A receptor (Briscoe et al. (1995) Am. J. Physiol. 1233: 134).

[0253] In one embodiment of the invention, the therapeutic compounds of the invention are formulated in liposomes. In a more preferred embodiment, the liposomes include a targeting moiety. In a most preferred embodiment, the therapeutic compounds in the liposomes are delivered by bolus injection to a site proximal to the desired area, e.g., the site of a tumor. The composition must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.

[0254] In a further embodiment, antibodies of the invention can be formulated to prevent or reduce their transport across the placenta. This can be done by methods known in the art, e.g., by PEGylation of the antibodies or by use of F(ab)2' fragments. Further references can be made to "Cunningham-Rundles C, Zhuo Z, Griffith B, Keenan J. (1992) Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation. J. Immunol. Methods, 152: 177-190; and to "Landor M. (1995) Maternal-fetal transfer of immunoglobulins, Ann. Allergy Asthma Immunol. 74: 279-283.

[0255] A "therapeutically effective dosage" for tumor therapy can be measured by objective tumor responses which can either be complete or partial. A complete response (CR) is defined as no clinical, radiological or other evidence of disease. A partial response (PR) results from a reduction in aggregate tumor size of greater than 50%. Median time to progression is a measure that characterizes the durability of the objective tumor response.

[0256] A "therapeutically effective dosage" for tumor therapy can also be measured by its ability to stabilize the progression of disease. The ability of a compound to inhibit cancer can be evaluated in an animal model system predictive of efficacy in human tumors. Alternatively, this property of a composition can be evaluated by examining the ability of the compound to inhibit cell growth or apoptosis by in vitro assays known to the skilled practitioner. A therapeutically effective amount of a therapeutic compound can decrease tumor size, or otherwise ameliorate symptoms in a subject. One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.

[0257] The composition must be sterile and fluid to the extent that the composition is deliverable by syringe. In addition to water, the carrier can be an isotonic buffered saline solution, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by use of coating such as lecithin, by maintenance of required particle size in the case of dispersion and by use of surfactants. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition. Long-term absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.

[0258] When the active compound is suitably protected, as described above, the compound may be orally administered, for example, with an inert diluent or an assimilable edible carrier.

IV. Uses and Methods of the Invention

[0259] The antibodies (including immunoconjugates, bispecifics/multispecifics, compositions and other derivatives described herein) of the present invention have numerous therapeutic utilities involving the treatment of disorders involving cells expressing CLD18. For example, the antibodies can be administered to cells in culture, e.g., in vitro or ex vivo, or to human subjects, e.g., in vivo, to treat or prevent a variety of disorders such as those described herein. As used herein, the term "subject" is intended to include human and non-human animals which respond to the antibodies against CLD18. Preferred subjects include human patients having disorders that can be corrected or ameliorated by killing diseased cells, in particular cells characterized by an altered expression pattern of CLD18 compared to normal cells.

[0260] A therapeutic effect in the treatments discussed herein is preferably achieved through the functional properties of the antibodies of the invention to mediate killing of cells e.g. by inducing complement dependent cytotoxicity (CDC) mediated lysis, antibody dependent cellular cytotoxicity (ADCC) mediated lysis, apoptosis, homotypic adhesion, and/or phagocytosis, preferably by inducing CDC mediated lysis and/or ADCC mediated lysis.

[0261] For example, in one embodiment, antibodies of the present invention can be used to treat a subject with a tumorigenic disorder, e.g., a disorder characterized by the presence of tumor cells expressing CLD18 including, for example, gastric cancer. Examples of tumorigenic diseases which can be treated and/or prevented encompass all CLD18 expressing cancers and tumor entities including stomach cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, breast cancer, colorectal cancer, hepatic cancer, cancer of the gallbladder and head-neck cancer. These cancers may be in early, intermediate or advanced stages, e.g. metastasis.

[0262] The pharmaceutical compositions and methods of treatment described according to the invention may also be used for immunization or vaccination to prevent a disease described herein.

[0263] In another embodiment, antibodies of the invention can be used to detect levels of CLD18 or particular forms of CLD18, or levels of cells which contain CLD18 on their membrane surface, which levels can then be linked to certain diseases or disease symptoms such as described above. Alternatively, the antibodies can be used to deplete or interact with the function of CLD18 expressing cells, thereby implicating these cells as important mediators of the disease. This can be achieved by contacting a sample and a control sample with the anti-CLD18 antibody under conditions that allow for the formation of a complex between the antibody and CLD18. Any complexes formed between the antibody and CLD18 are detected and compared in the sample and a control sample, i.e. a reference sample.

[0264] Antibodies of the invention can be initially tested for their binding activity associated with therapeutic or diagnostic uses in vitro. For example, the antibodies can be tested using flow cytometric assays as described herein.

[0265] Moreover, activity of the antibodies in triggering at least one effector-mediated effector cell activity, including inhibiting the growth of and/or killing of cells expressing CLD18, can be assayed. For example, the ability of the antibodies to trigger CDC and/or apoptosis can be assayed. Protocols for assaying for CDC, homotypic adhesion, molecular clustering or apoptosis are described herein.

[0266] The antibodies of the invention can be used to elicit in vivo or in vitro one or more of the following biological activities: to inhibit the growth of and/or differentiation of a cell expressing CLD18; to kill a cell expressing CLD18; to mediate phagocytosis or ADCC of a cell expressing CLD18 in the presence of effector cells; to mediate CDC of a cell expressing CLD18 in the presence of complement; to mediate apoptosis of a cell expressing CLD18; to induce homotypic adhesion; and/or to induce translocation into lipid rafts upon binding CLD18.

[0267] In a particular embodiment, the antibodies are used in vivo or in vitro to treat, prevent or diagnose a variety of CLD18-related diseases. Examples of CLD18-related diseases include, among others, cancers such as gastric cancer, pancreatic cancer, esophageal cancer, lung cancer and cancers as those listed above.

[0268] CLD18A2 is also expressed in differentiated normal stomach cells. Possible antibody induced clinical side effects by killing of these cells may be reduced or avoided by parallel administration of stomach protective drugs such as antacids, or inhibitors of the gastric proton pump such as omeprazol or related drugs.

[0269] Suitable routes of administering the antibody compositions of the invention in vivo and in vitro are well known in the art and can be selected by those of ordinary skill.

[0270] As described above, anti-CLD18 antibodies of the invention can be co-administered with one or other more therapeutic agents, e.g., a cytotoxic agent, a radiotoxic agent, antiangiogenic agent or and immunosuppressive agent to reduce the induction of immune responses against the antibodies of invention. The antibody can be linked to the agent (as an immunocomplex) or can be administered separate from the agent. In the latter case (separate administration), the antibody can be administered before, after or concurrently with the agent or can be co-administered with other known therapies, e.g., an anti-cancer therapy, e.g., radiation. Such therapeutic agents include, among others, anti-neoplastic agents such as listed above. Co-administration of the anti-CLD18 antibodies of the present invention with chemotherapeutic agents provides two anti-cancer agents which operate via different mechanisms yielding a cytotoxic effect to tumor cells. Such co-administration can solve problems due to development of resistance to drugs or a change in the antigenicity of the tumor cells which would render them unreactive with the antibody.

[0271] In another particular embodiment of the invention, the subject being administered the antibody is additionally treated with an antiangiogenic agent including antibodies targeting VEGF or VEGFR and one or more chemical compounds inhibiting angiogenesis. Pretreatment with or parallel application of these drugs may improve the penetration of antibodies in bulk tumors.

[0272] In another particular embodiment of the invention, the subject being administered the antibody is additionally treated with a compound inhibiting growth factor receptor signaling including monoclonal antibodies binding to the EGFR receptor as well as chemical compounds inhibiting signaling initiated by the EGFR, Her1 or Her2/neu receptor.

[0273] Target-specific effector cells, e.g., effector cells linked to compositions (e.g. antibodies, multispecific and bispecific molecules) of the invention can also be used as therapeutic agents. Effector cells for targeting can be human leukocytes such as macrophages, neutrophils or monocytes. Other cells include eosinophils, natural killer cells and other IgG- or IgA-receptor bearing cells. If desired, effector cells can be obtained from the subject to be treated. The target-specific effector cells can be administered as a suspension of cells in a physiologically acceptable solution. The number of cells administered can be in the order of 10^8 to 10^9 but will vary depending on the therapeutic purpose. In general, the amount will be sufficient to obtain localization at the target cell, e.g., a tumor cell expressing CLD18, and to effect cell killing by, e.g., phagocytosis. Routes of administration can also vary.

[0274] Therapy with target-specific effector cells can be performed in conjunction with other techniques for removal of targeted cells. For example, anti-tumor therapy using the compositions of the invention and/or effector cells armed with these compositions can be used in conjunction with chemotherapy. Additionally, combination immunotherapy may be used to direct two distinct cytotoxic effector populations toward tumor cell rejection. For example, anti-CLD18 antibodies linked to anti-Fc-RI or anti-CD3 may be used in conjunction with IgG- or IgA-receptor specific binding agents.

[0275] Bispecific and multispecific molecules of the invention can also be used to modulate Fc-gammaR or Fc-alphaR levels on effector cells, such as by capping and eliminating receptors on the cell surface. Mixtures of anti-Fc receptors

can also be used for this purpose.

[0276] The compositions (e.g., antibodies, multispecific and bispecific molecules and immunoconjugates) of the invention which have complement binding sites, such as portions from IgG1, -2, or -3 or IgM which bind complement, can also be used in the presence of complement. In one embodiment, ex vivo treatment of a population of cells comprising target cells with a binding agent of the invention and appropriate effector cells can be supplemented by the addition of complement or serum containing complement. Phagocytosis of target cells coated with a binding agent of the invention can be improved by binding of complement proteins. In another embodiment target cells coated with the compositions of the invention can also be lysed by complement. In yet another embodiment, the compositions of the invention do not activate complement.

[0277] The compositions of the invention can also be administered together with complement. Accordingly, within the scope of the invention are compositions comprising antibodies, multispecific or bispecific molecules and serum or complement. These compositions are advantageous in that the complement is located in close proximity to the antibodies, multispecific or bispecific molecules.

[0278] Alternatively, the antibodies, multispecific or bispecific molecules of the invention and the complement or serum can be administered separately. Binding of the compositions of the present invention to target cells causes translocation of the CLD18 antigen-antibody complex into lipid rafts of the cell membrane. Such translocation creates a high density of antigen-antibody complexes which may efficiently activate and/or enhance CDC.

[0279] Also within disclosed are kits, comprising the antibody compositions of the invention (e.g., antibodies and immunoconjugates) and instructions for use. The kit can further contain one or more additional reagents, such as an immunosuppressive reagent, a cytotoxic agent or a radiotoxic agent, or one or more additional antibodies of the invention (e.g., an antibody having a complementary activity).

[0280] Accordingly, patients treated with antibody compositions of the invention can be additionally administered (prior to, simultaneously with, or following administration of an antibody of the invention) with another therapeutic agent, such as a cytotoxic or radiotoxic agent, which enhances or augments the therapeutic effect of the antibodies of the invention.

[0281] The subject can be additionally treated with an agent that modulates, e.g., enhances or inhibits, the expression or activity of Fc-gamma or Fc-alpha receptors by, for example, treating the subject with a cytokine. Preferred cytokines include granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon- γ (IFN- γ), and tumor necrosis factor (TNF). Other important agents for increasing the therapeutic efficacy of the antibodies and pharmaceutical compositions described herein are β -glucans which are homopolysaccharides of branched glucose residues and are produced by a variety of plants and microorganisms, for example, bacteria, algae, fungi, yeast and grains. Fragments of β -glucans produced by organisms may be also be used. Preferably, the β -glucan is a polymer of β (1,3) glucose wherein at least some of the backbone glucose units, e.g. 3-6 % of the backbone glucose units, possess branches such as β (1,6) branches.

[0282] The specification also discloses methods for detecting the presence of CLD18 antigen in a sample, or measuring the amount of CLD18 antigen, comprising contacting the sample, and a control sample, with a antibody which specifically binds to CLD18, under conditions that allow for formation of a complex between the antibody or portion thereof and CLD18. The formation of a complex is then detected, wherein a difference complex formation between the sample compared to the control sample is indicative for the presence of CLD 18 antigen in the sample.

[0283] The specification also discloses a method for detecting the presence or quantifying the amount of CLD18-expressing cells in vivo or in vitro. The method comprises (i) administering to a subject a composition of the invention conjugated to a detectable marker; (ii) exposing the subject to a means for detecting said detectable marker to identify areas containing CLD18-expressing cells.

[0284] Methods as described above are useful, in particular, for diagnosing CLD18-related diseases and/or the localization of CLD18-related diseases such as cancer diseases. Preferably an amount of CLD18, preferably CLD18-A2 in a sample which is higher than the amount of CLD18, preferably CLD18-A2, in a control sample is indicative for the presence of a CLD18-related disease in a subject, in particular a human, from which the sample is derived.

[0285] Immunoconjugates of the invention can be used to target compounds (e.g., therapeutic agents, labels, cytotoxins, radiotoxins immunosuppressants, etc.) to cells which have CLD18 expressed on their surface by linking such compounds to the antibody. Thus, the specification also discloses methods for localizing ex vivo or in vitro cells expressing CLD18, such as circulating tumor cells.

[0286] The present invention is further illustrated by the following examples.

EXAMPLES

1. Generation of murine antibodies against CLD18

a. Immunizations:

[0287] Balb/c or C57/BL6 mice were immunized with eucaryotic expression vectors, encoding human CLD18 fragments (SEQ ID NO: 15, 16; 17, 18). 50 µg or 25 µg of plasmid DNA was injected into the quadriceps (intramuscular, i.m.) on days 1 and 10 for generation of monoclonal antibodies of Set1 or alternatively on days 1 and 9, 1 and 11, or 1, 16 and 36 for generation of monoclonal antibodies of Set2 in the presence of adjuvants, for example CpG (for details see Tab. 1b). CpG as well as cells transfected with CLD18A2 (SEQ ID NO: 1) alone or co-transfected additionally with murine soluble CD40L encoding RNA were injected intramuscularly, PEI-Man was injected intramuscularly or intraperitoneally. The presence of antibodies directed against human CLD18 in sera of mice was monitored by immune fluorescence microscopy between day 16 and 43 depending on the specific immunization protocol used. The immune fluorescence was determined using HEK293 cells transiently transfected with a nucleic acid encoding a fusion construct comprising human CLD18A2 (SEQ ID NOs: 1, 2) and a fluorescent reporter protein. Mice with detectable immune responses (Fig. 1) were boosted three days prior to splenectomy for generation of monoclonal antibodies of Set1 or mice were boosted three days, three and two days, or mice were boosted four, three and two days prior to splenectomy for generation of monoclonal antibodies of Set2 by intraperitoneal injection of 5×10^7 or alternatively 1×10^8 HEK293 cells transiently transfected with a nucleic acid encoding human CLD18A2 (SEQ ID NOs: 1, 2) (for details see Tab. 1b). In Tab. 1a the immunization protocols used are dedicated to the respective monoclonal antibodies.

Tab. 1a: Immunisation protocols used for generation of monoclonal antibodies

mAB	Immunisation protocol*	mAB	Immunisation protocol
Set1			
24H5	40	42E12	45
26B5	40	43A11	45
26D12	40	44E10	45
28D10	40	47D12	45
37G11	45	61C2	45
37H8	45	75B8	6
38G5	45	85A3	6
38H3	45	9E8	40
39F11	45	19B9	40
41C6	45		
Set2			
45C1	53	166E2	51
125E1	45	175D10	51
163E12	51		
* For specific immunization protocols see Tab. 1b			

Tab. 1b: Detailed immunisation protocols

Immunisation protocol	Immunisation (prime and boosts with DNA)			Serum -monitoring	Boosts with transfected cells		
	with DNA vectors encoding CLD18 fragments	with adjuvant	on day		Cells transfected with CLD18A2 (SEQ ID NO: 1) alone	Cells co-transfected with CLD18A2 (SEQ ID NO: 1) and with murine soluble CD40L encoding RNA	days prior to splenectomy
6	SEQ ID NO: 15: 50µg	50µg CpG	1 and 10	18	5 x 10 ⁷ transfected MC3T3 cells	none	3
40	SEQ ID NO: 17: 50µg	50µg CpG	1 and 10	18		5 x 10 ⁷ HEK293 cells; 100µg CPG as adjuvant	3
45	SEQ ID NO: 15: 50µg	50µg CpG	1 and 9	16		1 x 10 ⁸ HEK293 cells	3
51	SEQ ID NO: 15: 25µg	2,5 µl PEI-Man* (150 mM) in H ₂ O with 5% Glucose	1, 16 and 36	22,30 and 43	5 x 10 ⁷ transfected HEK293 cells	none	3 and 2
53	Priming: SEQ ID NO: 15: 25µg, and SEQ ID NO: 17 : 25µg; Boosting: SEQ ID NO: 17: 50µg	50µg CpG in H ₂ O with 5% Glucose	1 and 11	20	5 x 10 ⁷ transfected HEK293 cells	none	4, 3 and 2
* in vivo-jetPEI™ Man from PolyPlus Transfection							

b. Generation of hybridomas producing human monoclonal antibodies to CLD18:

[0288] Mouse splenocytes were isolated and fused with PEG to a mouse myeloma cell line based on standard protocols. The resulting hybridomas were then screened for production of immunoglobulines with CLD18 specificity using HEK293 cells transfected with a nucleic acid encoding human CLD18 by FACS analysis. Single cell suspensions of splenic lymphocytes from immunized mice were fused with P3X63Ag8U.1 nonsecreting mouse myeloma cells (ATCC, CRL 1597) in a 2:1 ratio using 50% PEG (Roche Diagnostics, CRL 738641). Cells were plated at approximately 3 x 10⁴/well in flat bottom microtiter plates, followed by about two week incubation in selective medium containing 10% fetal bovine serum, 2% hybridoma fusion and cloning supplement (HFCS, Roche Diagnostics, CRL 1 363 735) plus 10 mM HEPES, 0.055 mM 2-mercaptoethanol, 50 µg/ml gentamycin and 1x HAT (Sigma, CRL H0262). After 10 to 14 days individual wells were screened by flow cytometry for anti-CLD18 monoclonal antibodies. The antibody secreting hybridomas were replated, screened again and, if still positive for anti-CLD18 monoclonal antibodies, were subcloned by limiting dilution.

EP 2 311 877 B1

The stable subclones were then cultured in vitro to generate small amounts of antibody in tissue culture medium for characterization. At least one clone from each hybridoma, which retained the reactivity of parent cells (by FACS), was chosen. 9 vial cell banks were generated for each clone and stored in liquid nitrogen.

c. Selection of monoclonal antibodies binding to CLD18:

[0289] To determine the isotype of antibodies, an isotype ELISA was performed. The mouse monoAB ID Kit (Zymed, CRL 90-6550) or alternatively the IsoStrip Mouse Monoclonal Antibody Isotyping Kit (Roche, Cat. No. 1493027) was used to determine Ig subclasses of the identified CLD18 reactive monoclonal antibodies. Defined as Set1, nineteen hybridoma cell lines were generated, six from a fusion of cells from a C57/BL6 mouse immunized with CLD18A2-LoopD3 (SEQ ID NOs: 17, 18), thirteen from a fusion of cells from a Balb/c mouse immunized with CLD18A2-LoopI (SEQ ID NOs: 15, 16), expressing the following antibodies:

24H5, 26B5, 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, 61C2, 75B8, 85A3, 9E8, 19B9

24H5: mouse monoclonal IgG2b, antibody, 182-D758-034

26B5: mouse monoclonal IgG2a, antibody, 182-D758-035, DSM ACC2745

26D12: mouse monoclonal IgG3, antibody, 182-D758-036, DSM ACC2746

28D10: mouse monoclonal IgG3, antibody, 182-D758-040, DSM ACC2747

37G11: mouse monoclonal IgG2a, antibody, 182-D1106-055, DSM ACC2737

37H8: mouse monoclonal IgG3, antibody, 182-D1106-056, DSM ACC2738

38G5: mouse monoclonal IgG3, antibody, 182-D1106-057, DSM ACC2739

38H3: mouse monoclonal IgG3, antibody, 182-D1106-058, DSM ACC2740

39F11: mouse monoclonal IgG3, antibody, 182-D1106-059, DSM ACC2741

41C6: mouse monoclonal IgG2a, antibody, 182-D1106-060

42E12: mouse monoclonal IgG2a, antibody, 182-D1106-061, DSM ACC2748

43A11: mouse monoclonal IgG2a, antibody, 182-D1106-062, DSM ACC2742

44E10: mouse monoclonal IgG3, antibody, 182-D1106-063

47D12: mouse monoclonal IgG3, antibody, 182-D1106-064

61C2: mouse monoclonal IgG2b, antibody, 182-D1106-067, DSM ACC2743

75B8: mouse monoclonal IgM, antibody, 182-D756-001

85A3: mouse monoclonal IgM, antibody, 182-D756-002

9E8: mouse monoclonal IgM, antibody, 182-D758-011

19B9: mouse monoclonal IgM, antibody, 182-D758-024

[0290] Defined as Set2, five hybridoma cell lines were generated, one from a fusion of cells from a Balb/c mouse immunized with CLD18A2-LoopD3 (SEQ ID NOs: 17, 18) and CLD18A2-LoopD1 (SEQ ID NOs: 15, 16), four from a fusion of cells from a Balb/c mouse immunized with CLD18A2-LoopD1 (SEQ ID NOs: 15, 16), expressing the following antibodies:

45C1, 125E1, 163E12, 166E2, 175D10

45C1: mouse monoclonal IgG2a, antibody, 182-D758-187

125E1: mouse monoclonal IgG2a, antibody, 182-D1106-279, DSM ACC2808

163E12: mouse monoclonal IgG3, antibody, 182-D1106-294, DSM ACC2809

166E2: mouse monoclonal IgG3, antibody, 182-D1106-308

175D10: mouse monoclonal IgG1, antibody, 182-D1106-362, DSM ACC2810

2. Production of Monoclonal Antibodies

[0291] Production and purification of monoclonal antibodies reactive to CLD18:

To produce mg amounts of antibody for functional characterization, hybridoma cells were seeded in dialysis based bioreactors (CELLLine CL1000, Integra, Chur, CH) at 2×10^6 cells / ml. Antibody containing supernatant was harvested once weekly. Mouse monoclonal antibody was purified using Melon Gel (Pierce, Rockford, USA) and concentrated by ammonium sulphate precipitation or alternatively purified by ProteinA using FPLC. Antibody concentration and purity was determined by BCA-Assay and purity checked by sodium dodecylsulphate gel electrophoresis and coomassie staining.

3. Binding Characteristics of Monoclonal Antibodies

a. Quality control of transfectants in WB, IF:

[0292] To generate CLD18A2 expressing cells, HEK293 or CHO cells were transfected with nucleic acids encoding CLD18A2 (SEQ ID NOs: 1, 2) or CLD18A2-myc (SEQ ID NOs: 3, 4).

[0293] HEK293 cells were transfected with CLDN18A2-myc (SEQ ID NOs: 3, 4) or left untransfected. 24 hours post transfection, cells were harvested, lysed and subjected to sodium dodecylsulphate gel electrophoresis. The gel was blotted and stained with a mouse anti-myc antibody. After incubation with a peroxidase labelled anti mouse antibody, the blot was developed with ECL reagent and visualized using a LAS-3000 imager (Fuji). Only in the transfected cells but not in the negative control, a band with the expected molecular weight of CLD18-myc was observed (Fig. 2).

[0294] CHO cells were transfected with CLD18A2 (SEQ ID NOs: 1, 2) and grown on chamber slides for 24 h. Cells were fixed with methanol and stained with a rabbit polyclonal antibody against CLD 18 at 1 µg/ml for 60 min. at 25°C. After washing, cells were stained with an Alexa488 labelled goat anti-rabbit IgG (Molecular Probes) and evaluated by fluorescence microscopy. Fig. 3 shows transfected CHO cells, expressing CLD18 on the cell membrane as well as untransfected cells.

[0295] These heterologously CLD18 expressing cells were used for the following assays to test the specificity of antibody binding.

b. Selection of Monoclonal Antibodies Binding to CLD18/Primary Screens by Flow Cytometry:

[0296] HEK293 cells were co-transfected with expression vectors encoding human CLD18A2 (SEQ ID NOs: 1, 2) and a fluorescing reporter protein 40 h prior to the assay or alternatively HEK293 cells stably expressing human CLD18A2 (HEK293-CLD18A2) were used and counterstained with propidium iodide (PI). After cell detachment using 2mM EDTA/PBS cells were washed with complete growth medium and plated at approximately $1-5 \times 10^5$ cells/well in U-bottom microtiter plates. Cells were incubated for 30 min. at 4° C with hybridoma supernatant followed by two washing steps with 1% heatinactivated FBS/PBS and finally incubation with APC or Alexa647-conjugated anti-mouse IgG specific secondary antibody. After two washing steps, co-transfected cells were fixed with CellFIX (BD Biosciences). Binding was assessed by flow cytometry using a BD FACSAArray. Fluorescence marker expression is plotted on the horizontal axis against antibody binding on the vertical axis. All mouse antibodies 24H5, 26B5, 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, 61C2, 75B8, 85A3, 9E8, 19B9, 45C1, 125E1, 163E12, 166E2, and 175D10 were detected to bind specifically to the surface of fluorescence marker expressing cells (Fig. 4, cells in Q2) as exemplified for hybridoma supernatants containing monoclonal antibodies 24H5 (Fig. 4A, cells in Q2), 85A3 (Fig. 4B), 175D10, 125E1, 163E12, 166E2 and 45C1 (Fig. 4C, cells in Q1).

c. Comparison of antibody binding to Myc- or HA-tagged CLD18A2:

[0297] The binding characteristics of the identified CLD18-specific monoclonal antibodies were further specified. Therefore, monoclonal antibody binding was analyzed to CLD18A2 mutants, created by insertion of epitope tags. CLD18A2-HA (SEQ ID NO: 6) contains a HA-epitope tag in CLD18A2-loop1, whereas CLD18A2-Myc (SEQ ID NO: 4) contains a Myc-epitope tag inserted into CLD18A2-loop2. As insertion of these tags causes destruction of epitopes, the identified monoclonal antibodies, can be grouped according to the loss of binding to any of the mutants.

[0298] HEK293 cells transiently co-transfected with a fluorescence marker and human CLD18A2, or with a fluorescence marker and CLD18A2-HA, or with a fluorescence marker and CLD18A2-Myc were incubated with hybridoma supernatants containing CLD18-specific monoclonal antibodies for 30 min. at 4°C, followed by incubation with Alexa647-conjugated anti-mouse IgG secondary antibody. Before analysis on a BD FACSAArray, cells were fixed using CellFIX. As exemplified for 24H5, 9E8, 26B5 and 19B9 in Fig. 5, monoclonal antibodies could be separated based on their binding characteristics into four different groups: (i) antibodies that bind to unmodified CLD18A2 as well as to CLD18A2-HA and CLD18A2-Myc, e.g. 24H5, (Fig. 5A), or (ii) antibodies that do not bind to CLD18A2-HA, e.g. 9E8, (Fig. 5B), or (iii) antibodies that do not bind to CLD18A2-Myc, e.g. 26B5, (Fig. 5C), or (iv) antibodies that do not bind to CLD18A2-HA nor to CLD18A2-Myc, e.g. 19B9, (Fig. 5D).

d. Comparison of antibody binding to human CLD18A1 versus CLD18A2 transfectants by flow cytometry:

[0299] Binding specificity of the identified monoclonal antibodies to CLD18A2 isoforms was analyzed by flow cytometry. HEK293 cells stably expressing human CLD18A2 (HEK293-CLD18A2) and HEK293 cells stably expressing human CLD18A1 (SEQ ID NOs: 7, 8) (HEK293-CLD18A1) were incubated for 30 min. at 4°C with hybridoma supernatants containing monoclonal antibodies, followed by incubation with Alexa647-conjugated anti-mouse IgG secondary antibody

and fixation of cells or alternatively without fixation but with PI counterstaining. Binding was assessed by flow cytometry using a BD FACSArray. Fig. 6 shows examples for the two groups of monoclonal antibodies that were identified in the panel comprised of 24H5, 26B5, 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, 61C2, 75B8, 85A3, 9E8, 19B9, 45C1, 125E1, 163E12, 166E2, 175D10: (i) monoclonal antibodies 43A11, 45C1, and 163E12 bind specifically to human CLD18A2 but not to human CLD18A1 (Fig 6A,B), and (ii) monoclonal antibody 37H8 binds to both human isoforms (Fig 6A).

e. Comparison of antibody binding to human CLD18A1 versus CLD18A2 transfectants by immunofluorescence microscopy:

[0300] HEK293 cells were transiently transfected with an expression vector encoding a fusion protein of CLD18A1 (SEQ ID NO: 8) or CLD18A2 (SEQ ID NO: 2) with a fluorescence reporter and grown on chamber slides. Cells were either stained unfixed or after paraformaldehyde fixation with monoclonal antibody containing tissue culture supernatant for 30 min. at 37°C. After washing, cells were stained with an Alexa555-labelled anti-mouse Ig antibody (Molecular Probes). Binding of antibodies was evaluated by fluorescence microscopy. As shown in Fig. 7, antibody 37G11 specifically reacted with CLD18A2 (Fig. 7A) but not with CLD18A1 (Fig. 7B). In contrast, antibody 26B5 was reactive with both, CLD18A2 and CLD18A1 (Fig. 8).

[0301] For antibodies 24H5, 26B5; 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, 61C2, 75B8, 85A3, 9E8, 19B9, a clear difference between staining of living cells and paraformaldehyde fixed cells was observed. The antibodies formed an uniform membrane staining when cells were fixed (Fig. 7C, 8C, 8D). In contrast, incubation of living cells with these antibodies leads to the generation of protein clusters, visible as a speckle like staining pattern (Fig. 7A, 8A, 8B). This shows that all antibodies bind to native epitopes as found on the surface of living cells.

f. Determination of endogenously expressing cell lines:

[0302] A CLD18A2 gene-specific primer pair (SEQ ID NO: 11, 12) was used in RT-PCR analyses to screen cell lines for expression of CLD18A2. Human gastric carcinoma cell lines NCI-SNU-16 (ATCC CRL-5974), NUGC-4 (JCRB0834) and KATO-III (ATCC HTB-103) and human pancreas adenocarcinoma cell line DAN-G (DSMZ ACC249) were found to display robust endogenous expression of CLD18 (Fig. 9). Expression was confirmed on protein level by staining with a rabbit polyclonal serum against CLD18.

g. Staining of endogenously expressing cell lines with CLD18 specific antibodies and immunofluorescence analysis:

[0303] DAN-G, SNU-16, NUGC-4 and KATO-III cells were grown on chamber slides under standard conditions. Cells were unfixed or alternatively fixed with methanol and stained with the respective antibodies. For antibodies 24H5, 26B5, 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, 61C2, 75B8, 85A3, 9E8, 19B9 staining of the cell surface was observed as exemplified in Fig. 10, 11 and 12A. For antibodies 45C1, 125E1, 163E12, 166E2, and 175D10 native epitope recognition was assayed and cell surface staining was observed on unfixed cells as shown in Fig 12B. Subgroups of antibodies showed homogenous staining of the cell membrane either preponderantly at cell-cell interfaces or at free parts of the membrane not adjacent to other cells. Other antibodies stained discrete foci and aggregates on the cell membrane altogether demonstrating that the respective antibodies bind to different epitopes including epitopes which are masked by homotypic or heterotypic association of CLD18 as well as CLD18 epitopes accessible in preformed tight junctions.

h. Staining of endogenously expressing cell lines by flow cytometry:

[0304] Surface expression of constitutively expressed CLD18A2 on KATO-III and NUGC-4 living cells was analyzed by flow cytometry. This is exemplified by KATO-III and NUGC-4 cells stained with monoclonal antibody 61C2 or 163E12, followed by incubation with Alexa647-conjugated anti-mouse IgG secondary antibody and fixation of cells or alternatively without fixation. Binding was assessed by flow cytometry using a BD FACSArray. Fig. 13 shows a strong binding of 61C2 to at least 70.3% of KATO-III cells and of 163E12 to CLD18A2 on KATO-III and NUGC-4 cells.

i. Sequence alignment of mouse and human CLD18A1 and CLD18A2:

[0305] Human CLD18A2 (NP_001002026) and human CLD18A1 (NP_057453) in a sequence comparison differ in the N-terminus and mouse CLD18 variants (NP_062789 and AAL15636) demonstrate high homology and sequence variation sites between the molecules (see Fig. 14).

j. Reactivity of antibodies with murine CLD18A1 and murine CLD18A2 analyzed by flow cytometry:

[0306] Binding of the identified monoclonal antibodies to murine CLD18A2 and CLD18A1 was analyzed by flow cytometry. HEK293 cells transiently co-transfected with a fluorescence marker and murine CLD18A2 (SEQ ID NOs: 33, 35) or with a fluorescence marker and murine CLD18A1 (SEQ ID NOs: 36, 37) were incubated with hybridoma supernatants containing the human CLD18-specific monoclonal antibodies 38G5, 38H3, 37G11, 45C1 and 163E12, respectively, for 30 min. at 4°C, followed by incubation with Alexa647-conjugated anti-mouse IgG secondary antibody and fixation of cells. Binding was assessed by flow cytometry using a BD FACSArray. Fig. 15 shows three different binding profiles: 38G5, and 45C1 do not bind to any of the murine CLD18 isoforms, 37G11, and 163E12 bind to murine CLD18A2 but not to murine CLD18A1, and 38H3 binds to murine CLD18A1 and CLD18A2. These antibodies are valuable tools to determine a potential toxicity of CLD18 monoclonal antibodies in preclinical studies.

[0307] Altogether these data show, that monoclonal antibodies of the invention 24H5, 26B5, 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, 61C2, 75B8, 85A3, 9E8, 19B9, 45C1, 125E1, 163E12, 166E2, and 175D10 generated against CLD18 represents a diversity of binding characteristics to different epitopes and topologies of human CL18.

[0308] A combination of different properties described in examples 3b, c, d, e, g, h, and j can be used to categorize monoclonal antibodies into such different classes.

4. Immunohistochemistry (IHC)

[0309] A CLD18A2 epitope specific antibody generated by immunization with the peptide of SEQ ID NO: 21 was used for immunohistochemical characterisation of CLD18A2 expression. Paraffin embedded tissue sections derived from a comprehensive panel of normal and tumor tissues were used for protein expression and localisation analyses. No significant expression was detected in any other normal organ tissue except stomach (see Tab. 2, Fig. 16A). In contrast, CLD18A2 expression was verified by immunohistochemistry in different cancers including stomach cancer and lung cancer (Fig. 16B).

[0310] Interestingly, expression of CLD18A2 protein in gastric mucosa was restricted to terminally differentiated cells of the gastric epithelium in the base and pit regions.

[0311] In contrast, cells in the neck region of gastric mucosa, in particular gastric stem cells in the isthmus part, which replenish the entire mucosa, do not express CLD18A2 (Fig. 16C).

Tab. 2: CLD18A2 expression in normal and tumor tissues as analysed by IHC

Tissue type	Result
Adrenal	-
Bladder	-
Blood cells	-
Bone Marrow	-
Breast	-
Colon	-
Endothelium	-
Esophagus	-
Fallopian tube	-
Heart	-
Kidney (glomerulus, tubule)	-
Liver	-
Lung	-
Lymph node	-
Ovary	-
Pancreas	-
Parathyroid	-
Pituitary	-
Placenta	-
Prostate	-
Skin	-
Spleen	-

(continued)

	Tissue type	Result
	Stomach	+
5	Striated muscle	-
	Testis	-
	Thymus	-
	Thyroid	-
	Ureter	-
10	Uterus (cervix, endometrium)	-

[0312] The monoclonal antibody 39F11 was used for immunohistochemical CLD18A2 specific studies. As shown in Fig. 17A, no significant reactivity was detectable on all tested normal tissues except stomach (Fig. 17A), whereas stomach carcinomas and lung carcinomas remain strongly positive (Fig. 17B).

[0313] Another group of antibodies of the invention shows a specific cancer staining pattern with binding to stomach cancer but no reactivity with normal stomach tissue. Such a staining pattern is shown in Fig. 18A with monoclonal antibody 26B5.

[0314] Immunohistochemistry was used for specificity analysis of 175D10 (Fig. 18B), 43A11 (Fig. 18C), 163E12 (Fig. 18D) and 45C1 (Fig. 18E) on sections derived from HEK293 tumor cell lines; HEK293 tumor cell lines stably expressing human CLD18A2 (HEK293-CLD18A2) or CLD18A1 (HEK293-CLD18A1) or being transfected with an expression control plasmid containing only the antibiotic resistance gene for selection (HEK293-mock) were xenografted into mice to form solid tumors. No expression was detectable in mock-transfected HEK293 xenograft tumors. In contrast, strong and homogeneous membran-staining was observed in HEK293-CLD18A2 xenograft tumors and in stomach carcinoma specimens.

5. Complement Dependent Cytotoxicity (CDC)

a. CDC of monoclonal antibodies of Set1 as measured by flow cytometry:

[0315] Plasma for complement lysis was prepared by drawing blood from healthy volunteers into S-Monovette-EDTA vacutainer tubes (Sarstedt, Nümbrecht, Germany) which were then centrifuged at 600 g for 20 min. Plasma was harvested and stored at -20°C.

[0316] In a first set of experiments hybridoma supernatants were analyzed for their capability to induce complement dependent cytotoxicity (CDC) against HEK293 cells stably expressing human CLD18A2 (HEK293-CLD18A2). Cells were incubated with hybridoma supernatants containing monoclonal antibodies 85A3, 28D10, 24H5 or 26D12, respectively for 20 min. at room temperature. Following centrifugation (5 min. at 450 g) the supernatant was removed and 20% human plasma in DMEM (prewarmed to 37°C) was added to the cells and incubated for another 20 min. at 37°C. Thereafter, cell lysis was determined on FACS by using the propidium iodide (PI) staining method. PI was added to a final concentration of 2.5 µg/ml. For flow cytometry, a BD FACSArray flow cytometer was used (BD Biosciences, Mountain View, CA). At least 10000 events were collected for analysis with cell debris excluded by adjustment of the forward sideward scatter (FCS) threshold. The percentage of lysed cells (PI-positive cells) is shown in Figure 19. Monoclonal antibodies 85A3, 28D10 and 26D12 induced lysis of 33.5%, 38.2% and 39.2%, respectively of HEK293-CLD18A2 cells, whereas CDC mediated by 24H5 was only 19.3%.

b. CDC of monoclonal antibodies of Set1:

[0317] In a second set of experiments the specificity of monoclonal antibodies to induce CDC on CLD18A2 expressing cells was analyzed. Therefore, a set of antibodies binding either specific to human CLD18A2 or also binding to human CLD18A1 was tested for CDC-induction against CHO cells stably transfected with human CLD18A2 (CHO-CLD18A2) or human CLD18A1 (CHO-CLD18A1). CHO-CLD18A2 and CHO-CLD18A1 cells were seeded 24 h before the assay with a density of 3×10^4 /well in tissue-culture flat-bottom microtiter plates. The next day growth medium was removed and the cells were incubated in triplicates with hybridoma supernatants adjusted to a concentration of 10 µg/ml containing monoclonal antibodies 24H5, 26D12, 28D10, 37G11, 37H8, 38G5, 38H3, 39F11, 41C6, 42E12, 43A11, 44E10, 47D12, and 61C2, respectively. Control cells were incubated with growth medium or growth medium containing 0.2% saponin for the determination of background lysis and maximal lysis, respectively. After incubation for 20 min. at room temperature supernatant was removed and 20% human plasma in DMEM (prewarmed to 37°C) was added to the cells and incubated for another 20 min. at 37°C. Then, supernatants were replaced by PBS containing 2.5 µg/ml ethidium bromide and

fluorescence emission after excitation at 520 nm was measured using a Tecan Safire. The percentage specific lysis was calculated as follows: % specific lysis = (fluorescence sample - fluorescence background) / (fluorescence maximal lysis - fluorescence background) x 100. Fig. 20 shows that monoclonal antibodies 26D12, 28D10, 37H8, 38H3 and 39F11 mediate high, monoclonal antibody 38G5 mediates medium, monoclonal antibodies 41C6 and 61C2 mediate low, and monoclonal antibodies 24H5, 37G11, 42E12, 43A11, 44E10 and 47D12 mediate no CDC against CHO-CLD18A2 cells. In contrast, none of the antibodies is capable of inducing CDC against CHO-CLDA1 cells, although 26D12, 28D10, 37H8, 38H3, 39F11, 41C6, 47D12 and 61C2 also bind to CLD18A1 as determined by flow cytometry and immunofluorescence.

c. Monoclonal antibody titration and CDC using monoclonal antibodies of Set1 :

[0318] To measure the ability of the anti-CLD18 antibodies to induce CDC at low concentrations, an experiment was performed where three different antibodies were titrated. CHO-CLD18A2 cells growing in microtiter plates were incubated with a concentration range of 75B8 (100, 30, 10, 3 and 1 µg/ml), 37H8 (10, 3.3 and 1 µg/ml) and 28D10 (10, 1 and 0.1 µg/ml), respectively, for 20 min. at room temperature. Supernatant was removed and 20% human plasma in DMEM (prewarmed to 37°C) was added to the cells and incubated for another 20 min. at 37°C. Before analysis using a Tecan Safire, supernatants were replaced by PBS containing 2.5 µg/ml ethidium bromide. Figures 21A-C show the percentage of specific lysis as a function of antibody concentration. Monoclonal antibody 75B8 induces lysis of 31.0% CHO-CLD18A2 cells at 10 µg/ml, and drops to 6.2% at 1 µg/ml (Fig. 21A), whereas monoclonal antibodies 28D10 and 37H8 still induce 39% and 26.5 % specific lysis at 1 µg/ml (Fig. 21B, C), respectively.

d. CDC of monoclonal antibodies of Set2 as measured by flow cytometry:

[0319] Serum for complement lysis was prepared by drawing blood from healthy volunteers into Serum-Monovette vacutainer tubes (Sarstedt, Nümbrecht, Germany) which were then centrifuged at 600 g for 20 min. Serum was harvested and stored at -20°C. Control serum was heat inactivated at 56°C for 30 min before storage.

[0320] Hybridoma supernatants were analyzed for their capability to induce complement dependent cytotoxicity (CDC) against KATO-III cells endogenously expressing human CLD18A2. Cells were incubated with crude or purified hybridoma supernatants containing monoclonal antibodies 45C1, 125E1, 163E12, 166E2, and 175D10, respectively for 30 min. at 37°C. 20% human serum in RPMI was added to the cells and incubated for another 30 min. at 37°C. Thereafter, cell lysis was determined on FACS by using the propidium iodide (PI) staining method. PI was added to a final concentration of 2.5 µg/ml. For flow cytometry a BD FACSAArray flow cytometer was used (BD Biosciences, Mountain View, CA). At least 10000 events were collected for analysis with cell debris excluded by adjustment of the forward side scatter (FSC/SSC) threshold. Specific lysis was calculated by the following formula: specific lysis = (% PI-positive cells in sample - % PI-positive cells in sample with heat inactivated serum). Robust CDC mediated lysis was observed in particular for 163E12.

6. Antibody-Dependent Cellular Cytotoxicity (ADCC)

[0321] Hybridoma supernatants were analyzed for their capability to induce antibody-dependent cellular cytotoxicity (ADCC) against HEK293 cells stably expressing human CLD18A2 (HEK293-CLD18A2) or human CLD18A1 (HEK293-CLD18A1).

[0322] a. Enrichment of human peripheral blood mononuclear cells: Human blood from healthy donors was diluted twice in phosphate buffer (PBS) and blood cells were layered on Ficoll (Lymphocyte Separation Medium 1077 g/ml, PAA Laboratories, cat. no. J15-004). Peripheral blood mononuclear cells (MNCs) were collected from the interphase, washed and resuspended in RPMI 1640 culture medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L- glutamine.

[0323] b. ADCC set up: Target cells were labeled with with a fluorescence enhancing ligand (BADTA, Perkin Elmer cytotoxicity assay kit DELFIA EuTDA Cytotoxicity Reagents, cat. no. AD0116) for 30 minutes. After extensive washing in RPMI-10 supplemented with 10 mM probenecid (Sigma, cat. no. P8761), 10-20 mM HEPES, and 10% heat-inactivated fetal calf serum, the cells were adjusted to 1 x 10⁵ cells/ml. Labeled target cells, effector cells (MNCs), and supernatants containing monoclonal antibodies adjusted to a concentration of 10 µg/ml were added to round-bottom microtiter plates. For isolated effector cells, an effector to target (E:T) ratio of 100:1 (data not shown for 50:1 and 25:1) was used. After incubation (2 hours, 37°C), assays were stopped by centrifugation, and fluorescence ligand release from duplicates was measured in europium counts in a time-resolved fluorometer. Percentage of cellular cytotoxicity was calculated using the following formula: % specific lysis = (experimental release counts - spontaneous release counts) / (maximal release counts - spontaneous release counts) x 100, with maximal fluorescence ligand release determined by adding Triton X-100 (0,25% final concentration) to target cells, and spontaneous release measured in the absence of antibodies and

effector cells. Figure 22 shows that monoclonal antibodies 26B5, 37H8, 38G5, 47D12, and 61C2 mediate ADCC against HEK293-CLD18A2 cells. In contrast, these antibodies induce no significant or only low level cytotoxicity on CLD18A1 targets demonstrating a CLD18A2 specific ADCC (Figure 23).

7. Proliferation Inhibition

[0324] Purified murine monoclonal antibodies were analyzed for their capability to inhibit cell growth of KATO-III cells endogenously expressing human CLD18A2.

[0325] 1×10^4 target cells endogenously expressing CLD18A2 (KATO-III) were cultured in the presence of approximately 10 μ g monoclonal antibodies.

[0326] DELFIA Cell Proliferation Kit (Perkin-Elmer, Cat. No. AD0200) is a non-isotopic immunoassay based on the measurement of 5-bromo-2'-deoxyuridine (BrdU) incorporation during DNA synthesis of proliferating cells in microplates. Incorporated BrdU is detected using europium labelled monoclonal antibody. To allow antibody detection cells are fixed and DNA denatured using Fix solution. Unbound antibody is washed away and DELFIA inducer is added to dissociate europium ions from the labelled antibody into solution, where they form highly fluorescent chelates with components of the DELFIA Inducer. The fluorescence measured - utilizing time-resolved fluorometry in the detection - is proportional to the DNA synthesis in the cell of each well.

[0327] Strong inhibition of proliferation was observed with antibodies 125E1, 163E12, 45C1, 37G11, 37H8, 28D10 and 166E2, respectively.. Moderate inhibition of proliferation was observed with murine antibodies 43A11, 175D10, 42E12, 26D12, 61C2 and 38H3, respectively.

8. Performance in therapeutic mouse xenograft models

[0328] Therapeutic potential of the identified monoclonal antibodies binding specifically to CLD18A2 was studied in therapeutic xenograft models.

a. Early treatment of highly CLD18A2 expressing tumors in mice

[0329] SCID mice were subcutaneously inoculated with 1×10^7 HEK293 cells stably expressing high levels of human CLD18A2 (HEK293-CLD18A2). Expression levels of human CLD18A2 in HEK293-CLD18A2 cells were comparable with expression levels in primary gastric cancers from patients. Each experimental treatment group comprised 10 mice (number of mice per group $n=10$). Therapy of mice started 3 days after tumor inoculation. 200 μ g of purified hybridoma supernatants representing murine monoclonal antibodies 26B5, 26D12, 28D10, 37G11, 37H8, 38G5, 39F11, 42E12, 43A11, 38H3, or 61C2 were injected once per week for 4 weeks intravenously. Alternatively 200 μ g of purified hybridoma supernatants containing murine monoclonal antibodies 45C1, 125E1, 163E12, 166E2, or 175D10 were administered twice per week for 6 weeks by alternating intravenous and intraperitoneal injection. Tumor growth of treated mice was monitored twice per week (Tumor Volume = Length x Width x Width divided by 2 in mm^3). The mice were killed if the tumor reached a volume of 500 mm^3 or in case of severe morbidity. Fig. 24 exemplifies robust inhibition of HEK293-CLD18A2 tumor cell growth by antibodies of the invention. Fig. 25A and 25B show prolongation of survival by treatment with antibodies of the invention in an early treatment xenograft model using HEK293-CLD18A2 cells.

b. Late onset treatment of advanced highly CLD18A2 expressing tumors in mice

[0330] The same tumor xenograft model based on HEK293-CLD18A2 cells was designed as a late therapy onset protocol as opposed to the early treatment described above. On day 27 after tumor cell inoculation mice were randomized in test groups each comprising 5-6 mice and therapy was initiated with 200 μ g of purified hybridoma supernatants containing murine monoclonal antibodies 43A11, 163E12, and 175D10, respectively. Antibodies were administered twice per week for 6 weeks by alternating intravenous and intraperitoneal injection. Also in this model antibodies of the invention were shown to inhibit tumor growth. For several antibodies this resulted in prolongation of survival (Fig. 26).

c. Early treatment of tumors expressing low levels of CLD18A2

[0331] SCID mice were subcutaneously inoculated with 2×10^5 cells of the DAN-G tumor cell line, an infiltrating human pancreatic adenocarcinoma cell line that constitutively expresses CLD18A2 protein at low level. Treatment of mice (10 per group) was initiated 3 days after tumor grafting: 200 μ g of purified hybridoma supernatants containing murine monoclonal antibodies 45C1, 125E1, 163E12, 166E2, or 175D10 were administered twice per week for 6 weeks by alternating intravenous and intraperitoneal injection. Owing to the aggressive and fast tumor growth of the pancreatic DAN-G tumor cell line in vivo mice developed tumor cachexia and died within a few days. Even though, as a consequence,

the window for measuring therapeutic effects was narrow, tumor growth inhibition and prolonged survival mediated by antibodies of the invention was also observed in this model (Fig. 27A and 27B).

d. Antibodies of the invention do not elicit side effects in mice

[0332] A murine CLD18A2-specific primer pair (s: CTA CCA AGG GCT ATG GCG TTC, as: GCA CCG AAG GTG TAC CTG GTC) was used in RT-PCR analyses to amplify cDNA derived from a comprehensive panel of normal mouse tissues (see Fig. 28).

[0333] Expression of murine CLD18A2 was not detectable in any tested normal tissues, except stomach (see Fig. 28). Furthermore, an CLD18A2 specific antibody, which crossreacts with human and mouse CLD18A2, was used for immunohistochemical analysis of CLD18A2 expression in a large panel of normal mouse tissues (see Tab. 3). Except for normal gastric tissue all tested normal tissues show no CLD18A2 expression. As we observed for the human CLD18A2, we also found for the mouse counterpart that while the surface epithelia- and deeper crypt cells express CLD18A2 at their cell surface, the central neck region is CLD18A2 negative (see Fig. 29 A-C). In summary, tissue distribution of CLD18A2 appears to be identical in men and mice.

Tab. 3: CLD18 expression within murine normal tissues as analysed by immunohistochemistry

tissue	CLD18 expression
cerebellum	-
cerebrum	-
colon	-
esophagus	-
heart	-
kidney	-
liver	-
lung	-
lymph node	-
ovary	-
pancreas	-
skeletal muscle	-
spleen	-
stomach	+
thymus	-
bladder	-

[0334] We further investigated potential side effects mediated by antibodies 125E1, 163E12, 166E2 and 175D10 in mice. All of these antibodies had been previously shown by FACS analysis to react with the murine CLD18A2 as well as with the human protein.

[0335] Neither were any visible side effects observed in mice during and after treatment with these antibodies, nor were any histomorphological correlates of toxicity observed in the gastric mucosa of antibody treated mice as compared to untreated (PBS- treated) mice (see Figure 30).

9. Chimerization of antibodies

a. Generation of mouse/human Chimeric monoclonal antibodies

[0336] Total RNA and subsequently single stranded cDNA was prepared from human peripheral blood mononuclear cells (PBMC) and from human spleen tissue by standard methods known to those skilled in the art, for example by using RNeasy Midi Kit (Qiagen) and Superscript II reverse transcriptase (Invitrogen).

[0337] The constant region of the human kappa light chain was amplified from PBMC cDNA by PCR. The sense oligomer (SEQ ID NO:38) added a BamHI restriction site at the 5' end of the constant region and changed the original nucleic acid sequence 5'-CGAAGT-3' coding for the first two amino acids (Arg-Thr) of the constant region into 5'-CGTACG-3', generating a BsiWI restriction site without changing the amino acid sequence. The antisense oligomer (SEQ ID NO:39) included a stop codon and added a NotI restriction site at the 3' end of the amplified constant region. The PCR product as well as a standard expression vector (for example pcDNA3.1(+), Invitrogen) were sequentially incubated with

BamHI and NotI restriction enzymes. The vector was additionally treated with calf intestinal alkaline phosphatase to prevent recirculation. The constant region was finally ligated into the vector, so that any forthcoming fusion of a variable region in front of the constant region is now possible via a HindIII restriction site (5'-AAGCTT-3') from the residual vector multiple cloning site and via the BsiWI restriction site (5'-CGTACG-3') generated with the PCR product. The sequence of the human kappa light chain constant region inserted into the vector is listed as SEQ ID NO:40, the amino acid sequence of the human kappa constant region is listed as SEQ ID NO:41.

[0338] The constant region of the human gamma-1 heavy chain was amplified from spleen cDNA by PCR. The 5' phosphorylated sense oligomer (SEQ ID NO:42) was placed over the naturally occurring Apal restriction site, located 11 nucleotides downstream of the beginning of the constant region, and added a HindIII restriction site at the 5' end of the amplified part of the constant region. The 5' phosphorylated antisense oligomer (SEQ ID NO: 43) included a stop codon and added a NotI restriction site at the 3' end of the thus amplified constant region. The thus generated PCR product was blunt ended and 5' phosphorylated. The amplified gamma constant region was verified to be of the IgG1 subclass by PCR with a discriminating antisense oligomer (SEQ ID NO: 44) and by sequencing. A standard expression vector (for example pcDNA3.1(+)/Hygro, Invitrogen) with a different antibiotic resistance (for example hygromycin) than that of the vector used for expression of the light chain (for example neomycin) was incubated with PmeI restriction enzyme to completely remove the multiple cloning site leaving blunt ends. The vector was additionally treated with calf intestinal alkaline phosphatase to prevent recirculation. The constant region was finally ligated into the vector, so that any forthcoming fusion of a variable region in front of the constant region is now possible via the HindIII restriction site (5'-AAGCTT-3') and via the Apal restriction site (5'-GGGCCC-3'), both generated with the PCR product. The correct orientation of the constant region in the vector, i.e. suitable for the preceding promoter of the vector, was verified by sequencing. Due to the position of the Apal restriction site, any amplification of a variable region for this purpose has to include the first 11 nucleotides of the sequence of the human gamma-1 constant region in addition to the sequence of the Apal site. The sequence of the thus amplified human gamma-1 heavy chain constant region inserted into the vector is listed as SEQ ID NO:45, the amino acid sequence of the thus expressed human gamma-1 constant region is listed as SEQ ID NO: 46.

Tab. 4: mouse hybridoma cell lines used for antibody cloning

	clone	mAb	Isotype	variable region	oligomer pair in PCR	chimerized antibody
heavy chain	43A11	182-D1106-062	IgG2a	SEQ ID NO:55, 132	SEQ ID NO:70, 71	SEQ ID NO:100, 115
	163E12	182-D1106-294	IgG3	SEQ ID NO:56, 133	SEQ ID NO:72, 73	SEQ ID NO:101, 116
	125E1	182-D1106-279	IgG2a	SEQ ID NO:57, 134	SEQ ID NO:74, 75	SEQ ID NO:102, 117
	166E2	182-D1106-308	IgG3	SEQ ID NO:59, 136	SEQ ID NO:78, 79	SEQ ID NO:104, 119
	175D10	182-D1106-362	IgG1	SEQ ID NO:58, 135	SEQ ID NO:76, 77	SEQ ID NO:103, 118
	45C1	182-D758-187	IgG2a	SEQ ID NO:60, 137	SEQ ID NO:80,81	SEQ ID NO:105, 120
light chain	43A11	182-D1106-062	IgK	SEQ ID NO:62, 139	SEQ ID NO:84, 85	SEQ ID NO:107, 122
	163E12	182-D1106-294	IgK	SEQ ID NO:61, 138	SEQ ID NO:82, 83	SEQ ID NO:106, 121
	125E1	182-D1106-279	IgK	SEQ ID NO:63, 140	SEQ ID NO:86, 87	SEQ ID NO:108, 123
	166E2	182-D1106-308	IgK	SEQ ID NO:66, 143	SEQ ID NO:92, 93	SEQ ID NO:111, 126
	175D10	182-D1106-362	IgK	SEQ ID NO:65, 142	SEQ ID NO:90, 91	SEQ ID NO:110, 125
	45C1	182-D758-187	IgK	SEQ ID NO:64, 141	SEQ ID NO:88, 89	SEQ ID NO:109, 124
	45C1	182-D758-18787	IgK	SEQ ID NO:67, 144	SEQ ID NO:94, 95	SEQ ID NO:112, 127

(continued)

clone	mAb	Isotype	variable region	oligomer pair in PCR	chimerized antibody
45C1	182-D758-187	IgK	SEQ ID NO:68, 145	SEQ ID NO:96, 97	SEQ ID NO:113, 128
45C1	182-D758-187	IgK	SEQ ID NO:69, 146	SEQ ID NO:98, 99	SEQ ID NO:114, 129

[0339] Corresponding to their murine counterparts the chimeric monoclonal antibodies were named adding the prefix "ch-" e.g. ch-43A11, ch-163E12, ch-125E1, ch-166E2, ch-175D10, ch-45C1. Amplification of the murine variable regions of light and heavy chains was carried out according to the "step-out PCR" method described in Matz et al. (Nucleic Acids Research, 1999, Vol. 27, No. 6). For this, total RNA was prepared from monoclonal hybridoma cell lines (see Tab. 4) by standard methods known to those skilled in the art, for example with the use of RNeasy Mini Kit (Qiagen). Single stranded cDNA was prepared according to the template-switch" method also described in Matz et al. (Nucleic Acids Research, 1999, Vol. 27, No. 6, 1558). In addition to an (dT)30 oligomer (SEQ ID NO: 47), it included a DNA/RNA hybrid oligomer (SEQ ID NO: 48) serving as an 5' adaptor for template switching during polymerization of the cDNA strand. In this adaptor oligomer the last three nucleotides were ribo- instead of deoxyribonucleotides. The subsequent "step-out PCR" used an antisense oligomer targeted to the constant region of the mouse kappa chain or to the constant region of the subclasses 1, 2a or 3 of the gamma chains (SEQ ID NO: 49 to 52, respectively). The IgG subclass of the murine monoclonal antibody produced by the hybridoma cell lines was afore immunologically analyzed with IsoStrip (see Example 1), and the appropriate antisense oligomer was chosen accordingly (see Tab. 4). A primer mix served as the sense oligomer in the "step-out PCR", comprising the two oligomers listed in SEQ ID NO: 53 and 54. Some hybridoma cell lines expressed more than one heavy or light chain (in addition to the chains expressed by the myeloma cell line used for the generation of hybridomas). Table 4 summarizes the SEQ ID NOs of the cloned and sequenced variable regions of the murine antibody chains (SEQ ID NO: 55 to 69 and SEQ ID NO: 132 to 146) and of the cloned and sequenced full-length chimeric antibody chains (SEQ ID NO: 100 to 129).

[0340] The identified murine variable regions were then amplified by PCR omitting the 5' UTR and the 3' mouse constant region, adding restriction sites to the ends which allowed subcloning into the prepared expression vectors carrying the human constant regions. In addition, the sense oligomers provided a consensus Kozak sequence (5'-GCCGCCACC-3' or 5'-AGCCACC-3') and the antisense oligomers for heavy chain variable regions included the first 11 nucleotides of the human gamma-1 constant region in addition to the Apal restriction site (see Tab. 4, SEQ ID NO: 70 to 99). Kappa light chain variable regions were cloned using HindIII and BsiWI restriction enzymes, gamma heavy chain variable regions demanded HindIII and Apal restriction enzymes. The heavy gamma chain variable region of monoclonal antibody 45C1 contained an internal HindIII restriction site - here, the compatible BsaI enzyme was used instead (see SEQ ID NO: 80). SEQ ID NO: 100 to 114 show the nucleic acid sequences of the resulting chimerized antibodies (see Tab. 4). SEQ ID NO: 115 to 129 show the amino acid sequences of the accordingly expressed chimerized antibodies (see Tab. 4).

b. Generation and production of chimeric antibodies against CLD18

[0341] Mammalian cell lines producing chimeric antibodies with CLD18 specificity were generated. The cell lines derived from HEK293T cells (ATCC CRL-11268). One day before transfection, 2.5×10^7 cells were plated in a 14.5 cm tissue culture dish and cultured in 20 ml of complete medium, or alternatively 1×10^7 cells were plated in a 10 cm tissue culture dish and cultured in 10 ml of complete medium, or alternatively 0.6×10^6 cells were plated in a well of a 12-well tissue plate and cultured in 2-3 ml of complete medium (complete medium: DMEM:F12 medium supplemented with 10% FBS without antibiotics). The recommended cell density at the time of transfection should be 90 % confluence. Immediately before transfection, medium was replaced by fresh medium. HEK293T cells were transfected with transfection reagents, e.g. Lipofectamine 2000 (Invitrogen, 11668-019) or alternatively Polyethylenimine (Sigma-Aldrich, 408727). Exemplified for transfection of HEK293T cells a total DNA amount of 110 μ g or 296 μ g was used for a 14.5 cm tissue dish, and the ratio of transfection agent to DNA was 1:2.5 and 1:12 for Lipofectamine 2000 and PEI, respectively. 24 h after transfection medium was replaced with a GMP suitable medium, e.g. X-Vivo 15 (Cambrex) or a chemical defined medium like Pro293a (Cambrex) without serum. Transfected HEK293T cells producing chimeric monoclonal antibodies against CLD18 were cultured for further 96 h. Crude supernatants were harvested, sterile filtered and purified by protein A-sepharose. Antibody concentration was determined by BCA Assay and purity checked by sodium dodecylsulphate gel electrophoresis and coomassie staining.

c. Binding Characteristics of Chimeric Monoclonal Antibodies

[0342] Binding specificity of the cloned and generated chimeric monoclonal antibodies to CLD18A2 was analyzed by flow cytometry as described in Example 3. HEK293 living cells stably expressing human CLD18A2 (HEK293-CLD18A2) and HEK293 cells stably expressing human CLD18A1 (SEQ ID NOs: 7, 8) (HEK293-CLD18A1) were incubated for 30 min. at 4°C with purified HEK293T cell culture supernatants containing chimeric monoclonal antibodies, followed by incubation with APC-conjugated F(ab')₂ fragment goat anti-human IgG Fcγ secondary antibody and counterstained with PI. Binding was assessed by flow cytometry using a BD FACSArray.

[0343] Similarly, endogenously CLD18A2 expressing human tumor cell lines, for example KATO-III and NUGC-4 cells, were analyzed by flow cytometry.

[0344] Fig. 31A and B show flowcytometric analyses of chimeric antibodies ch-43A11, ch-125E1, ch-163E12, ch-166E2, and ch-175D10. All of them show native epitope recognition and exhibit specific and strong binding to CLD18A2 but not CLD18A1 expressing cells.

d. Complement Dependent Cytotoxicity (CDC)

[0345] Serum for complement lysis was prepared by drawing blood from healthy volunteers into Serum-Monovette vacutainer tubes (Sarstedt, Nümbrecht, Germany) which were then centrifuged at 600 g for 20 min. Serum was harvested and stored at -20°C. Control serum was heat inactivated at 56°C for 30 min before storage.

[0346] Protein A-sepharose-purified chimeric antibodies of this invention were analyzed for their capability to induce complement dependent cytotoxicity (CDC) against KATO-III cells endogenously expressing human CLD18A2, as well as stably transfected CHO-CLD18A2 cells. Cells were incubated with monoclonal antibodies ch-163E12, ch-166E2, and ch-175D10, respectively, in a final concentration of 2.5 µg/ml to 35 µg/ml for 30 min. at 37°C. 20% human serum in RPMI was added to the cells and incubated for another 30 min. at 37°C. Thereafter, dead and living cells were discriminated by PI staining in a final concentration of 2.5 µg/ml and percentage of antibody-mediated cell lysis was determined by flow cytometry. For flow cytometric analysis a BD FACSArray flow cytometer was used (BD Biosciences, Mountain View, CA). At least 10000 events were collected for analysis with cell debris excluded by adjustment of the forward sideward scatter (FSC/SSC) threshold. Specific lysis was calculated by the following formula: specific lysis = (% PI-positive cells in sample - % PI-positive cells in sample with heat inactivated serum). Specific lysis mediated by CDC was shown for several antibodies. All three antibodies mediated robust CDC on CHO-CLD18A2 cells (Figure 32). On KATO-III cells antibodies ch-163E12 and ch-175D10 were inducers of robust CDC.

e. Antibody-Dependent Cellular Cytotoxicity (ADCC)

[0347] FPLC-purified, chimeric antibodies of the invention were analyzed for their capability to induce antibody-dependent cellular cytotoxicity (ADCC) against KATO-III cells endogenously expressing human CLD18A2.

[0348] Human blood from healthy donors was diluted twice in phosphate buffer (PBS) and blood cells were layered on Ficoll (1077 g/ml, Pharmacia). After centrifugation, peripheral blood mononuclear cells (PBMC) were collected from the interphase, washed and resuspended in X-Vivo-15 culture medium supplemented with 5% heat-inactivated human serum.

[0349] 15h before the assay, KATO-III cells were transfected with luciferase and plated at 5 x 10⁴ cells/well in a white microplate.

[0350] For the assay, effector cells (PBMC, prepared as described above) at an effector to target (E:T) ratio of 20:1 and FPLC-purified chimeric antibodies were added and incubated for 2 - 3h at 37 °C, 5% CO₂. Final concentration of the antibody in the well was 50 µg/ml. After 2-3h of pre-incubation, lucifer yellow (BD Biosciences, San Jose USA) was added at 1mg/ml. Luminescence resulting from the oxidation of lucifer yellow by the luciferase of viable cells was measured continually for up to 6h using a microplate-reader (Infinite200, Tecan, Switzerland). Percentage of cellular cytotoxicity was calculated using the following formula:

$$\% \text{ specific lysis} = 100 - \left(\frac{\text{sample luminescence counts} - \text{spontaneous luminescence counts}}{\text{maximal luminescence counts} - \text{spontaneous luminescence counts}} \times 100 \right), \text{ with the spontaneous luminescence determined by adding Triton X-100 (0,2\% final concentration),}$$

and the maximal signal measured in the absence of antibodies.

[0351] Using this assay it was shown that monoclonal antibodies ch-163E12 and ch-175D10 mediate strong ADCC

on KATO-III cells (Fig. 33).

f. Proliferation Inhibition

[0352] FPLC-purified chimeric antibodies of the invention were analyzed for their capability to inhibit cell growth of KATO-III cells endogenously expressing human CLD18A2.

[0353] Target cells (KATO-III) were cultured in the presence of chimeric respective antibodies (see proliferation inhibition of murine antibodies, Example 7). FPLC purified chimeric antibodies ch-163E12 and ch-166E2 were shown to inhibit cell proliferation.

10. Selection of antibodies as clinical lead candidates

[0354] Ideal clinical leads may cover a wide range of therapeutic and diagnostic applications (see also section IV - Uses and Methods of the Invention). According to the invention antibodies directed to CLD18-A2 are provided. It is shown that the antibodies provided according to the invention offer a broad spectrum of properties regarding specificity, ability to induce CDC and ADCC and inhibit proliferation of cells expressing CLD18, in particular tumor cells. Furthermore, it has been demonstrated that chimerisation of antibodies may lead to the acquisition of additional Fc-dependent effector functions not present in the parental murine molecule. For example, it is shown herein that antibody 175D10 with murine IgG1 does not induce complement dependent cytotoxicity (see Example 5), while ch-175D10 with human IgG1 induces specific lysis of constitutively CLD18 expressing tumor cells (see Tab. 5 and Tab. 6).

[0355] Antibodies provided according to the present invention may be categorized into distinct classes according to their binding properties and their ability to mediate effector functions on cells expressing CLD18. From the antibodies provided according to the present invention, clinical lead candidates may be selected based on their functional characteristics. An overview of properties for selected murine and chimeric antibodies of the invention is given in Tab. 5 and Tab. 6, respectively.

[0356] Clinical lead candidates of the invention may have one or more of the following properties:

- a) binding to human CLD18A2 but not to human CLD18A1 (e.g. 43A11, 45C1, 125E1, 163E12, 166E2 and 175D10, and ch-43A11, ch-45C1, ch-125E1, ch-163E12, ch-166E2 and ch-175D10). For examples, see figures 6A and 6B.
- b) binding to mouse CLD18A2 but not to mouse CLD18A1 (e.g. 125E1, 163E12, 166E2 and 175D10). For examples, see figures 15A and 15B.
- c) binding to CLD18 naturally expressed by tumor cells (e.g. 45C1, 43A11, 125E1, 163E12, 166E2 and 175D10, and ch-45C1, ch-43A11, ch-125E1, ch-163E12, ch-166E2 and ch-175D10). For examples, see figure 13
- d) binding to CLD18 in intercellular contact zones (e.g. 45C1, 43A11, 125E1, 163E12, 166E2 and 175D10). For examples, see figures 12A and 12B.
- e) mediating CDC induced killing of cells, which express CLD18 (e.g. 45C1, 125E1, 163E12, 166E2 and 175D10, and ch-163E12 and ch-175D10). For examples, see figure 32.
- f) mediate ADCC induced killing of cells expressing CLD18 (e.g. ch-163E12 and ch-175D10). For examples, see figure 33.
- g) inhibiting proliferation of cells expressing CLD18 (e.g. 45C1, 125E1, 163E12, 166E2 and 175D10, and ch-163E12 and ch-166E2).
- h) inhibiting tumor growth in xenograft models with cells expressing CLD18 (e.g. 43A11, 125E1, 163E12, 166E2, and 175D10). For examples, see figure 24.
- i) prolonging survival in xenograft models with cells expressing CLD18 (e.g. 43A11, 125E1, 163E12, 166E2 and 175D10). For examples, see figure 25B.

Exemplary overview of properties for lead candidate selection

[0357]

Table 5: murine antibodies

antibody	binding of human CLD18A2 but not A1	binding of mouse CLD18A2 but not A1	binding of CLD18 on naturally expressing tumor cells	binding to CLD18 in contact zones	mediating CDC on CLD18 expressing cells	inhibiting proliferation of cells expressing CLD18	inhibiting tumor growth in xenograft expressing CLD18	prolonging survival in xenograft expressing CLD18
45C1	+	-	+	+	(+)	+	(+)	(+)
125E1	+	+	+	+	(+)	+	+	+
163E12	+	+	+	+	+	+	+	+
175D10	+	+	+	+	(+)	(+)	+	+
legend: + excellent performance, (+) performance in different setups.								

Table 6: chimeric antibodies

antibody	binding of human, CLD18A2 but not A1	binding of CLD18 on naturally expressing tumor cells	mediating CDC on CLD18 expressing cells	mediating ADCC on CLD18 expressing cells	inhibiting proliferation of cells expressing CLD18
ch-45C1	+	+	n.d.	n.d.	n.d.
ch-125E1	+	+	n.d.	n.d.	n.d.
ch-163E12	+	+	+	+	+
ch-175D10	+	+	+	+	n.d.
legend: + excellent performance, (+) performance in different setups, n.d. not done.					

SEQUENCE LISTING

[0358]

<110> Ganymed Pharmaceuticals AG

<120> Monoclonal antibodies against claudin-18 for treatment of cancer

<130> 342-31 EPT2

<150> EP 05 025 657.7

<151> 2005-11-24

<160> 150

<170> PatentIn version 3.3

<210> 1

<211> 786

<212> DNA

<213> Homo sapiens

<400> 1

EP 2 311 877 B1

atggccgtga ctgcctgtca gggccttgggg ttcgtgggtt cactgattgg gattgcgggc 60
 atcattgctg ccacctgcat ggaccagtgg agcacccaag acttgtaaa caaccccgta 120
 5 acagctgttt tcaactacca ggggctgtgg cgctcctgtg tccgagagag ctctggcttc 180
 accgagtgcc ggggctactt caccctgctg gggctgccag ccatgctgca ggcagtgcga 240
 gccctgatga tcgtaggcat cgtcctgggt gccattggcc tcctgggtatc catctttgcc 300
 10 ctgaaatgca tccgcattgg cagcatggag gactctgcca aagccaacat gacactgacc 360
 tccgggatca tgttcattgt ctcaggtcct tgtgcaattg ctggagtgtc tgtgtttgcc 420
 aacatgctgg tgactaactt ctggatgtcc acagctaaca tgtacaccgg catgggtggg 480
 atggtgcaga ctgttcagac caggtacaca tttggtgcgg ctctgttcgt gggctgggtc 540
 15 gctggaggcc tcacactaat tgggggtgtg atgatgtgca tcgcctgccg gggcctggca 600
 ccagaagaaa ccaactacaa agccgtttct tateatgcct cgggccacag tgttgccctac 660
 aagcctggag gcttcaaggc cagcactggc tttgggtcca acacaaaaa caagaagata 720
 20 tacgatggag gtgcccgcac agaggacgag gtacaatctt atccttccaa gcacgactat 780
 gtgtaa 786

<210> 2
 25 <211> 261
 <212> PRT
 <213> Homo sapiens

<400> 2

30 Met Ala Val Thr Ala Cys Gln Gly Leu Gly Phe Val Val Ser Leu Ile
 1 5 10 15

35 Gly Ile Ala Gly Ile Ile Ala Ala Thr Cys Met Asp Gln Trp Ser Thr
 20 25 30

40

45

50

55

EP 2 311 877 B1

Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala Val Phe Asn Tyr Gln Gly
 35 40 45
 5 Leu Trp Arg Ser Cys Val Arg Glu Ser Ser Gly Phe Thr Glu Cys Arg
 50 55 60
 Gly Tyr Phe Thr Leu Leu Gly Leu Pro Ala Met Leu Gln Ala Val Arg
 65 70 75 80
 10 Ala Leu Met Ile Val Gly Ile Val Leu Gly Ala Ile Gly Leu Leu Val
 85 90 95
 15 Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Glu Asp Ser
 100 105 110
 Ala Lys Ala Asn Met Thr Leu Thr Ser Gly Ile Met Phe Ile Val Ser
 115 120 125
 20 Gly Leu Cys Ala Ile Ala Gly Val Ser Val Phe Ala Asn Met Leu Val
 130 135 140
 25 Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Thr Gly Met Gly Gly
 145 150 155 160
 Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe Gly Ala Ala Leu Phe
 165 170 175
 30 Val Gly Trp Val Ala Gly Gly Leu Thr Leu Ile Gly Gly Val Met Met
 180 185 190
 Cys Ile Ala Cys Arg Gly Leu Ala Pro Glu Glu Thr Asn Tyr Lys Ala
 195 200 205
 35 Val Ser Tyr His Ala Ser Gly His Ser Val Ala Tyr Lys Pro Gly Gly
 210 215 220
 40 Phe Lys Ala Ser Thr Gly Phe Gly Ser Asn Thr Lys Asn Lys Lys Ile
 225 230 235 240
 Tyr Asp Gly Gly Ala Arg Thr Glu Asp Glu Val Gln Ser Tyr Pro Ser
 245 250 255
 45 Lys His Asp Tyr Val
 260

<210> 3

50 <211> 816

<212> DNA

<213> Homo sapiens

55 <400> 3

EP 2 311 877 B1

atggccgtga ctgcctgtca gggcttgggg ttcgtggttt cactgattgg gattgcgggc 60
 atcattgctg ccacctgcat ggaccagtgg agcaccacaag acttgtaaa caaccccgta 120
 5 acagctgttt tcaactacca ggggctgtgg cgctcctgtg tccgagagag ctctggcttc 180
 accgagtgcc ggggctactt caccctgctg gggctgccag ccatgctgca ggcagtgcga 240
 gccctgatga tcgtaggcat cgtcctgggt gccattggcc tcctgggtatc catctttgcc 300
 10 ctgaaatgca tccgcattgg cagcatggag gactctgcca aagccaacat gacactgacc 360
 tccgggatca tgttcattgt ctcaggtctt tgtgcaattg ctggagtgtc tgtgtttgcc 420
 aacatgctgg tgactaactt ctggatgtcc acagctaaca tgtacaccgg catgggtgaa 480
 15 caaaaactca tctcagaaga ggatctgggg atggtgcaga ctgttcagac cagggtacaca 540
 tttggtgcgg ctctgttcgt gggctgggtc gctggaggcc tcacactaat tgggggtgtg 600
 atgatgtgca tcgcctgccg gggcctggca ccagaagaaa ccaactacaa agccgtttct 660
 20 tatcatgcct cgggccacag tgttcctac aagcctggag gcttcaaggc cagcactggc 720
 tttgggtcca acacaaaaa caagaagata tacgatggag gtgcccgcac agaggacgag 780
 gtacaatctt atccttccaa gcacgactat gtgttaa 816

25 <210> 4
 <211> 271
 <212> PRT
 <213> Homo sapiens

30 <400> 4

Met Ala Val Thr Ala Cys Gln Gly Leu Gly Phe Val Val Ser Leu Ile
 1 5 10 15
 35 Gly Ile Ala Gly Ile Ile Ala Ala Thr Cys Met Asp Gln Trp Ser Thr
 20 25 30
 40 Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala Val Phe Asn Tyr Gln Gly
 35 40 45
 Leu Trp Arg Ser Cys Val Arg Glu Ser Ser Gly Phe Thr Glu Cys Arg
 50 55 60
 45 Gly Tyr Phe Thr Leu Leu Gly Leu Pro Ala Met Leu Gln Ala Val Arg
 65 70 75 80
 50 Ala Leu Met Ile Val Gly Ile Val Leu Gly Ala Ile Gly Leu Leu Val
 85 90 95
 Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Glu Asp Ser

55

EP 2 311 877 B1

		100		105		110	
5		Ala Lys Ala Asn Met Thr Leu Thr Ser Gly Ile Met Phe Ile Val Ser					
		115		120		125	
		Gly Leu Cys Ala Ile Ala Gly Val Ser Val Phe Ala Asn Met Leu Val					
		130		135		140	
10		Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Thr Gly Met Gly Glu					
		145		150		155	160
		Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Met Val Gln Thr Val Gln					
15			165		170		175
		Thr Arg Tyr Thr Phe Gly Ala Ala Leu Phe Val Gly Trp Val Ala Gly					
			180		185		190
20		Gly Leu Thr Leu Ile Gly Gly Val Met Met Cys Ile Ala Cys Arg Gly					
			195		200		205
		Leu Ala Pro Glu Glu Thr Asn Tyr Lys Ala Val Ser Tyr His Ala Ser					
25			210		215		220
		Gly His Ser Val Ala Tyr Lys Pro Gly Gly Phe Lys Ala Ser Thr Gly					
			225		230		235
		Phe Gly Ser Asn Thr Lys Asn Lys Lys Ile Tyr Asp Gly Gly Ala Arg					
30			245		250		255
		Thr Glu Asp Glu Val Gln Ser Tyr Pro Ser Lys His Asp Tyr Val					
			260		265		270
35		<210> 5					
		<211> 813					
		<212> DNA					
		<213> Homo sapiens					
40		<400> 5					
		atggcgtga ctgectgtca gggcttgagg ttegtgggtt cactgattgg gattgcgggc					60
45		atcattgctg ccacctgcat ggaccagtgg agcaccacaag acttgtagaa caaccccgta					120
		acagctgttt tcaactacca ggggctgtgg cgctcctgtg tccgagagag ctctggcttc					180
		accgagtgcc ggggctactt caccctgtac ccatacgacg tgccagacta cgcactgggg					240
50		ctgccagcca tgctgcaggc agtgcgagcc ctgatgatcg taggcatcgt cctgggtgcc					300
		attggcctcc tgggtatccat ctttgcctcg aaatgcatcc gcattggcag catggaggac					360
		tctgccaaag ccaacatgac actgacctcc gggatcatgt tcattgtctc aggtctttgt					420
55		gcaattgctg gagtgtctgt gtttgccaac atgctgggtga ctaacttctg gatgtccaca					480

EP 2 311 877 B1

gctaacatgt acaccggcat ggggtgggatg gtgcagactg ttcagaccag gtacacattt 540
 ggtgcggctc tgttcgtggg ctgggtcgct ggaggcctca cactaattgg ggggtgtgatg 600
 5 atgtgcatcg cctgccgggg cctggcacca gaagaaacca actacaaagc cgtttcttat 660
 catgcctcgg gccacagtgt tgcctacaag cctggaggct tcaaggccag cactggcttt 720
 gggtcacaaca ccaaaaacaa gaagatatac gatggagggt cccgcacaga ggacgaggtta 780
 10 caatcttatc cttccaagca cgactatgtg taa 813

<210> 6

<211> 270

<212> PRT

15 <213> Homo sapiens

<400> 6

20 Met Ala Val Thr Ala Cys Gln Gly Leu Gly Phe Val Val Ser Leu Ile
 1 5 10 15
 Gly Ile Ala Gly Ile Ile Ala Ala Thr Cys Met Asp Gln Trp Ser Thr
 20 25 30
 25 Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala Val Phe Asn Tyr Gln Gly
 35 40 45
 30 Leu Trp Arg Ser Cys Val Arg Glu Ser Ser Gly Phe Thr Glu Cys Arg
 50 55 60
 Gly Tyr Phe Thr Leu Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Gly
 65 70 75 80
 35 Leu Pro Ala Met Leu Gln Ala Val Arg Ala Leu Met Ile Val Gly Ile
 85 90 95
 40 Val Leu Gly Ala Ile Gly Leu Leu Val Ser Ile Phe Ala Leu Lys Cys
 100 105 110
 Ile Arg Ile Gly Ser Met Glu Asp Ser Ala Lys Ala Asn Met Thr Leu
 115 120 125
 45 Thr Ser Gly Ile Met Phe Ile Val Ser Gly Leu Cys Ala Ile Ala Gly
 130 135 140
 Val Ser Val Phe Ala Asn Met Leu Val Thr Asn Phe Trp Met Ser Thr
 145 150 155 160
 50 Ala Asn Met Tyr Thr Gly Met Gly Gly Met Val Gln Thr Val Gln Thr
 165 170 175
 55

EP 2 311 877 B1

	Arg Tyr Thr Phe Gly Ala Ala Leu Phe Val Gly Trp Val Ala Gly Gly	
	180 185 190	
5	Leu Thr Leu Ile Gly Gly Val Met Met Cys Ile Ala Cys Arg Gly Leu	
	195 200 205	
	Ala Pro Glu Glu Thr Asn Tyr Lys Ala Val Ser Tyr His Ala Ser Gly	
10	210 215 220	
	His Ser Val Ala Tyr Lys Pro Gly Gly Phe Lys Ala Ser Thr Gly Phe	
	225 230 235 240	
15	Gly Ser Asn Thr Lys Asn Lys Lys Ile Tyr Asp Gly Gly Ala Arg Thr	
	245 250 255	
	Glu Asp Glu Val Gln Ser Tyr Pro Ser Lys His Asp Tyr Val	
20	260 265 270	
	<210> 7	
	<211> 786	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 7	
30	atgtccacca ccacatgcc a g t g g t g g c g t t c c t c t g t c c a t c c t g g g g c t g g c c g g c	60
	t g c a t c g c g g c c a c c g g g a t g g a c a t g t g g a g c a c c c a g g a c c t g t a c g a c a c c c c g t c	120
	a c c t c c g t g t t c c a g t a c g a a g g g c t c t g g a g a g c t g c g t g a g g c a g a g t t c a g g c t t c	180
	a c c g a a t g c a g g c c t a t t t c a c c a t c c t g g g a c t t c c a g c c a t g c t g c a g g c a g t g c g a	240
35	g c c e t g a t g a t c g t a g g c a t c g t c c t g g g t g c c a t t g g c c t c c t g g t a t c a t c t t t g c c	300
	c t g a a a t g c a t c c g c a t t g g c a g c a t g g a g g a c t c t g c c a a g c c a a c a t g a c a c t g a c c	360
	t c c g g g a t c a t g t t c a t t g t c t c a g g t c t t t g t g c a a t t g c t g g a g t g t c t g t g t t t g c c	420
40	a a c a t g c t g g t g a c t a a c t t c t g g a t g t c c a c a g c t a a c a t g t a c a c c g g c a t g g g t g g g	480
	a t g g t g c a g a c t g t t c a g a c c a g g t a c a c a t t t g g t g c g g c t c t g t t c g t g g g c t g g g t c	540
	g c t g g a g g c c t c a c a c t a a t t g g g g t g t g a t a t g t g c a t c g c c t g c c g g g c c t g g c a	600
45	c c a g a a g a a a c c a a c t a c a a a g c c g t t t c t a t c a t g c c t c a g g c c a c a g t g t t g c c t a c	660
	a a g c c t g g a g g c t t c a a g g c c a g c a c t g g c t t t g g g t c c a a c a c c a a a a c a a g a a g a t a	720
	t a c g a t g g a g g t g c c c g c a c a g a g g a c g a g g t a c a a t c t t a t c c t t c c a a g c a c g a c t a t	780
50	g t g t a a	786
	<210> 8	
	<211> 261	
	<212> PRT	
55	<213> Homo sapiens	
	<400> 8	

EP 2 311 877 B1

[illegible]

<210> 9

EP 2 311 877 B1

<211> 795
<212> DNA
<213> Mus musculus

5 <400> 9

```

          atggccacca ccacgtgcc a ggtggtaggg cttctcctgt ccctcctggg tctggccggc      60
          tgcatagcag ccactgggat ggacatgtgg agcactcaag acctgtatga caaccagtc      120
10      accgccgtgt tccagtatga agggctctgg aggagttgag tgcaacagag ctgggggttc      180
          accgagtgcc ggccatactt caccatcctg ggccttcag ccatgctgca agctgtacga      240
          gccctgatga tcgtgggcat tgttctgggg gtcacggta tcctcgtgtc catcttcgcc      300
15      ctgaagtgca ttcgcattgg tagcatggat gactctgcca aggccaagat gactctgact      360
          tctgggatct tgttcatcat ctccggcatc tgtgcaatca ttgggtgtgtc tgtgtttgcc      420
          aacatgctgg tgaccaactt ctggatgtcc acagctaaca tgtacagcgg catgggcggc      480
20      atgggtggca tgggtgcagac cgttcagacc aggtacacct ttgggtgcagc tctgttcgtg      540
          ggctggggtg ctggaggcct caccctgatt gggggagtgat tgatgtgcat cgccctgccg      600
          ggccctgacac cagatgacag caacttcaaa gctgtgtctt acctgcctc tggccaaaat      660
25      gttgcctaca ggccctggagg ctttaaggcc agcactggct ttgggtccaa caccagaaac      720
          aagaagatct acgatggggg tgcccgacac gaagacgatg aacagtctca tcctaccaag      780
          tatgactatg tgtag                                     795

```

30 <210> 10
<211> 795
<212> DNA
<213> Mus musculus

35 <400> 10

```

          atgtcgggtga ccgcctgcc a gggcttgggg tttgtgggtg cactgatcgg gtttgccggc      60
          atcattgcag ccacttgtat ggaccagtgg agcaccagc atttatacaa caaccgggtg      120
          accgctgtat tcaactacca agggctatgg cgttcatgag tccgagagag ctctggcttc      180
          accgagtgcc gaggtactt caccctgttg ggggtgcag ccatgctgca agctgtacga      240
          gccctgatga tcgtgggcat tgttctgggg gtcacggta tcctcgtgtc catcttcgcc      300
          ctgaagtgca ttcgcattgg tagcatggat gactctgcca aggccaagat gactctgact      360
          tctgggatct tgttcatcat ctccggcatc tgtgcaatca ttgggtgtgtc tgtgtttgcc      420
          aacatgctgg tgaccaactt ctggatgtcc acagctaaca tgtacagcgg catgggcggc      480

```

55

EP 2 311 877 B1

atgggtggca tgggtgcagac cgttcagacc aggtacacct ttggtgcagc tctgttcgtg 540
 ggctggggttg ctggaggcct caccctgatt gggggagtga tgatgtgcat cgcctgccgt 600
 5 ggcctgacac cagatgacag caacttcaaa gctgtgtctt accatgcctc tggccaaaat 660
 gttgcctaca ggcctggagg ctttaaggcc agcactggct ttgggtccaa caccagaaac 720
 aagaagatct acgatggggg tgcccgcaca gaagacgatg aacagtctca tcctaccaag 780
 10 tatgactatg tgtag 795

<210> 11

<211> 21

<212> DNA

15 <213> Artificial

<220>

<223> Description of artificial sequence: Oligonucleotide

20 <400> 11

tggtctgtg tcgacactgt g 21

<210> 12

<211> 21

25 <212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: Oligonucleotide

30 <400> 12

gtgtacatgt tagctgtgga c 21

<210> 13

35 <211> 55

<212> PRT

<213> Homo sapiens

<400> 13

40

Met Asp Met Trp Ser Thr Gln Asp Leu Tyr Asp Asn Pro Val Thr Ser
1 5 10 15

45 Val Phe Gln Tyr Glu Gly Leu Trp Arg Ser Cys Val Arg Gln Ser Ser
20 25 30

Gly Phe Thr Glu Cys Arg Pro Tyr Phe Thr Ile Leu Gly Leu Pro Ala
35 40 45

50

Met Leu Gln Ala Val Arg Ala
50 55

<210> 14

55 <211> 153

<212> PRT

<213> Homo sapiens

EP 2 311 877 B1

<400> 14

5 Met Asp Met Trp Ser Thr Gln Asp Leu Tyr Asp Asn Pro Val Thr Ser
1 5 10 15

Val Phe Gln Tyr Glu Gly Leu Trp Arg Ser Cys Val Arg Gln Ser Ser
20 25 30

10 Gly Phe Thr Glu Cys Arg Pro Tyr Phe Thr Ile Leu Gly Leu Pro Ala
35 40 45

Met Leu Gln Ala Val Arg Ala Leu Met Ile Val Gly Ile Val Leu Gly
50 55 60

15 Ala Ile Gly Leu Leu Val Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile
65 70 75 80

20 Gly Ser Met Glu Asp Ser Ala Lys Ala Asn Met Thr Leu Thr Ser Gly
85 90 95

Ile Met Phe Ile Val Ser Gly Leu Cys Ala Ile Ala Gly Val Ser Val
100 105 110

25 Phe Ala Asn Met Leu Val Thr Asn Phe Trp Met Ser Thr Ala Asn Met
115 120 125

30 Tyr Thr Gly Met Gly Gly Met Val Gln Thr Val Gln Thr Arg Tyr Thr
130 135 140

Phe Gly Ala Ala Leu Phe Val Gly Trp
145 150

<210> 15
<211> 390
<212> DNA
<213> Homo sapiens

<400> 15

atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggg 60

45 gacgcggccc agccggccag gcgcgcgcgc cgtacgaagc ttggtaccga gctcggatcc 120

actccagtgt ggtggaattc tgcagatggc cgcattggacc agtggagcac ccaagacttg 180

tacaacaacc ccgtaacagc tgttttcaac taccaggggc tgtggcgctc ctgtgtccga 240

50 gagagctctg gcttcaccga gtgccggggc tacttcaccc tgctggggct gccagccatg 300

ctgcaggcag tgcgagcggc catccagcac agtggcgggc gctcaggagg ggcccgaaca 360

aaaactcatc tcagaagagg atctgaatag 390

<210> 16
<211> 129
<212> PRT
<213> Homo sapiens

EP 2 311 877 B1

<400> 16

5 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ala Ala Gln Pro Ala Arg Arg Ala Arg Arg Thr
20 25 30

10 Lys Leu Gly Thr Glu Leu Gly Ser Thr Pro Val Trp Trp Asn Ser Ala
35 40 45

Asp Gly Arg Met Asp Gln Trp Ser Thr Gln Asp Leu Tyr Asn Asn Pro
50 55 60

15 Val Thr Ala Val Phe Asn Tyr Gln Gly Leu Trp Arg Ser Cys Val Arg
65 70 75 80

20 Glu Ser Ser Gly Phe Thr Glu Cys Arg Gly Tyr Phe Thr Leu Leu Gly
85 90 95

Leu Pro Ala Met Leu Gln Ala Val Arg Ala Ala Ile Gln His Ser Gly
100 105 110

25 Gly Arg Ser Arg Arg Ala Arg Thr Lys Thr His Leu Arg Arg Gly Ser
115 120 125

30 Glu

<210> 17
<211> 411
<212> DNA
<213> Homo sapiens

<400> 17

atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttcactggt 60

40 gacgcggccc agccggccag gcgcgcgcgc cgtacgaagc ttggtaccga gctcggatcc 120

actccagtgt ggtggaattc tgcagatggc cgcgcctga tgatcgtagg catcgtcctg 180

ggtgccattg gcctcctggt atccatcttt gccctgaaat gcatccgcat tggcagcatg 240

45 gaggactctg ccaaagccaa catgacactg acatccggga tcatgttcat tgtctcaggt 300

ctttgtgcaa ttgctggagt gtctgtgttt gccaacgcgg ccattccagca cagtggcggc 360

cgctcgagga gggcccgaac aaaaactcat ctccagaagag gatctgaata g 411

<210> 18
<211> 136
<212> PRT
<213> Homo sapiens

<400> 18

EP 2 311 877 B1

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

5 Gly Ser Thr Gly Asp Ala Ala Gln Pro Ala Arg Arg Ala Arg Arg Thr
20 25 30

Lys Leu Gly Thr Glu Leu Gly Ser Thr Pro Val Trp Trp Asn Ser Ala
35 40 45

10 Asp Gly Arg Ala Leu Met Ile Val Gly Ile Val Leu Gly Ala Ile Gly
50 55 60

15 Leu Leu Val Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met
65 70 75 80

Glu Asp Ser Ala Lys Ala Asn Met Thr Leu Thr Ser Gly Ile Met Phe
85 90 95

20 Ile Val Ser Gly Leu Cys Ala Ile Ala Gly Val Ser Val Phe Ala Asn
100 105 110

25 Ala Ala Ile Gln His Ser Gly Gly Arg Ser Arg Arg Ala Arg Thr Lys
115 120 125

Thr His Leu Arg Arg Gly Ser Glu
130 135

30 <210> 19
<211> 531
<212> DNA
<213> Homo sapiens

35 <400> 19

atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60
gacgcggccc agccggccag gcgcgccatg gaccagtgga gcaccaaga cttgtacaac 120
40 aaccccgtaa cagctgtttt caactaccag gggctgtggc gtcctgtgt ccgagagagc 180
tctggcttca ccgagtgccg gggtacttc accctgctgg ggctgccagc catgctgcag 240
gcagtgcgag cctgatgat cgtaggcatc gtcctgggtg ccattggcct cctggtatcc 300
45 atctttgccc tgaaatgcat ccgcattggc agcatggagg actctgcaa agccaacatg 360
aactgacct ccgggatcat gttcattgtc tcagggtctt gtgcaattgc tggagtgtct 420
gtgtttgcca acatgctggg gactaacttc tggatgtcca cagctaacat gtacaccggc 480

50 atgggtggga tgggcagac tggtcagacc aggtacacat ttggtgcgta g 531

55 <210> 20
<211> 176
<212> PRT
<213> Homo sapiens

EP 2 311 877 B1

<400> 20

5 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ala Ala Gln Pro Ala Arg Arg Ala Met Asp Gln
20 25 30

10 Trp Ser Thr Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala Val Phe Asn
35 40 45

Tyr Gln Gly Leu Trp Arg Ser Cys Val Arg Glu Ser Ser Gly Phe Thr
50 55 60

15 Glu Cys Arg Gly Tyr Phe Thr Leu Leu Gly Leu Pro Ala Met Leu Gln
65 70 75 80

20 Ala Val Arg Ala Leu Met Ile Val Gly Ile Val Leu Gly Ala Ile Gly
85 90 95

Leu Leu Val Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met
100 105 110

25 Glu Asp Ser Ala Lys Ala Asn Met Thr Leu Thr Ser Gly Ile Met Phe
115 120 125

30 Ile Val Ser Gly Leu Cys Ala Ile Ala Gly Val Ser Val Phe Ala Asn
130 135 140

Met Leu Val Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Thr Gly
145 150 155 160

35 Met Gly Gly Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe Gly Ala
165 170 175

<210> 21
<211> 10
<212> PRT
<213> Homo sapiens

<400> 21

Asp Gln Trp Ser Thr Gln Asp Leu Tyr Asn
1 5 10

<210> 22
<211> 11
<212> PRT
<213> Homo sapiens

<400> 22

Asn Asn Pro Val Thr Ala Val Phe Asn Tyr Gln
1 5 10

EP 2 311 877 B1

<210> 23
 <211> 14
 <212> PRT
 <213> Homo sapiens
 5
 <400> 23

 Ser Thr Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala Val Phe
 1 5 10
 10
 <210> 24
 <211> 12
 <212> PRT
 <213> Homo sapiens
 15
 <400> 24

 Asp Met Trp Ser Thr Gln Asp Leu Tyr Asp Asn Pro
 1 5 10
 20
 <210> 25
 <211> 12
 <212> PRT
 <213> Homo sapiens
 25
 <400> 25

 Cys Arg Pro Tyr Phe Thr Ile Leu Gly Leu Pro Ala
 1 5 10
 30
 <210> 26
 <211> 13
 <212> PRT
 <213> Homo sapiens
 35
 <400> 26

 Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Thr Gly
 1 5 10
 40
 <210> 27
 <211> 13
 <212> PRT
 <213> Homo sapiens
 45
 <400> 27

 Asp Ser Ala Lys Ala Asn Met Thr Leu Thr Ser Gly Ile
 1 5 10
 50
 <210> 28
 <211> 55
 <212> PRT
 <213> Homo sapiens
 55
 <400> 28

EP 2 311 877 B1

Met Asp Gln Trp Ser Thr Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala
1 5 10 15

5 Val Phe Asn Tyr Gln Gly Leu Trp Arg Ser Cys Val Arg Glu Ser Ser
20 25 30

Gly Phe Thr Glu Cys Arg Gly Tyr Phe Thr Leu Leu Gly Leu Pro Ala
35 40 45

10 Met Leu Gln Ala Val Arg Ala
50 55

<210> 29
15 <211> 24
<212> PRT
<213> Homo sapiens

<400> 29

20 Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Glu Asp Ser Ala Lys
1 5 10 15

25 Ala Asn Met Thr Leu Thr Ser Gly
20

<210> 30
30 <211> 40
<212> PRT
<213> Homo sapiens

<400> 30

35 Ala Asn Met Leu Val Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr
1 5 10 15

Thr Gly Met Gly Gly Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe
20 25 30

40 Gly Ala Ala Leu Phe Val Gly Trp
35 40

45 <210> 31
<211> 153
<212> PRT
<213> Homo sapiens

50 <400> 31

55

EP 2 311 877 B1

Met Asp Gln Trp Ser Thr Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala
1 5 10 15

Val Phe Asn Tyr Gln Gly Leu Trp Arg Ser Cys Val Arg Glu Ser Ser
20 25 30

Gly Phe Thr Glu Cys Arg Gly Tyr Phe Thr Leu Leu Gly Leu Pro Ala
35 40 45

Met Leu Gln Ala Val Arg Ala Leu Met Ile Val Gly Ile Val Leu Gly
50 55 60

Ala Ile Gly Leu Leu Val Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile
65 70 75 80

Gly Ser Met Glu Asp Ser Ala Lys Ala Asn Met Thr Leu Thr Ser Gly
85 90 95

Ile Met Phe Ile Val Ser Gly Leu Cys Ala Ile Ala Gly Val Ser Val
100 105 110

Phe Ala Asn Met Leu Val Thr Asn Phe Trp Met Ser Thr Ala Asn Met
115 120 125

Tyr Thr Gly Met Gly Gly Met Val Gln Thr Val Gln Thr Arg Tyr Thr
130 135 140

Phe Gly Ala Ala Leu Phe Val Gly Trp
145 150

<210> 32
<211> 3359
<212> DNA
<213> Homo sapiens

<400> 32

40 cacaccttcg gcagcaggag ggcggcagct tctcgcaggc ggcagggcgg gcggccagga 60
tcattgtccac caccacatgc caagtgggtg cgttcctcct gtccatcctg gggctggccg 120
45 gctgcatcgc ggccaccggg atggacatgt ggagcaccca ggacctgtac gacaaccccc 180
tcacctccgt gttccagtac gaagggtctt ggaggagctg cgtgaggcag agttcaggct 240
tcaccgaatg caggccctat ttcaccatcc tgggacttcc agccatgctg caggcagtcg 300
50 gagccctgat gatcgtaggc atcgtcctgg gtgccattgg cctcctggta tccatctttg 360
ccctgaaatg catccgcatt ggcagcatgg aggactctgc caaagccaac atgacactga 420

55

EP 2 311 877 B1

	cctccgggat catgttcatt gtctcaggtc tttgtgcaat tgctggagtg tctgtgtttg	480
	ccaacatgct ggtgactaac ttctggatgt ccacagctaa catgtacacc ggcattgggtg	540
5	ggatggtgca gactgttcag accagggtaca catttggtgc ggctctgttc gtgggctggg	600
	tcgctggagg cctcacacta attgggggtg tgatgatgtg catcgctgc cggggcctgg	660
	caccagaaga aaccaactac aaagccgttt cttatcatgc ctcaggccac agtggtgcct	720
10	acaagcctgg aggttcaag gccagcactg gctttgggtc caacaccaa aacaagaaga	780
	tatacgatgg aggtgcccgc acagaggacg aggtacaatc ttatccttcc aagcacgact	840
	atgtgtaatg ctctaagacc tctcagcacg ggcggaagaa actcccgag agctcaccca	900
15	aaaaacaagg agatcccatc tagatttctt cttgcttttg actcacagct ggaagttaga	960
	aaagcctcga tttcatcttt ggagaggcca aatggtctta gcctcagtct ctgtctctaa	1020
	atattccacc ataaaacagc tgagttatct atgaattaga ggctatagct cacattttca	1080
20	atcctctatt tcttttttta aatataactt tctactctga tgagagaatg tggttttaat	1140
	ctctctctca cattttgatg atttagacag actccccctc ttctctctag tcaataaacc	1200
	cattgatgat ctatttccca gcttatcccc aagaaaactt ttgaaaggaa agagtagacc	1260
25	caaagatggt attttctgct gtttgaattt tgtctcccca cccccaactt ggctagtaat	1320
	aaacacttac tgaagaagaa gcaataagag aaagatatct gtaatctctc cagcccatga	1380
	tctcggtttt cttacactgt gatcttaaaa gttaccaaac caaagtcatt ttcagtttga	1440
30	ggcaacccaa cctttctact gctgttgaca tcttcttatt acagcaacac cattctagga	1500
	gtttcctgag ctctccactg gagtcctctt tctgtcgcgg gtcagaaatt gtccctagat	1560
	gaatgagaaa attatttttt ttaatttaag tcctaaatat agttaaata aataatgttt	1620
35	tagtaaaatg atacactatc tctgtgaaat agcctcaccc ctacatgtgg atagaaggaa	1680
	atgaaaaaat aattgctttg acattgtcta tatggactt tgtaaagtca tgcttaagta	1740
	caaattccat gaaaagctca ctgatcctaa tttcttccct ttgaggctctc tatggctctg	1800
40	attgtacatg atagtaagtg taagccatgt aaaaagtaaa taatgtctgg gcacagtggc	1860
	tcacgcctgt aatcctagca ctttgggagg ctgaggagga aggatcactt gagcccagaa	1920
	gttcgagact agcctgggca acatggagaa gccctgtctc taaaaatac agagagaaaa	1980
45	aatcagccag tcatggtggc ctacacctgt agtcccagca ttccgggagg ctgagggtggg	2040
	aggatcactt gagcccaggg aggttggggc tgcagtgagc catgatcaca ccactgcact	2100
	ccagccaggt gacatagcga gatcctgtct aaaaaataa aaaataaata atggaacaca	2160
50	gcaagtccta ggaagtaggt taaaactaat tctttaaaaa aaaaaaaaag ttgagcctga	2220
	attaatgta atgtttccaa gtgacaggta tccacatttg catggttaca agccactgcc	2280
55	agttagcagt agcactttcc tggcactgtg gtcgggtttg ttttgttttg ctttgtttag	2340

EP 2 311 877 B1

	agacggggtc tcactttcca ggctggcctc aaactcctgc actcaagcaa ttcttctacc	2400
	ctggcctccc aagtagctgg aattacaggt gtgcgccatc acaactagct ggtggtcagt	2460
5	tttgttactc tgagagctgt tcacttctct gaattcacct agagtgggtg gaccatcaga	2520
	tgtttgggca aaactgaaag ctctttgcaa ccacacacct tccctgagct tacatcactg	2580
	cccttttgag cagaaagtct aaattccttc caagacagta gaattccatc ccagtaccaa	2640
10	agccagatag gccccctagg aaactgaggt aagagcagtc tctaaaaact acccacagca	2700
	gcattgggtgc aggggaactt ggccattagg ttattatttg agaggaaagt cctcacatca	2760
	atagtacata tgaaagtgac ctccaagggg attggtgaat actcataagg atcttcaggc	2820
15	tgaacagact atgtctgggg aaagaacgga ttatgcccc ttaaataaca agttgtgttc	2880
	aagagtccaga gcagtgagct cagaggccct tctcactgag acagcaacat ttaaaccaaa	2940
	ccagaggaag tatttgtgga actcactgcc tcagtttggg taaaggatga gcagacaagt	3000
20	caactaaaga aaaaagaaaa gcaaggagga ggggtgagca atctagagca tggagtttgt	3060
	taagtgtctc ctggatttga gttgaagagc atccatttga gttgaaggcc acagggcaca	3120
	atgagctctc ccttctacca ccagaaagtc cctggtcagg tctcaggtag tgcggtgtgg	3180
25	ctcagctggg tttttaatta gcgcattctc tatccaacat ttaattgttt gaaagcctcc	3240
	atatagttag attgtgcttt gtaattttgt tgtgtgtgct ctatcttatt gtatatgcat	3300
	tgagtattaa cctgaatggt ttgttactta aatattaaaa acactgttat cctacagtt	3359
30	<210> 33	
	<211> 849	
	<212> DNA	
	<213> Mus musculus	
35	<400> 33	
	gagaacctgc ctgtctcttg tcctctccat ttgtgtggac tctgtgctcc atcatgtcgg	60
	tgaccgcctg ccagggcttg gggtttgtgg tgcactgat cgggtttgag ggcattcattg	120
40	cagccacttg tatggaccag tggagcacc aggatttata caacaaccg gtgaccgctg	180
	tattcaacta ccaagggtta tggcgttcat gcgtccgaga gagctctggc ttcaccgagt	240
	gccgaggcta cttcaccctg ttggggttgc cagccatgct gcaagctgta cgagccctga	300
45	tgatcgtggg cattgttctg ggggtcatcg gtatcctcgt gtccatcttc gccctgaagt	360
	gcattcgcac ttgtagcatg gatgactctg ccaaggccaa gatgactctg acttctggga	420
	tcttgttcat catctccggc atctgtgcaa tcattggtgt gtctgtgttt gccaacatgc	480
50	tggtgaccaa cttctggatg tccacagcta acatgtacag cggcatgggc ggcattgggtg	540
	gcattggtgca gaccgttcag accaggtaca ccttcgggtg agctctgttc gtgggctggg	600
	ttgctggagg cctcaccctg attgggggag tgatgatgtg catcgctgc cgtggcctga	660
55	caccagatga cagcaacttc aaagctgtgt cttaccatgc ctctggccaa aatgttgctt	720

EP 2 311 877 B1

	acaggcctgg aggcctttaag gccagcactg gctttggggtc caacaccaga aacaagaaga	780
	tctacgatgg ggggtgcccgc acagaagacg atgaacagtc tcatcctacc aagtatgact	840
5	atgtgtagt	849
	<210> 34	
	<211> 3350	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 34	
15	agaattgcgc tgtccacttg tegtgtggct ctgtgtcgac actgtgcgcc accatggccg	60
	tgactgcctg tcagggcctg ggggttcgtgg ttctactgat tgggattgcg ggcacattg	120
	ctgccacctg catggaccag tggagcacc cagacttgta caacaacccc gtaacagctg	180
20	ttttcaacta ccaggggctg tggcgctcct gtgtccgaga gagctctggc ttcaccgagt	240
	gcgggggcta cttcacctg ctggggctgc cagccatgct gcaggcagtg cgagccctga	300
	tgatcgtagg catcgtcctg ggtgccattg gcctcctggt atccatcttt gccctgaaat	360
25	gcatccgcat tggcagcatg gaggactctg ccaaagccaa catgacactg acctccggga	420
	tcatgttcat tgtctcaggt ctttgtgcaa ttgctggagt gtctgtgttt gccaacatgc	480
	tggtgactaa cttctggatg tccacagcta acatgtacac cggcatgggt gggatggtgc	540
	agactgttca gaccaggtac acatttggtg cggtctctgt cgtgggctgg gtctgctggag	600
30	gcctcacact aattgggggt gtgatgatgt gcatcgccctg ccggggcctg gcaccagaag	660
	aaaccaacta caaagccgtt tcttatcatg cctcaggcca cagtgttgcc tacaagcctg	720
	gaggcttcaa ggccagcact ggctttgggt ccaacaccaa aaacaagaag atatacgatg	780
35	gagggtgccc cagagaggac gaggtacaat cttatccttc caagcacgac tatgtgtaat	840
	gctctaagac ctctcagcac gggcggaaga aactcccga gagctcacc aaaaaacaag	900
	gagatcccat ctagatttct tcttgctttt gactcacagc tggaggttag aaaagcctcg	960
40	atttcatctt tggagaggcc aaatggtctt agcctcagtc tctgtctcta aatattccac	1020
	cataaaacag ctgagttatt tatgaattag aggtatagc tcacattttc aatcctctat	1080
	ttcttttttt aatatataact ttctactctg atgagagaat gtgggtttta tctctctctc	1140
45	acattttgat gatttagaca gactccccct cttcctccta gtcaataaac ccattgatga	1200
	tctatttccc agcttatccc caagaaaact tttgaaagga aagagtagac ccaaagatgt	1260
	tattttctgc tgtttgaatt ttgtctcccc acccccact tggctagtaa taaacactta	1320
50	ctgaagaaga agcaataaga gaaagatatt tgtaatctct ccagcccatg atctcggttt	1380
	tcttacctg tgatcttaaa agttaccaa ccaaagtc at tttcagtttg aggcaaccaa	1440
55	acctttctac tgctgttgac atcttcttat tacagcaaca ccattctagg agtttctctga	1500

EP 2 311 877 B1

	gctctccact ggagtcctct ttctgtcgcg ggtcagaaat tgtccctaga tgaatgagaa	1560
	aattattttt ttttaatttaa gtctaaata tagttaaaat aaataatgtt ttagtaaaat	1620
5	gatacactat ctctgtgaaa tagcctcacc cctacatgtg gatagaagga aatgaaaaaa	1680
	taattgcttt gacattgtct atatggtact ttgtaaagtc atgcttaagt acaaattcca	1740
	tgaaaagctc actgatccta attctttccc tttagaggct ctatggctct gattgtacat	1800
10	gatagtaagt gtaagccatg taaaaagtaa ataatgtctg ggcacagtgg ctcacgcctg	1860
	taatcctagc actttgggag gctgaggagg aaggatcact tgagcccaga agttcgagac	1920
	tagcctgggc aacatggaga agccctgtct ctacaaaata cagagagaaa aaatcagcca	1980
15	gtcatgggtgg cctacacctg tagtcccagc attccgggag gctgagggtg gaggatcact	2040
	tgagcccagg gaggttgggg ctgcagttag ccatgatcac accactgcac tccagccagg	2100
	tgacatagcg agatcctgtc taaaaaata aaaaaataat aatggaacac agcaagtcct	2160
20	aggaagtagg ttaaaactaa ttctttaaaa aaaaaaaaaa gttgagcctg aattaaatgt	2220
	aatgtttcca agtgacagg atccacattt gcatggttac aagccactgc cagttagcag	2280
	tagcacttcc ctggcactgt ggtcggtttt gttttgtttt gctttgttta gagacggggt	2340
25	ctcactttcc aggtggcct caaactcctg cactcaagca attcttctac cctggcctcc	2400
	caagtagctg gaattacagg tgtcgccat cacaactagc tgggtggtcag ttttgttact	2460
	ctgagagctg ttcacttctc tgaattcacc tagagtgggt ggaccatcag atgtttgggc	2520
30	aaaactgaaa gctctttgca accacacacc ttccctgagc ttacatcact gcccttttga	2580
	gcagaaagtc taaattcctt ccaagacagt agaattccat cccagtacca aagccagata	2640
	ggccccctag gaaactgagg taagagcagt ctctaaaaac taccacagc agcattggtg	2700
35	caggggaact tggccattag gttattattt gagaggaaag tcctcacatc aatagtacat	2760
	atgaaagtga cctccaaggg gattggtgaa tactcataag gatcttcagg ctgaacagac	2820
	tatgtctggg gaaagaacgg attatgcccc attaaataac aagttgtgtt caagagtcag	2880
40	agcagtgagc tcagaggccc ttctcactga gacagcaaca tttaaacc aa accagaggaa	2940
	gtatttgtgg aactcactgc ctgagtttgg gtaaaggatg agcagacaag tcaactaaag	3000
	aaaaaagaaa agcaaggagg agggttgagc aatctagagc atggagtttg ttaagtgtc	3060
45	tctggatttg agttgaagag catccatttg agttgaaggc cacagggcac aatgagctct	3120
	cccttctacc accagaaagt ccctggtcag gtctcaggta gtgcgggtgtg gctcagctgg	3180
	gtttttaatt agcgattct ctatccaaca ttaattgtt tgaaagcctc catatagtta	3240
	gattgtgctt tgtaattttg ttgttgttgc tctatcttat tgtatatgca ttgagtatta	3300
50	acctgaatgt tttgttactt aaatattaaa aacactgtta tcctacagtt	3350

<210> 35

<211> 264

<212> PRT

55 <213> Mus musculus

<400> 35

EP 2 311 877 B1

	Met	Ser	Val	Thr	Ala	Cys	Gln	Gly	Leu	Gly	Phe	Val	Val	Ser	Leu	Ile	
	1				5					10					15		
5	Gly	Phe	Ala	Gly	Ile	Ile	Ala	Ala	Thr	Cys	Met	Asp	Gln	Trp	Ser	Thr	
				20					25				30				
	Gln	Asp	Leu	Tyr	Asn	Asn	Pro	Val	Thr	Ala	Val	Phe	Asn	Tyr	Gln	Gly	
10			35					40					45				
	Leu	Trp	Arg	Ser	Cys	Val	Arg	Glu	Ser	Ser	Gly	Phe	Thr	Glu	Cys	Arg	
		50					55					60					
15	Gly	Tyr	Phe	Thr	Leu	Leu	Gly	Leu	Pro	Ala	Met	Leu	Gln	Ala	Val	Arg	
	65					70					75					80	
	Ala	Leu	Met	Ile	Val	Gly	Ile	Val	Leu	Gly	Val	Ile	Gly	Ile	Leu	Val	
20					85					90					95		
	Ser	Ile	Phe	Ala	Leu	Lys	Cys	Ile	Arg	Ile	Gly	Ser	Met	Asp	Asp	Ser	
				100					105					110			
25	Ala	Lys	Ala	Lys	Met	Thr	Leu	Thr	Ser	Gly	Ile	Leu	Phe	Ile	Ile	Ser	
			115					120					125				
	Gly	Ile	Cys	Ala	Ile	Ile	Gly	Val	Ser	Val	Phe	Ala	Asn	Met	Leu	Val	
30		130					135					140					
	Thr	Asn	Phe	Trp	Met	Ser	Thr	Ala	Asn	Met	Tyr	Ser	Gly	Met	Gly	Gly	
	145					150					155					160	
35	Met	Gly	Gly	Met	Val	Gln	Thr	Val	Gln	Thr	Arg	Tyr	Thr	Phe	Gly	Ala	
					165					170					175		
	Ala	Leu	Phe	Val	Gly	Trp	Val	Ala	Gly	Gly	Leu	Thr	Leu	Ile	Gly	Gly	
40				180					185					190			
	Val	Met	Met	Cys	Ile	Ala	Cys	Arg	Gly	Leu	Thr	Pro	Asp	Asp	Ser	Asn	
			195					200					205				
45	Phe	Lys	Ala	Val	Ser	Tyr	His	Ala	Ser	Gly	Gln	Asn	Val	Ala	Tyr	Arg	
		210					215					220					
	Pro	Gly	Gly	Phe	Lys	Ala	Ser	Thr	Gly	Phe	Gly	Ser	Asn	Thr	Arg	Asn	
50		225				230					235					240	
	Lys	Lys	Ile	Tyr	Asp	Gly	Gly	Ala	Arg	Thr	Glu	Asp	Asp	Glu	Gln	Ser	
				245						250					255		
55	His	Pro	Thr	Lys	Tyr	Asp	Tyr	Val									
				260													

<210> 36
<211> 2786

EP 2 311 877 B1

<212> DNA

<213> Mus musculus

<400> 36

5

10

15

20

25

30

35

40

45

50

55

```

ggccgggaac cttcccagca agaggggtggt ggttgtctct ggaagcctgc gccagcagc 60
tgaagccatg gccaccacca cgtgccagggt ggtagggctt ctctgtctcc tctgggtct 120
ggccggctgc atagccgcca ctgggatgga catgtggagc actcaagacc tgtatgacaa 180
cccagtcacc gccgtgttcc agtatgaagg gctctggagg agttgcgtgc aacagagctc 240
gggggttcacc gagtgccggc catacttcac catcctgggc cttccagcca tgctgcaagc 300
tgtacgagcc ctgatgatcg tgggcattgt tctgggggtc atcggtatcc tctgttccat 360
cttcgccctg aagtgcattc gcattggtag catggatgac tctgccaagg ccaagatgac 420
tctgacttct gggatcttgt tcatcatctc cggcatctgt gcaatcattg gtgtgtctgt 480
gtttgccaac atgctggtga ccaacttctg gatgtccaca gctaacatgt acagcggcat 540
gggcgccatg ggtggcatgg tgcagaccgt tcagaccagg tacaccttcg gtgcagctct 600
gttcgtgggc tgggttctct gaggcctcac cctgattggg ggagtgatga tgtgcatcgc 660
ctgccgtggc ctgacaccag atgacagcaa cttcaaagct gtgtcttacc atgcctctgg 720
ccaaaatgtt gcctacaggc ctggaggctt taaggccagc actggctttg ggtccaacac 780
cagaaacaag aagatctacg atgggggtgc ccgcacagaa gacgatgaac agtctcatcc 840
taccaagtat gactatgtgt agtgctctaa gaccgcgcaa cctgtgtgca ggaggaaccc 900
ttccccaaga agagctcacc ccaaagcaac gggagtctac cttgttcctt tgttgatttc 960
aactgacatc tgaaagttag taaagcctga tttcatcca tagggaggct agacagtctt 1020
ggccacatgt gtctgcctct aaatatccca tcacaaaaca gctgagttat cgtttatgag 1080
ttagaggcca taacactcac tttagcccaa ccctctgctt tttaccgtag actttctttt 1140
catctggtga tggaatggaa tttgactcac agactaatac tttaatgggt tagagaaact 1200
ttccttcctc gtacttaata agcctgtgta tggtegattt tccagcttga ccaccaaggg 1260
aaattttaaa aggaaaaaaa aatacattaa aaggcattat ttcctactca attgtgcctt 1320
accaccccc aacttgactg ataataataa tgaacaccac ttaaagaaag aatgccagag 1380
gaaagatagt tgtgtttccc ccagccagc catctgagtc cccctatgtg gtgatctaga 1440

```

EP 2 311 877 B1

acattactcg ccacagtgat tttcaaagaa ggcaagcgag cctgttcgct ctgctcagca 1500
 tctgctgatt ccagcaaggc ccttccagag ctttccacta gaagtcctcc ttctctcgga 1560
 5 agtcagaaat tccccctaga agagtaagaa atagattctt ttgggtaacc tgagtcctag 1620
 gtatagttat aataaatagt atattagcaa aacgggtttg tatctcagtg aattagtttc 1680
 agccttacat atagaaaaag ctggggaaaa aaaaagcatc ccttgacatt gtctatagcg 1740
 10 taagatccta tataaatcca agcttcaaca aaagctcact gagtctaata gttttctttt 1800
 gaggtctcca cggccttagt actcatagat gcagcccctg tttaaaagta aaaaaattaa 1860
 agtagcttaa aacgggttct tttttttttt ttttttttca aaaaatccaa tagagacctg 1920
 15 tgtgtctggc atagctacag ttactgccaa tcgacagggc cacttctttg gtctttagg 1980
 cagttttgca gttctgacag ctgcgccggg catcaatatg cagaccacac ccttctctgt 2040
 gctttagtagga cgaccgttc aaggagaaag catgaactcc atctccatgt gagcctgaat 2100
 20 gctcccagga aatggagata ggggtctctc caaaaccac ctgaacctga aacagctgta 2160
 gcgctatgct gtaagagcct ggccatcaag ttcctatgga gaaaagggc agtccttgca 2220
 ttaatagtgc atatataagt ggcctctggg gggcagggat gaatattcag tgggtggctcc 2280
 gagtatgtac agaccgtcta aggagctgtg ttgaccaaga gccagggtta tacgcagagt 2340
 25 ttttccact gggactacag tgattttaga ctatactgaa gaaggccctc tggaaaatca 2400
 ttatctgaaa tggcataaag aatgaacaga ccaaacaatt taaggggagg gggcagggtg 2460
 aaggaggggg aaggaggtag aaataagaat ctagggcag aagattgtta aggttcttgg 2520
 30 ggtccaaatg gaaggtcacc cctttgaggc catggacaca atgcaccca cccctacccc 2580
 cacctgcca cccaccagaa agtccttggc cggactggag gcagtgagaa tcagctgttt 2640
 tcagttagtg ggtctcgggtg tagcacctgg ctgtttcaaa gcttcccctt gctttgccgt 2700
 35 tttttccgcc attgctgtct tgtttctgtt gttattaacc tccatgtttt gtacgttaaa 2760
 tattaaaaca ctgttaacat ccattc 2786

<210> 37

40 <211> 264

<212> PRT

<213> Mus musculus

<400> 37

45

Met Ala Thr Thr Thr Cys Gln Val Val Gly Leu Leu Leu Ser Leu Leu
 1 5 10 15

50

Gly Leu Ala Gly Cys Ile Ala Ala Thr Gly Met Asp Met Trp Ser Thr
 20 25 30

Gln Asp Leu Tyr Asp Asn Pro Val Thr Ala Val Phe Gln Tyr Glu Gly
 35 40 45

55

EP 2 311 877 B1

	Leu	Trp	Arg	Ser	Cys	Val	Gln	Gln	Ser	Ser	Gly	Phe	Thr	Glu	Cys	Arg	
	50						55					60					
5	Pro	Tyr	Phe	Thr	Ile	Leu	Gly	Leu	Pro	Ala	Met	Leu	Gln	Ala	Val	Arg	
	65					70					75					80	
	Ala	Leu	Met	Ile	Val	Gly	Ile	Val	Leu	Gly	Val	Ile	Gly	Ile	Leu	Val	
					85					90					95		
10	Ser	Ile	Phe	Ala	Leu	Lys	Cys	Ile	Arg	Ile	Gly	Ser	Met	Asp	Asp	Ser	
				100					105					110			
	Ala	Lys	Ala	Lys	Met	Thr	Leu	Thr	Ser	Gly	Ile	Leu	Phe	Ile	Ile	Ser	
15				115					120					125			
	Gly	Ile	Cys	Ala	Ile	Ile	Gly	Val	Ser	Val	Phe	Ala	Asn	Met	Leu	Val	
		130					135					140					
20	Thr	Asn	Phe	Trp	Met	Ser	Thr	Ala	Asn	Met	Tyr	Ser	Gly	Met	Gly	Gly	
	145					150					155					160	
	Met	Gly	Gly	Met	Val	Gln	Thr	Val	Gln	Thr	Arg	Tyr	Thr	Phe	Gly	Ala	
25					165					170					175		
	Ala	Leu	Phe	Val	Gly	Trp	Val	Ala	Gly	Gly	Leu	Thr	Leu	Ile	Gly	Gly	
				180					185					190			
30	Val	Met	Met	Cys	Ile	Ala	Cys	Arg	Gly	Leu	Thr	Pro	Asp	Asp	Ser	Asn	
			195					200					205				
	Phe	Lys	Ala	Val	Ser	Tyr	His	Ala	Ser	Gly	Gln	Asn	Val	Ala	Tyr	Arg	
35		210					215					220					
	Pro	Gly	Gly	Phe	Lys	Ala	Ser	Thr	Gly	Phe	Gly	Ser	Asn	Thr	Arg	Asn	
	225					230					235					240	
40	Lys	Lys	Ile	Tyr	Asp	Gly	Gly	Ala	Arg	Thr	Glu	Asp	Asp	Glu	Gln	Ser	
					245					250					255		
	His	Pro	Thr	Lys	Tyr	Asp	Tyr	Val									
45				260													
	<210>	38															
	<211>	40															
	<212>	DNA															
	<213>	Artificial															
50	<220>																
	<223>	Description of artificial sequence: Oligonucleotide															
	<400>	38															
55		gagaggatcc	cgtagcgtgg	ctgcaccatc	tgtcttcac											40	
	<210>	39															
	<211>	37															

EP 2 311 877 B1

<212> DNA
<213> Artificial

<220>

5 <223> Description of artificial sequence: Oligonucleotide

<400> 39
gagagcggcc gcctaact ctcccgtt gaagctc 37

10 <210> 40
<211> 324
<212> DNA
<213> Artificial

15 <220>
<223> Description of artificial sequence: PCR product

<400> 40

20 **cgtagcggtag ctgcaccatc tgtcttcac ttcccgcac ctgatgagca gttgaaatct 60**
ggaactgcct ctgttgtag cctgctgaat aacttctatc ccagagaggc caaagtacag 120
tggaaggtag ataacgcct ccaatcgggt aactcccagg agagtgtcac agagcaggac 180
25 **agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240**
aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300
agcttcaaca ggggagagtg ttag 324

30 <210> 41
<211> 107
<212> PRT
<213> Artificial

35 <220>
<223> Description of artificial sequence: Translation of PCR product

<400> 41

40 **Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu**
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
45 **20 25 30**
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45
50 **Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser**
50 55 60

55

EP 2 311 877 B1

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80

5 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

10

<210> 42
<211> 34
<212> DNA
<213> Artificial

15

<220>
<223> Description of artificial sequence: Oligonucleotide

20 <400> 42
gagaaagctt tcaccaagg gcccatoggt cttc 34

25 <210> 43
<211> 36
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: Oligonucleotide

30 <400> 43
gagagcggcc gctcatttac ccggagacag ggagag 36

35 <210> 44
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: Oligonucleotide

40

<400> 44
taccagtga actgacctc a 21

45 <210> 45
<211> 981
<212> DNA
<213> Artificial

50 <220>
<223> Description of artificial sequence: PCR product

<400> 45

55 ggcccatcgg tcttccccct ggcaccctcc tccaagagca cctctggggg cacagcggcc 60
ctgggctgcc tgggtcaagga ctacttcccc gaaccgggtga cgggtgtcgtg gaactcaggc 120
gccctgacca gcggcgtgca caccttcccc gctgtcctac agtcttcagg actctactcc 180

EP 2 311 877 B1

ctcagcagcg tgggtaccgt gccctccagc agcttgggca cccagaccta catctgcaac 240
 gtgaatcaca agcccagcaa caccaagggtg gacaagaaag ttgagcccaa atcttgtgac 300
 5 aaaactcaca catgcccacc gtgcccagca cctgaactcc tgggggggacc gtcagtcttc 360
 ctcttccccc caaaacccaa ggacaccctc atgatctccc ggaccctga ggtcacatgc 420
 gtgggtgggtg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc 480
 10 gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt 540
 gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc 600
 aagggtctcca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg 660
 15 cagccccgag aaccacaggt gtacaccctg ccccatccc gggatgagct gaccaagaac 720
 caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg 780
 gagagcaatg ggagccgga gaacaactac aagaccacgc ctcccgctgc ggactccgac 840
 20 ggctccttct tcctctatag caagctcacc gtggacaaga gcaggtggca gcaggggaac 900
 gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc 960
 tcctgtctc cgggtaaatg a 981

25 <210> 46
 <211> 326
 <212> PRT
 <213> Artificial

30 <220>
 <223> Description of artificial sequence: Translation of PCR product

<400> 46

35 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
 1 5 10 15
 40 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 20 25 30
 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 35 40 45
 45 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 50 55 60
 50 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
 65 70 75 80
 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
 85 90 95

55

EP 2 311 877 B1

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
 100 105 110
 5 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 115 120 125
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 130 135 140
 10 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
 145 150 155 160
 15 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
 165 170 175
 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
 180 185 190
 20 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
 195 200 205
 25 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
 210 215 220
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
 225 230 235 240
 30 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 245 250 255
 35 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 260 265 270
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 275 280 285
 40 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 290 295 300
 45 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 305 310 315 320
 Ser Leu Ser Pro Gly Lys
 325

50 <210> 47
 <211> 32
 <212> DNA
 <213> Artificial

55 <220>
 <223> Description of artificial sequence: Oligonucleotide

<220>

<221> misc_feature
 <222> (31)..(32)
 <223> n is a, c, g, or t

5 <400> 47
 tttttttt tttttttt tttttttt nn 32

<210> 48
 <211> 30
 10 <212> DNA
 <213> Artificial

<220>
 <223> Description of artificial sequence: Oligonucleotide

15 <400> 48
 aagcagtggg atcaacgcag agtacgcggg 30

<210> 49
 20 <211> 26
 <212> DNA
 <213> Artificial

<220>
 25 <223> Description of artificial sequence: Oligonucleotide

<400> 49
 ctgctcactg gatggtggga agatgg 26

30 <210> 50
 <211> 25
 <212> DNA
 <213> Artificial

35 <220>
 <223> Description of artificial sequence: Oligonucleotide

<400> 50
 40 gggacagtca ctgagctgct cagag 25

<210> 51
 <211> 25
 <212> DNA
 <213> Artificial

45 <220>
 <223> Description of artificial sequence: Oligonucleotide

<400> 51
 50 acaggggcca gtggatagac cgatg 25

<210> 52
 <211> 27
 <212> DNA
 55 <213> Artificial

<220>
 <223> Description of artificial sequence: Oligonucleotide

EP 2 311 877 B1

<400> 52
 agccagggac caagggatag acagatg 27

5 <210> 53
 <211> 45
 <212> DNA
 <213> Artificial

10 <220>
 <223> Description of artificial sequence: Oligonucleotide

<400> 53
 gtaatacgac tcactatagg gcaagcagtg gtatcaacgc agagt 45

15 <210> 54
 <211> 22
 <212> DNA
 <213> Artificial

20 <220>
 <223> Description of artificial sequence: Oligonucleotide

25 <400> 54
 gtaatacgac tcactatagg gc 22

30 <210> 55
 <211> 351
 <212> DNA
 <213> Artificial

35 <220>
 <223> Description of artificial sequence: PCR product

<400> 55

40

cagggttcagc	tgcagcagtc	tggagctgag	ctgatgaagc	ctggggcctc	agtgaagata	60
tcctgcaagg	ctactggcta	cacattcagt	agctactgga	tagagtgggt	aaagcagagg	120
cctggacatg	gccttgagtg	gattggagag	atcttacctg	gaagtggtag	tactaactac	180
aatgagaagt	tcaagggcaa	ggccacattc	actgcagata	catectccaa	cacagcctac	240
atgcaactca	gcagcctgac	atctgaggac	tctgccgtct	attactgtgc	aagatatgat	300
taccctcgtg	ttgcttactg	gggccaaggg	actctgggtc	ctgtctctgc	a	351

45

50 <210> 56
 <211> 354
 <212> DNA
 <213> Artificial

<220>
 <223> Description of artificial sequence: PCR product

55 <400> 56

EP 2 311 877 B1

	cagatccagt	tggtgcagtc	tggacctgag	ctgaagaagc	ctggagagac	agtcaagatc	60
	tcctgcaagg	cttctgggta	taccttcaca	aactatggaa	tgaactgggt	gaagcaggct	120
5	ccaggaaagg	gtttaaagtg	gatgggctgg	ataaacacca	acactggaga	gccaacatat	180
	gctgaagagt	tcaagggacg	gtttgccttc	tctttggaaa	cctctgccag	cactgcctat	240
	ttgcagatca	acaacctcaa	aaatgaggac	acggctacat	atttctgtgc	aagactgggt	300
10	tttggtaatg	ctatggacta	ctgggggtcaa	ggaacctcag	tcaccgtctc	ctca	354

<210> 57

<211> 348

<212> DNA

15 <213> Artificial

<220>

<223> Description of artificial sequence: PCR product

20 <400> 57

	caggttcagc	tgagcagtc	tggagctgag	ctggcgaggc	ccggggcttc	agtgaagctg	60
25	tcctgcaagg	cttctggcta	caccttcaact	gactactata	taaactgggt	gaagcagagg	120
	actggacagg	gccttgagtg	gattggagag	atttatcctg	gaagtggtaa	tacttactac	180
	aatgagaagt	tcaagggcaa	ggccacactg	actgcagaca	aatcctccag	cacagcctac	240
30	atgcagctca	gcagcctgac	atctgaggac	tctgcagtct	atttctgtgc	aagatcgtat	300
	gggtgcctttg	actactgggg	ccaaggcacc	actctcacag	tctcctca		348

<210> 58

<211> 354

35 <212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: PCR product

40 <400> 58

	caggtccaac	tgagcagcc	tggggctgag	ctgggtgagc	ctggggcttc	agtgaagctg	60
45	tcctgcaagg	cttctggcta	caccttcacc	agctactgga	taaactgggt	gaagcagagg	120
	cctggacaag	gccttgagtg	gatcggaat	atttatcctt	ctgatagtta	tactaactac	180
	aatcaaaagt	tcaaggacaa	ggccacattg	actgtagaca	aatcctccag	cacagcctac	240
50	atgcagctca	gcagcccgac	atctgaggac	tctgcggtct	attactgtac	aagatcgtgg	300
	aggggtaact	cctttgacta	ctggggccaa	ggcaccactc	tcacagtctc	ctca	354

<210> 59

55 <211> 354

<212> DNA

<213> Artificial

EP 2 311 877 B1

<220>

<223> Description of artificial sequence: PCR product

<400> 59

5

```

cagggttcagc tgcagcagtc tggacctgag ctggtgaagc ctggggcttc agtgaagatg      60
tcttgcaagg cttctggata cacattcact gactatgtta taagctgggt gaagcagaga      120
actggacagg gccttgagtg gattggagag atttatcctg gaagtggtag tacttactac      180
aatgagaagt tcaagggcaa ggccacactg actgcagaca aatcctccaa cacagcctac      240
atgcagctca gcagcctgac atctgaggac tctgcggtct atttctgtgc aagaggggta      300
ttactacggg ctatggacta ctgggggtcaa ggaacctcag tcacctctc ctca          354

```

10

15

<210> 60

<211> 360

<212> DNA

<213> Artificial

20

<220>

<223> Description of artificial sequence: PCR product

<400> 60

25

```

cagggttcacc tacaacagtc tggttctgaa ctgaggagtc ctgggtcttc agtaaagctt      60
tcatgcaagg attttgattc agaagtcttc ccttttgctt atatgagttg gattaggcag      120
aagcctgggc atggatttga atggattgga gacatactcc caagtattgg tagaacaatc      180
tatggagaga agtttgagga caaagccaca ctggatgcag acacagtgtc caacacagcc      240
tacttgagac tcaacagtct gacatctgag gactctgcta tctactactg tgcaaggggg      300
gagggctacg gtgcctgggt tgcttactgg ggccaaggga ctctgggtcac tgtctctgca      360

```

30

35

<210> 61

<211> 339

<212> DNA

<213> Artificial

40

<220>

<223> Description of artificial sequence: PCR product

<400> 61

45

```

gacattgtga tgacacagtc tccatcctcc ctgactgtga cagcaggaga gaaggtcact      60
atgagctgca agtccagtca gagtctgtta aacagtggaa atcaaaagaa ctacttgacc      120
tggtaccagc agaaaccagg gcagcctcct aaactgttga tctactgggc atccactagg      180
gaatctgggg tccctgatcg cttcacaggc agtggatctg gaacagattt cactctcacc      240
atcagcagtg tgcaggctga agacctggca gtttattact gtcagaatga ttatagttat      300
ccgctcacgt tcggtgctgg gaccaagctg gagctgaaa          339

```

50

55

EP 2 311 877 B1

<210> 62
<211> 318
<212> DNA
<213> Artificial

5

<220>
<223> Description of artificial sequence: PCR product

<400> 62

10

```

caaattgttc tcaccagtc tccagcaatc atgtctgcat ctccagggga gaaggtcacc 60
ataacctgca gtgccagctc aagtgttaagt tacatgcact ggttccagca gaagccaggc 120
acttctccca aactctggat ttatagcaca tccaacctgg cttctggagt ccttgctcgc 180
ttcagtggca gtggatctgg gacctcttac tctctcacia tcagccgaat ggaggctgaa 240
gatgctgcca cttattactg ccagcaaagg agtagttacc caccacggt cggagggggg 300
accaagctgg aaataaaa 318

```

20

<210> 63
<211> 321
<212> DNA
<213> Artificial

25

<220>
<223> Description of artificial sequence: PCR product

<400> 63

30

```

gacattgtga tgaccagtc tcaaaaattc atgtccacat cagtaggaga cagggtcagc 60
atcacctgca aggccagtca gaatgttcgt actgctgtag cctgggtatca acagaaacca 120
gggcagtctc cttaaagcact gatttacttg gcatccaacc ggcacactgg agtccctgat 180
cgtttcacag gcagtggatc tgggacagat ttcactctca ccattagcaa tgtgcaatct 240
gaagacctgg cagattattt ctgtctgcaa cattggaatt atcctctgac gttcgggtgga 300
ggcaccaagc tggaaatcaa a 321

```

40

<210> 64
<211> 339
<212> DNA
<213> Artificial

45

<220>
<223> Description of artificial sequence: PCR product

<400> 64

50

55

EP 2 311 877 B1

5
10

gacattgtga	tg	tcacagtc	tccatcctcc	ctagctgtgt	cagttggaga	gaagggtact	60
atgagctgca	agtccagtc	gagcctttta	tatagtagca	atcaaaagaa	ctacttggcc		120
tggtaccagc	agaaaccagg	gcagtcctct	aaactgctga	tttactgggc	atccactagg		180
gaatctgggg	tccctgatcg	cttcacaggc	agtggatctg	ggacagattt	cactctcacc		240
atcagcagtg	tgaaggctga	agacctggca	gtttattact	gtcagcaata	ttatagctat		300
ccgctcacgt	tcggtgctgg	gaccaagctg	gagctgaaa				339

<210> 65

<211> 339

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: PCR product

<400> 65

25
30

gacattgtga	tg	acacagtc	tccatcctcc	ctgactgtga	cagcaggaga	gaagggtact	60
atgagctgca	agtccagtc	gagtctgtta	aacagtggaa	atcaaaagaa	ctacttgacc		120
tggtaccagc	agaaaccagg	gcagctctct	aaactgttga	tctactgggc	atccactagg		180
gaatctgggg	tccctgatcg	cttcacaggc	agtggatctg	gaacagattt	cactctcacc		240
atcagcagtg	tcgaggctga	agacctggca	gtttattact	gtcagaatga	ttatagttat		300
ccattcacgt	tcgggtcggg	gacaaagttg	gaaataaaa				339

<210> 66

<211> 336

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: PCR product

<400> 66

45
50

gacattgtga	tg	tcacagtc	tccatcctcc	ctggctgtgt	cagcaggaga	gaagggtact	60
atgagctgca	aatccagtc	gagtctgttc	aacagttagaa	cccgaagaa	ctacttggct		120
tggtaccagc	agaaaccagg	gcagtcctct	aaactgctga	tctactgggc	atccactagg		180
gaatctgggg	tccctgatcg	cttcacaggc	agtggatctg	ggacagattt	cactctcacc		240
atcagcagtg	tcgaggctga	agacctggca	gtttattact	gcaagcaatc	ttataatctg		300
tacacgttcg	gaggggggac	caagctggaa	ataaaa				336

<210> 67

<211> 339

<212> DNA

<213> Artificial

EP 2 311 877 B1

<220>

<223> Description of artificial sequence: PCR product

<400> 67

5

```

gacatcgtga tgtcacagtc tccatcctcc ctagctgtgt cagttggaga gaagggtact    60
atgagctgca agtccagtca gagcctttta tatagtagca atcaaaagaa ctacttggcc    120
tggtaccagc agaaaccagg gcagtctcct aaactgctga tttactgggc atccactagg    180
gaatctgggg tccctgatcg cttcacaggc agtggatctg caacagattt cactctgacc    240
atcagcagtg tgcaggctga agaccttgca gattatcact gtggacaggg ttacagctat    300
ccgtacacgt tcggaggggg gaccaagctg gaaataaaa    339

```

10

15

<210> 68

<211> 339

<212> DNA

<213> Artificial

20

<220>

<223> Description of artificial sequence: PCR product

<400> 68

25

```

gacattgtga tgtcacagtc tccatcctcc ctagctgtgt cagttggaga gaagggtact    60
atgagctgca agtccagtca gagcctttta tatagtagca atcaaaagaa ctacttggcc    120
tggtaccagc agaaaccagg gcagtctcct aaactgctga tttactgggc atccactagg    180
gaatctgggg tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc    240
atcagcagtg tgaaggctga agacctggca gtttattact gtcagcaata ttatagctat    300
ccgctcacgt tcggtgctgg gaccaagctg gagctgaaa    339

```

30

35

<210> 69

<211> 321

<212> DNA

<213> Artificial

40

<220>

<223> Description of artificial sequence: PCR product

<400> 69

45

```

aacattgtaa tgaccaaatc tcccaaatcc atgtccatgt cagtaggaga gagggtcacc    60
ttgacctgca aggccagtga gaatgtgggt acttatgttt cctgggtatca acagaaacca    120
gagcagcttc ctaaactgct gatatacggg gcatccaacc ggtacactgg ggtccccgat    180
cgcttcacag gcagtggatc tgcaacagat ttcactctca ccatcagcag tgtgaaggct    240
gaagacctgg cagtttatta ctgtcagcaa tattatagct atccgctcac gttcgggtgct    300
gggaccaagc tggagctgaa a    321

```

50

55

<210> 70
 <211> 43
 <212> DNA
 <213> Artificial
 5
 <220>
 <223> Description of artificial sequence: Oligonucleotide
 <400> 70
 10 gagaaagctt gccgccacca tggatggac ctgggtcttt ctc 43
 <210> 71
 <211> 43
 <212> DNA
 15 <213> Artificial
 <220>
 <223> Description of artificial sequence: Oligonucleotide
 <400> 71
 20 gagagggccc ttggtggagg ctgcagagac agtgaccaga gtc 43
 <210> 72
 <211> 47
 25 <212> DNA
 <213> Artificial
 <220>
 <223> Description of artificial sequence: Oligonucleotide
 30 <400> 72
 gagaaagctt gccgccacca tggattggct gtggaacttg ctattcc 47
 <210> 73
 35 <211> 44
 <212> DNA
 <213> Artificial
 <220>
 40 <223> Description of artificial sequence: Oligonucleotide
 <400> 73
 gagagggccc ttggtggagg ctgaggagac ggtgactgag gttc 44
 45 <210> 74
 <211> 46
 <212> DNA
 <213> Artificial
 50 <220>
 <223> Description of artificial sequence: Oligonucleotide
 <400> 74
 55 gagaaagctt gccgccacca tggatggat ctggatcttt ctcttc 46
 <210> 75
 <211> 44
 <212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: Oligonucleotide

5

<400> 75
gagagggccc ttggtggagg ctgaggagac tgtgagagtg gtgc 44

<210> 76

10 <211> 46
<212> DNA
<213> Artificial

<220>

15 <223> Description of artificial sequence: oligonucleotide

<400> 76
gagaaagctt gccgccacca tgggatggag ctgtatcatc ctcttc 46

20 <210> 77
<211> 43
<212> DNA
<213> Artificial

25 <220>

<223> Description of artificial sequence: Oligonucleotide

<400> 77
gagagggccc ttggtggagg ctgaggagac tgtgagagtg gtg 43

30 <210> 78
<211> 47
<212> DNA
<213> Artificial

35 <220>

<223> Description of artificial sequence: Oligonucleotide

<400> 78
40 gagaaagctt gccgccacca tggaatggag gatctttctc ttcattcc 47

<210> 79
<211> 44
<212> DNA

45 <213> Artificial

<220>

<223> Description of artificial sequence: Oligonucleotide

50 <400> 79
gagagggccc ttggtggagg ctgaggagac ggtgactgag gtgc 44

<210> 80
<211> 51
<212> DNA

55 <213> Artificial

<220>

EP 2 311 877 B1

<223> Description of artificial sequence: Oligonucleotide

<400> 80

gagaggtctc aagcttagcc accatggact ggatttggat catgctccat c 51

5

<210> 81

<211> 44

<212> DNA

<213> Artificial

10

<220>

<223> Description of artificial sequence: Oligonucleotide

<400> 81

15

gagagggccc ttggtggagg ctgcagagac agtgaccaga gtcc 44

<210> 82

<211> 43

<212> DNA

<213> Artificial

20

<220>

<223> Description of artificial sequence: Oligonucleotide

<400> 82

25

gagaaagctt gccgccacca tggatcaca gactcaggtc ctc 43

<210> 83

<211> 34

<212> DNA

<213> Artificial

30

<220>

<223> Description of artificial sequence: Oligonucleotide

<400> 83

35

cacacgtacg ttccagctcc agcttgggcc cagc 34

<210> 84

<211> 46

<212> DNA

<213> Artificial

40

<220>

<223> Description of artificial sequence: Oligonucleotide

<400> 84

45

gagaaagctt gccgccacca tgcatttca agtcagatt ttcagc 46

<210> 85

<211> 30

<212> DNA

<213> Artificial

50

<220>

<223> Description of artificial sequence: Oligonucleotide.

<400> 85

55

EP 2 311 877 B1

cacacgtacg ttttattcc agcttggtcc 30

<210> 86
 <211> 44
 5 <212> DNA
 <213> Artificial

<220>
 <223> Description of artificial sequence: Oligonucleotide

10 <400> 86
 gagaaagctt gccgccacca tggagttca gaccagggtc ttg 44

<210> 87
 15 <211> 33
 <212> DNA
 <213> Artificial

<220>
 20 <223> Description of artificial sequence: Oligonucleotide

<400> 87
 cacacgtacg ttgattcc agcttggtgc ctc 33

25 <210> 88
 <211> 46
 <212> DNA
 <213> Artificial

30 <220>
 <223> Description of artificial sequence: Oligonucleotide

<400> 88
 gagaaagctt gccgccacca tggattcaca ggcccagggt cttatg 46

35 <210> 89
 <211> 30
 <212> DNA
 <213> Artificial

40 <220>
 <223> Description of artificial sequence: Oligonucleotide

<400> 89
 45 cacacgtacg tttcagctcc agcttggtcc 30

<210> 90
 <211> 46
 <212> DNA
 50 <213> Artificial

<220>
 <223> Description of artificial sequence: Oligonucleotide

55 <400> 90
 gagaaagctt gccgccacca tggaaacaca gactcagggtc ctcattg 46

<210> 91

<211> 30
 <212> DNA
 <213> Artificial

5 <220>
 <223> Description of artificial sequence: Oligonucleotide

<400> 91
 cacacgtacg tttatttcc aacttgtcc 30

10 <210> 92
 <211> 49
 <212> DNA
 <213> Artificial

15 <220>
 <223> Description of artificial sequence: Oligonucleotide

<400> 92
 20 gagaaagctt gccgccacca tggattcaca ggcccagggt cttatattg 49

<210> 93
 <211> 30
 <212> DNA
 25 <213> Artificial

<220>
 <223> Description of artificial sequence: oligonucleotide

30 <400> 93
 cacacgtacg tttatttcc agcttgggcc 30

<210> 94
 <211> 46
 35 <212> DNA
 <213> Artificial

<220>
 <223> Description of artificial sequence: Oligonucleotide

40 <400> 94
 gagaaagctt gccgccacca tggattcaca ggcccagggt cttatg 46

<210> 95
 <211> 30
 45 <212> DNA
 <213> Artificial

<220>
 <223> Description of artificial sequence: Oligonucleotide

50 <400> 95
 cacacgtacg tttatttcc agcttgggcc 30

55 <210> 96
 <211> 46
 <212> DNA
 <213> Artificial

EP 2 311 877 B1

<220>

<223> Description of artificial sequence: oligonucleotide

<400> 96

5 gagaaagctt gccgccacca tggattcaca ggctcagggtt ctatg 46

<210> 97

<211> 33

<212> DNA

10 <213> Artificial

<220>

<223> Description of artificial sequence: oligonucleotide

<400> 97

15 cacacgtacg ttccagctcc agcttggtcc cag 33

<210> 98

<211> 41

20 <212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: Oligonucleotide

25

<400> 98

gagaaagctt agccacatg gaatcacaga ctctggtctt c 41

<210> 99

30 <211> 30

<212> DNA

<213> Artificial

<220>

35 <223> Description of artificial sequence: oligonucleotide

<400> 99

cacacgtacg ttccagctcc agcttggtcc 30

40 <210> 100

<211> 1401

<212> DNA

<213> Artificial

45 <220>

<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 100

50

55

EP 2 311 877 B1

	atggaatgga cctgggtctt tctcttcctc ctgtcagtaa ctgcaggtgt ccactcccag	60
	gttcagctgc agcagctctg agctgagctg atgaagcctg gggcctcagt gaagatatcc	120
5	tgcaaggcta ctggctacac attcagtagc tactggatag agtgggtaaa gcagaggcct	180
	ggacatggcc ttgagtggat tggagagatt ttacctggaa gtggtagtag taactacaat	240
	gagaagttca agggcaaggc cacattcact gcagatacat cctccaacac agcctacatg	300
10	caactcagca gcctgacatc tgaggactct gccgtctatt actgtgcaag atatgattac	360
	ccctggtttg cttactgggg ccaagggact ctggctactg tctctgcagc ctccaccaag	420
	ggcccatcgg tcttccccct ggcaccctcc tccaagagca cctctggggg cacagcggcc	480
15	ctgggctgcc tgggtcaagga ctacttcccc gaaccggtga cgggtgctgt gaactcaggc	540
	gccctgacca gggcggtgca caccttcccc gctgtcctac agtcctcagg actctactcc	600
	ctcagcagcg tgggtaccgt gccctccagc agcttgggca cccagaccta catctgcaac	660
20	gtgaatcaca agcccagcaa caccaagggtg gacaagaaag ttgagcccaa atcttgtgac	720
	aaaactcaca catgcccacc gtgcccagca cctgaactcc tgggggggacc gtcagtcttc	780
	ctcttcccc caaaacccaa ggacaccctc atgatctccc ggaccctga ggtcacatgc	840
25	gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc	900
	gtggagggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt	960
	gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc	1020
30	aaggctctcca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg	1080
	cagccccgag aaccacaggt gtacaccctg ccccatccc gggatgagct gaccaagaac	1140
	caggtcagcc tgacctgctt ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg	1200
35	gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac	1260
	ggctccttct tcctctatag caagctcacc gtggacaaga gcagggtggca gcaggggaac	1320
	gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc	1380
40	tcctgtctc cgggtaaagt a	1401

<210> 101

<211> 1404

<212> DNA

45 <213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

50 <400> 101

55

EP 2 311 877 B1

	atggattggc tgtggaactt gctattcctg atggcagctg cccaaagtat ccaagcacag	60
	atccagttgg tgcagtctgg acctgagctg aagaagcctg gagagacagt caagatctcc	120
5	tgcaaggctt ctgggtatac cttcacaaac tatggaatga actgggtgaa gcaggctcca	180
	ggaaaggggt taaagtggat gggctggata aacaccaaca ctggagagcc aacatatgct	240
	gaagagttca agggacgggt tgccttctct ttggaacct ctgccagcac tgcctatttg	300
10	cagatcaaca acctcaaaaa tgaggacacg gctacatatt tctgtgcaag actgggtttt	360
	ggtaatgcta tggactactg ggggcaagga acctcagtc cctgtctctc agcctccacc	420
	aagggcccat cgggtcttccc cctggcacc cctccaaga gcacctctgg gggcacagcg	480
15	gccctgggct gcctgggtcaa ggactacttc cccgaaccgg tgacgggtgtc gtggaactca	540
	ggcgccctga ccagcggcgt gcacacette ccggtgttc tacagtctc aggactctac	600
	tccctcagca gcgtgggtgac cgtgccctcc agcagcttg gcacccagac ctacatctgc	660
20	aacgtgaatc acaagcccag caacaccaag gtggacaaga aagttgagcc caaatcttgt	720
	gacaaaactc acacatgcc accgtgccc gcacctgaac tctgggggg accgtcagtc	780
	tctctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca	840
25	tgctgtgtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac	900
	ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac	960
	cgtgtgttca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag	1020
30	tgcaaggctc ccaacaaagc cctcccagcc cccatcgaga aaacctctc caaagccaaa	1080
	gggcagcccc gagaaccaca ggtgtacacc ctgccccat cccgggatga gctgaccaag	1140
	aaccaggtca gcctgacctg cctgggtcaaa ggcttctatc ccagcgacat cgccgtggag	1200
35	tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc	1260
	gacggctcct tcttctctta tagcaagctc accgtggaca agagcaggtg gcagcagggg	1320
	aacgtcttct catgtcccgt gatgcatgag gctctgcaca accactacac gcagaagagc	1380
40	ctctccctgt ctccgggtaa atga	1404

<210> 102

<211> 1398

<212> DNA

45 <213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

50 <400> 102

55

EP 2 311 877 B1

atggaatgga tctggatctt tctcttcac cctcaggaa ctgcagggtg ccaactcccag 60
 gtccagctgc agcagctctg agctgagctg gcgaggcccg gggcttcagt gaagctgtcc 120
 5 tgcaaggctt ctggctacac cttcactgac tactatataa actgggtgaa gcagaggact 180
 ggacagggcc ttgagtggat tggagagatt tatcctggaa gtggtataac ttactacaat 240
 gagaagttca agggcaaggc cacactgact gcagacaaat cctccagcac agcctacatg 300
 10 cagctcagca gcctgacatc tgaggactct gcagtctatt tctgtgcaag atcgtatggt 360
 gcctttgact actggggcca aggcaccact ctcacagtct cctcagcctc caccaagggc 420
 ccatcggtct tccccctggc accctcctcc aagagcacct ctggggggcac agcggccctg 480
 15 ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgcgtggaa ctcaggcgcc 540
 ctgaccagcg gcgtgcacac cttcccggtt gtcctacagt cctcaggact ctactccctc 600
 agcagcgtgg tgaccgtgcc ctccagcagc ttggggcacc agacctacat ctgcaacgtg 660
 20 aatcacaagc ccagcaacac caaggtggac aagaaagtg agcccaaata ttgtgacaaa 720
 actcacacat gccaccgtg cccagcacct gaactcctgg ggggaccgtc agtcttctc 780
 tccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg 840
 25 gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcggtg 900
 gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgtgtg 960
 gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgaag 1020
 30 gtctccaaca aagccctccc agccccatc gagaaaacca tctccaaagc caaagggcag 1080
 ccccgagaac cacaggtgta caccctgccc ccatccggg atgagctgac caagaaccag 1140
 gtcagcctga cctgcctggt caaaggcttc tatccagcg acatcgccgt ggagtgggag 1200
 35 agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1260
 tccttcttcc tctatagcaa gctcaccgtg gacaagagca ggtggcagca ggggaacgtc 1320
 ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc 1380
 40 ctgtctccgg gtaaatga 1398

<210> 103

<211> 1404

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 103

EP 2 311 877 B1

	atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactcccag	60
	gtccaactgc agcagcctgg ggctgagctg gtgaggcctg gggcttcagt gaagctgtcc	120
5	tgcaaggctt ctggctacac cttcaccage tactggataa actgggtgaa gcagaggect	180
	ggacaaggcc ttgagtggat cggaaatatt tatccttctg atagttatac taactacaat	240
	caaaagtcca aggacaaggc cacattgact gtagacaaat cctccagcac agcctacatg	300
10	cagctcagca gcccagacatc tgaggactct gcggtctatt actgtacaag atcgtggagg	360
	ggtaactcct ttgactactg gggccaaggc accactctca cagtctcttc agcctccacc	420
	aaggggcccat cggctcttccc cctggcacc cctccaaga gcacctctgg gggcacagcg	480
15	gccctgggct gcctgggtcaa ggactacttc cccgaaccgg tgacgggtgc gtggaactca	540
	ggcgccctga ccagcggcgt gcacaccttc ccggtgtcc tacagtcttc aggactctac	600
	tccctcagca gcgtgggtgac cgtgccctcc agcagcttgg gcaccagac ctacatctgc	660
20	aacgtgaatc acaagcccag caacaccaag gtggacaaga aagttgagcc caaatcttgt	720
	gacaaaactc acacatgccc accgtgccc gcacctgaac tcctgggggg accgtcagtc	780
	ttctcttccc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca	840
25	tgcgtgggtg tggtacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac	900
	ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac	960
	cgtgtgggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag	1020
30	tgcaaggctc ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa	1080
	gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag	1140
	aaccaggtca gcctgacctg cctgggtcaaa ggcttctatc ccagcgacat cgccgtggag	1200
35	tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc	1260
	gacggctcct tcttctctca tagcaagctc accgtggaca agagcaggtg gcagcagggg	1320
	aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc	1380
40	ctctccctgt ctccgggtaa atga	1404

<210> 104

<211> 1401

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 104

EP 2 311 877 B1

	atggaatgga ggatctttct cttcatcctg tcaggaactg cagggtgtcca ctcccaggtt	60
	cagctgcagc agtctggacc tgagctggtg aagcctgggg cttcagtga gatgtcctgc	120
5	aaggcttctg gatacacatt cactgactat gttataagct ggggtgaagca gagaactgga	180
	cagggccttg agtggattgg agagatttat cctggaagtg gtagtactta ctacaatgag	240
	aagttcaagg gcaaggccac actgactgca gacaaatcct ccaacacagc ctacatgcag	300
10	ctcagcagcc tgacatctga ggactctgcg gtctatttct gtgcaagagg ggtattacta	360
	cgggctatgg actactgggg tcaaggaacc tcagtcaccg tctcctcagc ctccaccaag	420
	ggcccatcgg tcttccccct ggcacctcc tccaagagca cctctggggg cacagcggcc	480
15	ctgggtgcc tgggtcaagga ctacttcccc gaaccgggtg cgggtgtcgtg gaactcaggc	540
	gccctgacca gcggcgtgca caccttcccc gctgtcctac agtcctcagg actctactcc	600
	ctcagcagcg tgggtaccgt gccctccagc agcttgggca cccagaccta catctgcaac	660
20	gtgaatcaca agcccagcaa caccaagggtg gacaagaaag ttgagcccaa atcttgtgac	720
	aaaactcaca catgcccacc gtgcccagca cctgaactcc tggggggacc gtcagtcttc	780
	ctcttcccc caaaacccaa ggacacctc atgatctccc ggaccctga ggtcacatgc	840
25	gtggtggtgg acgtgagcca cgaagacct gaggtcaagt tcaactggta cgtggacggc	900
	gtggagggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag caggtaccgt	960
	gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc	1020
30	aaggcttcca acaaagccct cccagcccc atcgagaaaa ccatctccaa agccaaaggg	1080
	cagccccgag aaccacaggt gtacacctg ccccatccc gggatgagct gaccaagaac	1140
	caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg	1200
35	gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac	1260
	ggctccttct tcctctatag caagctcacc gtggacaaga gcagggtggca gcaggggaac	1320
	gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc	1380
40	tcctgtctc cgggtaaatg a	1401

<210> 105

<211> 1410

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 105

atggactgga tttggatcat gctccatctg ctggcagcag ctacaggtat ccaatcccag	60
---	----

EP 2 311 877 B1

gttcacctac aacagtctgg ttctgaactg aggagtcctg ggtcttcagt aaagctttca 120
tgcaaggatt ttgattcaga agtcttcctt tttgcttata tgagttggat taggcagaag 180
5 cctgggcatg gatttgaatg gattggagac ataactccaa gtattggtag aacaatctat 240
ggagagaagt ttgaggacaa agccacactg gatgcagaca cagtgtccaa cacagcctac 300
ttggagctca acagtctgac atctgaggac tctgctatct actactgtgc aaggggggag 360
10 ggctacggtg cctgggttgc ttactggggc caagggactc tggtcactgt ctctgcagcc 420
tccaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc 480
acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccgggtgac ggtgtcgtgg 540
15 aactcaggcg ccctgaccag cggcgtgcac accttccccg ctgtcctaca gtcctcagga 600
ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac 660
atctgcaacg tgaatcaca gccccagcaac accaagggtg acaagaaagt tgagcccaaa 720
20 tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg 780
tcagtcttcc tcttcccccc aaaacccaag gacacctca tgatctcccg gacctctgag 840
gtcacatgcg tgggtgtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 900
25 gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc 960
acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 1020
tacaagtgca aggtctccaa caaagccctc ccagccccc tgcagaaaac catctccaaa 1080
30 gccaaagggc agccccgaga accacagggtg tacacctgc ccccatcccg ggatgagctg 1140
accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc 1200
gtggagtggg agagcaatgg gcagccggag aacaactaca agaccagcc tcccgtgctg 1260
gactccgacg gctccttctt cctctatagc aagctcaccg tggacaagag cagggtggcag 1320
35 caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1380
aagagcctct ccctgtctcc gggtaaatga 1410

<210> 106

<211> 723

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 106

50 atggaatcac agactcaggc cctcatgtcc ctgctgttct gggatatctg tacctgtggg 60
gacattgtga tgacacagtc tccatcctcc ctgactgtga cagcaggaga gaaggtcact 120
atgagctgca agtccagtca gagtctgtta aacagtggaa atcaaaagaa ctacttgacc 180
55 tgggtaccagc agaaaccagg gcagcctcct aaactgttga tctactgggc atccactagg 240

EP 2 311 877 B1

5 gaatctgggg tccctgatcg cttcacaggc agtggatctg gaacagattt cactctcacc 300
 atcagcagtg tgcaggctga agacctggca gtttattact gtcagaatga ttatagttat 360
 ccgctcacgt tcggtgctgg gaccaagctg gagctgaaac gtacgggtggc tgcaccatct 420
 gtcttcacgt tcccggccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc 480
 ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaagggtgga taacgccctc 540
 10 caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag cacctacagc 600
 ctcagcagca ccctgacgct gagcaaagca gactacgaga aacacaaagt ctacgcctgc 660
 gaagtcaccc atcagggcct gagctcgccc gtcacaaaga gcttcaacag gggagagtgt 720
 15 tag 723

<210> 107

<211> 708

<212> DNA

20 <213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

25 <400> 107

30 atgcattttc aagtgcagat tttcagcttc ctgctaataca gtgcctcagt cataatgtcc 60
 agaggacaaa ttgttctcac ccagtctcca gcaatcatgt ctgcatctcc aggggagaag 120
 gtcaccataa cctgcagtgc cagctcaagt gtaagttaca tgcactgggt ccagcagaag 180
 ccaggcactt ctcccaaact ctggatttat agcacatcca acctggcttc tggagtccct 240
 gctcgcttca gtggcagtgg atctgggacc tcttactctc tcacaatcag ccgaatggag 300
 35 gctgaagatg ctgccactta ttactgccag caaaggagta gttaccacc cacttccgga 360
 ggggggacca agctggaaat aaaacgtacg gtggctgcac catctgtctt catcttcccg 420
 ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480
 40 tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540
 caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600
 acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt caccatcag 660
 45 ggctgagct cgcccgtcac aaagagcttc aacaggggag agtggttag 708

<210> 108

<211> 705

<212> DNA

50 <213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

55 <400> 108

atggagtttc agaccaggt ctttgtatcc gtgttgcctt gggtgtctgg tgttgatgga 60

EP 2 311 877 B1

	gacattgtga tgaccagtc tcaaaaattc atgtccacat cagtaggaga cagggtcagc	120
	atcacctgca aggccagtc gaattgttcgt actgctgtag cctgggtatca acagaaacca	180
5	gggcagtctc cttaaagcact gatttacttg gcatccaacc ggcacactgg agtccctgat	240
	cgcttcacag gcagtggatc tgggacagat ttcactctca ccattagcaa tgtgcaatct	300
	gaagacctgg cagattatct ctgtctgcaa cattggaatt atcctctgac gttcgggtgga	360
10	ggcaccaagc tggaaatcaa acgtacgggtg gctgcacat ctgtcttcat cttcccgcca	420
	tctgatgagc agttgaaatc tggaaactgcc tctgttgtgt gcctgctgaa taacttctat	480
	cccagagagg ccaaagtaca gtggaagggtg gataacgccc tccaatcggg taactcccag	540
15	gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg	600
	ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc	660
	ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag	705

20 <210> 109
 <211> 723
 <212> DNA
 <213> Artificial

25 <220>
 <223> Description of artificial sequence: chimeric monoclonal antibody
 <400> 109

30	atggattcac aggccaggt tcttatgtta ctgctgctat gggatatctgg tacctgtggg	60
	gacattgtga tgtcacagtc tccatectec cttagctgtgt cagttggaga gaagggtact	120
	atgagctgca agtccagtc gagcctttta tatagtagca atcaaaagaa ctacttggcc	180
35	tggtagcagc agaaaccagg gcagtctcct aaactgctga ttacttgggc atccactagg	240
	gaatctgggg tccctgatcg cttcacaggg agtggatctg ggacagattt cactctcacc	300
	atcagcagtg tgaaggctga agacctggca gtttattact gtcagcaata ttatagctat	360
40	ccgctcacgt tcgggtgctgg gaccaagctg gagctgaaac gtacgggtggc tgcacatct	420
	gtcttcatct tcccgcacat tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc	480
	ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaagggtgga taacgccctc	540
45	caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag cacctacagc	600
	ctcagcagca ccctgacgct gagcaaagca gactacgaga aacacaaagt ctacgcctgc	660
	gaagtcaccc atcagggcct gagctcgccc gtcacaaaga gcttcaacag gggagagtgt	720
50	tag	723

55 <210> 110
 <211> 723
 <212> DNA
 <213> Artificial

<220>
 <223> Description of artificial sequence: chimeric monoclonal antibody

EP 2 311 877 B1

<400> 110

	atggaatcac agactcaggt cctcatgtcc ctgctgttct gggatatctgg tacctgtggg	60
5	gacattgtga tgacacagtc tccatcctcc ctgactgtga cagcaggaga gaaggtcact	120
	atgagctgca agtccagtca gagtctgtta aacagtggaa atcaaaagaa ctacttgacc	180
	tggtaccagc agaaaccagg gcagcctcct aaactgttga tctactgggc atccactagg	240
10	gaatctgggg tccctgatcg cttcacaggc agtggatctg gaacagattt cactctcacc	300
	atcagcagtg tgcaggctga agacctggca gtttattact gtcagaatga ttatagttat	360
	ccattcacgt tcggctcggg gacaaagttg gaaataaaac gtacggtggc tgcaccatct	420
15	gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc	480
	ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaagggtgga taacgccttc	540
	caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag cacctacagc	600
20	ctcagcagca ccctgacgt gagcaaagca gactacgaga aacacaaagt ctacgcctgc	660
	gaagtcaccc atcagggcct gagctcgccc gtcacaaaga gcttcaacag gggagagtgt	720
	tag	723

25 <210> 111
 <211> 720
 <212> DNA
 <213> Artificial

30 <220>
 <223> Description of artificial sequence: chimeric monoclonal antibody

<400> 111

35	atggattcac aggcccaggt tcttatattg ctgctgctat gggatatctgg tacctgtggg	60
	gacattgtga tgtcacagtc tccatcctcc ctggctgtgt cagcaggaga gaaggtcact	120
	atgagctgca aatccagtca gagtctgctc aacagtagaa cccgaaagaa ctacttggct	180
40	tggtaccagc agaaaccagg gcagtctcct aaactgctga tctactgggc atccactagg	240
	gaatctgggg tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc	300
	atcagcagtg tgcaggctga agacctggca gtttattact gcaagcaate ttataatctg	360
45	tacacgttcg gaggggggac caagctggaa ataaaacgta cggtggctgc accatctgtc	420
	ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg	480
	ctgaataact tctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa	540
50	tcgggtaact ccagggagag tgtcacagag caggacagca aggacagcac ctacagcctc	600
	agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa	660
	gtcaccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg agagtgttag	720

55 <210> 112
 <211> 723
 <212> DNA
 <213> Artificial

EP 2 311 877 B1

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 112

5

```

atggattcac aggccaggt tcttatgtta ctgctgctat gggatatctgg tacctgtggg      60
gacatcgtga tgtcacagtc tccatcctcc ctagctgtgt cagttggaga gaaggttact      120
atgagctgca agtccagtc gagcctttta tatagtagca atcaaaagaa ctacttgccc      180
tgggtaccagc agaaaccagg gcagtctcct aaactgctga ttactgggc atccactagg      240
gaatctgggg tccctgatcg cttcacaggc agtggatctg caacagattt cactctgacc      300
atcagcagtg tgcaggctga agaccttgca gattatcact gtggacaggg ttacagctat      360
ccgtacacgt tcggaggggg gaccaagctg gaaataaaac gtacgggtggc tgcaccatct      420
gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc      480
ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaagggtgga taacgccctc      540
caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag cacctacagc      600
ctcagcagca ccctgacgct gagcaaagca gactacgaga aacacaaagt ctacgcctgc      660
gaagtcaccc atcagggcct gagctcgccc gtcacaaaga gcttcaacag gggagagtgt      720
tag                                                    723

```

10

15

20

25

<210> 113

<211> 723

30

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

35

<400> 113

```

atggattcac aggctcaggt tcttatgtta ctgctgctat gggatatctgg tacctgtggg      60
gacattgtga tgtcacagtc tccatcctcc ctagctgtgt cagttggaga gaaggttact      120
atgagctgca agtccagtc gagcctttta tatagtagca atcaaaagaa ctacttgccc      180
tgggtaccagc agaaaccagg gcagtctcct aaactgctga ttactgggc atccactagg      240
gaatctgggg tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc      300
atcagcagtg tgaaggctga agacctggca gtttattact gtcagcaata ttatagctat      360
ccgctcacgt tcggtgctgg gaccaagctg gagctgaaac gtacgggtggc tgcaccatct      420
gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc      480
ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaagggtgga taacgccctc      540

```

40

45

50

55

EP 2 311 877 B1

caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag cacctacagc 600
 ctcagcagca ccctgacgct gagcaaagca gactacgaga aacacaaagt ctacgcctgc 660
 5 gaagtcaccc atcagggcct gagctcgccc gtcacaaaga gcttcaacag gggagagtgt 720
 tag 723

<210> 114
 10 <211> 705
 <212> DNA
 <213> Artificial

<220>
 15 <223> Description of artificial sequence: chimeric monoclonal antibody
 <400> 114

atggaatcac agactctggc cttcatatcc atactgctct gggtatatgg agctgatggg 60
 aacattgtaa tgaccaatc tcccaaatcc atgtccatgt cagtaggaga gagggtcacc 120
 ttgacctgca aggccagtga gaattgtggtt acttatgttt cctgggtatca acagaaacca 180
 25 gagcagtctc cttaaactgct gatatacggg gcatccaacc ggtacactgg ggtccccgat 240
 cgcttcacag gcagtggatc tgcaacagat ttcactctca ccatcagcag tgtgaaggct 300
 gaagacctgg cagtttatta ctgtcagcaa tattatagct atccgctcac gttcgggtgt 360
 gggaccaagc tggagctgaa acgtacgggtg gctgcacat ctgtcttcat cttcccgcca 420
 30 tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480
 cccagagagg ccaaagtaca gtggaagggtg gataacgccc tccaatcggg taactcccag 540
 gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600
 35 ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 660
 ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705

<210> 115
 40 <211> 466
 <212> PRT
 <213> Artificial

<220>
 45 <223> Description of artificial sequence: chimeric monoclonal antibody
 <400> 115

Met Glu Trp Thr Trp Val Phe Leu Phe Leu Leu Ser Val Thr Ala Gly
 1 5 10 15
 Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys
 20 25 30
 55 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe
 35 40 45

EP 2 311 877 B1

	Ser	Ser	Tyr	Trp	Ile	Glu	Trp	Val	Lys	Gln	Arg	Pro	Gly	His	Gly	Leu	
	50						55					60					
5	Glu	Trp	Ile	Gly	Glu	Ile	Leu	Pro	Gly	Ser	Gly	Ser	Thr	Asn	Tyr	Asn	
	65					70					75					80	
	Glu	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Phe	Thr	Ala	Asp	Thr	Ser	Ser	Asn	
10					85					90					95		
	Thr	Ala	Tyr	Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	
				100					105					110			
15	Tyr	Tyr	Cys	Ala	Arg	Tyr	Asp	Tyr	Pro	Trp	Phe	Ala	Tyr	Trp	Gly	Gln	
			115					120					125				
	Gly	Thr	Leu	Val	Thr	Val	Ser	Ala	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	
20							135					140					
	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	
	145					150					155					160	
25	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	
					165					170					175		
	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	
30				180					185					190			
	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	
			195					200					205				
35	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	
	210						215					220					
	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	
40						230					235					240	
	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	
					245					250					255		
45	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	
				260					265					270			
	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	
			275					280					285				
50	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	
	290						295					300					
55																	

EP 2 311 877 B1

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 305 310 315 320
 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 325 330 335
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 340 345 350
 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 355 360 365
 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 370 375 380
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 385 390 395 400
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 405 410 415
 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 420 425 430
 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 435 440 445
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 450 455 460
 Gly Lys
 465
 <210> 116
 <211> 467
 <212> PRT
 <213> Artificial
 <220>
 <223> Description of artificial sequence: chimeric monoclonal antibody
 <400> 116
 Met Asp Trp Leu Trp Asn Leu Leu Phe Leu Met Ala Ala Ala Gln Ser
 1 5 10 15
 Ile Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys
 20 25 30

EP 2 311 877 B1

Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

5 Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu
50 55 60

Lys Trp Met Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala
65 70 75 80

10 Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser
85 90 95

15 Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr
100 105 110

Tyr Phe Cys Ala Arg Leu Gly Phe Gly Asn Ala Met Asp Tyr Trp Gly
115 120 125

20 Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140

25 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
145 150 155 160

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175

30 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180 185 190

35 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
210 215 220

40 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
225 230 235 240

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
245 250 255

45 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
260 265 270

50 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
275 280 285

55

EP 2 311 877 B1

	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val
	290						295					300				
5	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr
	305					310					315					320
	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly
10					325					330					335	
	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile
				340					345					350		
15	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val
			355					360					365			
	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser
20		370					375					380				
	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu
	385					390					395					400
	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro
25					405					410					415	
	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val
30				420					425					430		
	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met
		435						440					445			
35	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser
	450						455					460				
	Pro	Gly	Lys													
	465															
40	<210> 117															
	<211> 465															
	<212> PRT															
	<213> Artificial															
45	<220>															
	<223> Description of artificial sequence: chimeric monoclonal antibody															
	<400> 117															
50	Met	Glu	Trp	Ile	Trp	Ile	Phe	Leu	Phe	Ile	Leu	Ser	Gly	Thr	Ala	Gly
	1				5					10					15	
	Val	His	Ser	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Ala	Arg
55				20					25					30		

EP 2 311 877 B1

	Pro	Gly	Ala	Ser	Val	Lys	Leu	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	
			35					40					45				
5	Thr	Asp	Tyr	Tyr	Ile	Asn	Trp	Val	Lys	Gln	Arg	Thr	Gly	Gln	Gly	Leu	
		50					55					60					
	Glu	Trp	Ile	Gly	Glu	Ile	Tyr	Pro	Gly	Ser	Gly	Asn	Thr	Tyr	Tyr	Asn	
	65					70					75					80	
10																	
	Glu	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Lys	Ser	Ser	Ser	
					85					90					95		
15	Thr	Ala	Tyr	Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	
				100					105					110			
	Tyr	Phe	Cys	Ala	Arg	Ser	Tyr	Gly	Ala	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	
			115					120					125				
20																	
	Thr	Thr	Leu	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	
							135					140					
25	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	
	145					150					155					160	
	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	
					165					170					175		
30																	
	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	
				180					185					190			
	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	
35			195					200					205				
	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	
		210					215					220					
40	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	
	225					230					235					240	
	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	
45					245					250					255		
	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	
				260					265					270			
50	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	
			275					280					285				
55																	

EP 2 311 877 B1

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
290 295 300

5 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
305 310 315 320

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
325 330 335

10 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
340 345 350

15 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
355 360 365

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
370 375 380

20 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
385 390 395 400

25 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
405 410 415

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
420 425 430

30 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
435 440 445

35 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
450 455 460

Lys
465

40 <210> 118
<211> 467
<212> PRT
<213> Artificial

45 <220>
<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 118

50 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

EP 2 311 877 B1

Val His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg
20 25 30

5 Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Ser Tyr Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
50 55 60

10 Glu Trp Ile Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn
65 70 75 80

15 Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser
85 90 95

Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val
100 105 110

20 Tyr Tyr Cys Thr Arg Ser Trp Arg Gly Asn Ser Phe Asp Tyr Trp Gly
115 120 125

25 Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
145 150 155 160

30 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175

35 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180 185 190

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205

40 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
210 215 220

45 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
225 230 235 240

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
245 250 255

50 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
260 265 270

55

EP 2 311 877 B1

	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His
			275					280					285			
5	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val
		290					295					300				
	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr
10	305					310					315					320
	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly
					325					330					335	
15	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile
				340					345					350		
	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val
20			355					360					365			
	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser
		370					375					380				
25	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu
	385					390					395					400
	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro
30					405					410					415	
	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val
				420					425					430		
35	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met
			435					440					445			
	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser
40		450					455					460				
	Pro	Gly	Lys													
	465															
	<210>	119														
	<211>	466														
45	<212>	PRT														
	<213>	Artificial														
	<220>															
50	<223>	Description of artificial sequence: chimeric monoclonal antibody														
	<400>	119														
55	Met	Glu	Trp	Arg	Ile	Phe	Leu	Phe	Ile	Leu	Ser	Gly	Thr	Ala	Gly	Val
	1				5					10					15	

EP 2 311 877 B1

	His	Ser	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Leu	Val	Lys	Pro	
				20					25					30			
5	Gly	Ala	Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	
			35					40					45				
	Asp	Tyr	Val	Ile	Ser	Trp	Val	Lys	Gln	Arg	Thr	Gly	Gln	Gly	Leu	Glu	
10		50					55					60					
	Trp	Ile	Gly	Glu	Ile	Tyr	Pro	Gly	Ser	Gly	Ser	Thr	Tyr	Tyr	Asn	Glu	
	65					70					75					80	
15	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Lys	Ser	Ser	Asn	Thr	
					85					90					95		
	Ala	Tyr	Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	
20				100					105					110			
	Phe	Cys	Ala	Arg	Gly	Val	Leu	Leu	Arg	Ala	Met	Asp	Tyr	Trp	Gly	Gln	
			115				120						125				
25	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	
		130					135					140					
	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	
30		145				150					155					160	
	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	
				165						170					175		
35	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	
				180					185					190			
	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	
40			195					200					205				
	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	
		210					215					220					
45	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	
		225				230					235					240	
	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	
					245					250					255		
50	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	
				260					265						270		

55

EP 2 311 877 B1

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 275 280 285
 5 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 290 295 300
 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 305 310 315 320
 10 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 325 330 335
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 340 345 350
 15 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 355 360 365
 20 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 370 375 380
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 385 390 395 400
 25 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 405 410 415
 30 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 420 425 430
 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 435 440 445
 35 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 450 455 460
 40 Gly Lys
 465

<210> 120

<211> 469

<212> PRT

<213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 120

EP 2 311 877 B1

	Met	Asp	Trp	Ile	Trp	Ile	Met	Leu	His	Leu	Leu	Ala	Ala	Ala	Thr	Gly	
	1				5					10					15		
5	Ile	Gln	Ser	Gln	Val	His	Leu	Gln	Gln	Ser	Gly	Ser	Glu	Leu	Arg	Ser	
				20					25					30			
	Pro	Gly	Ser	Ser	Val	Lys	Leu	Ser	Cys	Lys	Asp	Phe	Asp	Ser	Glu	Val	
			35					40					45				
10	Phe	Pro	Phe	Ala	Tyr	Met	Ser	Trp	Ile	Arg	Gln	Lys	Pro	Gly	His	Gly	
	50						55					60					
	Phe	Glu	Trp	Ile	Gly	Asp	Ile	Leu	Pro	Ser	Ile	Gly	Arg	Thr	Ile	Tyr	
15	65					70					75					80	
	Gly	Glu	Lys	Phe	Glu	Asp	Lys	Ala	Thr	Leu	Asp	Ala	Asp	Thr	Val	Ser	
					85					90					95		
20	Asn	Thr	Ala	Tyr	Leu	Glu	Leu	Asn	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	
				100					105					110			
	Ile	Tyr	Tyr	Cys	Ala	Arg	Gly	Glu	Gly	Tyr	Gly	Ala	Trp	Phe	Ala	Tyr	
25			115					120					125				
	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ala	Ala	Ser	Thr	Lys	Gly	
		130					135					140					
30	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	
	145					150					155					160	
	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	
35					165					170					175		
	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	
				180					185					190			
40	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	
			195					200					205				
	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	
45		210					215					220					
	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	
	225					230					235					240	
50	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	
					245					250					255		

55

EP 2 311 877 B1

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 260 265 270
 5 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 275 280 285
 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 290 295 300
 10 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 305 310 315 320
 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 325 330 335
 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 340 345 350
 20 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 355 360 365
 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 370 375 380
 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 385 390 395 400
 30 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 405 410 415
 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 420 425 430
 35 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 435 440 445
 40 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 450 455 460
 Leu Ser Pro Gly Lys
 465

<210> 121

<211> 240

<212> PRT

<213> Artificial

<220>

<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 121

EP 2 311 877 B1

	Met	Glu	Ser	Gln	Thr	Gln	Val	Leu	Met	Ser	Leu	Leu	Phe	Trp	Val	Ser	
	1				5				10						15		
5	Gly	Thr	Cys	Gly	Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Thr	
				20					25					30			
	Val	Thr	Ala	Gly	Glu	Lys	Val	Thr	Met	Ser	Cys	Lys	Ser	Ser	Gln	Ser	
10			35					40					45				
	Leu	Leu	Asn	Ser	Gly	Asn	Gln	Lys	Asn	Tyr	Leu	Thr	Trp	Tyr	Gln	Gln	
		50					55					60					
15	Lys	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Trp	Ala	Ser	Thr	Arg	
	65					70					75					80	
	Glu	Ser	Gly	Val	Pro	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	
20					85					90					95		
	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Val	Gln	Ala	Glu	Asp	Leu	Ala	Val	Tyr	
				100					105					110			
25	Tyr	Cys	Gln	Asn	Asp	Tyr	Ser	Tyr	Pro	Leu	Thr	Phe	Gly	Ala	Gly	Thr	
			115					120					125				
	Lys	Leu	Glu	Leu	Lys	Arg	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	
30		130					135					140					
	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	
	145					150				155						160	
35	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	
					165					170					175		
	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	
40				180					185					190			
	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	
			195					200					205				
45	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	
		210					215					220					
	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys	
	225					230					235					240	
50	<210> 122																
	<211> 235																
	<212> PRT																
	<213> Artificial																
55	<220>																
	<223> Description of artificial sequence: chimeric monoclonal antibody																
	<400> 122																

EP 2 311 877 B1

Met His Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1 5 10 15
 Val Ile Met Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Ile
 5 20 25 30
 Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Ser Ala Ser
 10 35 40 45
 Ser Ser Val Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Thr Ser
 50 55 60
 Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro
 15 65 70 75 80
 Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
 20 85 90 95
 Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg
 100 105 110
 Ser Ser Tyr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 25 115 120 125
 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
 130 135 140
 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
 30 145 150 155 160
 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
 35 165 170 175
 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
 180 185 190
 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
 40 195 200 205
 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
 210 215 220
 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 123

50 <211> 234

<212> PRT

<213> Artificial

<220>

55 <223> Description of artificial sequence: chimeric monoclonal antibody

<400> 123

EP 2 311 877 B1

	Met	Glu	Phe	Gln	Thr	Gln	Val	Phe	Val	Phe	Val	Leu	Leu	Trp	Leu	Ser	
	1				5					10					15		
5	Gly	Val	Asp	Gly	Asp	Ile	Val	Met	Thr	Gln	Ser	Gln	Lys	Phe	Met	Ser	
				20					25					30			
	Thr	Ser	Val	Gly	Asp	Arg	Val	Ser	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asn	
			35					40					45				
10	Val	Arg	Thr	Ala	Val	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ser	Pro	
		50					55					60					
15	Lys	Ala	Leu	Ile	Tyr	Leu	Ala	Ser	Asn	Arg	His	Thr	Gly	Val	Pro	Asp	
	65					70					75					80	
	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	
					85					90					95		
20	Asn	Val	Gln	Ser	Glu	Asp	Leu	Ala	Asp	Tyr	Phe	Cys	Leu	Gln	His	Trp	
				100					105					110			
25	Asn	Tyr	Pro	Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	
			115					120					125				
	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	
		130					135					140					
30	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	
	145					150					155					160	
35	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	
					165					170					175		
	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	
				180					185					190			
40	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	
			195				200						205				
45	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	
		210					215					220					
	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys							
	225						230										
50	<210> 124																
	<211> 240																
	<212> PRT																
	<213> Artificial																
55	<220>																
	<223> Description of artificial sequence: chimeric monoclonal antibody																
	<400> 124																

EP 2 311 877 B1

	Met Asp Ser Gln Ala Gln Val Leu Met Leu Leu Leu Leu Trp Val Ser	
	1 5 10 15	
5	Gly Thr Cys Gly Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala	
	20 25 30	
	Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser	
10	35 40 45	
	Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln	
	50 55 60	
15	Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg	
	65 70 75 80	
	Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp	
20	85 90 95	
	Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr	
	100 105 110	
25	Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr	
	115 120 125	
	Lys Leu Glu Leu Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe	
30	130 135 140	
	Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys	
	145 150 155 160	
35	Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val	
	165 170 175	
	Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln	
40	180 185 190	
	Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser	
	195 200 205	
45	Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His	
	210 215 220	
	Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys	
	225 230 235 240	
50	<210> 125	
	<211> 240	
	<212> PRT	
	<213> Artificial	
55	<220>	
	<223> Description of artificial sequence: chimeric monoclonal antibody	
	<400> 125	

EP 2 311 877 B1

	Met	Glu	Ser	Gln	Thr	Gln	Val	Leu	Met	Ser	Leu	Leu	Phe	Trp	Val	Ser	
	1				5				10						15		
5	Gly	Thr	Cys	Gly	Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Thr	
				20					25					30			
	Val	Thr	Ala	Gly	Glu	Lys	Val	Thr	Met	Ser	Cys	Lys	Ser	Ser	Gln	Ser	
			35					40					45				
10	Leu	Leu	Asn	Ser	Gly	Asn	Gln	Lys	Asn	Tyr	Leu	Thr	Trp	Tyr	Gln	Gln	
		50					55					60					
	Lys	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Trp	Ala	Ser	Thr	Arg	
15		65				70					75					80	
	Glu	Ser	Gly	Val	Pro	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	
					85					90					95		
20	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Val	Gln	Ala	Glu	Asp	Leu	Ala	Val	Tyr	
				100					105					110			
	Tyr	Cys	Gln	Asn	Asp	Tyr	Ser	Tyr	Pro	Phe	Thr	Phe	Gly	Ser	Gly	Thr	
25			115					120					125				
	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	
		130					135					140					
30	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	
		145				150					155					160	
	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	
35					165					170					175		
	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	
				180				185						190			
40	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	
			195					200					205				
	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	
45		210					215					220					
	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys	
		225				230					235					240	

<210> 126

50 <211> 239

<212> PRT

<213> Artificial

<220>

55 <223> Description of artificial sequence: chimeric monoclonal antibody

<400> 126

EP 2 311 877 B1

Met Asp Ser Gln Ala Gln Val Leu Ile Leu Leu Leu Trp Val Ser
1 5 10 15

5 Gly Thr Cys Gly Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala
20 25 30

Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser
35 40 45

10 Leu Leu Asn Ser Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln
50 55 60

15 Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
65 70 75 80

Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp
85 90 95

20 Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr
100 105 110

25 Tyr Cys Lys Gln Ser Tyr Asn Leu Tyr Thr Phe Gly Gly Thr Lys
115 120 125

Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
130 135 140

30 Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
145 150 155 160

35 Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp
165 170 175

Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
180 185 190

40 Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
195 200 205

45 Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln
210 215 220

Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235

50 <210> 127
<211> 240
<212> PRT
<213> Artificial

55 <220>
<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 127

EP 2 311 877 B1

Met Asp Ser Gln Ala Gln Val Leu Met Leu Leu Leu Trp Val Ser
1 5 10 15

5 Gly Thr Cys Gly Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala
20 25 30

Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser
35 40 45

10 Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln
50 55 60

15 Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
65 70 75 80

Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Ala Thr Asp
85 90 95

20 Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr
100 105 110

25 His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr
115 120 125

Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
130 135 140

30 Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
145 150 155 160

35 Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
165 170 175

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln
180 185 190

40 Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
195 200 205

45 Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His
210 215 220

Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235 240

50 <210> 128
<211> 240
<212> PRT
<213> Artificial

55 <220>
<223> Description of artificial sequence: chimeric monoclonal antibody

<400> 128

EP 2 311 877 B1

	Met	Asp	Ser	Gln	Ala	Gln	Val	Leu	Met	Leu	Leu	Leu	Leu	Trp	Val	Ser	
	1				5					10					15		
5	Gly	Thr	Cys	Gly	Asp	Ile	Val	Met	Ser	Gln	Ser	Pro	Ser	Ser	Leu	Ala	
				20					25					30			
	Val	Ser	Val	Gly	Glu	Lys	Val	Thr	Met	Ser	Cys	Lys	Ser	Ser	Gln	Ser	
			35					40					45				
10	Leu	Leu	Tyr	Ser	Ser	Asn	Gln	Lys	Asn	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	
	50						55					60					
	Lys	Pro	Gly	Gln	Ser	Pro	Lys	Leu	Leu	Ile	Tyr	Trp	Ala	Ser	Thr	Arg	
15	65					70					75					80	
	Glu	Ser	Gly	Val	Pro	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	
					85					90					95		
20	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Val	Lys	Ala	Glu	Asp	Leu	Ala	Val	Tyr	
				100					105					110			
	Tyr	Cys	Gln	Gln	Tyr	Tyr	Ser	Tyr	Pro	Leu	Thr	Phe	Gly	Ala	Gly	Thr	
25			115					120					125				
	Lys	Leu	Glu	Leu	Lys	Arg	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	
		130					135					140					
30	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	
	145					150					155					160	
	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	
35					165					170					175		
	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	
				180					185					190			
40	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	
			195					200					205				
	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	
45		210					215					220					
	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys	
	225					230					235					240	
50	<210> 129																
	<211> 234																
	<212> PRT																
	<213> Artificial																
55	<220>																
	<223> Description of artificial sequence: chimeric monoclonal antibody																
	<400> 129																

EP 2 311 877 B1

Met Glu Ser Gln Thr Leu Val Phe Ile Ser Ile Leu Leu Trp Leu Tyr
1 5 10 15

5 Gly Ala Asp Gly Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser
20 25 30

Met Ser Val Gly Glu Arg Val Thr Leu Thr Cys Lys Ala Ser Glu Asn
35 40 45

10 Val Val Thr Tyr Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro
50 55 60

15 Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp
65 70 75 80

Arg Phe Thr Gly Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

20 Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr
100 105 110

25 Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg
115 120 125

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
130 135 140

30 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
145 150 155 160

35 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
165 170 175

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
180 185 190

40 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
195 200 205

45 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
210 215 220

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230

50 <210> 130
<211> 18
<212> DNA
<213> Artificial

55 <220>
<223> Description of artificial sequence: Oligonucleotide

<400> 130

EP 2 311 877 B1

ccaagggcta tggcggtc 18

<210> 131

<211> 18

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: Oligonucleotide

<400> 131

ccgaaggtgt acctggtc 18

<210> 132

<211> 117

<212> PRT

<213> Artificial

<220>

<223> Description of artificial sequence: Translation of PCR product

<400> 132

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Ser Tyr
20 25 30

Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Leu Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Asp Tyr Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ala
115

<210> 133

<211> 118

<212> PRT

<213> Artificial

<220>

<223> Description of artificial sequence: Translation of PCR product

<400> 133

EP 2 311 877 B1

	Gln	Ile	Gln	Leu	Val	Gln	Ser	Gly	Pro	Glu	Leu	Lys	Lys	Pro	Gly	Glu	
	1				5					10					15		
5	Thr	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Asn	Tyr	
				20					25					30			
	Gly	Met	Asn	Trp	Val	Lys	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Lys	Trp	Met	
10			35					40					45				
	Gly	Trp	Ile	Asn	Thr	Asn	Thr	Gly	Glu	Pro	Thr	Tyr	Ala	Glu	Glu	Phe	
	50					55						60					
15	Lys	Gly	Arg	Phe	Ala	Phe	Ser	Leu	Glu	Thr	Ser	Ala	Ser	Thr	Ala	Tyr	
	65					70					75					80	
	Leu	Gln	Ile	Asn	Asn	Leu	Lys	Asn	Glu	Asp	Thr	Ala	Thr	Tyr	Phe	Cys	
20					85					90					95		
	Ala	Arg	Leu	Gly	Phe	Gly	Asn	Ala	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	
				100					105					110			
25	Ser	Val	Thr	Val	Ser	Ser											
				115													

	<210>	134
	<211>	116
30	<212>	PRT
	<213>	Artificial
	<220>	
	<223>	Description of artificial sequence: Translation of PCR product
35		
	<400>	134

40

45

50

55

EP 2 311 877 B1

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1 5 10 15

5 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

Tyr Ile Asn Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Tyr Pro Gly Ser Gly Asn Thr Tyr Tyr Asn Glu Lys Phe
50 55 60

[illegible]

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg Ser Tyr Gly Ala Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu
100 105 110

25 Thr Val Ser Ser
115

<210> 135

<211> 118

<212> PRT

30 <213> Artificial

<220>

<223> Description of artificial sequence: Translation of PCR product

35 <400> 135

40

45

50

55

EP 2 311 877 B1

1 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala
 5 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 10 Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 15 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 20 Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 25 Thr Arg Ser Trp Arg Gly Asn Ser Phe Asp Tyr Trp Gly Gln Gly Thr
 30 Thr Leu Thr Val Ser Ser

<210> 136

<211> 118

<212> PRT

<213> Artificial

<220>

<223> Description of artificial sequence: Translation of PCR product

<400> 136

1 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 20 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 30

EP 2 311 877 B1

Val Ile Ser Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile
35 40 45

5 Gly Glu Ile Tyr Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr
65 70 75 80

10 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

15 Ala Arg Gly Val Leu Leu Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr
100 105 110

Ser Val Thr Val Ser Ser
115

20 <210> 137
<211> 120
<212> PRT
<213> Artificial

25 <220>
<223> Description of artificial sequence: Translation of PCR product

30 <400> 137

Gln Val His Leu Gln Gln Ser Gly Ser Glu Leu Arg Ser Pro Gly Ser
1 5 10 15

35 Ser Val Lys Leu Ser Cys Lys Asp Phe Asp Ser Glu Val Phe Pro Phe
20 25 30

Ala Tyr Met Ser Trp Ile Arg Gln Lys Pro Gly His Gly Phe Glu Trp
35 40 45

40 Ile Gly Asp Ile Leu Pro Ser Ile Gly Arg Thr Ile Tyr Gly Glu Lys
50 55 60

45 Phe Glu Asp Lys Ala Thr Leu Asp Ala Asp Thr Val Ser Asn Thr Ala
65 70 75 80

Tyr Leu Glu Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr
85 90 95

50 Cys Ala Arg Gly Glu Gly Tyr Gly Ala Trp Phe Ala Tyr Trp Gly Gln
100 105 110

55 Gly Thr Leu Val Thr Val Ser Ala
115 120

<210> 138
<211> 113

EP 2 311 877 B1

<212> PRT
<213> Artificial

<220>

5 <223> Description of artificial sequence: Translation of PCR product

<400> 138

```

10      Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
      1             5             10             15

      Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
      20             25             30

15      Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
      35             40             45

      Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
      50             55             60

20      Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
      65             70             75             80

25      Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
      85             90             95

      Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu
      100            105            110

      Lys

```

<210> 139
<211> 106
<212> PRT
<213> Artificial

<220>

40 <223> Description of artificial sequence: Translation of PCR product

<400> 139

```

45      Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
      1             5             10             15

      Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
      20             25             30

50      His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr
      35             40             45

55

```

EP 2 311 877 B1

Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
 50 55 60
 5 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu
 65 70 75 80
 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Pro Thr
 85 90 95
 10 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 140
 <211> 107
 <212> PRT
 <213> Artificial

<220>
 20 <223> Description of artificial sequence: Translation of PCR product
 <400> 140

25 Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
 1 5 10 15
 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala
 20 25 30
 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
 35 40 45
 Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
 65 70 75 80
 40 Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu
 85 90 95
 45 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 141
 <211> 113
 <212> PRT
 50 <213> Artificial

<220>
 <223> Description of artificial sequence: Translation of PCR product
 55 <400> 141

EP 2 311 877 B1

Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly
 1 5 10 15
 5 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
 20 25 30
 Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
 35 40 45
 10 Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60
 15 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80
 Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln
 85 90 95
 20 Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu
 100 105 110
 Lys
 25
 <210> 142
 <211> 113
 <212> PRT
 <213> Artificial
 30
 <220>
 <223> Description of artificial sequence: Translation of PCR product
 <400> 142
 35
 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
 1 5 10 15
 40 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
 20 25 30
 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
 35 40 45
 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60
 50 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80
 55

EP 2 311 877 B1

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
85 90 95

5 Asp Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile
100 105 110

Lys

10 <210> 143
<211> 112
<212> PRT
<213> Artificial

15 <220>
<223> Description of artificial sequence: Translation of PCR product

<400> 143

20 Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly
1 5 10 15

25 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30

Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

30 Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

35 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln
85 90 95

40 Ser Tyr Asn Leu Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110

45 <210> 144
<211> 113
<212> PRT
<213> Artificial

<220>
<223> Description of artificial sequence: Translation of PCR product

50 <400> 144

55 Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly
1 5 10 15

EP 2 311 877 B1

Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30

5 Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

10 Pro Asp Arg Phe Thr Gly Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr
65 70 75 80

15 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr His Cys Gly Gln
85 90 95

Gly Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110

20 Lys

<210> 145

<211> 113

25 <212> PRT

<213> Artificial

<220>

<223> Description of artificial sequence: Translation of PCR product

30 <400> 145

35 Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly
1 5 10 15

Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30

40 Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

45 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

50 Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln
85 90 95

Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu
100 105 110

55 Lys

EP 2 311 877 B1

<210> 146
<211> 107
<212> PRT
<213> Artificial

<220>
<223> Description of artificial sequence: Translation of PCR product

<400> 146

```

Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly
1           5           10           15

Glu Arg Val Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr
15          20          25          30

Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile
20          35          40          45

Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
25          50          55          60

Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala
30          65          70          75          80

Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu
35          85          90          95

Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
40          100          105

```

<210> 147
<211> 324
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: codon optimized nucleic acid

<400> 147

```

cgtaagggtgg ccgctcccag cgtgttcate ttcccccca gcgacgagca gctgaagtcc      60
ggcacccgcca gcgtggtgtg cctgctgaac aacttctacc cccgggaggc caaggtgcag      120
tggaagggtgg acaacgccct gcagagcggc aacagccagg agagcggtcac cgagcaggac      180
agcaaggact ccacctacag cctgagcagc accctgaccc tgagcaaggc cgactacgag      240
aagcacaagg tgtacgcctg cgaggtgacc caccagggcc tgtccagccc cgtgaccaag      300
agcttcaaca ggggcgagtg ctag                                324

```

<210> 148
<211> 107
<212> PRT
<213> Artificial

EP 2 311 877 B1

<220>

<223> Description of artificial sequence: codon optimized protein

<400> 148

5

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15

10

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30

15

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60

20

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95

25

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> 149

30

<211> 981

<212> DNA

<213> Artificial

<220>

35

<223> Description of artificial sequence: codon optimized nucleic acid

<400> 149

40

ggcccaagcg tgttccccct ggccccccagc agcaagagca ccagcggcgg cacagccgcc 60

ctgggctgcc tggatgaagga ctacttcccc gagcccgtag ccgtgagctg gaacagcggg 120

gccctgacct ccggcgtgca caccttcccc gccgtgctgc agagcagcgg cctgtacagc 180

45

ctgagcagcg tggtagccgt gccagcagc agcctgggca cccagacctg catctgcaac 240

gtgaaccaca agcccagcaa caccaagggt gacaagagag tggagcccaa gagctgcgac 300

aagaccacaca cctgcccccc ctgccagcgc ccagagctgc tgggcggacc cagcgtgttc 360

50

ctgttcccc ccaagcccaa ggacaccctg atgatcagca ggacccccga ggtgacctgc 420

gtgggtggtg acgtgagcca cgaggaccca gaggtgaagt tcaactggta cgtggacggc 480

55

EP 2 311 877 B1

gtggaggtgc acaacgcca gaccaagccc agagaggagc agtacaacag cacctacagg 540
 gtggtgtccg tgctgaccgt gctgcaccag gactggctga acggcaagga atacaagtgc 600
 5 aaggtctcca acaaggccct gccagccccc atcgaaaaga ccatcagcaa ggccaagggc 660
 cagccacggg agccccaggt gtacaccctg cccccagcc gggaggagat gaccaagaac 720
 caggtgtccc tgacctgtct ggtgaagggc ttctacecca ggcacatcgc cgtggagtgg 780
 10 gagagcaacg gccagcccgga gaacaactac aagaccaccc cccagtgct ggacagcgac 840
 ggcagcttct tcctgtacag caagctgacc gtggacaagt ccaggtggca gcagggcaac 900
 gtgttcagct gcagcgtgat gcacgaggcc ctgcacaacc actacacca gaagtcctct 960
 15 agcctgagcc ccggcaagta g 981

<210> 150

<211> 326

<212> PRT

20 <213> Artificial

<220>

<223> Description of artificial sequence: codon optimized protein

25 <400> 150

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
 1 5 10 15
 30 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 20 25 30
 35 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 35 40 45
 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
 50 55 60
 40 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
 65 70 75 80
 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
 85 90 95
 45 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
 100 105 110
 50 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 115 120 125
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 130 135 140
 55

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
145 150 155 160

5 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
165 170 175

10 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
180 185 190

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
195 200 205

15 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
210 215 220

20 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
225 230 235 240

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
245 250 255

25 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
260 265 270

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
275 280 285

30 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
290 295 300

35 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
305 310 315 320

Ser Leu Ser Pro Gly Lys
325

40

Claims

- 45 1. A monoclonal antibody having the ability of binding to CLD18A2 and mediating killing of cells expressing CLD18A2, wherein the antibody binds to an epitope localized on the CLD18A2-loop1 or the CLD18A2-loopD3 and wherein killing is induced by binding of the antibody to CLD18A2 expressed by said cells, wherein the antibody mediates killing of cells by inducing complement dependent cytotoxicity (CDC) mediated lysis and/or antibody dependent cellular cytotoxicity (ADCC) mediated lysis.
- 50 2. The antibody of claim 1 which binds to CLD18A1 and CLD18A2 or binds to CLD18A2 but not to CLD18A1.
3. The antibody of claims 1 or 2 wherein said cells expressing CLD18A2 are cancer cells, wherein the cancer cells are preferably selected from the group consisting of tumorigenic gastric, esophageal, pancreatic and lung cancer cells.
- 55 4. The antibody of claim 3 wherein said ADCC mediated lysis takes place in the presence of effector cells selected from the group consisting of monocytes, mononuclear cells, NK cells and PMNs or said phagocytosis is by macrophages.

5. The antibody of any one of claims 1-4 which is a chimeric, human or humanized antibody, or a fragment of an antibody.
6. The antibody of any one of claims 1-5 selected from the group consisting of an IgG1, an IgG2, preferably IgG2a and IgG2b, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a
5 secretory IgA, an IgD, and an IgE antibody.
7. The antibody of any one of claims 2-6 wherein CLD18A2 has the amino acid sequence according to SEQ ID NO:2.
8. The antibody of any one of claims 2-7 wherein CLD18A1 has the amino acid sequence according to SEQ ID NO:8.
10
9. The antibody of any one of claims 1-8 which binds to native epitopes of CLD18A2 present on the surface of living cells.
10. The antibody of any one of claims 1-9 which is specific for cancer cells, preferably stomach cancer cells.
- 15 11. The antibody of any one of claims 1-10 which is obtainable by a method comprising the step of immunizing a non human animal with a protein or peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 16, 18, 20-23, and 26-31, or an immunogenic fragment thereof, or a nucleic acid or host cell expressing said protein or peptide, or immunogenic fragment thereof.
- 20 12. The antibody of claim 1 which comprises one or more of the complementarity-determining regions (CDRs), preferably at least the CDR3, of the heavy chain variable region (VH) and/or of the light chain variable region (VL) of an antibody which comprises a combination of VH and VL each comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (ix):
25 (i) VH: CDR1: positions 45-52 of SEQ ID NO: 115, CDR2: positions 70-77 of SEQ ID NO: 115, CDR3: positions 116-125 of SEQ ID NO: 115, VL: CDR1: positions 49-53 of SEQ ID NO: 122, CDR2: positions 71-73 of SEQ ID NO: 122, CDR3: positions 110-118 of SEQ ID NO: 122,
(ii) VH: CDR1: positions 45-52 of SEQ ID NO: 116, CDR2: positions 70-77 of SEQ ID NO: 116, CDR3: positions 116-126 of SEQ ID NO: 116, VL: CDR1: positions 47-58 of SEQ ID NO: 121, CDR2: positions 76-78 of SEQ
30 ID NO: 121, CDR3: positions 115-123 of SEQ ID NO: 121,
(iii) VH: CDR1: positions 45-52 of SEQ ID NO: 117, CDR2: positions 70-77 of SEQ ID NO: 117, CDR3: positions 116-124 of SEQ ID NO: 117, VL: CDR1: positions 47-52 of SEQ ID NO: 123, CDR2: positions 70-72 of SEQ ID NO: 123, CDR3: positions 109-117 of SEQ ID NO: 123,
(iv) VH: CDR1: positions 44-51 of SEQ ID NO: 119, CDR2: positions 69-76 of SEQ ID NO: 119, CDR3: positions 115-125 of SEQ ID NO: 119, VL: CDR1: positions 47-58 of SEQ ID NO: 126, CDR2: positions 76-78 of SEQ
35 ID NO: 126, CDR3: positions 115-122 of SEQ ID NO: 126,
(v) VH: CDR1: positions 45-52 of SEQ ID NO: 118, CDR2: positions 70-77 of SEQ ID NO: 118, CDR3: positions 116-126 of SEQ ID NO: 118, VL: CDR1: positions 47-58 of SEQ ID NO: 125, CDR2: positions 76-78 of SEQ ID NO: 125, CDR3: positions 115-123 of SEQ ID NO: 125,
(vi) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 124, CDR2: positions 76-78 of SEQ
40 ID NO: 124, CDR3: positions 115-123 of SEQ ID NO: 124,
(vii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 127, CDR2: positions 76-78 of SEQ
45 ID NO: 127, CDR3: positions 115-123 of SEQ ID NO: 127,
(viii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 128, CDR2: positions 76-78 of SEQ ID NO: 128, CDR3: positions 115-123 of SEQ ID NO: 128, and
(ix) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-52 of SEQ ID NO: 129, CDR2: positions 70-72 of SEQ ID
50 NO: 129, CDR3: positions 109-117 of SEQ ID NO: 129.
13. The antibody of claim 1 which comprises a VH comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (vi):
55 (i) CDR1: positions 45-52 of SEQ ID NO: 115, CDR2: positions 70-77 of SEQ ID NO: 115, CDR3: positions 116-125 of SEQ ID NO: 115,
(ii) CDR1: positions 45-52 of SEQ ID NO: 116, CDR2: positions 70-77 of SEQ ID NO: 116, CDR3: positions

116-126 of SEQ ID NO: 116,

(iii) CDR1: positions 45-52 of SEQ ID NO: 117, CDR2: positions 70-77 of SEQ ID NO: 117, CDR3: positions 116-124 of SEQ ID NO: 117,

(iv) CDR1 positions 45-52 of SEQ ID NO: 118, CDR2: positions 70-77 of SEQ ID NO: 118, CDR3: positions 116-126 of SEQ ID NO: 118,

(v) CDR1: positions 44-51 of SEQ ID NO: 119, CDR2: positions 69-76 of SEQ ID NO: 119, CDR3: positions 115-125 of SEQ ID NO: 119, and

(vi) CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120.

14. The antibody of claims 1 which comprises a VL comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (ix):

(i) CDR1: positions 47-58 of SEQ ID NO: 121, CDR2: positions 76-78 of SEQ ID NO: 121, CDR3: positions 115-123 of SEQ ID NO: 121,

(ii) CDR1: positions 49-53 of SEQ ID NO: 122, CDR2: positions 71-73 of SEQ ID NO: 122, CDR3: positions 110-118 of SEQ ID NO: 122,

(iii) CDR1: positions 47-52 of SEQ ID NO: 123, CDR2: positions 70-72 of SEQ ID NO: 123, CDR3: positions 109-117 of SEQ ID NO: 123,

(iv) CDR1: positions 47-58 of SEQ ID NO: 124, CDR2: positions 76-78 of SEQ ID NO: 124, CDR3: positions 115-123 of SEQ ID NO: 124,

(v) CDR1: positions 47-58 of SEQ ID NO: 125, CDR2: positions 76-78 of SEQ ID NO: 125, CDR3: positions 115-123 of SEQ ID NO: 125,

(vi) CDR1: positions 47-58 of SEQ ID NO: 126, CDR2: positions 76-78 of SEQ ID NO: 126, CDR3: positions 115-122 of SEQ ID NO: 126,

(vii) CDR1: positions 47-58 of SEQ ID NO: 127, CDR2: positions 76-78 of SEQ ID NO: 127, CDR3: positions 115-123 of SEQ ID NO: 127,

(viii) CDR1: positions 47-58 of SEQ ID NO: 128, CDR2: positions 76-78 of SEQ ID NO: 128, CDR3: positions 115-123 of SEQ ID NO: 128, and

(ix) CDR1: positions 47-52 of SEQ ID NO: 129, CDR2: positions 70-72 of SEQ ID NO: 129, CDR3: positions 109-117 of SEQ ID NO: 129.

15. The antibody of claim 1 which comprises a combination of VH and VL each comprising a set of complementarity-determining regions CDR1, CDR2 and CDR3 selected from the following (i) to (ix):

(i) VH: CDR1: positions 45-52 of SEQ ID NO: 115, CDR2: positions 70-77 of SEQ ID NO: 115, CDR3: positions 116-125 of SEQ ID NO: 115, VL: CDR1: positions 49-53 of SEQ ID NO: 122, CDR2: positions 71-73 of SEQ ID NO: 122, CDR3: positions 110-118 of SEQ ID NO: 122,

(ii) VH: CDR1: positions 45-52 of SEQ ID NO: 116, CDR2: positions 70-77 of SEQ ID NO: 116, CDR3: positions 116-126 of SEQ ID NO: 116, VL: CDR1: positions 47-58 of SEQ ID NO: 121, CDR2: positions 76-78 of SEQ ID NO: 121, CDR3: positions 115-123 of SEQ ID NO: 121,

(iii) VH: CDR1: positions 45-52 of SEQ ID NO: 117, CDR2: positions 70-77 of SEQ ID NO: 117, CDR3: positions 116-124 of SEQ ID NO: 117, VL: CDR1: positions 47-52 of SEQ ID NO: 123, CDR2: positions 70-72 of SEQ ID NO: 123, CDR3: positions 109-117 of SEQ ID NO: 123,

(iv) VH: CDR1: positions 44-51 of SEQ ID NO: 119, CDR2: positions 69-76 of SEQ ID NO: 119, CDR3: positions 115-125 of SEQ ID NO: 119, VL: CDR1: positions 47-58 of SEQ ID NO: 126, CDR2: positions 76-78 of SEQ ID NO: 126, CDR3: positions 115-122 of SEQ ID NO: 126,

(v) VH: CDR1: positions 45-52 of SEQ ID NO: 118, CDR2: positions 70-77 of SEQ ID NO: 118, CDR3: positions 116-126 of SEQ ID NO: 118, VL: CDR1: positions 47-58 of SEQ ID NO: 125, CDR2: positions 76-78 of SEQ ID NO: 125, CDR3: positions 115-123 of SEQ ID NO: 125,

(vi) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 124, CDR2: positions 76-78 of SEQ ID NO: 124, CDR3: positions 115-123 of SEQ ID NO: 124,

(vii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 127, CDR2: positions 76-78 of SEQ ID NO: 127, CDR3: positions 115-123 of SEQ ID NO: 127,

(viii) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-58 of SEQ ID NO: 128, CDR2: positions 76-78 of SEQ

ID NO: 128, CDR3: positions 115-123 of SEQ ID NO: 128, and

(ix) VH: CDR1: positions 45-53 of SEQ ID NO: 120, CDR2: positions 71-78 of SEQ ID NO: 120, CDR3: positions 117-128 of SEQ ID NO: 120, VL: CDR1: positions 47-52 of SEQ ID NO: 129, CDR2: positions 70-72 of SEQ ID NO: 129, CDR3: positions 109-117 of SEQ ID NO: 129.

5

16. The antibody of claim 1 which comprises a heavy chain variable region (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 132, 133, 134, 135, 136, 137, and a fragment thereof.

10

17. The antibody of claim 1 which comprises a light chain variable region (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 138, 139, 140, 141, 142, 143, 144, 145, 146, and a fragment thereof.

18. The antibody of claim 1 which comprises a combination of heavy chain variable region (VH) and light chain variable region (VL) selected from the following possibilities (i) to (ix):

15

(i) the VH comprises an amino acid sequence represented by SEQ ID NO: 132 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 139 or a fragment thereof,

(ii) the VH comprises an amino acid sequence represented by SEQ ID NO: 133 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 138 or a fragment thereof,

20

(iii) the VH comprises an amino acid sequence represented by SEQ ID NO: 134 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 140 or a fragment thereof,

(iv) the VH comprises an amino acid sequence represented by SEQ ID NO: 136 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 143 or a fragment thereof,

(v) the VH comprises an amino acid sequence represented by SEQ ID NO: 135 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 142 or a fragment thereof,

25

(vi) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 141 or a fragment thereof,

(vii) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 144 or a fragment thereof,

30

(viii) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 145 or a fragment thereof,

(ix) the VH comprises an amino acid sequence represented by SEQ ID NO: 137 or a fragment thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 146 or a fragment thereof.

19. The antibody of claim 1 which comprises

35

(i) a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 115, 116, 117, 118, 119, 120, and a fragment thereof and/or

40

(ii) a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 121, 122, 123, 124, 125, 126, 127, 128, 129, and a fragment thereof.

20. The antibody of claim 1 which comprises a combination of heavy chains and light chains selected from the following possibilities (i) to (ix):

45

(i) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 115 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 122 or a fragment thereof,

(ii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 116 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 121 or a fragment thereof,

50

(iii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 117 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 123 or a fragment thereof,

(iv) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 119 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 126 or a fragment thereof,

(v) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 118 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 125 or a fragment thereof,

55

(vi) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 124 or a fragment thereof,

(vii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 127 or a fragment thereof,

(viii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 128 or a fragment thereof, and
(ix) the heavy chain comprises an amino acid sequences represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 129 or a fragment thereof.

21. A hybridoma capable of producing the antibody of any one of claims 1 to 20.
22. A conjugate comprising an antibody of any one of claims 1 to 20 coupled to a therapeutic agent, wherein the therapeutic agent preferably is a toxin, a radioisotope, a drug or a cytotoxic agent.
23. A pharmaceutical composition comprising an antibody of any one of claims 1 to 20 and/or a conjugate of claim 22, and a pharmaceutically acceptable carrier.
24. An antibody of any one of claims 1 to 20 and/or a conjugate of claim 22 for use in a method of inhibiting growth and/or killing of a cell expressing CLD18A2.
25. An Antibody of any one of claims. 1 to 20, a conjugate of claim 22 or a pharmaceutical composition of claim 23 for use in a method of treating or preventing a disease or disorder involving cells expressing CLD18A2.
26. The antibody, conjugate or pharmaceutical composition for use according to claim 25 wherein the disease or disorder is a tumor-related disease, wherein the tumor-related disease preferably is selected from the group consisting of breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, colorectal cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.
27. The antibody, conjugate or pharmaceutical composition for use according to claim 25 or 26, wherein the method further comprises treating with a chemotherapeutic agent, radiation, or a cytokine.
28. The antibody, conjugate or pharmaceutical composition for use according to claim 27, wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cisplatin, taxotere, 5 fluoruracil, methotrexat, gemcitabin and cyclophosphamide.
29. The antibody, hybridoma, conjugate or pharmaceutical composition of any one of claims 1-23, and the antibody, conjugate or pharmaceutical composition for use according to any one of claims 24 to 28, wherein said CLD18A2 is expressed on the surface of said cells.

Patentansprüche

1. Monoklonaler Antikörper, der die Fähigkeit aufweist, an CLD18A2 zu binden und ein Abtöten von Zellen, die CLD18A2 exprimieren, zu vermitteln, wobei der Antikörper an ein Epitop bindet, das auf der CLD18A2-Schleife1 oder der CLD18A2-SchleifeD3 liegt, und wobei ein Abtöten durch Binden des Antikörpers an CLD18A2, das von den Zellen exprimiert wird, induziert wird, wobei der Antikörper ein Abtöten von Zellen durch Induktion von durch komplementabhängige Zytotoxizität (CDC) vermittelter Lyse und/oder durch antikörperabhängige zelluläre Zytotoxizität (ADCC) vermittelter Lyse vermittelt.
2. Antikörper nach Anspruch 1, der an CLD18A1 und CLD18A2 bindet oder an CLD18A2, jedoch nicht an CLD18A1 bindet.
3. Antikörper nach Anspruch 1 oder 2, wobei die Zellen, die CLD18A2 exprimieren, Krebszellen sind, wobei die Krebszellen vorzugsweise ausgewählt sind aus der Gruppe, bestehend aus krebserzeugenden Magen-, Ösophagus-, Pankreas- und Lungenkrebszellen.
4. Antikörper nach Anspruch 3, wobei die durch ADCC vermittelte Lyse in Gegenwart von Effektorzellen stattfindet, die ausgewählt sind aus der Gruppe, bestehend aus Monozyten, mononukleären Zellen, NK-Zellen und PMN, oder die Phagozytose durch Makrophagen erfolgt.
5. Antikörper nach einem der Ansprüche 1-4, der ein chimärer, humaner oder humanisierter Antikörper oder ein Fragment eines Antikörpers ist.

6. Antikörper nach einem der Ansprüche 1-5, der ausgewählt ist aus der Gruppe, bestehend aus einem IgG1-, einem IgG2-, vorzugsweise IgG2a- und IgG2b-, einem IgG3-, einem IgG4-, einem IgM-, einem IgA1-, einem IgA2-, einem sekretorischen IgA-, einem IgD- und einem IgE-Antikörper.

7. Antikörper nach einem der Ansprüche 2-6, wobei CLD18A2 die Aminosäuresequenz gemäß SEQ ID NO: 2 aufweist.

8. Antikörper nach einem der Ansprüche 2-7, wobei CLD18A1 die Aminosäuresequenz gemäß SEQ ID NO: 8 aufweist.

9. Antikörper nach einem der Ansprüche 1-8, der an native Epitope von CLD18A2 bindet, die auf der Oberfläche von lebenden Zellen vorliegen.

10. Antikörper nach einem der Ansprüche 1-9, der für Krebszellen, vorzugsweise Magenkrebszellen spezifisch ist.

11. Antikörper nach einem der Ansprüche 1-10, der durch ein Verfahren erhältlich ist, das den Schritt einer Immunisierung eines nicht menschlichen Tieres mit einem Protein oder Peptid, das eine Aminosäuresequenz aufweist, die ausgewählt ist aus der Gruppe, bestehend aus SEQ ID NO: 2, 4, 6, 16, 18, 20-23 und 26-31, oder einem immunogenen Fragment davon, oder einer Nukleinsäure oder Wirtszelle, die das Protein oder Peptid oder ein immunogenes Fragment davon exprimiert, umfasst.

12. Antikörper nach Anspruch 1, der eine oder mehrere der komplementaritätsbestimmenden Regionen (CDRs), vorzugsweise mindestens die CDR3, der schwere Kette-variablen Region (VH) und/oder der leichte Kette-variablen Region (VL) eines Antikörpers umfasst, der eine Kombination von VH und VL umfasst, die jeweils einen Satz von komplementaritätsbestimmenden Regionen CDR1, CDR2 und CDR3 umfassen, der aus den nachstehenden (i) bis (ix) ausgewählt ist:

(i) VH: CDR1: Positionen 45-52 von SEQ ID NO: 115, CDR2: Positionen 70-77 von SEQ ID NO: 115, CDR3: Positionen 116-125 von SEQ ID NO: 115, VL: CDR1: Positionen 49-53 von SEQ ID NO: 122, CDR2: Positionen 71-73 von SEQ ID NO: 122, CDR3: Positionen 110-118 von SEQ ID NO: 122,

(ii) VH: CDR1: Positionen 45-52 von SEQ ID NO: 116, CDR2: Positionen 70-77 von SEQ ID NO: 116, CDR3: Positionen 116-126 von SEQ ID NO: 116, VL: CDR1: Positionen 47-58 von SEQ ID NO: 121, CDR2: Positionen 76-78 von SEQ ID NO: 121, CDR3: Positionen 115-123 von SEQ ID NO: 121,

(iii) VH: CDR1: Positionen 45-52 von SEQ ID NO: 117, CDR2: Positionen 70-77 von SEQ ID NO: 117, CDR3: Positionen 116-124 von SEQ ID NO: 117, VL: CDR1: Positionen 47-52 von SEQ ID NO: 123, CDR2: Positionen 70-72 von SEQ ID NO: 123, CDR3: Positionen 109-117 von SEQ ID NO: 123,

(iv) VH: CDR1: Positionen 44-51 von SEQ ID NO: 119, CDR2: Positionen 69-76 von SEQ ID NO: 119, CDR3: Positionen 115-125 von SEQ ID NO: 119, VL: CDR1: Positionen 47-58 von SEQ ID NO: 126, CDR2: Positionen 76-78 von SEQ ID NO: 126, CDR3: Positionen 115-122 von SEQ ID NO: 126,

(v) VH: CDR1: Positionen 45-52 von SEQ ID NO: 118, CDR2: Positionen 70-77 von SEQ ID NO: 118, CDR3: Positionen 116-126 von SEQ ID NO: 118, VL: CDR1: Positionen 47-58 von SEQ ID NO: 125, CDR2: Positionen 76-78 von SEQ ID NO: 125, CDR3: Positionen 115-123 von SEQ ID NO: 125,

(vi) VH: CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120, VL: CDR1: Positionen 47-58 von SEQ ID NO: 124, CDR2: Positionen 76-78 von SEQ ID NO: 124, CDR3: Positionen 115-123 von SEQ ID NO: 124,

(vii) VH: CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120, VL: CDR1: Positionen 47-58 von SEQ ID NO: 127, CDR2: Positionen 76-78 von SEQ ID NO: 127, CDR3: Positionen 115-123 von SEQ ID NO: 127,

(viii) VH: CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120, VL: CDR1: Positionen 47-58 von SEQ ID NO: 128, CDR2: Positionen 76-78 von SEQ ID NO: 128, CDR3: Positionen 115-123 von SEQ ID NO: 128, und

(ix) VH: CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120, VL: CDR1: Positionen 47-52 von SEQ ID NO: 129, CDR2: Positionen 70-72 von SEQ ID NO: 129, CDR3: Positionen 109-117 von SEQ ID NO: 129.

13. Antikörper nach Anspruch 1, der eine VH umfasst, die einen Satz von komplementaritätsbestimmenden Regionen CDR1, CDR2 und CDR3 umfasst, der aus den nachstehenden (i) bis (vi) ausgewählt ist:

(i) CDR1: Positionen 45-52 von SEQ ID NO: 115, CDR2: Positionen 70-77 von SEQ ID NO: 115, CDR3: Positionen 116-125 von SEQ ID NO: 115,

- (ii) CDR1: Positionen 45-52 von SEQ ID NO: 116, CDR2: Positionen 70-77 von SEQ ID NO: 116, CDR3: Positionen 116-126 von SEQ ID NO: 116,
- (iii) CDR1: Positionen 45-52 von SEQ ID NO: 117, CDR2: Positionen 70-77 von SEQ ID NO: 117, CDR3: Positionen 116-124 von SEQ ID NO: 117,
- (iv) CDR1: Positionen 45-52 von SEQ ID NO: 118, CDR2: Positionen 70-77 von SEQ ID NO: 118, CDR3: Positionen 116-126 von SEQ ID NO: 118,
- (v) CDR1: Positionen 44-51 von SEQ ID NO: 119, CDR2: Positionen 69-76 von SEQ ID NO: 119, CDR3: Positionen 115-125 von SEQ ID NO: 119, und
- (vi) CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120.

14. Antikörper nach Anspruch 1, der eine VL umfasst, die einen Satz von komplementaritätsbestimmenden Regionen CDR1, CDR2 und CDR3 umfasst, der aus den nachstehenden (i) bis (ix) ausgewählt ist:

- (i) CDR1: Positionen 47-58 von SEQ ID NO: 121, CDR2: Positionen 76-78 von SEQ ID NO: 121, CDR3: Positionen 115-123 von SEQ ID NO: 121,
- (ii) CDR1: Positionen 49-53 von SEQ ID NO: 122, CDR2: Positionen 71-73 von SEQ ID NO: 122, CDR3: Positionen 110-118 von SEQ ID NO: 122,
- (iii) CDR1: Positionen 47-52 von SEQ ID NO: 123, CDR2: Positionen 70-72 von SEQ ID NO: 123, CDR3: Positionen 109-117 von SEQ ID NO: 123,
- (iv) CDR1: Positionen 47-58 von SEQ ID NO: 124, CDR2: Positionen 76-78 von SEQ ID NO: 124, CDR3: Positionen 115-123 von SEQ ID NO: 124,
- (v) CDR1: Positionen 47-58 von SEQ ID NO: 125, CDR2: Positionen 76-78 von SEQ ID NO: 125, CDR3: Positionen 115-123 von SEQ ID NO: 125,
- (vi) CDR1: Positionen 47-58 von SEQ ID NO: 126, CDR2: Positionen 76-78 von SEQ ID NO: 126, CDR3: Positionen 115-122 von SEQ ID NO: 126,
- (vii) CDR1: Positionen 47-58 von SEQ ID NO: 127, CDR2: Positionen 76-78 von SEQ ID NO: 127, CDR3: Positionen 115-123 von SEQ ID NO: 127,
- (viii) CDR1: Positionen 47-58 von SEQ ID NO: 128, CDR2: Positionen 76-78 von SEQ ID NO: 128, CDR3: Positionen 115-123 von SEQ ID NO: 128, und
- (ix) CDR1: Positionen 47-52 von SEQ ID NO: 129, CDR2: Positionen 70-72 von SEQ ID NO: 129, CDR3: Positionen 109-117 von SEQ ID NO: 129.

15. Antikörper nach Anspruch 1, der eine Kombination von VH und VL umfasst, die jeweils einen Satz von komplementaritätsbestimmenden Regionen CDR1, CDR2 und CDR3 umfassen, der aus den nachstehenden (i) bis (ix) ausgewählt ist:

- (i) VH: CDR1: Positionen 45-52 von SEQ ID NO: 115, CDR2: Positionen 70-77 von SEQ ID NO: 115, CDR3: Positionen 116-125 von SEQ ID NO: 115, VL: CDR1: Positionen 49-53 von SEQ ID NO: 122, CDR2: Positionen 71-73 von SEQ ID NO: 122, CDR3: Positionen 110-118 von SEQ ID NO: 122,
- (ii) VH: CDR1: Positionen 45-52 von SEQ ID NO: 116, CDR2: Positionen 70-77 von SEQ ID NO: 116, CDR3: Positionen 116-126 von SEQ ID NO: 116, VL: CDR1: Positionen 47-58 von SEQ ID NO: 121, CDR2: Positionen 76-78 von SEQ ID NO: 121, CDR3: Positionen 115-123 von SEQ ID NO: 121,
- (iii) VH: CDR1: Positionen 45-52 von SEQ ID NO: 117, CDR2: Positionen 70-77 von SEQ ID NO: 117, CDR3: Positionen 116-124 von SEQ ID NO: 117, VL: CDR1: Positionen 47-52 von SEQ ID NO: 123, CDR2: Positionen 70-72 von SEQ ID NO: 123, CDR3: Positionen 109-117 von SEQ ID NO: 123,
- (iv) VH: CDR1: Positionen 44-51 von SEQ ID NO: 119, CDR2: Positionen 69-76 von SEQ ID NO: 119, CDR3: Positionen 115-125 von SEQ ID NO: 119, VL: CDR1: Positionen 47-58 von SEQ ID NO: 126, CDR2: Positionen 76-78 von SEQ ID NO: 126, CDR3: Positionen 115-122 von SEQ ID NO: 126,
- (v) VH: CDR1: Positionen 45-52 von SEQ ID NO: 118, CDR2: Positionen 70-77 von SEQ ID NO: 118, CDR3: Positionen 116-126 von SEQ ID NO: 118, VL: CDR1: Positionen 47-58 von SEQ ID NO: 125, CDR2: Positionen 76-78 von SEQ ID NO: 125, CDR3: Positionen 115-123 von SEQ ID NO: 125,
- (vi) VH: CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120, VL: CDR1: Positionen 47-58 von SEQ ID NO: 124, CDR2: Positionen 76-78 von SEQ ID NO: 124, CDR3: Positionen 115-123 von SEQ ID NO: 124,
- (vii) VH: CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120, VL: CDR1: Positionen 47-58 von SEQ ID NO: 127, CDR2: Positionen 76-78 von SEQ ID NO: 127, CDR3: Positionen 115-123 von SEQ ID NO: 127,

(viii) VH: CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120, VL: CDR1: Positionen 47-58 von SEQ ID NO: 128, CDR2: Positionen 76-78 von SEQ ID NO: 128, CDR3: Positionen 115-123 von SEQ ID NO: 128, und

(ix) VH: CDR1: Positionen 45-53 von SEQ ID NO: 120, CDR2: Positionen 71-78 von SEQ ID NO: 120, CDR3: Positionen 117-128 von SEQ ID NO: 120, VL: CDR1: Positionen 47-52 von SEQ ID NO: 129, CDR2: Positionen 70-72 von SEQ ID NO: 129, CDR3: Positionen 109-117 von SEQ ID NO: 129.

16. Antikörper nach Anspruch 1, der eine schwere Kette-variable Region (VH) umfasst, die eine Aminosäuresequenz umfasst, die ausgewählt ist aus der Gruppe, bestehend aus SEQ ID NO: 132, 133, 134, 135, 136, 137 und einem Fragment davon.

17. Antikörper nach Anspruch 1, der eine leichte Kette-variable Region (VL) umfasst, die eine Aminosäuresequenz umfasst, die ausgewählt ist aus der Gruppe, bestehend aus SEQ ID NO: 138, 139, 140, 141, 142, 143, 144, 145, 146 und einem Fragment davon.

18. Antikörper nach Anspruch 1, der eine Kombination von schwere Kette-variabler Region (VH) und leichte Kette-variabler Region (VL) umfasst, die ausgewählt ist aus den nachstehenden Möglichkeiten (i) bis (ix):

(i) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 132 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 139 dargestellt ist, oder ein Fragment davon,

(ii) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 133 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 138 dargestellt ist, oder ein Fragment davon,

(iii) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 134 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 140 dargestellt ist, oder ein Fragment davon,

(iv) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 136 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 143 dargestellt ist, oder ein Fragment davon,

(v) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 135 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 142 dargestellt ist, oder ein Fragment davon,

(vi) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 137 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 141 dargestellt ist, oder ein Fragment davon,

(vii) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 137 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 144 dargestellt ist, oder ein Fragment davon,

(viii) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 137 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 145 dargestellt ist, oder ein Fragment davon,

(ix) die VH umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 137 dargestellt ist, oder ein Fragment davon und die VL umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 146 dargestellt ist, oder ein Fragment davon.

19. Antikörper nach Anspruch 1, der umfasst

(i) eine schwere Kette, die eine Aminosäuresequenz umfasst, die ausgewählt ist aus der Gruppe, bestehend aus SEQ ID NO: 115, 116, 117, 118, 119, 120 und einem Fragment davon, und/oder

(ii) eine leichte Kette, die eine Aminosäuresequenz umfasst, die ausgewählt ist aus der Gruppe, bestehend aus SEQ ID NO: 121, 122, 123, 124, 125, 126, 127, 128, 129 und einem Fragment davon.

20. Antikörper nach Anspruch 1, der eine Kombination von schweren Ketten und leichten Ketten umfasst, die ausgewählt ist aus den nachstehenden Möglichkeiten (i) bis (ix):

(i) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 115 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 122 dargestellt

ist, oder ein Fragment davon,

(ii) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 116 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 121 dargestellt ist, oder ein Fragment davon,

(iii) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 117 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 123 dargestellt ist, oder ein Fragment davon,

(iv) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 119 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 126 dargestellt ist, oder ein Fragment davon,

(v) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 118 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 125 dargestellt ist, oder ein Fragment davon,

(vi) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 120 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 124 dargestellt ist, oder ein Fragment davon,

(vii) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 120 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 127 dargestellt ist, oder ein Fragment davon,

(viii) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 120 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 128 dargestellt ist, oder ein Fragment davon, und

(ix) die schwere Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 120 dargestellt ist, oder ein Fragment davon und die leichte Kette umfasst eine Aminosäuresequenz, die durch SEQ ID NO: 129 dargestellt ist, oder ein Fragment davon.

21. Hybridom, das zur Produktion des Antikörpers nach einem der Ansprüche 1-20 fähig ist.

22. Konjugat, das einen Antikörper nach einem der Ansprüche 1-20 in Kopplung an ein Therapeutikum umfasst, wobei das Therapeutikum vorzugsweise ein Toxin, ein Radioisotop, ein Arzneimittel oder ein zytotoxischer Wirkstoff ist.

23. Pharmazeutische Zusammensetzung, die einen Antikörper nach einem der Ansprüche 1-20 und/oder ein Konjugat nach Anspruch 22 und einen pharmazeutisch verträglichen Träger umfasst.

24. Antikörper nach einem der Ansprüche 1-20 und/oder Konjugat nach Anspruch 22 für eine Verwendung in einem Verfahren zur Hemmung des Wachstums und/oder zum Abtöten einer Zelle, die CLD18A2 exprimiert.

25. Antikörper nach einem der Ansprüche 1-20, Konjugat nach Anspruch 22 oder pharmazeutische Zusammensetzung nach Anspruch 23 für eine Verwendung in einem Verfahren zur Behandlung oder Vermeidung einer Erkrankung oder Störung, die Zellen einbezieht, die CLD18A2 exprimieren.

26. Antikörper, Konjugat oder pharmazeutische Zusammensetzung für eine Verwendung nach Anspruch 25, wobei die Erkrankung oder Störung eine Tumor-bezogene Erkrankung ist, wobei die Tumor-bezogene Erkrankung vorzugsweise ausgewählt ist aus der Gruppe, bestehend aus Brustkrebs, Magenkrebs, Ösophaguskrebs, Pankreaskrebs, Lungenkrebs, Ovarialkrebs, Kolonkrebs, Kolorektalkrebs, Leberkrebs, Kopf- und Halskrebs, Krebs der Gallenblase und den Metastasen davon.

27. Antikörper, Konjugat oder pharmazeutische Zusammensetzung für eine Verwendung nach Anspruch 25 oder 26, wobei das Verfahren ferner eine Behandlung mit einem Chemotherapeutikum, Strahlung oder einem Zytokin umfasst.

28. Antikörper, Konjugat oder pharmazeutische Zusammensetzung für eine Verwendung nach Anspruch 27, wobei das Chemotherapeutikum ausgewählt ist aus der Gruppe, bestehend aus Doxorubicin, Cisplatin, Taxot, 5-Fluoruracil, Methotrexat, Gemcitabin und Cyclophosphamid.

29. Antikörper, Hybridom, Konjugat oder pharmazeutische Zusammensetzung nach einem der Ansprüche 1-23 und Antikörper, Konjugat oder pharmazeutische Zusammensetzung für eine Verwendung nach einem der Ansprüche 24-28, wobei das CLD18A2 auf der Oberfläche der Zellen exprimiert wird.

Revendications

1. Anticorps monoclonal ayant l'aptitude à se lier à CLD18A2 et à assurer la médiation de la destruction des cellules exprimant CLD18A2, tandis que l'anticorps se lie à un épitope localisé sur la boucle CLD18A2-loop1 ou la boucle CLD18A2-loopD3, et tandis que la destruction est induite par la liaison de l'anticorps à CLD18A2 exprimée par lesdites cellules, tandis que l'anticorps assure la médiation de la destruction des cellules par induction d'une lyse à médiation par une cytotoxicité dépendante du complément (CDC) et/ou une lyse à médiation par une cytotoxicité cellulaire dépendante d'un anticorps (ADCC).
2. Anticorps selon la revendication 1, qui se lie à CLD18A1 et CLD18A2 ou se lie à CLD18A2 mais pas à CLD18A1.
3. Anticorps selon les revendications 1 ou 2, dans lequel lesdites cellules exprimant CLD18A2 sont des cellules cancéreuses, tandis que les cellules cancéreuses sont de préférence choisies dans le groupe consistant en cellules cancéreuses gastriques, oesophagiennes, pancréatiques et pulmonaires tumorigènes.
4. Anticorps selon la revendication 3, dans lequel ladite lyse à médiation par ADCC a lieu en présence de cellules effectrices choisies dans le groupe consistant en monocytes, cellules mononucléaires, cellules NK et PMNs ou ladite phagocytose est réalisée par des macrophages.
5. Anticorps selon l'une quelconque des revendications 1-4, qui est un anticorps chimérique, humain ou humanisé, ou un fragment d'un anticorps.
6. Anticorps selon l'une quelconque des revendications 1-5, choisi dans le groupe consistant en une IgG1, une IgG2, de préférence IgG2a et IgG2b, une IgG3, une IgG4, une IgM, une IgA1, une IgA2, une IgA sécrétoire, une IgD, et un anticorps IgE.
7. Anticorps selon l'une quelconque des revendications 2-6, dans lequel CLD18A2 a la séquence d'acides aminés selon SEQ ID NO: 2.
8. Anticorps selon l'une quelconque des revendications 2-7, dans lequel CLD18A1 a la séquence d'acides aminés selon SEQ ID NO: 8.
9. Anticorps selon l'une quelconque des revendications 1-8, qui se lie à des épitopes natifs de CLD18A2 présente sur la surface de cellules vivantes.
10. Anticorps selon l'une quelconque des revendications 1-9, qui est spécifique pour des cellules cancéreuses, de préférence des cellules cancéreuses de l'estomac.
11. Anticorps selon l'une quelconque des revendications 1-10, qui peut être obtenu par un procédé comprenant l'étape d'immunisation d'un animal non humain avec une protéine ou un peptide ayant une séquence d'acides aminés choisie dans le groupe consistant en SEQ ID NO: 2, 4, 6, 16, 18, 20-23, et 26-31, ou un fragment immunogène de celles-ci, ou un acide nucléique ou une cellule hôte exprimant ladite protéine ou ledit peptide, ou un fragment immunogène de celui(celle)-ci.
12. Anticorps selon la revendication 1, qui comprend une ou plusieurs des régions déterminant la complémentarité (CDRs), de préférence au moins la CDR3, de la région variable de chaîne lourde (VH) et/ou de la région variable de chaîne légère (VL) d'un anticorps qui comprend une combinaison de VH et VL, comprenant chacune un ensemble de régions déterminant la complémentarité CDR1, CDR2, et CDR3 choisies parmi les (i) à (ix) ci-après:
 - (i) VH: CDR1: positions 45-52 de SEQ ID NO:115, CDR2: positions 70-77 de SEQ ID NO:115, CDR3: positions 116-125 de SEQ ID NO:115, VL: CDR1: positions 49-53 de SEQ ID NO:122, CDR2: positions 71-73 de SEQ ID NO:122, CDR3: positions 110-118 de SEQ ID NO:122,
 - (ii) VH: CDR1: positions 45-52 de SEQ ID NO:116, CDR2: positions 70-77 de SEQ ID NO:116, CDR3: positions 116-126 de SEQ ID NO:116, VL: CDR1: positions 47-58 de SEQ ID NO:121, CDR2: positions 76-78 de SEQ ID NO:121, CDR3: positions 115-123 de SEQ ID NO:121,
 - (iii) VH: CDR1: positions 45-52 de SEQ ID NO:117, CDR2: positions 70-77 de SEQ ID NO:117, CDR3: positions 116-124 de SEQ ID NO:117, VL: CDR1: positions 47-52 de SEQ ID NO:123, CDR2: positions 70-72 de SEQ ID NO:123, CDR3: positions 109-117 de SEQ ID NO:123,

- (iv) VH: CDR1: positions 44-51 de SEQ ID NO:119, CDR2: positions 69-76 de SEQ ID NO:119, CDR3: positions 115-125 de SEQ ID NO:119, VL: CDR1: positions 47-58 de SEQ ID NO:126, CDR2: positions 76-78 de SEQ ID NO:126, CDR3: positions 115-122 de SEQ ID NO:126,
- (v) VH: CDR1: positions 45-52 de SEQ ID NO:118, CDR2: positions 70-77 de SEQ ID NO:118, CDR3: positions 116-126 de SEQ ID NO:118, VL: CDR1: positions 47-58 de SEQ ID NO:125, CDR2: positions 76-78 de SEQ ID NO:125, CDR3: positions 115-123 de SEQ ID NO:125,
- (vi) VH: CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120, CDR3: positions 117-128 de SEQ ID NO:120, VL: CDR1: positions 47-58 de SEQ ID NO:124, CDR2: positions 76-78 de SEQ ID NO:124, CDR3: positions 115-123 de SEQ ID NO:124,
- (vii) VH: CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120, CDR3: positions 117-128 de SEQ ID NO:120, VL: CDR1: positions 47-58 de SEQ ID NO:127, CDR2: positions 76-78 de SEQ ID NO:127, CDR3: positions 115-123 de SEQ ID NO:127,
- (viii) VH: CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120 CDR3: positions 117-128 de SEQ ID NO:120, VL: CDR1: positions 47-58 de SEQ ID NO:128, CDR2: positions 76-78 de SEQ ID NO:128, CDR3: positions 115-123 de SEQ ID NO:128, et
- (ix) VH: CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120, CDR3: positions 117-128 de SEQ ID NO:120, VL: CDR1: positions 47-52 de SEQ ID NO:129, CDR2: positions 70-72 de SEQ ID NO:129, CDR3: positions 109-117 de SEQ ID NO:129.

13. Anticorps selon la revendication 1, qui comprend une VH comprenant un ensemble de régions de détermination de complémentarité CDR1, CDR2 et CDR3 choisies parmi les (i) à (vi) suivantes:

- (i) CDR1: positions 45-52 de SEQ ID NO:115, CDR2: positions 70-77 de SEQ ID NO:115, CDR3: positions 116-125 de SEQ ID NO:115,
- (ii) CDR1: positions 45-52 de SEQ ID NO:116, CDR2: positions 70-77 de SEQ ID NO:116, CDR3: positions 116-126 de SEQ ID NO:116,
- (iii) CDR1: positions 45-52 de SEQ ID NO:117, CDR2: positions 70-77 de SEQ ID NO:117, CDR3: positions 116-124 de SEQ ID NO:117,
- (iv) CDR1: positions 45-52 de SEQ ID NO:118, CDR2: positions 70-77 de SEQ ID NO:118, CDR3: positions 116-124 de SEQ ID NO:118,
- (v) CDR1: positions 44-51 de SEQ ID NO:119, CDR2: positions 69-76 de SEQ ID NO:119, CDR3: positions 115-125 de SEQ ID NO:119, et
- (vi) CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120 CDR3: positions 117-128 de SEQ ID NO:120.

14. Anticorps selon la revendication 1, qui comprend une VL comprenant un ensemble de régions de détermination de complémentarité CDR1, CDR2 et CDR3 choisies parmi les (i) à (ix) suivantes:

- (i) CDR1: positions 47-58 de SEQ ID NO:121, CDR2: positions 76-78 de SEQ ID NO:121, CDR3: positions 115-123 de SEQ ID NO:121,
- (ii) CDR1: positions 49-53 de SEQ ID NO:122, CDR2: positions 71-73 de SEQ ID NO:122, CDR3: positions 110-118 de SEQ ID NO:122,
- (iii) CDR1: positions 47-52 de SEQ ID NO:123, CDR2: positions 70-72 de SEQ ID NO:123, CDR3: positions 109-117 de SEQ ID NO:123,
- (iv) CDR1: positions 47-58 de SEQ ID NO:124, CDR2: positions 76-78 de SEQ ID NO:124, CDR3: positions 115-123 de SEQ ID NO:124,
- (v) CDR1: positions 47-58 de SEQ ID NO:125, CDR2: positions 76-78 de SEQ ID NO:125, CDR3: positions 115-123 de SEQ ID NO:125,
- (vi) CDR1: positions 47-58 de SEQ ID NO:126, CDR2: positions 76-78 de SEQ ID NO:126, CDR3: positions 115-122 de SEQ ID NO:126,
- (vii) CDR1: positions 47-58 de SEQ ID NO:127, CDR2: positions 76-78 de SEQ ID NO:127, CDR3: positions 115-123 de SEQ ID NO:127,
- (viii) CDR1: positions 47-58 de SEQ ID NO:128, CDR2: positions 76-78 de SEQ ID NO:128, CDR3: positions 115-123 de SEQ ID NO:128, et
- (ix) CDR1: positions 47-52 de SEQ ID NO:129, CDR2: positions 70-72 de SEQ ID NO:129, CDR3: positions 109-117 de SEQ ID NO:129.

15. Anticorps selon la revendication 1, qui comprend une combinaison de VH et VL comprenant chacune un ensemble

de régions de détermination de complémentarité CDR1, CDR2 et CDR3 choisies parmi les (i) à (ix) suivantes:

- (i) VH: CDR1: positions 45-52 de SEQ ID NO:115, CDR2: positions 70-77 de SEQ ID NO:115, CDR3: positions 116-125 de SEQ ID NO:115, VL: CDR1: positions 49-53 de SEQ ID NO:122, CDR2: positions 71-73 de SEQ ID NO:122, CDR3: positions 110-118 de SEQ ID NO:122,
- (ii) VH: CDR1: positions 45-52 de SEQ ID NO:116, CDR2: positions 70-77 de SEQ ID NO:116, CDR3: positions 116-126 de SEQ ID NO:116, VL: CDR1: positions 47-58 de SEQ ID NO:121, CDR2: positions 76-78 de SEQ ID NO:121, CDR3: positions 115-123 de SEQ ID NO:121,
- (iii) VH: CDR1: positions 45-52 de SEQ ID NO:117, CDR2: positions 70-77 de SEQ ID NO:117, CDR3: positions 116-124 de SEQ ID NO:117, VL: CDR1: positions 47-52 de SEQ ID NO:123, CDR2: positions 70-72 de SEQ ID NO:123, CDR3: positions 109-117 de SEQ ID NO:123,
- (iv) VH: CDR1: positions 44-51 de SEQ ID NO:119, CDR2: positions 69-76 de SEQ ID NO:119, CDR3: positions 115-125 de SEQ ID NO:119, VL: CDR1: positions 47-58 de SEQ ID NO:126, CDR2: positions 76-78 de SEQ ID NO:126, CDR3: positions 115-122 de SEQ ID NO:126,
- (v) VH: CDR1: positions 45-52 de SEQ ID NO:118, CDR2: positions 70-77 de SEQ ID NO:118, CDR3: positions 116-126 de SEQ ID NO:118, VL: CDR1: positions 47-58 de SEQ ID NO:125, CDR2: positions 76-78 de SEQ ID NO:125, CDR3: positions 115-123 de SEQ ID NO:125,
- (vi) VH: CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120, CDR3: positions 117-128 de SEQ ID NO:120, VL: CDR1: positions 47-58 de SEQ ID NO:124, CDR2: positions 76-78 de SEQ ID NO:124, CDR3: positions 115-123 de SEQ ID NO:124,
- (vii) VH: CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120, CDR3: positions 117-128 de SEQ ID NO:120, VL: CDR1: positions 47-58 de SEQ ID NO:127, CDR2: positions 76-78 de SEQ ID NO:127, CDR3: positions 115-123 de SEQ ID NO:127,
- (viii) VH: CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120, CDR3: positions 117-128 de SEQ ID NO:120, VL: CDR1: positions 47-58 de SEQ ID NO:128, CDR2: positions 76-78 de SEQ ID NO:128, CDR3: positions 115-123 de SEQ ID NO:128, et
- (ix) VH: CDR1: positions 45-53 de SEQ ID NO:120, CDR2: positions 71-78 de SEQ ID NO:120, CDR3: positions 117-128 de SEQ ID NO:120, VL: CDR1: positions 47-52 de SEQ ID NO:129, CDR2: positions 70-72 de SEQ ID NO:129, CDR3: positions 109-117 de SEQ ID NO:129.

16. Anticorps selon la revendication 1, qui comprend une région variable de chaîne lourde (VH) comprenant une séquence d'acides aminés choisie dans le groupe consistant en SEQ ID NO: 132, 133, 134, 135, 136, 137, et un fragment de celles-ci.

17. Anticorps selon la revendication 1, qui comprend une région variable de chaîne légère (VL) comprenant une séquence d'acides aminés choisie dans le groupe consistant en SEQ ID NO:138, 139, 140, 141, 142, 143, 144, 145, 146, et un fragment de celles-ci.

18. Anticorps selon la revendication 1, qui comprend une combinaison de région variable de chaîne lourde (VH) et de région variable de chaîne légère (VL) choisies parmi possibilités (i) à (ix) suivantes:

- (i) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:132 ou un fragment de celle-ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:139 ou un fragment de celle-ci,
- (ii) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:133 ou un fragment de celle-ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:138 ou un fragment de celle-ci,
- (iii) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:134 ou un fragment de celle-ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:140 ou un fragment de celle-ci,
- (iv) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:136 ou un fragment de celle-ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:143 ou un fragment de celle-ci,
- (v) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:135 ou un fragment de celle-ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:142 ou un fragment de celle-ci,
- (vi) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:137 ou un fragment de celle-ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:141 ou un fragment de celle-ci,
- (vii) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:137 ou un fragment de celle-ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:144 ou un fragment de celle-ci,
- (viii) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:137 ou un fragment de celle-ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:145 ou un fragment de celle-ci,
- (ix) la VH comprend une séquence d'acides aminés représentée par SEQ ID NO:137 ou un fragment de celle-ci

ci et la VL comprend une séquence d'acides aminés représentée par SEQ ID NO:146 ou un fragment de celle-ci.

19. Anticorps selon la revendication 1, qui comprend

- 5 (i) une chaîne lourde comprenant une séquence d'acides aminés choisie dans le groupe consistant en SEQ ID NO: 115, 116, 117, 118, 119, 120, et un fragment de celles-ci et/ou
(ii) une chaîne légère comprenant une séquence d'acides aminés choisie dans le groupe consistant en SEQ ID NO: 121, 122, 123, 124, 125, 126, 127, 128, 129, et un fragment de celles-ci.

10

20. Anticorps selon la revendication 1, qui comprend une combinaison de chaînes lourdes et de chaînes légères choisie parmi les possibilités (i) à (ix) suivantes:

- 15 (i) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:115 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:122 ou un fragment de celle-ci,
(ii) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:116 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:121 ou un fragment de celle-ci,
20 (iii) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:117 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:123 ou un fragment de celle-ci,
(vi) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:119 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:126 ou un fragment de celle-ci,
25 (v) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:118 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:125 ou un fragment de celle-ci,
(vi) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:120 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:124 ou un fragment de celle-ci,
30 (vii) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:120 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:127 ou un fragment de celle-ci,
(viii) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:120 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:128 ou un fragment de celle-ci, et
35 (ix) la chaîne lourde comprend une séquence d'acides aminés représentée par SEQ ID NO:120 ou un fragment de celle-ci et la chaîne légère comprend une séquence d'acides aminés représentée par SEQ ID NO:129 ou un fragment de celle-ci.

40

21. Hybridome capable de produire l'anticorps selon l'une quelconque des revendications 1 à 20.

45 **22.** Conjugué comprenant un anticorps selon l'une quelconque des revendications 1 à 20 couplé à un agent thérapeutique, tandis que l'agent thérapeutique est de préférence une toxine, un radio-isotope, un médicament ou un agent cytotoxique.

23. Composition pharmaceutique comprenant un anticorps selon l'une quelconque des revendications 1 à 20 et/ou un conjugué selon la revendication 22, et un vecteur pharmaceutiquement acceptable.

50

24. Anticorps selon l'une quelconque des revendications 1 à 20 et/ou conjugué selon la revendication 22 pour utilisation dans un procédé pour inhiber la croissance et/ou la destruction d'une cellule exprimant CLD18A2.

55 **25.** Anticorps selon l'une quelconque des revendications 1 à 20, conjugué selon la revendication 22 ou composition pharmaceutique selon la revendication 23 pour utilisation dans un procédé pour le traitement ou la prévention d'une maladie ou d'un trouble faisant intervenir des cellules exprimant CLD18A2.

26. Anticorps, conjugué ou composition pharmaceutique pour utilisation selon la revendication 25, dans lequel(laquelle)

la maladie ou le trouble est une affection liée à une tumeur, tandis que l'affection liée à une tumeur est de préférence choisie dans le groupe consistant en cancer du sein, cancer gastrique, cancer oesophagien, cancer pancréatique, cancer du poumon, cancer des ovaires, cancer du côlon, cancer colorectal, cancer du foie, cancer de la tête et du cou, cancer de la vésicule biliaire, et leurs métastases.

5

27. Anticorps, conjugué ou composition pharmaceutique pour utilisation selon la revendication 25 ou 26, dans lequel(la-
quelle) le procédé comprend en outre le traitement avec un agent chimiothérapeutique, une irradiation, ou une
cytokine.

10

28. Anticorps, conjugué ou composition pharmaceutique pour utilisation selon la revendication 27, dans lequel(laquelle)
l'agent chimiothérapeutique est choisi dans le groupe consistant en doxorubicine, cisplatine, taxotère, fluoro-5-
uracile, méthotrexate, gémcitabine et cyclophosphamide.

15

29. Anticorps, hybridome, conjugué ou composition pharmaceutique selon l'une quelconque des revendications 1-23,
et anticorps, conjugué ou composition pharmaceutique pour utilisation selon l'une quelconque des revendications
24 à 28, dans lequel(laquelle) ladite CLD18A2 est exprimée sur la surface desdites cellules.

20

25

30

35

40

45

50

55







Fig. 1

Fig. 2






Fig. 3

Fig. 4




Fig. 4C




Fig. 5






Fig. 5

HEK293-
CLD18A2




(C)


HEK293-
CLD18A2-X2-Myc





HEK293-
CLD18A2-X1-HA



26B5 (182-D758-035)



(D)



19B9 (182-D758-024)

Fig. 6A





Fig. 6B






Fig. 7

Fig. 7





Fig. 8








Fig. 8

(C)

(D)




Fig. 9




Fig. 10




Fig. 11




Fig. 12A

Fig. 12B




Fig. 13




Fig. 14

1

NP_062789	(1)	-----MATTTCQWVGLSLISLEAGACIAATGMDMWSSTQDLYDNPTAV	50
NP_057453	(1)	-----MSTTTCQWVAFDLSIGLAGCIAATGMDMWSSTQDLYDNPTAV	
AAL15636	(1)	-----MSVTACQGHGFVMSLIGFAGTAAATCNDQWSTQDLYNNPTAV	
NP_001002026	(1)	-----MAVTACQGLGFVYSLIGFAGTAAATCNDQWSTQDLYNNPTAV	
Extrazellulär			
NP_062789	(44)	FOYEGLRSCVQSSGFTECRPYFTLLGLPAMLQAVRALMIVGIVLGAIG	100
NP_057453	(44)	FOYEGLRSCVQSSGFTECRPYFTLLGLPAMLQAVRALMIVGIVLGAIG	
AAL15636	(44)	FNVQGLWRSCVRESGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGAIG	
NP_001002026	(44)	FNVQGLWRSCVRESGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGAIG	
Extrazellulär 1			
NP_062789	(94)	LLVSI FALKCIRIGSMDDSAKAWLTSTGIFLITSGICAIGVSVFANML	150
NP_057453	(94)	LLVSI FALKCIRIGSMEDSAKAWLTSGIMFIVSGICAIGVSVFANML	
AAL15636	(94)	LLVSI FALKCIRIGSMDDSAKAWLTSTGIFLITSGICAIGVSVFANML	
NP_001002026	(94)	LLVSI FALKCIRIGSMEDSAKAWLTSGIMFIVSGICAIGVSVFANML	
Extra / intra 3 N-Glyc			
NP_062789	(144)	VTNFWMTANNMYGCGMGGNVQTVQTRYTFGAALFVGWVAGGLTLIGGV	200
NP_057453	(144)	VTNFWMTANNMYGCGMGGNVQTVQTRYTFGAALFVGWVAGGLTLIGGV	
AAL15636	(144)	VTNFWMTANNMYGCGMGGNVQTVQTRYTFGAALFVGWVAGGLTLIGGV	
NP_001002026	(144)	VTNFWMTANNMYGCGMGGNVQTVQTRYTFGAALFVGWVAGGLTLIGGV	
Extrazellulär 2			
NP_062789	(194)	MMCIACRGLTPDDSNKAVSVHASGNVAVPGGFKASTGFGSNTNKKI	250
NP_057453	(191)	MMCIACRGLAPETINAKAVSVHASGSHVAYKPGGFKASTGFGSNTNKKI	
AAL15636	(194)	MMCIACRGLTPDDSNKAVSVHASGNVAVPGGFKASTGFGSNTNKKI	
NP_001002026	(191)	MMCIACRGLAPETINAKAVSVHASGSHVAYKPGGFKASTGFGSNTNKKI	
Extrazellulär 3			
NP_062789	(244)	YDGGARTEDDEQSHPKVDYV	271
NP_057453	(241)	YDGGARTEDDEQSHPKVDYV	
AAL15636	(244)	YDGGARTEDDEQSHPKVDYV	
NP_001002026	(241)	YDGGARTEDDEQSHPKVDYV	

Fig. 15A




Fig. 15B




Fig. 16






Fig. 16

Stomach carcinomas



(B)




Lung carcinomas




(c)

Fig. 16

Fig. 17




Kidney



Lung alveoli



Stomach




Breast


(A)

Fig. 17

Stomach carcinomas




(B)



Lung carcinomas

Fig. 18A

Stomach normal



Stomach carcinomas





Fig. 18B

Hek293-mock



Gastric Cancer



Hek293-GC182A2



Gastric Cancer




Fig. 18C

Hek293-GC182A2



Hek293-mock





Gastric Cancer

Fig. 18D

Hek293-GC182A2




Hek293-mock



Gastric Cancer

Fig. 18E

Hek293-GC182A2



Hek293-mock




Fig. 19




Fig. 20




Fig. 21




Fig. 21

(C)




Fig. 22




Fig. 23




Fig. 24




Fig. 25A




Fig. 25B




Fig. 26




Fig. 27A




Fig. 27B





Fig. 28






Fig. 29

Fig. 30




Fig. 31A




Fig. 31B




Fig. 32





Fig. 33



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2004047863 A [0004]
- US 20030118592 A [0044] [0109] [0201]
- US 20030133939 A [0044] [0109] [0201]
- US 20030017534 A [0092]
- US 5624821 A [0151]
- US 5648260 A [0151]
- US 6121022 A [0152]
- US 6194551 B [0152]
- US 6277375 B [0152]
- WO 0243478 A [0157]
- WO 2004035607 A [0166]
- WO 8704462 A [0172]
- WO 8901036 A [0172]
- EP 338841 A [0172]
- WO 9945962 A [0174]
- US 4946778 A, Ladner [0201]
- WO 8800052 A [0204]
- US 4954617 A [0204]
- WO 9410332 A [0204]
- US 4474893 A [0211]
- US 5260203 A [0214]
- US 5455030 A [0214]
- US 4881175 A [0214]
- US 5132405 A [0214]
- US 5091513 A [0214]
- US 5476786 A [0214]
- US 5013653 A [0214]
- US 5258498 A [0214]
- US 5482858 A [0214]
- US 5399163 A [0251]
- US 5383851 A [0251]
- US 5312335 A [0251]
- US 5064413 A [0251]
- US 4941880 A [0251]
- US 4790824 A [0251]
- US 4596556 A [0251]
- US 4487603 A [0251]
- US 4486194 A [0251]
- US 4447233 A [0251]
- US 4447224 A [0251]
- US 4439196 A [0251]
- US 4475196 A [0251]
- US 4522811 A [0252]
- US 5374548 A [0252]
- US 5399331 A [0252]
- US 5416016 A, Low [0252]

Non-patent literature cited in the description

- TAYLOR et al. *J. Neurosc. Res.*, 2000, vol. 62, 15-27 [0005]
- NIIMI. *Mol. Cell. Biol.*, 2001, vol. 21, 7380-90 [0007]
- WARD et al. *Nature*, 1989, vol. 341, 544-546 [0109]
- BIRD et al. *Science*, 1988, vol. 242, 423-426 [0109]
- HUSTON et al. *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 5879-5883 [0109]
- HOLLIGER, P. et al. *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0112]
- POLJAK, R. J. et al. *Structure*, 1994, vol. 2, 1121-1123 [0112]
- Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory press, 1989 [0144]
- Current Protocols in Molecular Biology. John Wiley & Sons, Inc, [0144]
- SMITH ; WATERMAN. *Ads App. Math.*, 1981, vol. 2, 482 [0148]
- NEDDLEMAN ; WUNSCH. *J. Mol. Biol.*, 1970, vol. 48, 443 [0148]
- PEARSON ; LIPMAN. *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 2444 [0148]
- SHIELD et al. *JBC*, 2002, vol. 277, 26733 [0153]
- KOHLER ; MILSTEIN. *Nature*, 1975, vol. 256, 495 [0163]
- SPIEKER-POLET et al. *Proc. Natl. Acad. Sci. U.S.A.*, 1995, vol. 92, 9348 [0165]
- ROSSI et al. *Am. J. Clin. Pathol.*, 2005, vol. 124, 295 [0165]
- MORRISON, S. *Science*, 1985, vol. 229, 1202 [0171]
- VERMA, R. et al. *J. Immunol. Meth.*, 1998, vol. 216, 165-181 [0172]
- POLLOCK et al. *J. Immunol. Meth.*, 1999, vol. 231, 147-157 [0172]
- FISCHER, R. et al. *Biol. Chem.*, 1999, vol. 380, 825-839 [0172]
- KRAUS et al. *Methods in Molecular Biology series. Recombinant antibodies for cancer therapy*, ISBN 0-89603-918-8 [0173]
- RIECHMANN, L. et al. *Nature*, 1998, vol. 332, 323-327 [0174]
- JONES, P. et al. *Nature*, 1986, vol. 321, 522-525 [0174]
- QUEEN, C. et al. *Proc. Natl. Acad. Sci. U. S. A.*, 1989, vol. 86, 10029-10033 [0174]

- **KOZAK.** *J. Biol. Chem.*, 1991, vol. 266, 19867-19870 [0175]
- **GLENN E. MORRIS.** Epitope Mapping Protocols. *Methods in Molecular Biology*, ISBN 089603-375-9 [0197]
- **OLWYN M. R. WESTWOOD ; FRANK C. HAY.** Epitope Mapping: A Practical Approach. *Practical Approach Series*, 248 [0197]
- **GRAZIANO, R. F. et al.** *J. Immunol.*, 1995, vol. 155 (10), 4996-5002 [0204]
- **MORTON, H. C. et al.** *Critical Reviews in Immunology*, 1996, vol. 16, 423-440 [0205]
- **MONTEIRO, R. C. et al.** *J. Immunol.*, 1992, vol. 148, 1764 [0205]
- **D. M. KRANZ et al.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 5807 [0211]
- **KARPOVSKY et al.** *J. Exp. Med.*, 1984, vol. 160, 1686 [0212]
- **LIU, MA et al.** *Proc. Natl. Acad. Sci. USA*, 1985, vol. 82, 8648 [0212]
- **PAULUS.** *Behring Ins. Mitt.*, 1985, 118-132 [0212]
- **BRENNAN et al.** *Science*, 1985, vol. 229, 81-83 [0212]
- **GLENNIE et al.** *J. Immunol.*, 1987, vol. 139, 2367-2375 [0212]
- Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy. **ARNON et al.** Monoclonal Antibodies And Cancer Therapy. Alan R. Liss, Inc, 1985, 243-56 [0219]
- Antibodies For Drug Delivery. **HELLSTROM et al.** Controlled Drug Delivery. Marcel Dekker, Inc, 1987, 623-53 [0219]
- Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review. **THORPE.** Monoclonal Antibodies '84: Biological And Clinical Applications. 1985, 475-506 [0219]
- Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy. Monoclonal Antibodies For Cancer Detection And Therapy. Academic Press, 1985, 303-16 [0219]
- **THORPE et al.** The Preparation And Cytotoxic Properties Of Antibody-Toxic Conjugates. *Immunol. Rev.*, 1982, vol. 62, 119-58 [0219]
- Remington: The Science and Practice of Pharmacy. Mack Publishing Co, 1995 [0221]
- **BERGE, S. M. et al.** *J. Pharm. Sci.*, 1977, vol. 66, 1-19 [0228]
- Sustained and Controlled Release Drug Delivery Systems. Marcel Dekker, Inc, 1978 [0230]
- **STREJAN et al.** *J. Neuroimmunol.*, 1984, vol. 7, 27 [0231]
- **YANG et al.** *PNAS*, 2003, vol. 100 (12), 6934-6939 [0244]
- **V.V. RANADE.** *J. Clin. Pharmacol.*, 1989, vol. 29, 685 [0252]
- **UMEZAWA et al.** *Biochem. Biophys. Res. Commun.*, vol. 153, 1038 [0252]
- **P.G. BLOEMAN et al.** *FEBS Lett.*, 1995, vol. 357, 140 [0252]
- **M. OWAIS et al.** *Antimicrob. Agents Chemother.*, 1995, vol. 39, 180 [0252]
- **BRISCOE et al.** *Am. J. Physiol.*, 1995, vol. 1233, 134 [0252]
- **CUNNINGHAM-RUNDLES C ; ZHUO Z ; GRIFFITH B ; KEENAN J.** Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation. *J. Immunol. Methods*, 1992, vol. 152, 177-190 [0254]
- **LANDOR M.** Maternal-fetal transfer of immunoglobulins. *Ann. Allergy Asthma Immunol.*, 1995, vol. 74, 279-283 [0254]
- **MATZ et al.** *Nucleic Acids Research*, 1999, vol. 27 (6) [0339]
- **MATZ et al.** *Nucleic Acids Research*, 1999, vol. 27 (6), 1558 [0339]

Szabadalmi igénypontok

1. Monoklonális ellenanyag, amely képes CLD18A2 kötésére és CLD18A2-t expresszáló sejtek elpusztításának közvetítésére, ahol az ellenanyag a CLD18A2-loop1-re vagy a CLD18A2-loopD3-ra lokalizált epitóphoz kötődik és ahol az elpusztítást az ellenanyagnak a sejteken lévő CLD18A2-höz való kötődése indukálja, ahol az ellenanyag a sejtek elpusztítását komplement-függő citotoxicitás (CDC) és/vagy ellenanyag-függő celluláris citotoxicitás (ADCC) közvetített lízis indukálásával közvetíti.

2. Az 1. igénypont szerinti ellenanyag, amely kötődik CLD18A1-hez és CLD18A2-höz vagy kötődik CLD18A2-höz de nem kötődik CLD18A1-hez.

3. Az 1. vagy 2. igénypont szerinti ellenanyag, ahol a CLD18A2-t expresszáló sejtek ráksejtek, ahol a ráksejtek előnyösen a következők által alkotott csoportból vannak kiválasztva: tumorigenikus gyomor, nyelőcső, hasnyálmirigy és tüdő ráksejtek.

4. A 3. igénypont szerinti ellenanyag, ahol az ADCC közvetített lízis a következők által alkotott csoportból kiválasztott effektor sejtek jelenlétében történik: monociták, mononukleáris sejtek, NK sejtek és PMN-ek, vagy a fagocitózis makrofágok általi.

5. Az 1-4. igénypontok bármelyike szerinti ellenanyag, amely kimerá, humán vagy humanizált ellenanyag, vagy ellenanyag fragmense.

6. Az 1-5. igénypontok bármelyike szerinti ellenanyag, amely a következők által alkotott csoportból van kiválasztva: IgG1, IgG2, előnyösen IgG2a és IgG2b, IgG3, IgG4, IgM, IgA1, IgA2, szekréciós IgA, IgD, és IgE ellenanyag.

7. A 2-6. igénypontok bármelyike szerinti ellenanyag, ahol a CLD18A2 aminosav-szekvenciája a SEQ ID NO:2 szerinti.

8. A 2-7. igénypontok bármelyike szerinti ellenanyag, ahol a CLD18A1 aminosav-szekvenciája a SEQ ID NO:8 szerinti.

9. Az 1-8. igénypontok bármelyike szerinti ellenanyag, amely CLD18A2 élő sejtek felszínén jelen lévő natív epitópjaihoz kötődik.

10. Az 1-9. igénypontok bármelyike szerinti ellenanyag, amely ráksejtekre specifikus, előnyösen gyomorrák-sejtekre.

11. Az 1-10. igénypontok bármelyike szerinti ellenanyag, amely olyan eljárással állítható elő, amely magában foglalja nem-humán állatnak a SEQ ID NO: 2, 4, 6, 16, 18, 20-23, és 26-31 által alkotott csoportból kiválasztott aminosav-szekvenciájú proteinnel vagy peptiddel, vagy annak immunogén fragmensével, vagy a proteint vagy peptidet vagy immunogén fragmensét expresszáló nukleinsavval vagy gazdasejttel való immunizálásának lépését.

12. Az 1. igénypont szerinti ellenanyag, amely olyan ellenanyag nehézlánc variábilis régiója (VH) és/vagy a könnyűlánc variábilis régiója (VL) egy vagy több komplementaritást meghatározó régióját (CDR) tartalmazza, előnyösen legalább a CDR3-at, amely a következő (i) - (ix) pontok által alkotott csoportból kiválasztott CDR1, CDR2 és CDR3 komplementaritást meghatározó régiók készletét tartalmazó VH és VL kombinációját tartalmazza:

(i) VH: CDR1: SEQ ID NO: 115 45-52 pozíciói, CDR2: SEQ ID NO: 115 70-77 pozíciói, CDR3: SEQ ID NO: 115 116-125 pozíciói, VL: CDR1: SEQ ID NO: 122 49-53 pozíciói, CDR2: SEQ ID NO: 122 71-73 pozíciói, CDR3: SEQ ID NO: 122 110-118 pozíciói,

(ii) VH: CDR1: SEQ ID NO: 116 45-52 pozíciói, CDR2: SEQ ID NO: 116 70-77 pozíciói, CDR3: SEQ ID NO: 116 116-126 pozíciói, VL: CDR1: SEQ ID NO: 121 47-58 pozíciói, CDR2: SEQ ID NO: 121 76-78 pozíciói, CDR3: SEQ ID NO: 121 115-123 pozíciói,

(iii) VH: CDR1 : SEQ ID NO: 117 45-52 pozíciói, CDR2: SEQ ID NO: 117 70-77 pozíciói, CDR3: SEQ ID NO: 117 116-124 pozíciói, VL: CDR1: SEQ ID NO: 123 47-52 pozíciói, CDR2: SEQ ID NO: 123 70-72 pozíciói, CDR3: SEQ ID NO: 123 109-117 pozíciói,

(iv) VH: CDR1: SEQ ID NO: 119 44-51 pozíciói, CDR2: SEQ ID NO: 119 69-76 pozíciói, CDR3: SEQ ID NO: 119 115-125 pozíciói, VL: CDR1: SEQ ID NO: 126 47-58 pozíciói, CDR2: SEQ ID NO: 126 76-78 pozíciói, CDR3: SEQ ID NO: 126 115-122 pozíciói,

(v) VH: CDR1: SEQ ID NO: 118 45-52 pozíciói, CDR2: SEQ ID NO: 118 70-77 pozíciói, CDR3: SEQ ID NO: 118 116-126 pozíciói, VL: CDR1: SEQ ID NO: 125 47-58 pozíciói, CDR2: SEQ ID NO: 125 76-78 pozíciói, CDR3: SEQ ID NO: 125 115-123 pozíciói,

(vi) VH: CDR1: SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO: 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói, VL: CDR1: SEQ ID NO: 124 47-58 pozíciói, CDR2: SEQ ID NO: 124 76-78 pozíciói, CDR3: SEQ ID NO: 124 115-123 pozíciói,

(vii) VH: CDR1 : SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO: 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói, VL: CDR1: SEQ ID NO: 127 47-58 pozíciói, CDR2: SEQ ID NO: 127 76-78 pozíciói, CDR3: SEQ ID NO: 127 115-123 pozíciói,

(viii) VH: CDR1: SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO: 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói, VL: CDR1: SEQ ID NO: 128 47-58 pozíciói, CDR2: SEQ ID NO: 128 76-78 pozíciói, CDR3: SEQ ID NO: 128 115-123 pozíciói, és

(ix) VH: CDR1: SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO: 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói, VL: CDR1: SEQ ID NO: 129 47-52 pozíciói, CDR2: SEQ ID NO: 129 70-72 pozíciói, CDR3: SEQ ID NO: 129 109-117 pozíciói.

13. Az 1. igénypont szerinti ellenanyag, amely a következő (i) - (vi) pontok által alkotott csoportból kiválasztott CDR1, CDR2 és CDR3 komplementaritást meghatározó régiók készletét tartalmazó VH-t tartalmaz:

(i) CDR1: SEQ ID NO: 115 45-52 pozíciói, CDR2: SEQ ID NO: 115 70-77 pozíciói, CDR3: SEQ ID NO: 115 116-125 pozíciói,

(ii) CDR1: SEQ ID NO: 116 45-52 pozíciói, CDR2: SEQ ID NO: 116 70-77 pozíciói, CDR3: SEQ ID NO: 116 116-126 pozíciói,

(iii) CDR1 : SEQ ID NO: 117 45-52 pozíciói, CDR2: SEQ ID NO: 117 70-77 pozíciói, CDR3: SEQ ID NO: 117 116-124 pozíciói,

(iv) CDR1: SEQ ID NO: 118 45-52 pozíciói, CDR2: SEQ ID NO: 118 70-77 pozíciói, CDR3: SEQ ID NO: 118 116-126 pozíciói,

(v) CDR1: SEQ ID NO: 119 44-51 pozíciói, CDR2: SEQ ID NO: 119 69-76 pozíciói, CDR3: SEQ ID NO: 119 115-125 pozíciói, és

(vi) CDR1: SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói.

14. Az 1. igénypont szerinti ellenanyag, amely a következő (i) - (ix) pontok által alkotott csoportból kiválasztott CDR1, CDR2 és CDR3 komplementaritást meghatározó régiók készletét tartalmazó VL-t tartalmaz:

(i) CDR1: SEQ ID NO:121 47-58 pozíciói, CDR2: SEQ ID NO: 121 76-78 pozíciói, CDR3: SEQ ID NO: 121 115-123 pozíciói,

(ii) CDR1: SEQ ID NO: 122 49-53 pozíciói, CDR2: SEQ ID NO 122 71-73 pozíciói, CDR3: SEQ ID NO: 122 110-118 pozíciói,

(iii) CDR1 : SEQ ID NO: 123 47-52 pozíciói, CDR2: SEQ ID NO: 123 70-72 pozíciói, CDR3: SEQ ID NO: 123 109-117 pozíciói,

(iv) CDR1: SEQ ID NO:124 47-58 pozíciói, CDR2: SEQ ID NO: 124 76-78 pozíciói, CDR3: SEQ ID NO: 124 115-123 pozíciói,

(v) CDR1: SEQ ID NO: 125 47-58 pozíciói, CDR2: SEQ ID NO: 125 76-78 pozíciói, CDR3: SEQ ID NO: 125 115-123 pozíciói,

(vi) CDR1: SEQ ID NO: 126 47-58 pozíciói, CDR2: SEQ ID NO 126 76-78 pozíciói, CDR3: SEQ ID NO: 126 115-122 pozíciói,

(vii) CDR1: SEQ ID NO:127 47-58 pozíciói, CDR2: SEQ ID NO: 127 76-78 pozíciói, CDR3: SEQ ID NO: 127 115-123 pozíciói,

(viii) CDR1: SEQ ID NO: 128 47-58 pozíciói, CDR2: SEQ ID NO: 128 76-78 pozíciói, CDR3: SEQ ID NO: 128 115-123 pozíciói, és

(ix) CDR1 : SEQ ID NO: 129 47-52 pozíciói, CDR2: SEQ ID NO: 129 70-72 pozíciói, CDR3: SEQ ID NO: 129 109-117 pozíciói.

15. Az 1. igénypont szerinti ellenanyag, amely a következő (i) - (ix) pontok által alkotott csoportból kiválasztott CDR1, CDR2 és CDR3 komplementaritást meghatározó régiók készletét tartalmazó VH és VL kombinációját tartalmazza:

(i) VH: CDR1: SEQ ID NO: 115 45-52 pozíciói, CDR2: SEQ ID NO: 115 70-77 pozíciói, CDR3: SEQ ID NO: 115 116-125 pozíciói, VL: CDR1: SEQ ID NO: 122 49-53 pozíciói, CDR2: SEQ ID NO: 122 71-73 pozíciói, CDR3: SEQ ID NO: 122 110-118 pozíciói,

(ii) VH: CDR1: SEQ ID NO: 116 45-52 pozíciói, CDR2: SEQ ID NO 116 70-77 pozíciói, CDR3: SEQ ID NO: 116 116-126 pozíciói, VL: CDR1: SEQ ID NO: 121 47-58 pozíciói, CDR2: SEQ ID NO: 121 76-78 pozíciói, CDR3: SEQ ID NO: 121 115-123 pozíciói,

(iii) VH: CDR1 : SEQ ID NO: 117 45-52 pozíciói, CDR2: SEQ ID NO: 117 70-77 pozíciói, CDR3: SEQ ID NO: 117 116-124 pozíciói, VL: CDR1: SEQ ID NO: 123 47-52 pozíciói, CDR2: SEQ ID NO: 123 70-72 pozíciói, CDR3: SEQ ID NO:123 109-117 pozíciói,

(iv) VH: CDR1: SEQ ID NO:119 44-51 pozíciói, CDR2: SEQ ID NO: 119 69-76 pozíciói, CDR3: SEQ ID NO: 119 115-125 pozíciói, VL: CDR1: SEQ ID NO: 126 47-58 pozíciói, CDR2: SEQ ID NO: 126 76-78 pozíciói, CDR3: SEQ ID NO:126 115-122 pozíciói,

(v) VH:CDR1:SEQ ID NO: 118 45-52 pozíciói, CDR2: SEQ ID NO: 118 70-77 pozíciói, CDR3: SEQ ID NO: 118 116-126 pozíciói, VL: CDR1: SEQ ID NO: 125 47-58 pozíciói, CDR2: SEQ ID NO: 125 76-78 pozíciói, CDR3: SEQ ID NO: 125 115-123 pozíciói,

(vi) VH: CDR1: SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO: 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói, VL: CDR1: SEQ ID NO: 124 47-58 pozíciói, CDR2: SEQ ID NO: 124 76-78 pozíciói, CDR3: SEQ ID NO: 124 115-123 pozíciói,

(vii) VH: CDR1 : SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO: 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói, VL: CDR1: SEQ ID NO: 127 47-58 pozíciói, CDR2: SEQ ID NO: 127 76-78 pozíciói, CDR3: SEQ ID NO: 127 115-123 pozíciói,

(viii) VH: CDR1: SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO: 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói, VL: CDR1: SEQ ID NO: 128 47-58 pozíciói, CDR2: SEQ ID NO: 128 76-78 pozíciói, CDR3: SEQ ID NO: 128 115-123 pozíciói, és

(ix) VH: CDR1: SEQ ID NO: 120 45-53 pozíciói, CDR2: SEQ ID NO: 120 71-78 pozíciói, CDR3: SEQ ID NO: 120 117-128 pozíciói, VL: CDR1: SEQ ID NO: 129 47-52 pozíciói, CDR2: SEQ ID NO: 129 70-72 pozíciói, CDR3: SEQ ID NO: 129 109-117 pozíciói.

16. Az 1. igénypont szerinti ellenanyag, amely a SEQ ID NO: 132, 133, 134, 135, 136, 137, és ezek fragmensei által alkotott csoportból kiválasztott aminosav-szekvenciát tartalmazó nehézlánc variábilis régiót (VH) tartalmaz.

17. Az 1. igénypont szerinti ellenanyag, amely a SEQ ID NO: 138, 139, 140, 141, 142, 143, 144, 145, 146, és ezek fragmensei által alkotott csoportból kiválasztott aminosav-szekvenciát tartalmazó könnyűlánc variábilis régiót (VL) tartalmaz.

18. Az 1. igénypont szerinti ellenanyag, amely a következő (i) - (ix) lehetőségek által alkotott csoportból kiválasztott nehézlánc variábilis régió (VH) és könnyűlánc variábilis régió (VL) kombinációját tartalmazza:

(i) a VH a SEQ ID NO: 132 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 139 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(ii) a VH a SEQ ID NO: 133 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 138 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(iii) a VH a SEQ ID NO: 134 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 140 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(iv) a VH a SEQ ID NO: 136 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 143 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(v) a VH a SEQ ID NO: 135 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 142 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(vi) a VH a SEQ ID NO: 137 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 141 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(vii) a VH a SEQ ID NO: 137 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 144 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(viii) a VH a SEQ ID NO: 137 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 145 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(ix) a VH a SEQ ID NO: 137 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a VL a SEQ ID NO: 146 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza.

19. Az 1. igénypont szerinti ellenanyag, tartalmaz

(i) a SEQ ID NO: 115, 116, 117, 118, 119, 120, és ezek fragmensei által alkotott csoportból kiválasztott aminosav-szekvenciát tartalmazó nehézláncot

és/vagy

(ii) a SEQ ID NO: 121, 122, 123, 124, 125, 126, 127, 128, 129, és ezek fragmensei által alkotott csoportból kiválasztott aminosav-szekvenciát tartalmazó könnyűláncot.

20. Az 1. igénypont szerinti ellenanyag, amely a következő (i) - (ix) lehetőségek által alkotott csoportból kiválasztott nehézláncok és könnyűláncok kombinációját tartalmazza:

(i) a nehézlánc a SEQ ID NO: 115 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 122 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(ii) a nehézlánc a SEQ ID NO: 116 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 121 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(iii) a nehézlánc a SEQ ID NO: 117 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 123 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(iv) a nehézlánc a SEQ ID NO: 119 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 126 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(v) a nehézlánc a SEQ ID NO: 118 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 125 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(vi) a nehézlánc a SEQ ID NO: 120 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 124 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(vii) a nehézlánc a SEQ ID NO: 120 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 127 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza,

(viii) a nehézlánc a SEQ ID NO: 120 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 128 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és

(ix) a nehézlánc a SEQ ID NO: 120 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza, és a könnyűlánc a SEQ ID NO: 129 szerinti aminosav-szekvenciát vagy fragmensét tartalmazza.

21. Hibridóma, amely képes az 1-20. igénypontok bármelyike szerinti ellenanyag termelésére.

22. Konjugátum, amely az 1-20. igénypontok bármelyike szerinti ellenanyagot tartalmazza terápiás szerhez kapcsolatosan, ahol a terápiás szer előnyösen toxin, radioizotóp, drog vagy citotoxikus szer.

23. Gyógyászati készítmény, amely az 1-20. igénypontok bármelyike szerinti ellenanyagot és/vagy 22. igénypont szerinti konjugátumot és gyógyászatiilag elfogadható hordozót tartalmaz.

24. Az 1-20. igénypontok bármelyike szerinti ellenanyag és/vagy a 22. igénypont szerinti konjugátum, CLD18A2-t expresszáló sejt növekedésének gátlására és/vagy elpusztítására szolgáló eljárásban történő alkalmazásra.

25. Az 1-20. igénypontok bármelyike szerinti ellenanyag vagy a 22. igénypont szerinti konjugátum vagy a 23. igénypont szerinti gyógyászati készítmény, olyan betegség vagy rendellenesség kezelésében vagy megelőzésében történő alkalmazásra, amely CLD18A2-t expresszálo sejtekkel kapcsolatos.

26. A 25. igénypont szerinti ellenanyag, konjugátum vagy gyógyászati készítmény alkalmazásra, ahol a betegség vagy rendellenesség daganattal kapcsolatos betegség, ahol a daganattal kapcsolatos betegség előnyösen a következők által alkotott csoportból van kiválasztva: emlőrák, gyomorrák, nyelőcsőrák, hasnyálmirigy rák, tüdőrák, petefészek rák, vastagbélrák, kolorektális rák, májrák, fej-nyak rák, epehólyagrák, és ezek metasztázisai.

27. A 25. vagy 26. igénypont szerinti ellenanyag, konjugátum vagy gyógyászati készítmény alkalmazásra, ahol az eljárás továbbá magában foglal kemoterápiás szerrel, sugárzással vagy citokinnel való kezelést is.

28. A 27. igénypont szerinti ellenanyag, konjugátum vagy gyógyászati készítmény alkalmazásra, ahol a kemoterápiás szer a következők által alkotott csoportból van kiválasztva: doxorubicin, ciszplatín, taxotér, 5-fluoruracil, metotrexát, gemcitabin és ciklofoszfamid.

29. Az 1-23. igénypontok bármelyike szerinti ellenanyag, hibridóma vagy gyógyászati készítmény, és a 24-28. igénypontok bármelyike szerinti ellenanyag, konjugátum vagy gyógyászati készítmény alkalmazásra, ahol a CLD18A2 a sejtek felszínén expresszáldik.